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SUMMARY 
The comparative study presented in this dissertation specifically aimed to assess fracture risk 
in black (Xhosa) and white South African women by evaluating known determinants of bone 
strength as well as the propensity to falls. We thus compared the prevalence of clinical 
(historic) risk factors for osteoporosis, measured and compared vertebral and femoral bone 
mineral density (BMD) employing dual energy X-ray absorptiometry (DEXA), ultrasound 
variables using the Sahara sonometer, serum parathyroid hormone (PTH) and 25-OH Vitamin 
D, mineral homeostasis and modern biochemical markers of bone turnover, bone geometry 
and the propensity to falls. Finally, we determined the prevalence of vertebral fractures in 
these black and white South African females. 
1. Significant ethnic differences were noted in the presence and frequency of historical 
clinical and lifestyle risk factors for osteoporosis. Blacks were heavier and shorter, they 
consumed less calcium, were more inactive, preferred depot-medroxyprogesterone 
acetate as contraceptive agent and were of higher parity. Whites smoked more, 
preferred oral oestrogen containing contraceptive tablets and were more likely to have 
a positive family history of osteoporosis. Hormone therapy was used almost exclusively 
by postmenopausal whites. Inter-ethnic differences in weight, physical activity and high 
parity was most marked in the older subjects. 
2. We found that peak spinal BMD was lower, but peak femoral BMD similar or higher 
(depending on the specific proximal femoral site measured) in black South-African 
females compared with whites. The lower peak spinal BMD was mainly attributed to 
lower BMD’s in the subgroup of black females with normal to low body weight, 
indicating that obesity either protected black females against a low spinal BMD or 
enhanced optimal attainment of bone mineral. An apparent slower rate of decline in 
both spinal- and femoral BMD with ageing was noted in the black females compared 
with whites in this cross-sectional study – an observation which will require 
confirmation in longitudinal, follow-up studies. This resulted in similar spinal BMD 
values in postmenopausal blacks and whites, but significantly higher femoral BMD 
measurements in blacks. The volumetric calculation of bone mineral apparent density 
(BMAD) at the lumbar spine and femoral neck yielded similar results to that of BMD. 
Spinal BMAD was similar in blacks and whites and femoral neck BMAD was consistently 
higher in all the menopausal subgroups studied. Weight significantly correlated with 
peak- and postmenopausal BMD at all sites in the black and white female cohorts. 
Greater and better maintained body weight may be partially responsible for slower 
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rates of bone loss observed in black postmenopausal females. Most of the observed 
ethnic difference in BMD was, in fact, explained by differences in body weight between 
the two cohorts and not by ethnicity per se. 
3. A low body weight and advanced age was identified as by far the most informative 
individual clinical risk factors for osteopenia in our black and white females, whereas 
physical inactivity was also identified as an important individual risk factor in blacks 
only. Risk assessment tools, developed and validated in Asian and European 
populations, demonstrated poor sensitivity for identification of South African women at 
increased risk of osteopenia. The osteoporosis risk assessment instrument (ORAI) 
showed the best results, with sensitivities to identify osteopenic whites at most skeletal 
sites approaching 80% (78% - 81%). The risk assessment tool scores appear to be 
inappropriate for our larger sized study cohort, especially our black subjects, thus 
resulting in incorrect risk stratification and poor test sensitivity. General discriminant 
analysis identified certain risk factor subsets for combined prediction of osteopenia in 
blacks and whites. These risk factor subsets were more sensitive to identify osteopenia 
in blacks at all skeletal sites, compared with the risk assessment tools described in the 
literature. 
4. Higher ultrasonographically measured broadband ultrasound attenuation (BUA) and 
speed of sound (SOS) values were documented in our elderly blacks compared with 
whites, even after correction for differences in DEXA determined BMD at the spine and 
proximal femoral sites. BUA and SOS showed no decline with ageing in blacks, in 
contrast to an apparent significant deterioration in both parameters in ageing whites. If 
these quantitative ultrasound (QUS) parameters do measure qualitative properties of 
bone in our black population, independent of BMD as has been suggested in previous 
work in Caucasian populations, the higher values documented in elderly blacks imply 
better preservation of bone quality in ageing blacks compared with whites. The 
correlation between QUS calcaneal BMD and DEXA measured BMD at the hip and spine 
was modest at best. QUS calcaneal BMD was therefore unable to predict DEXA 
measured BMD at clinically important fracture sites in our study population.  
5. Bone turnover, as assessed biochemically, was similar in the total pre- and 
postmenopausal black and white cohorts, but bone turnover rates appeared to differ 
with ageing between the two racial groups. A lower bone turnover rate was noted in 
blacks at the time of the menopausal transition and is consistent with the finding of a 
lower percentage bone loss at femoral sites at this time in blacks compared with 
whites. Bone turnover only increased in ageing postmenopausal blacks, and this could 
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be ascribed, at least in part, to the observed negative calcium balance and the more 
pronounced secondary hyperparathyroidism noted in blacks. Deleterious effects of 
secondary hyperparathyroidism on bone mineral density at the proximal femoral sites 
were demonstrated in our postmenopausal blacks and contest the idea of an absolute 
skeletal resistance to the action of PTH in blacks. The increase in bone turnover and 
the presence of secondary hyperparathyroidism due to a negative calcium balance may 
thus potentially aggravate bone loss in ageing blacks, especially at proximal femoral 
sites.  
6. Shorter, adult black women have a significantly shorter hip axis length (HAL) than 
whites. This geometric feature has been documented to protect against hip fracture. 
The approximately one standard deviation (SD) difference in HAL between our blacks 
and whites may therefore significantly contribute to the lower hip fracture rate 
previously reported in South African black females compared with whites. Average 
vertebral size was, however, smaller in black females and fail to explain the apparent 
lower vertebral fracture risk previously reported in this population. Racial differences in 
vertebral dimensions (height, width) and/or other qualitative bone properties as 
suggested by our QUS data may, however, account for different vertebral fracture rates 
in white and black women – that is, if such a difference in fact exists.  
7. The number of women with a history of falls was similar in our black and white cohorts, 
and in both ethnic groups the risk of falling increased with age. There is a suggestion 
that the nature of falls in our black and white postmenopausal females may differ, but 
this will have to be confirmed in a larger study. Fallers in our postmenopausal study 
population were more likely to have osteoporosis than non-fallers. Postmenopausal 
blacks in our study demonstrated poorer outcomes regarding neuromuscular function, 
Vitamin D status and visual contrast testing and were shown to be more inactive with 
ageing compared with whites. An increased fall tendency amongst the black females 
could not however be documented in this small study. Quadriceps weakness and slower 
reaction time indicated an increased fall risk amongst whites, but were unable to 
distinguish black female fallers from non-fallers.  
8. Vertebral fractures occurred in a similar percentage of postmenopausal blacks (11.5%) 
and whites (8.1%) in our study.  Proximal femoral BMD best identified black and white 
vertebral fracture cases in this study. Quite a number of other risk factors i.e. physical 
inactivity, alcohol-intake, poorer physical performance test results and a longer HAL 
were more frequent in the white fracture cases and could therefore serve as markers of 
increased fracture risk, although not necessarily implicated in the pathophysiology of 
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OP or falls. However, in blacks, only femoral BMD served as risk factor. Similar risk 
factors for blacks and whites cannot therefore be assumed and is deserving of further 
study. White fracture cases did not fall more despite lower 25-OH-Vitamin D, poorer 
physical performance and lower activity levels than non-fracture cases. Calcaneal 
ultrasonography and biochemical parameters of bone turnover were similar in fracture 
and non-fracture cases in both ethnic groups. Our study data on vertebral fractures in 
this cohort of urbanized blacks thus cautions against the belief that blacks are not at 
risk of sustaining vertebral compression fractures and emphasize the need for further 
studies to better define fracture prevalence in the different ethnic populations of South 
Africa. 
9. In our study, hormone therapy in postmenopausal white women improved bone 
strength parameters and reduced fall risk. In hormone treated whites compared with 
non-hormone users, a higher BMD at the spine and proximal femur as determined by 
DEXA were documented and all QUS measurements were also significantly higher. The 
biochemically determined bone turnover rate, as reflected by serum osteocalcin levels, 
was lower in hormone users. Fall frequency was lower in the older hormone treated 
women (≥ 60yrs) and greater quadriceps strength and reduced lateral sway was noted. 
Only one patient amongst the hormone users (2%) had radiological evidence of 
vertebral fractures compared with four patients (6%) amongst the never-users. As 
hormone therapy was used almost exclusively by whites in this study population, the 
impact of hormone therapy on postmenopausal black study subjects could not be 
assessed. 
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OPSOMMING 
Die doel van die vergelykende studie vervat in hierdie verhandeling was om fraktuur-risiko in 
swart en wit Suid-Afrikaanse vroue te bepaal en te vergelyk via die evaluasie van bekende 
beensterkte parameters en beoordeling van hul neiging tot valle. Swart en blanke Suid-
Afrikaanse vroue is derhalwe vergelyk ten opsigte van die prevalensie van bekende kliniese 
(historiese) risikofaktore vir osteoporose (OP), vertebrale en femorale beenmineraaldigtheid 
(BMD) gemeet met behulp van dubbel-energie-X-straal-absorptiometrie (DEXA), ultraklank 
parameters bepaal met die Sahara sonometer, biochemiese bepaling van serum 
paratiroiedhormoon, 25-OD-Vitamien D, mineraal homeostase en moderne biochemiese 
merkers van beenomset sowel as been-geometrie en die valneiging. Die prevalensie van 
vertebrale frakture in hierdie twee etniese studiegroepe is ten laaste ook bepaal en vergelyk. 
1. Betekenisvolle etniese verskille in die teenwoordigheid en frekwensie van historiese 
kliniese- en lewenstyl risikofaktore is genoteer. Swart vroue het ‘n hoër 
liggaamsgewig en is korter, hul dietêre kalsium-inname is laer, hul is meer onaktief, 
verkies depot medroksiprogesteroonasetaat as kontraseptiewe modaliteit en is van 
hoër pariteit. Wit vroue rook meer, verkies orale estrogeen-bevattende 
kontraseptiewe tablette en het ‘n hoёr voorkoms van familiële OP. Hormoonterapie is 
feitlik uitsluitlik in wit postmenopousale vroue gedokumenteer. Die etniese verskille in 
liggaamsgewig, fisiese aktiwiteitsvlakke en pariteit was mees uitgesproke in die ouer 
studiepasiënte. 
2. Piek vertebrale BMD was laer, maar piek femorale BMD soortgelyk of hoër 
(afhangende van die spesifieke proksimale femorale area gemeet) in swart vergeleke 
met wit Suid-Afrikaanse vroue. Die laer piek vertebrale BMD in swart vrouens was 
hoofsaaklik toeskryfbaar aan die laer vertebrale beenmineraaldigtheid in die subgroep 
van swart premenopousale vroue met normale tot lae liggaamsgewig. Hierdie 
bevinding was aanduidend van óf ‘n beskermende rol van obesiteit teen die 
ontwikkeling van ‘n lae vertebrale BMD óf dat obesiteit die bereiking van optimale 
piek vertebrale BMD potensieër. ‘n Oënskynlike stadiger afname in beide vertebrale- 
en femorale BMD met veroudering is verder gedokumenteer in swart vrouens 
vergeleke met wit vroue in hierdie deursnit studie – ‘n observasie wat bevestiging 
benodig in longutidinale opvolgstudies. Hierdie stadiger afname in BMD word 
weerspieël in die bevinding van soortgelyke vertebrale BMD en betekenisvolle hoër 
femorale BMD in postmenopousale swart vroue vergeleke met wit vroue. Soortgelyke 
resultate word verkry wanneer die volumetries berekende vertebrale en femorale nek 
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beenmineraaldigtheid van die twee etniese groepe met mekaar vergelyk word. 
Vertebrale volumetries berekende beenmineraaldigtheid is soortgelyk in swart en wit 
vroue, maar die volumetries berekende beenmineraaldigtheid van die femorale nek 
konsekwent hoër in swartes in al die bestudeerde menopousale subgroepe. ‘n 
Betekenisvolle korrelasie tussen gewig en piek- sowel as postmenopousale BMD van 
alle gemete skeletale areas was aantoonbaar in die swart- en wit studiegroepe. Die 
oënskynlik stadiger tempo van beenverlies in swart postmenopousale vroue mag 
deels toeskryfbaar wees aan hul hoër liggaamsgewig, asook die beter behoud van hul 
liggaamsgewig met veroudering. Verskille in beenmineraaldigthede tussen swartes en 
wit vroue in hierdie studie was inderwaarheid grotendeels verklaar deur verskille in 
liggaamsgewig en nie die gevolg van etnisiteit per se nie. 
3. ‘n Lae liggaamsgewig en gevorderde ouderdom is in hierdie studie geїdentifiseer as 
die belangrikste individuele kliniese risikofaktore vir osteopenie in ons swart en 
blanke vroue, terwyl fisiese onaktiwiteit ook as belangrike risikofaktor vir osteopenie 
in swartes alleen aangetoon is. Risiko-assesseringsinstrumente, ontwikkel en bevestig 
in Asiatiese en Europese populasies toon lae sensitiwiteit vir identifikasie van SA 
vroue met verhoogde risiko vir osteopenie. Die Osteoporose Risiko-
Assesseringsinstrument (ORAI) vertoon die beste in ons studiepopulasie, met ‘n 
sensitiwiteit vir identifikasie van osteopeniese wit vroue in die omgewing van 80% 
(78-81%). Tellings gebruik in hierdie risiko-assesseringsinstrumente blyk meesal 
ontoepaslik te wees vir ons fisies groter studiepopulasie, veral ons swart vroue, met 
gevolglike onakkurate risiko stratifikasie en swak toets sensitiwiteite. Risikofaktor 
kombinasies, geїdentifiseer by wyse van algemene diskriminant analise vir 
gekombineerde voorspelling van osteopenie, vertoon beter sensitiwiteite ten opsigte 
van die identifikasie van osteopenie vir alle skeletale areas in swartes vergeleke met 
die risiko-assesseringsinstrumente geëvalueer.   
4. Hoёr waardes van ultrasonografies gemete breёband ultraklank attenuasie (BUA) en 
spoed van klank (SOS) is gedokumenteer in ons ouer swart vroue vergeleke met wit 
vroue. Hierdie hoёr waardes in swartes is bevestig selfs na korreksie vir etniese 
verskille in DEXA gemete vertebrale en femorale BMD.  In kontras met ‘n oёnskynlik 
betekenisvolle verswakking van beide BUA en SOS parameters in wit vrouens met 
veroudering, is geen betekenisvolle afname in hierdie parameters in swartes 
gedokumenteer nie. Indien hierdie ultraklank parameters kwalitatiewe aspekte van 
been meet in ons swart populasie, onafhanklik van BMD, soos vantevore gesuggereer 
in Kaukasiёrs, impliseer hierdie bevindings ‘n beter behoud van beenkwaliteit in 
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verouderende swart vroue vergeleke met wit vroue. Die korrelasie tussen 
kwantitatiewe ultraklank gemete kalkaneale BMD en vertebrale sowel as femorale 
BMD soos gemeet met behulp van DEXA, was matig ten beste, en ultraklank gemete 
BMD dus by onvermoё om DEXA gemete BMD van die klinies relevante fraktuurareas 
te voorspel in ons studiepopulasie. 
5. Biochemies bepaalde beenomset was soortgelyk in die totale pre- en 
postmenopousale swart en wit studiegroepe. Oёnskynlike etniese verskille in die 
tempo van beenomset met veroudering is egter aangetoon. ‘n Laer beenomset is 
genoteer in swart vroue ten tye van die menopousale oorgang en verenigbaar met 
die bevinding van ‘n laer persentasie femorale beenverlies in swart vroue vergeleke 
met wit vroue. ’n Toename in beenomset is slegs aangetoon in swart, ouer 
postmenopousale vroue. Hierdie bevinding kan gedeeltelik verklaar word op grond 
van ‘n meer negatiewe kalsium-balans en derhalwe meer uitgesproke sekondêre 
hiperparatireose in swartes vergeleke met wit vroue. Nadelige effekte van sekondêre 
hiperparatireose op proksimale femorale beenmineraaldigthede is wel aangetoon in 
ons postmenopousale swart vroue en weerspreek die idée van ‘n absolute skeletale 
weerstandigheid teen paratiroiedhormoon in swartes. ‘n Toename in beenomset, 
vanweё ‘n onderliggende negatiewe kalsium-balans en sêkondere hiperparatireose, 
mag dus potensieёl beenverliese, veral van die proksimale femorale areas, 
aksensueer in verouderende swartes.  
6. Korter, volwasse Suid-Afrikaanse swart vroue het ‘n betekenisvolle korter heup-axis-
lengte (HAL) as wit vroue. Hierdie geometriese bevinding is vantevore in die 
literatuur gedokumenteer om beskerming te verleen teen die opdoen van 
heupfrakture. Die nagenoeg een standard deviasie verskil in HAL tussen swart en wit 
vroue mag derhalwe betekenisvol bydra tot die laer heupfraktuur-risiko soos 
voorheen gerapporteer in SA swart vroue vergeleke met wit vroue.  Gemiddelde 
vertebrale grootte was egter kleiner in swart vroue en derhalwe by onvermoё om die 
skynbaar laer vertebrale fraktuur-risiko, vroeёr gedokumenteer in SA swartes, te 
verklaar. Etniese verskille in werwelafmetings (hoogte, wydte) en/of kwalitatiewe 
beenaspekte soos gesuggereer deur ons ultraklank data, mag aanleiding gee tot 
verskille in vertebrale fraktuur-risiko en voorkoms in ons swart en wit vroue – indien 
sodanige verskille inderwaarheid bestaan.   
7. Die aantal vroue met ‘n positiewe geskiedenis van valle was soortgelyk in ons swart 
en wit studiegroepe en veroudering is aangetoon om valrisiko te verhoog in beide 
etniese groepe. Ons studiedata suggereer moontlike verskille in die aard van valle 
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tussen postmenopousale swart en wit vroue, maar hierdie observasie benodig 
bevestiging in ‘n groter studie. Postmenopousale swart- en wit vroue met ‘n positiewe 
valgeskiedenis was meer waarskynlik osteoporoties as dié sonder enige vooraf valle.  
Swakker neuromuskulêre funksie, 25-OD-Vitamien D status en visuele kontras 
toetsing is aangetoon in ons postmenopousale swart vroue vergeleke met wit vroue. 
Ouer swart vroue was addisioneel ook minder aktief as wit vroue. Ten spyte van 
hierdie bevindings is ‘n verhoogde valneiging in swart vroue nie in ons studie 
aangetoon nie. Quadriceps swakheid en ‘n stadiger reaksietyd was aanduidend van ‘n 
verhoogde valrisiko in wit vroue, maar by onvermoë om te onderskei tussen swart 
vroue met ‘n valgeskiedenis en dié daarsonder. 
8. Vertebrale fraktuur voorkoms was soortgelyk in ons swart (11.5%) en wit (8.1%) 
studiepopulasie. Proksimale femoral beenmineraaldigtheid was die beste voorspeller 
van swart- en wit fraktuurgevalle in hierdie studie. ‘n Hele aantal ander risikofaktore, 
te wete, fisiese onaktiwiteit, alkohol-inname, swakker uitkomste met fisiese toetsing 
en ‘n langer heup-aksis lengte was meer algemeen  in die wit fraktuurgevalle en kan 
dus beskou word as merkers van verhoogde fraktuur-risiko, alhoewel nie direk 
geїmpliseer in die patofisiologie van osteoporose of ‘n valneiging nie. In teenstelling 
met hierdie observasie in wit vroue, is slegs laer femorale beenmineraaldigtheid as 
risikofaktor vir frakture in swart vroue geїdentifiseer. ‘n Aanname dat soortgelyke 
risikofaktore verantwoordelik is vir vertebrale frakture in swart- en wit vroue is dus 
foutief en behoort verder bestudeer te word. Ten spyte van laer 25-OH-Vitamien D, 
swakker uitkomste met fisiese toetsing, en laer fisiese aktiwiteitsvlakke kon ‘n 
verhoogde valneiging nie in swart fraktuurgevalle aangetoon word nie. Kalkaneale 
ultrasonografie en biochemiese parameters van beenomset was soortgelyk in swart- 
en wit fraktuurgevalle. Vertebrale fraktuur data gedokumenteer in hierdie studie 
waarsku dus teen die veronderstelling dat swart vroue beskerm is, en derhalwe ‘n lae 
risiko het vir die opdoen van vertebrale frakture, en beklemtoon die belang en 
nodigheid van verdere studies ten einde die huidige fraktuur prevalensie in die 
verskillende etniese groepe van SA beter te definieër.   
9. Ons studie-data toon dat hormoon terapie in wit vroue beensterkte parameters 
betekenisvol verbeter en ook lei tot ‘n verlaagde valrisiko. ‘n Hoër vertebrale en 
femorale DEXA gemete BMD, asook betekenisvolle hoër ultraklank parameters is 
gedokumenteer in die hormoon behandelde wit vroue vergeleke met nie-gebruikers 
van hormoonterapie. Biochemiese evaluasie van beenomset, soos gereflekteer deur 
serum osteokalsien-vlakke, was laer in die hormoon-gebruikers. ‘n Laer frekwensie 
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van valle, sowel as beter quadriceps spierkrag en ‘n verminderde laterale 
bewegingsneiging is ook aangetoon in ouer hormoon-behandelde wit vroue (> 60jr). 
Radiologiese bewys van vertebrale frakture was slegs genoteer in een van die 
hormoon-behandelde wit vroue (2%) vergeleke met 4 gevalle (6%) onder die nie-
hormoon gebruikers. Die skeletale impak van hormoonterapie op swart 
postmenopousale Suid-Afrikaanse vroue is onbekend en benodig verdere studie.    
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CHAPTER 1 
RESEARCH OBJECTIVES 
African-American females have a significantly lower fracture prevalence compared with white 
American females, which is readily explained by their higher bone mineral density (BMD) at 
all skeletal sites. The higher BMD is primarily the result of higher peak bone mass 
attainment, but  a lower bone turnover and reduced early postmenopausal bone loss further 
enhance this difference by ensuring better preservation of the already higher peak bone 
mass in the African American.  
South African blacks also have a very low hip fracture prevalence. In contrast to the 
American data, BMD is not consistently higher in Black versus white South African females. 
In the only recent study of adult female South Africans, employing sophisticated techniques 
to measure BMD1, similar appendicular and lumbar bone densities were noted. Femoral bone 
density was, however, higher in both pre-and postmenopausal black females. These findings 
are in keeping with studies elsewhere on the African continent where bone mineral content 
(BMC) and bone mineral densities were noted to be similar or lower in Africans compared to 
white Europeans despite a paucity of fractures in the former. The rarity of fractures in these 
African communities, where BMC and BMD are low, challenges current concepts about the 
significance of bone mineral status as a primary determinant of fracture risk and imply the 
presence of other protective mechanisms that ensure skeletal integrity. 
This comparative study in black and white South African women specifically aimed to assess 
fracture risk by evaluating known determinants of bone strength as well as the propensity to 
falls. 
We specifically aimed to: 
1. Compare the prevalence of clinical (historic) risk factors, previously shown to 
predispose local Caucasian women to osteoporosis. 
2. Measure vertebral and femoral BMD (in pre- and postmenopausal women) employing 
DEXA, to confirm previous reports suggesting that lumbar BMD was similar in white 
and black South African women.   
3. Compare ultrasound variables (SOS, BUA, stiffness index) in black and white women, 
and to correlate these variables with BMD measurements (employing DEXA) made in 
the same patient. It has been suggested that speed of sound (SOS) primarily reflects 
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bone mass and that broadband ultrasound attenuation (BUA) is a parameter of 
porosity and bone quality2. While ultrasound seems to reflect many of the same 
influences as bone mass (e.g. age, menopause, exercise), it may also provide 
information about bone “quality” and could therefore complement BMD data. 
4. Measure serum parathyroid hormone (PTH) and 25-OH Vitamin D, mineral 
homeostasis and modern biochemical markers of bone turnover (serum osteocalcin, 
urine deoxypyrodinoline) to determine whether our black population’s low fracture 
risk might be ascribed to a lower bone turnover and relative skeletal resistance to 
PTH.  These biochemical parameters will also be correlated with BMD and ultrasound 
data in the same patient. 
5. Compare bone geometry (e.g. hip axis length) in white and black women. A longer 
HAL has been reported in whites3-6. 
6. The propensity to falls will be compared in black and white women, employing a 
standardized questionnaire and physical examination, as well as a number of 
validated tests to assess muscle strength, reaction time, body sway and visual 
contrast sensitivity. 
7. Determine the prevalence of vertebral fractures in these black and white South 
African females. 
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CHAPTER 2 
LITERATURE REVIEW 
A GENERAL OVERVIEW 
1. BACKGROUND 
Osteoporosis is a common, costly and serious systemic skeletal disorder and is expected to 
increase in significance with the growing elderly population. The condition affects both sexes 
and all races, albeit to different degrees. Osteoporosis predominantly affects 
postmenopausal Caucasian females. The disease is characterized by low bone mass and 
qualitative micro-architectural alterations of bone tissue leading to enhanced bone fragility 
and increased fracture risk. The most serious consequence of osteoporosis is hip fracture 
with significant morbidity (less than 50% able to function independently) and mortality 
(~20% die within 1 year of the event)7-11. 
Osteoporosis is a silent disease until complicated by fracture. Clinical application of bone 
densitometry has made it possible to diagnose osteoporosis before the first fracture has 
occurred. Bone mineral density (BMD) is strongly correlated with bone strength in vitro and a 
good predictor of future fracture risk. Since the relationship between bone density and 
fracture risk is a continuous one, similar to that between blood pressure and stroke, the 
choice of a BMD-value to define osteoporosis is necessarily somewhat arbitrary.  
In 1994, the World Health Organization (WHO) selected a BMD value of 2.5 standard 
deviations (SD) or more below the mean for normal young white women, or a T-score  
of ≤-2.512, to define osteoporosis in the white post-menopausal female population. This cut-
off value was based on epidemiologic fracture threshold data which captures most women at 
risk of osteoporotic fracture (hip, vertebrae, forearm, humerus and pelvis). The relationship 
between low BMD and fracture risk is, however, a gradient and not a threshold. Therefore 
this classification was extended to include a subset of patients with osteopenia (BMD more 
than 1 SD, but less than 2.5 SD below young normal mean) in whom the presence of 
additional risk factors other than BMD may lead to increased fracture risk13 (table 1).  
 8 
Table 1: Definition of osteoporosis:  
 
Adapted from World Health Organization Study Group,1997 13 
2. THE WORLD-WIDE EPIDEMIOLOGY OF OSTEOPOROTIC 
FRACTURES  
As the average age of the world’s population increases, the incidence of osteoporosis and its 
economic burden on society will increase further. Worldwide, approximately one-third of 
women aged 60-70 years and two-thirds of women aged 80 and older have osteoporosis14. 
The percentage of patients with osteoporosis increases progressively with age – 13% of US 
women in their 50’s, 27% in their 60’s, 47% in their 70’s and 67% in their 80’s meet the 
diagnostic criteria for osteoporosis15.  
Fragility fractures are projected to increase as well, because of larger numbers of persons at 
risk and age-specific increases in fracture incidence. The US surgeon general’s report on 
bone health and osteoporosis noted that 1 in 2 individuals older than 50 years will be at risk 
of sustaining an osteoporotic fracture16.  Estimates indicate that the number of osteoporotic 
hip fractures occurring in the world each year will rise from the estimated 1.66 million in 
1990 to 6.26 million by the year 205017, thereby implying an urgent need for preventative 
strategies. 
The overall prevalence of osteoporotic fractures rises dramatically in menopausal women. 
Bone loss is more abrupt for the first decade after the onset of menopause, followed by 
more gradual loss thereafter18. The incidence of hip fractures increases exponentially with 
age, particularly after age 70, and is most commonly seen in white women19 in developed 
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countries (figure 1). In developing countries, the gender difference in hip fracture incidence 
is largely eliminated20. 
 
Figure 1: Age-specific incidence for hip, vertebral and distal forearm fractures in women.  
Adapted from Cooper et al, J Bone Miner Res 1992; 7: 221—22719 
Hip fractures occur in about 32% of Caucasian women21,22. A Caucasian women’s risk of a 
hip fracture equals the combined risk of breast, uterine and ovarian cancer, and the risk of 
dying of hip fracture is equal to that of breast cancer23.  
3. PATHOGENESIS OF OSTEOPOROSIS AND FRACTURES 
The two main ethiopathogenetic factors involved in the development of skeletal fracture are 
decreased bone strength and increased risk of trauma and falls.  
3.1. BONE STRENGTH 
Osteoporosis is defined by the NIH as a systemic skeletal disorder characterized by 
compromised bone strength predisposing to an increased fracture risk24. Bone strength is a 
function of BMD and bone quality. 
3.1.1. Bone mineral density (BMD) 
BMD is an excellent predictor of bone strength and fracture risk at all skeletal sites. Ex vivo 
studies performed on human material have indicated a good correlation between BMD and 
bone strength (femoral neck, r=0.77, 0.84; vertebrae, r=0.66, 0.86) as evaluated by 
mechanical tests of the femoral neck25,26 or uni-axial compression testing of the  
vertebrae27-29. These studies indicated that BMD predicts approximately 66-74% of the 
variation in bone strength. As BMD declines, fracture risk increases in a predictable manner. 
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A decrease of 1 SD in BMD results in a doubling of fracture risk, irrespective of fracture type 
and site of BMD measurement30. In recent years, BMD testing has become more widely 
available and many countries have developed guidelines regarding testing. There is general 
agreement that a BMD measurement is indicated in individuals with clinical risk factor(s). 
The United States Preventative Services Task Force recommends that all women ≥ 65 years 
should be screened with DEXA irrespective of risk factors31.  According to UK32 and SA33 
guidelines, routine BMD screening is, however, not deemed cost-effective and the prevention 
and treatment of osteoporosis are thought to be best managed using a case finding 
approach employing specific risk factors. 
3.1.1.1. Pathogenesis of a low bone mass 
Changes in bone mass are brought about by an imbalance between bone resorption and 
bone formation, processes that are normally tightly coupled. Once peak bone mass has been 
reached in the third decade of life, bone resorption generally outstrips bone formation, and 
there is loss of skeletal mass.  There are thus two major pathogenetic reasons for low bone 
mass i.e. failure to achieve an optimal peak bone mass or increased bone loss after peak 
bone mass has been reached. Each can have genetic and environmental causes. 
(i) Failure to achieve an optimal peak bone mass 
Although peak bone mass is largely (±70%) genetically determined, it can be substantially 
affected by environmental factors such as poor nutrition, especially low calcium intake34-37 
and little physical activity during skeletal growth38-40. Peak bone mass can also be affected by 
alterations in gonadal hormones from a variety of causes, including delayed onset of 
puberty41,42, excessive exercise43-47, anorexia nervosa48,49  and hyperprolactinemia50,51. 
(ii) Increased Bone loss 
(a) Increased bone resorption 
Oestrogen-deficiency is a major factor contributing to increased bone resorption in women, 
especially after the menopause, and in ageing men as well52,53. During the menopausal 
transition in women, which is associated with dramatic reductions in circulating oestrogen 
levels, there is an increase in the rate of bone remodelling and an imbalance between 
formation and resorption within each bone remodelling unit. This imbalance appears to be 
due to aggressive osteoclastic resorption, with an increase in resorption cavity depth and an 
inability of osteoblasts to keep pace.  Calcium and vitamin D deficiency and reduced calcium 
absorption in older individuals, leading to parathyroid hormone excess, may contribute to 
bone loss54.  
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(b) Inadequate bone formation 
This may be due to complete loss of skeletal elements by excessive resorption, so that there 
is no template on which to form new bone, to age-related impairment of osteoblast function 
or to changes in local and systemic factors that regulate bone formation. 
3.1.1.2. Cellular control of bone mass 
(i) Regulation of bone resorption 
Bone resorption is controlled by a complex interaction of cells of the osteoblastic and 
osteoclastic lineages. Osteoblasts appear to control the activity of osteoclasts and may be 
the primary regulators of both bone formation and resorption.  
(a) Stimulation of osteoclastogenesis and bone resorption  
Osteoclasts are recruited from hematopoietic precursors as a result of interaction with cells 
of the osteoblastic lineage55. Osteoclast recruitment is effected by the expression of an 
osteoclast differentiation factor known as RANK-L (receptor activator of NF-Kβ-ligand) by 
cells of the osteoblastic lineage. RANK-L binds to a receptor (RANK) located on the surface of 
osteoclast precursors to initiate osteoclastogenesis56. Osteoblasts also produce macrophage 
colony stimulating factor (M-CSF) which enhances the replication of osteoclast precursors via 
its action on the c-fms receptor.  Numerous other local factors also lead to expansion of the 
osteoclastic pool due to increased osteoclast formation and elongation of their life-span57,58. 
These cytokines include TNF (tumour necrosis factor), prostaglandin E2, Interleukin (IL)-1 
and IL-6 and are well recognized to stimulate bone resorption. Estrogen prevents bone loss 
by blocking the production of these pro-inflammatory cytokines. There is now substantial 
evidence supporting the hypothesis that a network of estrogen-regulated cytokines 
(especially TNF and IL-1) is responsible for the changes in bone turnover, increased bone 
resorption and the loss of bone induced by estrogen deficiency59-61. 
Systemic hormones known to control bone metabolism, most notably parathyroid hormone 
(PTH) and 1,25 dihydroxy-vitamin D, do not generally act directly on the osteoclast, but 
interact with receptors on the stromal/osteoblastic cells that support them and have been 
shown to enhance RANK-L expression62,63. Recently Dempster et al demonstrated the 
presence of functional PTH-receptors on human osteoclasts suggesting that PTH may 
mediate bone resorption both indirectly (via OB) and directly (via OC)64. Glucocorticoid 
exposure is known to stimulate osteoclastic bone resorption indirectly, by causing a negative 
calcium balance (impaired intestinal absorption, increased renal calcium wasting) and 
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secondary hyperparathyroidism. Chronic glucocorticoid exposure is, however, characterized 
by inhibition of osteoclastogenesis65. 
(b) Inhibition of osteoclastogenesis and bone resorption 
Inhibitors of bone resorption can act through the osteoblastic and osteoclastic lineages. 
Osteoprotegerin, another osteoblast-derived cytokine and member of the TNF family, inhibits 
differentiation of osteoclasts by acting as a decoy receptor – it binds RANK-L and prevents its 
interaction with RANK56. 
It is well documented that oestrogen, the most important systemic inhibitor of bone 
resorption, reduces the number of osteoclasts in vivo, probably by suppressing osteoclast 
formation. Estrogen acts through altering cytokines such as IL-1, IL-6 or TNF-α as 
mentioned before, but there is also evidence for a direct action on osteoblasts to increase 
OPG production66, and on osteoclasts to enhance osteoclast apoptosis67. The other 
circulating inhibitor of bone resorption, calcitonin, acts largely by direct inhibition of 
osteoclasts, which express receptors for this hormone68.  
(ii) Regulation of bone formation  
Inadequate bone formation may result from:  
(a) Too little scaffold / template 
Excessive bone resorption may lead to complete loss of skeletal elements, so that there is no 
template on which to form new bone. 
(b) Senescent osteoblasts 
Part of the pathogenesis of osteoporosis is the inability of bone formation to keep pace with 
the increase in age related bone resorption. Some osteoporotic patients, however, could 
primarily have low bone formation rates, which could result in bone loss. 
(c) Local and systemic factors  
IGF-1 has been proposed as a candidate in the pathogenesis of  
osteoporosis69-71. Circulating IGF-1 decreases with age, and there is some clinical association 
between osteoporosis and low IGF-1 in serum. Insulin is also an important mitogen with 
decreased BMD documented in patients with absolute insulin deficiency (type 1 diabetes 
mellitus), and normal to high BMD noted in insulin resistance states with hyperinsulinism72. 
Sex hormone deficiency may play a role in impaired bone formation. There is evidence that 
both oestrogen and testosterone can increase bone formation73-76, although they may 
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indirectly diminish the overall rate of bone formation secondary to their inhibitory effects on 
bone resorption. Glucocorticoids inhibit bone formation via its effect on osteoblast 
proliferation and osteoblast survival (increase osteoblast apoptosis and increase 
transdifferentiation of osteoblasts to fat cells). Both thyroid hormone, as well as intermittent 
low dose PTH increase osteoblast proliferation and may enhance bone formation.  Leptin, an 
adipocyte derived hormone, has been recognized as a mediator of many biological processes 
and has also emerged as a potential regulator of bone  
metabolism77-79. Findings from in vitro studies have suggested that leptin enhances 
osteoblastic differentiation and inhibits osteoclastic generation via local mechanisms77,78. 
Cross-sectional studies in humans have, however, yielded contradictory results, varying from 
no association between BMD and leptin80 to a positive relationship that persisted81 or did not 
persist82,83 after adjustment for body mass index (BMI) or fat mass. Other studies found 
negative associations84,85. 
In 1965, Marshall Urist discovered that the extracellular matrix of bone contains a substance 
that has the capacity to induce new bone formation when implanted into extraskeletal 
sites86. Over the past fifteen years, investigators elucidated the molecular genetics of bone 
morphogenetic protein (BMP) biology and identified fourteen individual human BMP’s (BMP 
2–15) possessing varying degrees of cartilage and or bone inductive activities87,88. Clinical 
trials are currently conducted to evaluate the ability of certain BMP’s to induce/ promote 
fracture healing and spinal fusion in view of their osteogenic properties. 
(d)  Transdifferentiation of osteoblasts 
Impairment of bone formation during remodelling could occur, not only because of 
diminished cell function or a change in local regulators of osteoblasts, but also because the 
stromal cell population that normally gives rise to osteoblast precursors is diverted along 
another differentiation pathway i.e. is converted to adipocytes by activation of the PPAR-γ 
receptor89. 
3.1.1.3. Genetic determinants of susceptibility to osteoporosis and fracture 
(i) Peak bone mineral density (PBMD) 
Studies on the genetics of osteoporosis have focused mainly on the regulation of bone 
mineral density (BMD), a major determinant of osteoporotic fracture risk.  The majority of 
studies have concentrated on peak bone mass in females and have shown remarkably 
consistent results. Evidence for a genetic contribution to PBMD regulation comes primarily 
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from twin studies. The heritability of BMD at the spine and hip has been estimated to lie 
between 70-85%, with values of 50-60% for wrist BMD90-93.   
Genetic modelling has suggested that BMD is a polygenic trait and various candidate genes 
have been implicated in the regulation of BMD (table 2).  These include polymorphisms in 
the genes that encode collagen, the estrogen receptor, TGFβ, IL-6 and the Vitamin D 
receptor94-101. The vitamin D receptor (VDR) alleles defined by BsmI, ApaI, TaqI and FokI 
restriction fragment length polymorphisms (RFLP) have been shown to be associated with 
variations in BMD in Australian101, black and white North American99, Japanese96, Mexican97 
and other premenopausal women.  
The effect of the VDR genotype on BMD appears to be greatest, although not exclusively, in 
young adulthood, and declines in the elderly unless confounding factors (e.g. years since 
menopause, body mass etc.) are corrected97. A meta-analysis in 1996 concluded that the 
VDR genotype was associated with modest effects on BMD, amounting for a difference of 
about 0.15-0.20 Z-score units between genotypes102. The authors of a recent prospective 
multicenter large-scale association study including 26 242 participants concluded that the 
BsmI, ApaI, TaqI and FokI VDR polymorphisms are not associated with BMD or with 
fractures, but the CdX2 polymorphism may be associated with  risk for vertebral fractures103. 
The genes encoding type 1 collagen (COLIA 1 and COLIA 2) are important candidates for the 
pathogenesis of osteoporosis. The COLIA1 Sp1 polymorphism is associated with reduced 
BMD and predispose to incident vertebral fractures independent of BMD104. Significant ethnic 
differences have been reported in the population prevalence of COLIA 1 Sp1 alleles, it is 
common in Caucasian populations, but is rare in Africans and Asians105. This polymorphism 
may be of value as a marker of osteoporotic fracture risk, because it predicts fractures that 
are independent of BMD and interacts with BMD to enhance fracture prediction104,106. 
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Table 2: Candidate genes that have been studied in relation to bone mass. 
 
Adapted from Ralston SH et al.J Clin Endocrin Metab 2002; 87(6):2460-66107 
(ii) Bone loss 
Longitudinal studies of axial bone loss in perimenopausal women have shown that most of 
the variance is unexplained by environmental variables104. Although this suggests that 
genetic factors may also play a role in regulating bone loss, direct evidence in favour of this 
is conflicting90,108 and further work is required to determine whether genetic factors do 
contribute significantly to the regulation of bone loss.    
(iii) Fracture risk independent of bone mineral density 
In population based studies, a family history of hip fracture has been consistently shown to 
be a risk factor for fracture, independent of BMD109. Twin and family studies have also shown 
that genetic factors play a role in the determination of bone turnover110, skeletal 
geometry93,111, ultrasound properties of bone93, body mass index112, muscle strength113, age 
at menarche and age at menopause112,114. 
3.1.1.4. Clinical risk factors for low bone mineral density   
An individual’s peak bone mass attained and the subsequent bone loss that occurs with 
ageing determine his/her bone mineral density at any given time. A study on various sample 
populations’ show that about 50-85% of the variance in peak bone mass is attributable to 
hereditary factors90-93. The remaining variance in peak bone mass is caused by 
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environmental factors. Age-related bone loss is largely a function of osteoblast incompetence 
and the menopause. Lifestyle factors, drugs and diseases may augment the physiological 
osteopenia of ageing. 
(i) Clinical Risk factors 
Many risk factors for bone loss have been identified and are summarized in table 3. 
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      Table 3: SUMMARY: Clinical risk factors for bone loss 
CLINICAL RISK FACTORS FOR BONE LOSS 
NON-MODIFIABLE RISKS:  IMPACT ON BONE STATUS 
● INCREASING AGE The older, the more likely. Strongest known association with BMD 
and fracture 
● FAMILY HISTORY/GENETICS Positive, especially maternal 
● GENDER 
More in females. Hip fracture prevalence similar in men and women 
in developing countries 
● ETHNIC ORIGIN More in Caucasians and Asians, also mixed race population in RSA 
● HEIGHT Taller stature associated with higher BMD 
MODIFIABLE RISKS: 
 
● PREVIOUS FRAGILITY 
FRACTURE 
● LIFESTYLE: 
Markedly increased risk (3-5 fold) for subsequent fractures  
○ Dietary  Low calcium intake, Vitamin D 
Excess caffeine and protein (may be calciuric), protein malnutrition 
– fragile bone 
○ Smoking Mediated via changes in endogenous estrogen metabolism. 
○ Alcohol Positive association noted between moderate consumption and BMD 
in postmenopausal females, excessive intake (> 2U/day) has direct 
toxic effect and indirect adverse impact on bone health. 
○ Sedentary lifestyle Weight bearing has positive influence on skeleton, still subject of 
contention re bone loss in the postmenopausal years. Maintain 
muscle mass, reduce falls. 
● ANTHROPOMETRY:  
○ Body size:   Fat /Lean 
mass 
Rate of bone loss related to both variables, dependent on age and 
menopausal status 
○ Excessive leanness BMI < 19kg/m
2 
● GYNAECOLOGICAL VARIABLES  
○ Oral contraceptive use May have positive or negative impact on BMD  
○ Parity Conflicting data, effect of increasing parity may be positive, 
negative or absent 
○ Breast feeding (BF) Similar to parity, duration of BF may play role 
○ Age of menarche Younger age at menarche associated with higher BMD 
○ Menstrual cycle 
irregularities 
Oligomenorrhoea, amenorrhoea and lengthy cycles may have 
negative effects on BMD 
○ Menopause Oestrogen withdrawal following menopause associated with marked 
increase in bone loss 
○ Years post menopause 
(YSSM) 
BMD more dependent on YSSM than on the chronological age of the 
patient 
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(ii) Clinical prediction of OP and fracture 
Numerous epidemiological studies on the ability of clinical risk factors to predict the presence 
of osteopenia have found no consistent set of predictors for OP. In one of the most 
comprehensive investigations to date, the determinants of bone density were assessed 
cross-sectionally in the Study of Osteoporotic Fractures, a cohort of over 9500 elderly White 
and Asian women115 (table 4). Risk factors for reduced axial and appendicular (radial and 
femoral) bone density were analysed separately. 
Table 4: Risk factors (-) and Protective factors (+) for axial and appendicular bone density among elderly white 
women 
Variable Lumbar spine Femoral neck Distal radius 
Age  -- -- 
Weight +++ +++ +++ 
Height ++ ++ ++ 
Fracture in mother -- -- -- 
Age at menopause + + ++ 
Estrogen use +++ +++ +++ 
Quadriceps strength  ++  
Grip Strength   +++ 
Thiazide use +++ ++ +++ 
Current smoker    -- 
# of alcoholic drinks in lifetime +   
Dietary calcium intake  ++ + 
Lifetime caffeine intake   - 
Recent or past physical activity + +  
The strength of correlations from multivariate analysis is indicated by the number of symbols. Three symbols indicate > 3% 
change in bone density per unit change in the variable; two symbols a 1-3% change and one symbol a change of < 1%.  
Adapted from: Orwoll ES, Bauer DC, Vogt TM, et al. Ann Intern Med 1996; 124: 187-96 115 
Greater height and weight, older age at menopause, greater physical activity, and use of 
alcoholic beverages, diuretic treatment, and current oestrogen replacement therapy were 
associated with higher spinal BMD (SBMD), whereas later age at menarche and a maternal 
history of fractures were associated with lower SBMD values115. Increasing age was positively 
associated with SBMD in these ladies; probable because of associated degenerative spinal 
changes and false high SBMD readings on DEXA. Age was a risk factor for both low radial 
and femoral neck BMD.    
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Later age at menopause, estrogen or thiazide use, and greater height, weight, muscle 
strength and dietary calcium intake were all positively associated with distal radial BMD, 
whereas age, cigarette smoking, caffeine intake and maternal history of fracture were all 
negatively associated116. 
Femoral neck BMD was positively associated with most of the same protective factors, along 
with quadriceps strength and calcium intake. A maternal history of fracture and a personal 
history of previous wrist fracture correlated with low femoral neck BMD.   
Despite the large number of potential risk factors assessed in the Study of Osteoporotic 
Fractures, however, models incorporating all of the independent predictors together 
explained only 20% to 34% of the variance in bone density at the different skeletal sites116. 
In a population based study of 1600 perimenopausal females by Kröger and colleagues, only 
18.7–25.4% of the variance in BMD could be explained by current anthropometric and 
lifestyle factors117. 
Broussard et al118 identified a set of modifiable risk factors from published population based 
studies in white women and men and then determined the ability of these risk factors to 
predict osteoporosis and low BMD in a multi-ethnic population. The most frequently recurring 
statistically significant risk factors in addition to age were low BMI, inadequate dietary 
calcium intake, current cigarette smoking and low levels of physical activity. 
A single study by Blaauw et al in 1993119 identified a positive family history of OP, a fair  
complexion, lower body mass and height, no breastfeeding of babies, a history of smoking 
and fat distribution around the waist to be significant risk factors for OP in a subset of white 
South African females. 
To our knowledge no studies evaluating clinical risk factors for osteoporosis has been done 
in other SA ethnic groups, and thus no data exist regarding the performance of risk 
assessment tools in these groups. 
Numerous screening instruments based on clinical risk factors have also been developed to 
aid the assessment of osteoporotic risk in women120-126. These instruments facilitate 
identification of women most likely to have a low BMD, but cannot be used to diagnose 
osteoporosis and are not a substitute for BMD measurements125 (table 5).  
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Table 5: Instruments for estimation of risk of osteoporosis 
 
The threshold values for recommending BMD testing are shown next to the name of the instrument. The objective of the 
instrument is to identify four testing groups as specified, using risk factors  as shown in elements column. The performance of 
each instrument is evaluated by sensitivity and specificity. Adapted from: Wehren LE, Siris ES Journal of Internal Medicine 2004; 
256: 375–380125 
Age has the strongest known association with BMD and along with weight is included in all 
instruments. The prevalence of osteoporosis increases substantially with age, as reported in 
the Third National Health and Nutrition Survey (NHANES III)127 and shown in figure 2. These 
two variables have also been noted in other studies to be the most informative predictors for 
low bone mineral density126.   
 
 
 
 
 
 
 
 
Figure 2: Prevalence of low bone mass (osteopenia, shown in dark bars) and osteoporosis (shown in grey bars) 
amongst women in the US by age group, based on BMD measurements at the femoral neck in NHANES III. 
Osteoporosis was defined as a T-score ≤ 2.5 and osteopenia as a T-score below -1.0 and above 2.5 in NHANES 
III.Adapted from Looker et al J Bone Miner Res 1995: 10: 96-802127 
A great deal of work remains to be done before patients at high risk of osteoporosis can be 
identified on the basis of clinical risk factors only. Until that time, clinical risk factors may 
help the physician to identify a subset of patients for densitometric evaluation.  
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(iii) Known causes of excessive bone loss – the so called secondary osteoporoses 
Primary osteoporosis’ is often used to describe the condition in postmenopausal women and 
older subjects in whom no specific pathogenetic mechanisms other than estrogen deficiency, 
calcium deficiency, and age can be identified. ‘Secondary osteoporosis’ is used when specific 
pathogenetic mechanisms, such as systemic diseases and drugs are present. Osteoporosis, 
similar to other chronic degenerative diseases, is however often a multifactorial disease.  
Clinical risk factors and secondary causes of excessive bone loss may thus both be present in 
the same individual and the clear distinction between primary and secondary disease is not 
always possible. It is also sometimes difficult to decide whether a specific factor i.e. 
excessive alcohol intake, is a risk factor or a secondary cause.  
Regardless of the terminology employed, it is very important that the physician attending the 
patient with osteoporosis should be aware of all contributors to excessive bone loss, 
including conventional risk factors as well as possible underlying pathological processes. 
These factors should be actively sought, especially in low risk individuals presenting with 
excessive bone loss, i.e. males and the young128,129 (figure 3). 
 
Figure 3: Prevalence of secondary osteoporosis in women and men with vertebral fractures Adapted from Caplan et al, J R Soc 
Med 1994; 87: 200-202 and Baillie SP et al, Age Ageing 1992; 21: 139-141128,129 
The most frequently encountered secondary causes of osteoporosis are systemic 
glucocorticoid therapy, hypogonadism, alcoholism, myeloma and skeletal metastases as 
tabulated in table 6.  
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Table 6: Causes of Secondary Osteoporosis 
SECONDARY OSTEOPOROSIS 
ENDOCRINE 
Premature hypo-oestrogenemia 
Hypercortisolism 
Male hypogonadism 
Hyperthyroidism 
Type 1 Diabetes Mellitus 
Hyperprolactinemia 
DRUGS and TOXINS 
Glucocorticoids 
Chronic alcoholism 
Anticonvulsants 
Excessive thyroid hormone replacement 
Heparin  
Chemotherapy, Lithium, GnRH antagonists 
MALIGNANCY 
Multiple myeloma 
Solid tumours 
GASTRO-INTESTINAL DISEASE 
Inflammatory bowel disease 
Celiac disease 
COLLAGEN DISEASES 
Osteogenesis Imperfecta 
Marfan’s 
Ehlers Danlos 
Rheumatoid Arthritis 
OTHER 
Malnutrition / eating disorders (e.g. Anorexia Nervosa) 
Transplantation 
Organ failure (lung, liver, kidney) 
Thalassaemia, Mastocytosis 
3.1.2. Bone Quality 
Bone strength is a function of both BMD and bone quality. Bone quality describes the set of 
characteristics that influence bone strength independent of BMD and include both structural 
and material properties. The structural properties of bone include its geometry (size and 
shape) and microarchitecture (trabecular architecture – orientation, thickness, spacing and 
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connectivity of the trabeculae and cortical architecture - thickness/porosity). The material 
properties of bone include its mineral and collagen composition as well as the number, size 
and localization of microdamage.  The bone turnover rate is a function of the bone renewal 
process (modelling and remodelling) in which old or damaged bone is resorbed and new 
bone is created to replace it. An imbalance of bone turnover may significantly impact on all 
qualitative aspects of bone (figure 4). 
 
Figure 4: Factors that influence bone quality 
3.1.2.1. Bone quality and fracture risk 
At any given BMD, fracture risk may be modified by a set of BMD-independent determinants 
via their ability to impact on bone quality (table 7).  
Table 7: BMD-independent determinants of bone strength 
Determinants  
Age 
Genetics 
Ethnicity 
Bone Turnover status 
Previous fragility fractures 
Drugs and toxins (glucocorticoids, alcohol) 
 
 
BONE STRENGTH = BMD + BONE QUALITY 
BONE QUALITY 
 
MICRO-ARCHITECTURE AND GEOMETRY 
 
 
BONE TURNOVER 
  
 
    
 
 
MINERALIZATION        DAMAGE ACCUMULATION 
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(i) Age 
Fracture risk increases as a function of age130 (figure 5). Numerous adverse qualitative 
changes affect bone with ageing. Trabecular micro-architecture suffers progressive 
disruption with age due to a decline in trabecular thickness, a reduction in trabecular number 
and an increase in trabecular separation due to plate perforation131. Perforation of horizontal 
trabeculae that occurs predominantly in postmenopausal females132 along with the other 
qualitative changes may lead to a loss of bone strength which is disproportionate to the 
decrease in bone mass. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Baseline BMD and fracture risk.  
Adapted  from Cummings SR et al,  
JAMA 2002;288:1889- 1897130 
(ii) Genetics 
Osteoporosis and fracture risk is partially genetically determined. Certain genetic variants 
have been described that influence fracture risk independent of BMD and include the COLIA1 
Sp1 polymorphism and TT genotype and the VDR CC genotype, the Cdx2 polymorphism and 
others102-104,106. A parental history of fracture (especially hip fracture) confers an increased 
risk of fracture that is independent of BMD133,134. The mechanisms by which these genetic 
variants influence bone strength remain to be determined.  
Vertebral  
fractures 
Non-spine, low 
trauma fractures 
Hip fractures 
T-Score 
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(iii) Ethnicity 
Since a reduced absolute fracture risk at a given BMD has been documented in blacks135,136, 
it implies that factors other than BMD affecting bone fragility may also differ amongst 
different ethnic/race groups. These factors may include differences in inherent skeletal 
structure137, bone turnover rates138-142 and calcium and mineral homeostasis138-147. 
(iv) Bone Turnover 
Bone turnover is achieved by the process of bone remodelling. Remodelling occurs in both 
cortical and trabecular bone. Under normal circumstances the temporal sequence is always 
that of resorption followed by formation with these processes tightly coupled and balanced 
to ensure that the amount of bone resorbed and formed within individual bone remodelling 
units are quantitatively similar. An imbalance of bone turnover may significantly impact on 
bone quality. 
(a) High bone turnover 
In a high turnover state: 
(i) if the rate of resorption outstrips that of formation, more bone is removed in each 
remodelling cycle than is replaced and thus may result in a nett loss of bone.  
(ii) irreversible micro-architectural changes148,149, due to an increase in the number and 
depth of resorption cavities within the skeleton may occur.  Increased resorption may 
lead to thinning and even perforation of trabeculae with permanent loss of trabecular 
connectivity, thereby markedly compromising skeletal integrity and strength. It is 
especially loss of trabecular horizontal links that occur, thereby reducing bone 
strength. Thinning and increased porosity of cortical bone are also potential 
consequences of a high turnover state rendering bone more susceptible to injury.  
(iii) reversible structural changes also occur. Resorption cavities result in stress risers 
(figure 6), areas in trabecular bone that are thinner and thus prone to mechanical 
failure when loaded150.  
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Figure 6: Diagrammatic representation of stress risers in trabecular bone. In osteoporotic bone in which 
horizontal trabecular have   been lost, (shown on the right side of the figure) stress is concentrated in the 
vicinity of resorption cavities, and fractures occur, as indicated by the heavy black lines. In normal bone on the 
left, in contrast, cross-bracing from the horizontal trabeculae stabilizes the vertical trabeculae despite the 
presence of resorption cavities.Adapted from Parfitt et al (1991)150.  
(iv) mineralization may be impaired. A greater degree of mineralization of trabecular bone 
leads to greater stiffness and compressive strength. Secondary mineralization in newly 
formed bone may take years to complete and in states of high turnover there is a 
disproportionate increase in poorly mineralized bone rendering bone weaker and 
softer.   
(b) Severely Suppressed Bone Turnover    
Chronic over suppression of bone turnover, as a consequence of long-term antiresoptive 
therapy, may potentially impair some of the biomechanical properties of bone216-219. Potent 
inhibition of bone formation may result in increased mineralization and accumulation of 
microdamage. Hypermineralization render bone more “brittle’ and may contribute to reduced 
fracture toughness. In experimental animals marked suppression of bone turnover by 
pharmacological doses of bisphosphonates resulted in microdamage accumulation with 
associated reduction in bone toughness (the ability to sustain deformation without 
breaking)151,152.  Histomorphometric analysis in nine patients, who sustained spontaneous 
non-spinal fractures on long-term bisphosphonate therapy, showed markedly suppressed 
bone formation. This excessive suppression of bone turnover may affect biomechanical 
competence of bone and potentially increase susceptibility to fracture153,154. Recently 
bisphosphonate therapy has also been linked to painful refractory bone exposures in the 
jaws (osteonecrosis)155.  
(v) History of fragility fractures 
When patients are matched for BMD, those who have already sustained a fracture are at 
higher risk of sustaining another fracture; and, the greater the number of prevalent fractures 
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the greater is that risk, implying that some skeletons are inherently more fragile than others. 
That is, they have poorer bone quality than others at any given BMD (table 8). In fact, the 
most important risk factor for fracture, independent of bone mineral density and age, is a 
previous fragility fracture156-158. 
Table 8: Fracture risk and the presence of previous fragility fractures 
Number of Prevalent Vertebral fractures Incidence (%) Odds Ratio 
0 3.8 1.0 
1 8.9 1.9 
2 19.4 4.2 
3-4 30.8 5.6 
5+ 54.2 16.4 
Adapted from Nevitt MC, et al  Bone 1999 25: 613-619156 
(vi) Drug trial data (anti-resorptive agents) 
Anti-resorptive agents vary in their ability to increase BMD (1-8%), yet are quite similar (35-
40%) in their ability to lower vertebral fracture risk.  In other words, the reduction in 
fracture risk is not proportional to the change in BMD. This is once again indicative that 
factors other than absolute bone mass (e.g. reduction in trabecular plate perforation, 
improved bone mineralization in undermineralized bone) are modified by these agents and 
thus influence bone strength and future fracture risk159 (figure 7). 
 
Figure 7:  Change in BMD versus reduction in vertebral  
fracture  risk.  Adapted from Marcus R et al Endocrin  
Rev 2002; 23: 16-37159 
3.1.2.2. Bone geometry 
Fracture risk can also be affected by the macro-architecture of bone. Differences in the 
width, length and angle of the femoral neck may affect hip fracture risk160-166, whereas 
differences in vertebral body size may influence vertebral fracture risk167. 
Lumbar Spine (BMD) Incident Vertebral Fractures 
Relative  
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Numerous studies have shown a relationship between femur neck axis length or hip axis 
length (HAL) and risk of hip fracture, independent of bone mineral density status. Other 
geometric variables also noted to influence hip fracture risk include femoral neck width and 
the femoral neck-shaft angle. Studies have demonstrated that reduced thickness of the 
femoral neck, a wider intertrochanteric region and a longer hip axis length are predictive of 
hip fracture160-166. Analyses of results obtained in the study by Faulkner et al166 showed a 
near doubling of the risk of hip fracture with every SD increase in hip axis length. 
It has also been suggested that the intertrochanteric-head centre distance, a segment of the 
longer hip axis length, is an even better predictor of hip fracture risk than HAL per se163.  A 
larger femoral neck-shaft angle has also been implicated in hip fracture risk161.  Identifying 
women at high risk of hip fracture is likely to be substantially enhanced by combining bone 
density with data on the structural geometry of the hip.  
Vertebral bone size has been found to be reduced in women with spinal fractures167.  Smaller 
vertebral bone size was observed when patients with vertebral fracture were matched with 
controls with the same areal BMD. 
3.2. FALL RISK 
Bone density at the age of 75 is only about 4% lower than at the age of 65109. The incidence 
of hip fracture, however, is about four times as great at 75 as at 65 years and 12 times as 
great at 85 years. This increase is not primarily due to further loss of bone, but rather to a 
large increase in the risk of falling at more advanced ages. The increased propensity to fall 
and loss of protective responses constitute further role players in the ethiopathogenesis of 
osteoporotic fractures. Hip fractures occur almost exclusively after a fall, spontaneous hip 
fractures without prior falling is extremely rare.  About 90% of hip fractures in elderly people 
result from a fall168. A history of recent falls is a major contributing factor to the occurrence 
of symptomatic fractures in postmenopausal women, independent of and additive to the risk 
attributable to age and osteoporosis168-172. 
Epidemiological data have revealed that some 50% of osteoporotic patients have muscle 
loss/weakness (“sarcopenia”), 30% have postural hypotension and many have poor visual 
acuity or problems with depth perception, cognitive dysfunction or use drugs that may 
predispose to falls173-178. The skeletal protection provided by drugs such as estrogen, may be 
ascribed in part to their ability to improve reaction time which decreases the propensity of an 
individual to fall176.  
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B OSTEOPOROSIS IN AFRICAN-AMERICAN WOMEN 
1. BACKGROUND 
The prevalence of osteoporosis and minimal trauma fractures is thought to be substantially 
lower in people of African ancestry compared to Caucasians as shown by studies on the 
African Continent and in the United States of America. 
Osteoporosis and its consequences, however, is a real risk for any ageing women with an 
exponential increase in fracture risk associated with advancing age. The increase in fracture 
risk is expected to be more pronounced in developing countries of Asia and Africa, with a 
high population growth rate, versus developed first world countries14. As the world 
population ages, a significant number of black females across the world is expected to be 
affected by this potentially debilitating disease. Moreover, the impact of hip fracture is 
particularly devastating in black women, because the mortality and disability after fracture 
are higher than amongst white women179.  
Specific diagnostic criteria for osteoporosis in premenopausal females, men and blacks have 
not been formally established as the WHO-criteria were originally designed specifically for 
evaluation of postmenopausal White females12,13. The relationship between BMD and fracture 
risk is similar in women and men, even though gender differences in bone size and geometry 
cause men’s bones to fracture at a higher mean areal BMD than that of women180. The use 
of a young adult male mean reference to determine BMD T-scores produces estimates of 
osteoporosis occurrence that are more consistent with current fracture rates in men180,181. 
Based on such data, an international consensus development panel recommended that T-
scores in men be derived from a male normative data source182. 
Older African-American women have higher mean BMD values compared with whites. The 
use of race/ethnic specific T-scores in African-Americans would thus yield a higher 
prevalence of osteoporosis in this ethnic group than that calculated when white reference 
data are used. A recommendation regarding the use of race/ethnic group-specific T-scores 
can, however, not be made due to a lack of fracture data from various race/ethnic groups.  
The use of white women as a reference for all persons in a multi-ethnic population may well 
not be appropriate, but until these ethnic specific reference ranges become available, current 
clinical recommendation is to diagnose osteoporosis among blacks and other ethnic groups 
at or below a  T-score threshold of -2.5 using the uniform normative database for whites183. 
 30 
2. BONE STRENGTH 
2.1. Bone Mineral Density (BMD) 
Numerous studies have looked at BMD status in the African American population. Populations 
studied have included children, men and premenopausal, perimenopausal and 
postmenopausal females. Skeletal sites evaluated include the distal forearm, lumbar spine, 
proximal femur and the total body. Bone mineral density in these populations has also been 
assessed by various techniques, namely radiogrammetry, single photon absorptiometry, dual 
energy X-ray absorptiometry, quantitative computed tomography and ultrasonography.  
Higher BMD values at all skeletal sites have been repeatedly and consistently documented in 
African Americans (AA) compared to whites135,138,139,143-145,184-199. In the most recently 
published study, Finkelstein and co-workers199 studied BMD in a large multi-ethnic population 
including amongst others African-American and Caucasian females. Consistently higher BMD-
values were documented in the African-American compared to the Caucasian females.  
2.1.1. Methodological Considerations 
There is always concern, when comparing subjects from different ethnic and racial groups 
and thus potentially different body and bone size, that the observed difference in areal BMD 
is largely accounted for by these differences and thus more apparent than real. Assuming 
that bone mass acquisition increases in proportion to the skeletal bone volume, the 
traditional two-dimensional BMD measurement will tend to overestimate the BMD of 
taller/larger subjects while underestimating the BMD of shorter/smaller subjects (figure 8)200.  
 
Figure 8: Effect of specimen size on commonly measured bone mineral parameters. Using projected 
densitometry techniques one identifies a region of interest, or projected area, which is equal to the area of the 
front face of the sample. The bone mineral content (BMC) is the total amount of bone mineral (g) in the sample. 
An areal density (g/m2), bone mineral density (BMD) is calculated as BMC/ over projected area. Both samples 
have identical volumetric densities; however, the BMD of the larger sample is twice that of the smaller 
sample.Adapted from Carter et al. J Bone Miner Res. 1992; 7 (2): 137-145200 
2 
2 
4 
1cm 2cm 
1 
Volumetric bone density( g/cm3) 1.0 1.0 
Projected area (cm2)   2.0 8.0 
Volume (cm3) 2.0 16.0 
BMC (g) 2.0 16.0 
BMD g/m2 1.0 2.0 
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In an attempt to minimize the effect of differences in bone size, BMD is often statistically 
adjusted for, using height and weight or body mass index. These indices are unfortunately 
poor surrogates for the actual size of the bone being measured. In view of abovementioned 
shortfalls, several investigators have suggested techniques to adjust bone mass 
measurements for volumetric differences in body size, and thus bone size. Carter et al200 and 
Katzman et al201 recommend using a volumetric calculation of bone mineral density at the 
lumbar spine and femoral neck respectively. This volumetric assessment is referred to as 
bone mineral apparent density (BMAD) and is based on the assumption that the volume of 
bone can be calculated from the DEXA determined areal measurements.  
 
Significant ethnic differences do, however, remain after adjustment for bone size (via 
correction for body size or via use of calculated volumetric 
assessments)135,138,143,185,187,191,193,195,198,199 in most studies comparing African-American and 
Caucasians, including the large study of Finkelstein et al(figure 9)199. 
                
                
Figure 9: Lumbar spine BMD (A), lumbar spine BMAD (B), femoral neck BMD (C) and femoral neck BMAD (D) in 
the entire SWAN cohort.  African-American women data illustrated by the brown bars and Caucasian data by the 
red bars. The green and blue bars represent data on Chinese and Japanese women respectively. Bars with 
different numbers are significantly different. BMD and BMAD values (A-D) for African-American women 
statistically significantly higher than Caucasian women (p<0.001). Adapted from Finkelstein et al. J Clin 
Endocrinol Metab. 2002; 87(7):3057-3067199 
BMAD 
Lumbar spine:    mean BMC / (mean area)3/2  (Carter200) 
Femoral neck:     mean BMC / (area)2  (Katzman201) 
A B 
C D 
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2.1.2. Peak bone mineral density (PBMD) 
Much of the difference in BMD between AA and whites arises during childhood and 
adolescence and the majority of studies indicate that the higher bone mass in AA women is 
due to the attainment of a greater peak bone mass by early adulthood185,186,190,191,193,196-199. 
The magnitude of the increase in vertebral bone mineral density has been noted to be 
markedly higher in black versus white children in the later stages of puberty contributing to 
the finding of higher PBMD in blacks190 (figure 10). 
      
Figure 10: Vertebral cancellous bone density, black and white girls and boys at each stage of sexual 
development. Values are the mean ± SE. *, p = 0.05;, †  p = 0.007. Adapted from Gilsanz et al, NEJM 1991; 
325 (23): 1597-1600190 
2.1.3. Age-related bone loss 
A slower rate of cortical and trabecular bone loss, especially in the early postmenopausal 
period, has been noted in blacks in some139,184,197, but not all144,194,196  studies and may 
positively enhance the already present skeletal advantage in blacks (figure 11) .  
 
 
 
 
 
 
Figure 11: Comparison of the rates of radial and vertebral bone loss in pre- and postmenopausal women. The 
numbers within the bars represent the number of women within each group. African-Americans: pre-vs. early 
postmenopause, p<0.01, pre- vs. late postmenopause, p<0.01; early vs. late postmenopause, p=NS; whites 
pre- vs. early postmenopause, p<0.01, pre- vs. late postmenopause, p=0.1; early vs. late postmenopause, 
p<0.01. Large green arrows indicate more pronounced bone loss in white women in early postmenopause. 
Adapted from Luckey et al;  JCEM 1996; 81(8) 2948-2956184  
Change in Radial Bone Density (g/cm/y) Change in Vertebral Bone Density (g/cm2/yr) 
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2.1.4. Clinical risk factors for low bone mineral density 
Early detection of osteoporosis through BMD measurement is essential to decrease the 
morbidity and mortality of osteoporotic fractures. One of the major clinical challenges of 
fracture prevention is the identification of patients who qualify for a BMD measurement.  
Universal BMD testing (mass screening) has been recommended by the American NOF for 
Caucasian women aged 65 years and older31. Mass screening of younger postmenopausal 
women is not recommended because there are few studies that address screening cost-
effectiveness or long-term benefits of drug treatment in this group. The IOF32 and NOFSA33 
guidelines recommend a case finding approach based on clinical risk factors. There is also at 
present no data as to what BMD levels should be considered thresholds for future fractures 
in black women. 
Most clinical/historic risk assessment tools are based on data obtained in white 
postmenopausal women. It is not known how well these tools would perform in a multi-
ethnic population of women.  Broussard and colleagues therefore specifically looked at 
potential modifiable clinical risk factors in a multi-ethnic population utilizing the study 
population of the third National Health and Nutrition Examination Survey (NHANES III)118. 
Modifiable risk factors assessed included a low body mass index (BMI), low calcium intake, 
current cigarette smoking and physical inactivity. Age, a low BMI, current cigarette smoking 
and physical inactivity, which predicted low BMD and bone loss in longitudinal and cross-
sectional population-based studies of Whites, also identify African-Americans and Mexican-
Americans with low BMD and osteoporosis. A low body mass index (BMI) was shown to be 
the strongest modifiable determinant of low BMD in all groups studied.  The risk estimates 
for osteoporosis strengthened in the presence of more than one risk factor in a given 
individual (table 9). 
Table 9: Age-adjusted estimates of risk or osteoporosis and osteopenia given the presence of one or more (1+) and two or 
more (2+) risk factors (low BMI, current cigarette smoking and physical inactivity) for AA, MA and white women (n = 2590).  
 
Adapted from: Broussard et al. Osteopor Int 2004; 15:349-360118 
A low BMI and a sedentary lifestyle were also identified in a study by Woodson et al202 as 
modifiable risk factors for osteoporosis in postmenopausal African-American females. A 
 34 
positive family history and a bilateral oophorectomy also contributed to the risk of 
osteoporosis in the black women. 
2.1.5. Clinical Significance of BMD measurements 
Despite consistently higher mean BMD values documented in African-American female 
cohorts compared to Caucasian female cohorts, there is considerable overlap in BMD values 
amongst individuals within these ethnic groups and a substantial number of elderly blacks 
has reduced bone mass. This implies that a significant percentage of black patients may still 
be at risk to develop osteoporosis and its consequences especially as the world population is 
expected to age (table 10)192. 
Table 10: Occurrence of osteoporosis, osteopenia and low BMD among African American, Mexican-American and 
white women aged 50-64 and 65-79 years from NHANES III. 
 
*Race/ethnic and white T-score were used. Adapted from Looker et al. Osteoporos Int 1998;8: 468-489192 
2.2. Bone quality 
A lower bone turnover and alterations of the Vitamin D-Endocrine system in blacks with 
better renal calcium conservation and decreased sensitivity to parathyroid hormone (PTH) 
have been proposed as explanations for their higher PBMD and the slower rate of 
postmenopausal bone loss. To what extent these differences in hormones and biochemical 
markers contribute to and influence bone quality is uncertain. Since a reduced absolute 
fracture risk at a given BMD has been documented in blacks135,136, it implies that factors 
other than BMD affecting bone fragility may also differ amongst different ethnic/race groups. 
These factors may include bone architecture, turnover rates and differences in calcium 
homeostasis. 
2.2.1. Micro-architecture and bone size 
Racial differences in trabecular architecture have been described. African-Americans have 
thicker trabeculae than whites at the spine and iliac crest141,142,191. A greater cross-sectional 
area of the long bones in the appendicular skeleton of black versus white children was 
documented by Gilsanz and colleagues191. The placement of cortical bone further from the 
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central shaft axis in blacks than whites may confer greater resistance to bending irrespective 
of BMD203. 
2.2.2. Bone Turnover and Calcium homeostasis 
Few studies have compared bone turnover between people of different ethnic groups (most 
comparisons are between Caucasians and African-Americans).  
Biochemical assessment of bone formation markers (osteocalcin and bone specific alkaline 
phosphatase in serum) and bone resorption markers (urinary deoxypyrodinoline, cross linked 
N-telopeptides of Type I collagen and hydroxyproline) suggest that bone turnover is either 
lower138,142,147,196  or similar142,144,145 in American blacks compared with whites. The reasons for 
these somewhat discrepant results are not apparent. Ethnic differences in skeletal size may 
influence these measurements and should be corrected for.  
A lower bone turnover in blacks, as shown in most of the studies, may be responsible for the 
slower postmenopausal decline in trabecular and cortical bone observed in this ethnic group. 
In addition to the protective effects of a higher peak bone mass, a lower turnover could 
contribute significantly to the lower risk of fractures in African-American women. 
Whilst numerous non-invasive studies of bone turnover in American blacks and whites have 
been reported, only a few histological studies have been performed140,141,204. Weinstein and 
Bell140 reported on bone histomorphometry in free living American subjects pre-labelled with 
tetracycline. The rates of mineral apposition and bone formation were significantly lower in 
the black than in the white men and women based on dynamic indices of bone remodelling. 
On the assumption that coupling between resorption and formation is maintained, the 
authors suggested that the expected lower rate of bone resorption would help maintain bone 
mass and explain the higher peak bone mass observed in blacks compared with whites. The 
number of subjects in each group was, however, small and data in men and women were 
combined. Parfitt et al141 studied a group of 142 healthy black and white women and also 
noted a lower bone formation rate in blacks compared to whites. Looking at healthy 
premenopausal women, Parisien and co-workers204 could not document any significant 
difference in bone turnover between blacks and whites. Significant differences in the 
mechanism of bone formation were, however, noted with a lower rate of mineralized matrix 
apposition within each remodelling unit and a longer total formation period in the black 
subjects. These differences might potentially enhance bone mineral deposition and help 
explain the higher bone mass and better bone quality in black than white women. 
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Compared with whites, studies have reported lower 25-OH Vitamin D, higher 1,25 OH-
Vitamin D, higher PTH levels and lower urinary calcium excretion rates in blacks138,143-147,196 .  
The lower levels of 25-OH Vitamin D observed in blacks are largely the result of reduced skin 
synthesis of Vitamin D precursors due to increased skin pigment, and lead to mild secondary 
hyperparathyroidism. The resultant higher PTH-levels are expected to increase osteoclastic 
activity and bone turnover in blacks. Findings of similar or lower bone turnover rates in 
African-Americans compared with whites, along with consistently higher BMD values, have 
thus prompted the theory of a relative skeletal resistance to the action of PTH in African-
Americans138,144,146,196. 
Studies in low income, elderly black and white individuals with secondary 
hyperparathyroidism (HPT) caution against the belief that this is a benign condition with no 
deleterious skeletal effects145. The prevalence of secondary HPT is higher in African-
Americans compared with Caucasian adults. Although bone turnover has repeatedly been 
shown to be lower in black versus white groups, bone turnover is higher and BMD lower in 
the subgroups of patients with secondary HPT in both black and white ethnic groups145 
(figure 12). 
 
Figure 12: Mean heel BMD adjusted for age, sex, weight, and use of a walking aid in black and white adults by 
normal (N: bars with diagonal lines) and hyperparathyroid (HPTH: solid bars) status. Error bars, SEM; asterisks, 
differences by PTH status within race/sex groups (p< 0.05); parentheses, sample sizes. Adapted from Harris et 
al. JCEM(2001); 86(8): 3801-3804145 
Combining the histological and biochemical data, we can conclude that bone turnover is 
similar or lower in African-Americans compared with Caucasian adults despite a higher 
prevalence of secondary HPT. This supports the theory of skeletal resistance to the actions 
of PTH in blacks. The resistance is, however, relative and secondary hyperparathyroidism is 
known to exert deleterious skeletal effects in all ethnic groups.  
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2.2.3. Bone Geometry 
Worldwide data suggest that a longer hip axis length (HAL) or femur neck axis length (FNAL) 
is an independent risk factor for hip fracture in Caucasian females160-166. A study by Faulkner 
et al showed a near doubling of the risk of hip fracture with every SD increase in hip axis 
length166.  A larger femoral neck-shaft angle has also been implicated in hip fracture risk161. 
Most studies looking at hip geometry have documented a shorter HAL in Blacks versus 
Caucasians3,4. This finding may enhance the protective effects of a higher BMD in blacks with 
regard to fracture risk. The femoral-shaft angle was not found to be statistically significantly 
different in blacks compared with, whites3.  
Vertebral bone size has been found to be reduced in women with spinal fractures167. Smaller 
bone size was also observed when patients with vertebral fracture were matched with 
controls with the same areal BMD. Although African-American women are heavier than 
Caucasian women, their lumbar spine and femoral neck bone areas are actually smaller199. It 
has been noted that there are racial differences in upper and lower body segments. Although 
matched for height, American blacks have longer legs and shorter trunks than whites. This 
has been hypothesized as indicative of reduced skeletal sensitivity to estrogens in blacks as 
trunk growth is estrogen dependent whereas lower limb growth is primarily growth hormone 
dependent203. A shorter trunk implies reduced vertebral size and may potentially compromise 
vertebral strength and enhance vertebral fracture risk in blacks. 
3. FALL RISKS 
Falls are a major contributing factor to the occurrence of symptomatic fracture in 
postmenopausal women. Some studies205,206, but not all207,208, suggest that Caucasians may 
fall as much as 50-60% more often than African Americans or other ethnic groups. In a 
study by Faulkner and co-workers,209 the frequencies of falling between older Caucasian and 
African-Americans were similar, but the circumstances of falling differed. Ethnic differences 
in the fall location and surface, fall direction, and likelihood of falling on the hand/wrist were 
identified. These disparities in fall mechanisms may have an important role in serious fall-
related injuries and might partially explain ethnic differences in fracture risk. 
4. FRACTURE DATA 
Black women fracture less than their white counterparts135,136,243. Using data from women ≥ 
65 years of age enrolled in the US Medicare program from 1986 to 1990, Barrett et al found 
that the overall incidence of fractures attributed to osteoporosis was 3.1% in African-
American and 8% in white women237. Thus, osteoporotic fractures are 2.6 times more 
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common in older white women.  The lower fracture risk in American blacks has been readily 
attributed to their higher bone mineral density as has been documented in numerous 
studies135,138,143-145,184-199.  
Bone mineral density has been shown to be an important predictor of fracture risk based 
primarily on studies of North American and European white women. Less is known about the 
association of BMD with fracture risk in other ethnic populations.  In a recent study by 
Barrett-Conner et al low heel, forearm or finger BMD was associated with an increased one-
year risk of non-spinal fracture in black women. All the women studied showed a similar 
pattern of increasing fracture risk with decreasing BMD levels, regardless of race or ethnicity. 
Women with osteopenia or osteoporosis had an increased risk of fracture in every ethnic 
group, but the absolute risk of fracture at any given BMD does differ among ethnic 
groups136(table 11).  
Table 11: Risk of fracture by ethnicity 
 Osteoporotic fractures 
(relative risk 95%CI) 
Non-wrist fractures 
(relative risk 95%CI) 
Ethnicity 
  White 
 
1.00 
 
1.00 
  Black 
  Asian 
0.52 (0.38, 0.70) 
0.32 (0.15, 0.66) 
0.45 (0.30, 0.66) 
0.42 (0.19, 0.94) 
  Hispanic 0.95  (0.76,1.20) 1.01 (0.77, 1.33) 
BMD  
(per 1SD decrease in T-score) 
 
1.54 (1.48, 1,61) 
 
1.41 (1.34, 1.49) 
Risk of fracture by ethnicity, adjusted for covariates including BMD T score. Relative risk and CI based on Cox proportional 
hazard model adjusted for age, education, current health status, years since menopause, weight, estrogen use, cortisone use 
and BMD site/device. White is referent population (RR 1.00) Adapted from Barrett-Connor et al. J Bone Miner Res 2005; 20(2): 
185-194 136 
These findings were confirmed in a prospective study by Cauley et al135 who showed that 
reduced BMD of the total hip and femoral neck is associated with an increased risk of all 
non-spinal fractures in older black women, but that the absolute fracture incidence was 30 – 
40% lower among black women compared to whites. The lower fracture rate in black 
compared with white women was independent of BMD and other clinical risk factors. (table 
12).  
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Table 12: Relative Risk of Fracture in Black Compared with White Women 
 
* The reverent group is white women. 
† Multi-variable-adjusted model includes age, body weight, height, fracture since age 50 yrs, walking as form of exercise, 
current  calcium supplement use, current hormone therapy use, alcohol consumption in the last 30 days, diagnosis of 
osteoarthritis, diagnosis of chronic obstructive airway disease, fallen 2 or more times in the past year, use arms to stand up 
from chair, and current smoking. Adapted from Cauley et al; JAMA 2005; 293(17): 2102-2108135 
Data pertaining to vertebral fracture prevalence in multi-ethnic populations are scanty and 
old. A population based study by Cooper et al suggested a lower incidence of vertebral 
fractures amongst black postmenopausal females based on hospital discharge records249. 
Minimal published data is available regarding differences in the risk of spinal fractures 
between black and white females. Racial differences in the prevalence of vertebral fractures 
in older black and white men was recently documented in the Baltimore Men’s Osteoporosis 
Study with a higher prevalence documented in older white men (7.3% whites versus 0.9% 
blacks)210.  It is unknown whether this racial difference also holds true for females.  
5. CONCLUSION   
It therefore appears as if African American females fracture less than their white 
counterparts. They fracture less because their BMD’s are higher. Black Americans also 
fracture less than whites even when BMD has been corrected for and this might be ascribed 
to differences in bone quality, bone geometry and fall risk. African American women do, 
however, also fracture and should be considered for BMD testing if clinical risk factors for 
excessive bone loss are found to be present. 
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C OSTEOPOROSIS ON THE AFRICAN CONTINENT 
1. BACKGROUND 
In the United States, the higher prevalence of osteoporosis and fractures in whites compared 
with blacks may be readily attributed to the higher bone density in both black children and 
adults.  Both a higher peak bone mineral density and a slower rate of early postmenopausal 
bone loss have been documented in African Americans.  
In South Africa, osteoporosis related fractures also occur more frequently in whites. The only 
documented fracture data in South Africa, however, dates back to the 1970’s. Solomon et 
al20 noted that the urban Black population of the Johannesburg Metropolitan Area had a 
more than ten fold lower hip fracture rate compared to that seen in Western European 
populations and that black males and females are affected equally.  In 1968 Dent and co-
workers211 published their data regarding spinal osteoporosis in 3 subgroups i.e. rural and 
urban black females and white females residing in the Durban area. They noted severe 
osteoporosis of the spine (as defined by structural abnormalities of the vertebrae) in 14% of 
Whites compared to a 3% and 2% prevalence in the rural and urban blacks respectively.  In 
West Africa, a very low incidence of minimal trauma fractures of the hip and wrist has also 
been observed212. This clinical impression is supported by the experience of the UK Medical 
Research Council (MRC) field station in Keneba, The Gambia, where there have been no 
reported cases of osteoporosis-related fractures during the past 40 years.  
2. BONE STRENGTH 
Both the quantity and the quality of bone determine skeletal strength. 
2.1. Bone mineral density (BMD) 
Higher BMD at all skeletal sites have been repeatedly and consistently documented in 
Americans of African descent compared with whites135,138,143-145,184-199.  By contrast, African 
studies have not nearly been as unanimous on greater bone density in blacks.  
2.1.1. South Africa  
Appendicular bone mass appears to be similar or lower in black versus white South Africans. 
Earlier studies employing metacarpal radiogrammetry revealed similar or higher values in 
white compared with black South African adults213. A study of SA schoolchildren using single 
photon absorptiometry, did not find any significant difference in appendicular bone mass 
between the black and white groups214.  
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Despite markedly lower fracture rates noted in the urbanized black population of the 
Johannesburg Metropolitan Area compared to Caucasians, Solomon made the interesting 
observation that absolute values for skeletal mass and bone density were in fact greater in 
the Caucasians compared to the African blacks through most of the age range from 5 – 75 
years213.   
      
 
Based on metacarpal radiogrammetry, three distinct phases of change in bone mass was 
noted in the Caucasian population he studied i.e. an early phase of rapid increase in bone 
density during skeletal growth and maturation, a middle phase between the ages of 30–50 
years during which bone density falls slightly, especially in women, followed by a late phase 
characterized by a rapid decline in bone mass from 50 years onwards213 (figure 13). In 
Blacks, this middle phase is absent, implying that bone mass is either sustained at higher 
levels between the ages of 30–50 years or actually continues to rise (figure 14). 
It seemed unlikely that these small differences in bone mass and patterns of bone loss could 
account for the marked difference in fracture risk and the possibility of qualitative differences 
in bone between Blacks and Whites was already proposed by Solomon in the late 70’s213.   
In the only study to date employing more sophisticated techniques to assess BMD in South 
African adults, a selected group of Black and White South African nurses was studied by 
Daniels et al1.  Employing dual energy X-ray absorptiometry (DEXA), similar appendicular and 
areal lumbar bone mineral density values were documented in the black and white nurses, 
20–64 years of age. Areal femoral bone density (FBD) was, however, higher in both pre- and 
postmenopausal black females.  
After correction for weight and height, the black females had 7% higher FBD than whites in 
the premenopausal group and 13% higher FBD in the postmenopausal group. Bone density 
Figure 13: Mean values for bone density (D2 – 
d2)/D2, in Caucasian males and females Adapted 
from Solomon et al 1979, The Lancet: 1326-
13301213 
Figure 14: Mean values for bone density (D2 – 
d2)/D2, in Black males and females. Adapted from 
Solomon et al 1979, The Lancet: 1326-13301213  
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was higher in blacks than in whites in all the anatomically different parts of the proximal 
femur, namely, the femoral neck, the trochanteric and intertrochanteric areas, and Ward’s 
triangle. To further eliminate the possible confounding influence of ethnic differences in bone 
size on areal BMD measurements, volumetric bone mineral apparent density (BMAD) values 
were also calculated5. These BMAD findings suggest that pre- and postmenopausal white 
females have marginally lower bone mass at the lumbar spine and significantly lower bone 
mass at the femoral neck compared to black females.  
The difference in femoral bone density between the black and white nurses was noted to be 
more pronounced in the postmenopausal versus the premenopausal females, suggestive of 
slower postmenopausal bone loss in the black subjects. The pattern of bone loss, although 
not always statistically significantly different between the two ethnic groups, is remarkably 
similar to that observed by Solomon more than 30 years earlier. The black females appeared 
to reach peak bone mass at a later stage and showed very limited loss in the middle phase 
(late pre-menopausal and perimenopausal periods). In addition, a slower rate of 
postmenopausal decline in spinal bone density (SBD), femoral bone density (FBD) and radial 
bone density (RBD) was noted in black versus white female nurses in this study.  
Pettifor and colleagues recently studied a group of 9-year-old black and white South African 
children to determine the association between physical activity and bone mass215. Although a 
lower level of physical activity and lower calcium intake was documented in the black kids, 
significantly greater bone mineral density at the hip and spine employing DEXA was noted in 
black children, even after adjustment for body size. 
In a follow-up evaluation of a very similar cohort at age 10 years, Pettifor and colleagues 
once again documented significantly greater bone mass (BMC) at the proximal femur 
(femoral neck and total hip), whereas BMC of the lumbar spine was now noted to be similar 
in black and white children. These values were all corrected for gender, weight, height and 
puberty216. 
These findings suggest that the femoral neck and total hip bone mass patterns in our black 
children are likely to be under similar genetic influences to those of African-American 
children and that genetics are likely to significantly contribute to the finding of higher hip 
BMD in South African blacks compared with whites. This hypothesis is supported by studies 
that suggest that the South African black population and the African-American population 
share a common genetic pool as both originated and migrated from West-Africa217. The 
finding of similar vertebral bone mass (BMC) in black and white South-African children is in 
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keeping with findings in adult black females from South Africa1 and elsewhere on the African 
continent6,2,218-220. The reason(s) for this site-specific difference is unclear.  
Preferential increase in hip BMD in exercising (weight-bearing) school children have been 
described221, but physical activity scores were lower in urbanized South African black children 
compared with whites in the study by McVeigh215. Greater mechanical loading due to higher 
body weight in adult black versus white populations may potentially further enhance 
genetically determined femoral bone density more so than other “less weight-bearing” 
skeletal sites.   
Development of the axial skeleton is known to be predominantly oestrogen dependent.  It 
has been noted that there are racial differences in upper and lower body segments. The 
genetically determined shorter trunk length observed in American blacks may also be true for 
the South African blacks. This has been hypothesized as indicative of reduced skeletal 
sensitivity to oestrogen in blacks as trunk growth is oestrogen dependent whereas lower limb 
growth is primarily growth hormone dependent203. A shorter trunk implies reduced vertebral 
size and may potentially compromise vertebral strength and enhance vertebral fracture risk 
in blacks. Delayed menarche in South African blacks214 may potentially further compromise 
optimal development of vertebral size and accumulation of bone mineral content. The 
femoral neck of the hip consists of 25% trabecular bone, whereas in a vertebral body the 
percentage ranges from 66% to 90%221. Reduced calcium nutrition in blacks214 may 
stimulate bone turnover and have a more marked impact on metabolically active trabecular 
bone versus cortical bone. Because the amount of trabecular bone in the vertebrae is so 
high, the impact of poor calcium nutrition may be particularly apparent in the spine.  
2.1.2. Rest of Africa 
Prentice et al compared the bone mineral content (BMC) of the midshaft radius, determined 
by single photon absorptiometry, between a group of rural Gambian and British women 
across a wide age-range of 18–80yrs222. Gambian women had significantly lower forearm 
BMC than British women of the same age, but after adjusting for weight, height and bone 
width, the forearm BMC of Gambian women was shown to be slightly higher than that of 
British women (+2.1%, p<0.05). When analysis was confined to subjects older than 45 
years, there was no difference between the two studied groups (1%, p=0.6).  
In a more recent study in Gambia212, bone mineral content and bone mineral density were 
compared between rural Gambian women and white British females. The Gambian women 
had significantly lower BMC and BMD values at the lumbar spine and at the midshaft of the 
 44 
radius. Comparative femoral BMD data was not obtained in this study. These findings were 
surprising given the apparent very low fragility fracture rate in Gambia. 
In an attempt to explain the observed protection against fractures in Gambians compared 
with British whites despite very similar BMD-values, a detailed study comparing young 
Gambian men and women with British adults was conducted by Dibba, Prentice and co-
workers6.  In the female subgroup, BMD of the hip, spine and radius were similar in the 
Gambian and the British subjects.  
In a study by Riggs et al218 bone density was compared among persons of African Heritage 
and included African Americans and recent immigrants from Somalia. Compared to a group 
of white subjects, the Somali females had a lower lumbar spine BMD (4%), but a higher 
femoral neck BMD (11%).  Similar lumbar spine BMD data was documented in women from 
Oman (a country close to Somalia), who were also found to have lower values than healthy 
European women219. Spinal BMD Z-scores was significantly lower in recent sub-Saharan 
Sudanese immigrants than in African Americans or Caucasians in a study conducted in the 
United States220.  
Collectively these studies suggest that appendicular and spinal bone mass in black 
populations from the African continent are similar or lower than that observed in white 
individuals. Proximal femur BMD measurements, on the other hand, are higher in Africans 
compared to whites in most, but not all studies. 
2.2. Bone Quality 
The low fragility fracture rate in African Americans is sufficiently explained by greater bone 
mass, but the same explanation cannot be advanced for blacks from the African continent. 
Bone quantity is not uniformly higher in African blacks compared with whites, therefore the 
possibility of a qualitative advantage must be considered. 
2.2.1. Micro-architecture 
A histomorphometric analysis carried out on iliac crest bone from 171 South African black 
and 175 white men and women revealed significant racial differences in trabecular bone 
architecture131. Trabecular thickness was greater in blacks than in whites (p<0.01).  Age 
related microstructural changes also differed between the races. Black females showed no 
decline in trabecular number and no increase in trabecular separation, whereas whites 
suffered deterioration of trabecular architecture with regard to trabecular thickness, number 
and connectivity. The trabecular bone of South African blacks therefore appears to have a 
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sturdier microstructure, and undergoes a less destructive ageing process than that of South 
African whites.   
2.2.2. Bone Turnover and Calcium homeostasis 
An imbalance in bone turnover may significantly impact on all aspects of bone quality. 
Some138,140-142,146,196 but not all studies142,144,145 employing either histomorphometry or 
biochemical bone turnover markers have documented a lower bone turnover status in 
African-Americans compared with whites. Lower 25-hydroxy-vitamin D and lower biochemical 
parameters of bone turnover despite higher plasma parathyroid hormone (PTH) levels in 
black women, suggest that American blacks have a decreased skeletal sensitivity to PTH. 
This concept is supported by the finding of higher BMD in blacks.  American black women 
appear to conserve calcium more efficiently compared to whites with significantly lower 
urinary calcium excretion rates143,146. 
In contrast to the American data, a single histomorphometric study by Schnitzler et al 
suggested that black South African adults may have a higher bone turnover than whites131.  
Although generally accepted to render bone more susceptible to fracture, these authors 
suggested that the relatively higher bone turnover rates in black South Africans may 
contribute to better bone quality by minimizing the volume of bone damaged by fatigue and 
stress fractures, and hence, result in lower fracture rates in blacks compared to whites.  
Biochemical markers of bone turnover was, however, found to be comparable in black and 
white South African nurses in a more recent study and were unable to confirm the 
histological finding of a higher bone turnover rate in South African blacks5.  The 
postmenopausal blacks in the nurses’ study also had lower 25-OH Vitamin D, higher PTH and 
lower urinary calcium excretion rates than whites, data similar to that seen in African-
Americans.  Conversely, no differences in biochemical markers of bone turnover or 
calciotropic hormone concentrations were noted between British and Gambian subjects 
studied by Dibba et al6. Study numbers were, however, very small and may account for the 
lack of significant differences between groups (table 13).  
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Table 13: Markers of calcium metabolism and bone turnover in plasma obtained from fasting blood. 
 
Adapted from Dibba et al. Annals of human biology. 1999; 26(3):229-2426 
2.2.3. Bone Geometry 
A longer hip axis length (HAL) or femur neck axis length (FNAL) is an independent risk factor 
for hip fracture160-166. In America, most studies have documented a shorter FNAL in Blacks 
versus Caucasians3,4. A shorter FNAL was also noted in black versus white South African 
females5 and in Gambians compared with British subjects6.   
Lumbar vertebral heights, before and after correction for anthropometric differences were 
less in black boys and girls (p<0.01) in a study by Pettifor and colleagues216. The vertebral 
bone area in these children was similar in black and white children and these findings 
suggested that the vertebrae of black children are shorter, but wider. Geometrically, wider 
bones are stronger bones and may, independently of BMD provide protection against fragility 
fractures. Smaller vertebral bone area, on the other hand, has been associated with 
increased risk of vertebral fractures. 
3. FALL RISKS  
No data regarding possible differences in the propensity to fall between black and white 
South Africans exist. 
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4. FRACTURE DATA 
Higher femoral bone mineral density might partially explain the lower hip fracture prevalence 
in people of African ancestry compared to Caucasians. The rarity of other fragility fractures in 
African populations, however, cannot be explained on the basis of significantly higher BMD 
and challenges current ideas about the significance of bone mineral status as a the principal 
determinant of fracture risk, especially in these populations.   
Solomon et al20 performed the last epidemiological studies on the incidence of hip fractures 
in South Africa more than 30 years ago. He showed that hip fracture rates in South African 
Blacks are more than ten-fold lower than those observed in Caucasians, both locally and in 
Western European populations (Figures 15 and 16).   
More severe degrees of vertebral deformities in White vs. both rural and urban Black South 
Africans were also noted in a study conducted by Dent and co-workers in 1968211.  In-
patients and subjects in old age homes were recruited and a total of 100 cases were 
included in the three respective groups. (white, rural black and urban black).  Structural 
vertebral abnormalities in keeping with severe osteoporosis was documented in 14 whites 
(14%) and 5 blacks (2 urbanized and 3 rural blacks; 2.5% of blacks)[table 14].  
 
Figure 15: Annual incidence of femoral-neck 
fractures in the Johannesburg population over 
40 years. Adapted from Solomon et al; J Bone 
and Joint Surgery 1968, 50(B): 2-11211 
Figure 16: Age specific incidence of fractures of the femoral 
neck in Western European populations (Dundee and Malmo) and 
in the Johannesburg Blacks Adapted from Solomon et al; J Bone 
and Joint Surgery 1968, 50(B): 2-11211 
---  Black female 
     Black male 
---  Black female 
     Black male 
JOHANNESBURG 
        BLACKS 
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Table 14: Number of patients with pathological changes seen on lateral x-ray 
 
This study has limitations. The majority of patients included in the study by Dent et al was 
hospitalized in-patients and very little is known regarding the reasons for admission, 
especially in the white cohort. The study population may thus not be truly representative of 
the population at large. The mean age of the urbanized black cohort was lower than that of 
the white cohort and may influence the prevalence of fracture irrespective of race in the 
different studied groups. More white patients above the age of 75 years were also included 
in this study compared with both black cohorts (figure 17).  
 
Figure 17: Age distribution of the three groups. Adapted from Dent et al. British Medical Journal 1968; 4:76-79211 
The prevalence of vertebral fractures in other countries on the African continent is unknown. 
Data on the prevalence of osteoporosis related fractures in Africans are thus limited and 
nearly entirely based on old studies. Further research is clearly needed to define the current 
prevalence of spinal and non-spinal fractures in the different ethnic populations of Africa.    
Group A 
Rural blacks 
Group B 
Urban Blacks 
Group C 
Whites 
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5. CONCLUSIONS 
Studies suggest that South African black females, similar to their American counterparts, 
have a genetic tendency to greater proximal femur BMD than white females215. In adulthood, 
SA black females, realize this potential and femoral BMD appears to be significantly higher in 
blacks compared with whites1.  Vertebral BMD, on the other hand, appears to be similar in 
blacks and whites, both in childhood216 and in adult life1. 
Osteoporosis related hip fractures occur less in black compared to white South African 
females20. This can be readily attributed to significantly higher femoral BMD1, potentially 
better preservation of bone micro-architecture131 and a shorter FNAL5. 
It is uncertain whether, and if so, why SA black women have a lower vertebral fracture 
prevalence compared with white women211. The lower fracture rate cannot be ascribed to 
marked differences in spinal BMD since similar values were documented in adult black and 
white females1. Blacks do, however, appear to preserve bone quality better than whites with 
ageing131. Sturdier and better connected trabeculae may indeed enhance bone strength and 
provide better protection against fracture. Geometric differences with wider vertebrae may 
also potentially enhance resistance against vertebral injury216.  
No work has been done to assess fall risk, as a known significant contributor to fracture risk, 
in South Africans. 
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CHAPTER 3 
GENERAL METHODOLOGY 
This is a descriptive and cross-sectional study which compares fracture risk of White and 
Xhosa females by evaluating known determinants of bone strength as well as the propensity 
to falls. Informed consent was obtained from each subject, and the study was approved by 
the Ethical Review Board of the Faculty of Medicine, University of Stellenbosch. 
1. SUBJECTS 
1.1. Recruitment and patient selection 
The study population consisted of community-dwelling healthy Caucasian and Xhosa women 
residing in the Western Cape, South Africa. Volunteer subjects were recruited by word of 
mouth and through local church and community centers from the geographical area normally 
supplied of medical care by the Tygerberg Hospital. Due to known socio-economic 
differences between the two ethnic groups, recruitment aimed to include a representative 
sample of White and Xhosa females and did not specifically stratify patients based on socio-
economic status.   
Recruitment took place between May 1999 and November 2004 and all subjects were 
evaluated once by a single observer (Magda Conradie). 
Black and White race was determined by self-declaration and all women were resident in the 
Western Cape for the majority of their adult life.  
1.2. Exclusion criteria 
A telephonic questionnaire was used to screen volunteers prior to study entry (Addendum I). 
Any individual with a known metabolic bone disease (osteoporosis, osteomalacia, 
hyperparathyroidism, renal bone disease or Paget’s), those who suffered from diseases (e.g. 
endocrinopathies, malabsorption syndromes, malignancies, chronic alcoholism, renal or 
hepatic dysfunction) or used drugs (e.g. glucocorticoids, anticonvulsants, antacids, fluoride, 
bisphosphonates, pharmacological doses of Vitamin D) known to affect bone or mineral 
metabolism, were excluded from study entry. 
Only premenopausal subjects with a regular menstrual cycle were eligible for study entry. 
Postmenopausal subjects on hormone therapy were not excluded from this study, but bone 
mineral density employing DEXA, ultrasonography, biochemistry (including biochemical 
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assessment of bone turnover) and fall risk were analyzed separately. Only three of the 
postmenopausal black women entered into this study used hormone therapy compared with 
44 whites.  
1.2.1. Exclusions 
A total of 411 patients were evaluated, including 198 Caucasian females and 213 Xhosa 
females. 
Thirty eight volunteers (12 Caucasian females, 26 Xhosa females) who were included 
following the telephonic contact were subsequently excluded in view of the following 
(information not volunteered and/or unknown to patient at time of telephonic contact): 
 Active use of Depo Provera contraception with amenorrhea (19 patients, 17 blacks,  
2 whites)  
 Irregular menstrual cycles with oligo-/ amenorrhea, suspected perimenopausal state 
(7  patients)  
 Amiodarone induced hyperthyroidism (1 patient) 
 Heart failure, cause unknown (1 patient) 
 Primary ovarian failure (1 patient) 
 Eating disorder with hypogonadism (1 patient) 
 Diabetic nephropathy with renal failure (1 patient) 
 Positive HIV status (2 patients) 
 Immobility due to motor deficit L. arm and leg, associated R. optic atrophy ( 
1 patient) 
 Suspected alcohol abuse (4 patients)  
1.3. Classification and patient subgroups 
Subjects 20 – 82 years of age were recruited and stratified into premenopausal and 
postmenopausal groups. Women were classified as premenopausal if they reported monthly 
menstrual bleeding during each of the three months preceding study entry. The 
postmenopausal state was verified by a serum FSH-level > 40mIU/ml in all subjects.  
Postmenopausal women were sub-classified based on age into an early postmenopausal 
group (age less than 60 years) and a late postmenopausal group (age equal or older than  
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60 years). White postmenopausal females were further subdivided based on whether they 
were currently using hormone therapy (HT+) or not (HT-). 
To control for adiposity, BMD data were also analysed by dividing premenopausal and 
postmenopausal patients into weight subgroups i.e. those with normal to low body mass 
index (BMI <25kg/m2) and those defined as overweight based on BMI (BMI ≥ 25 kg/m2)223. 
To ensure sufficient numbers within each weight subgroup, the postmenopausal women 
were evaluated in total. As weight groups were compared primarily with regard to 
densitometric data, only postmenopausal women not on hormone therapy were included in 
these weight subgroups. 
 
 
 
 
 
 
 
PREMENOPAUSAL SUBJECTS 
Blacks (B) 
n = 87 
Whites (W) 
n = 76 
Normal to low 
n = 23 
Overweight 
n = 64 
Normal to low 
n = 47 
Overweight 
n = 29 
POSTMENOPAUSAL SUBJECTS (total) 
< 60 years ≥ 60 years 
Blacks 
n = 52 
Whites 
n = 63 
Blacks 
n = 48 
Whites 
n = 47 
 
 
FINAL COHORT = 373 
√ BLACKS = 187 
√ WHITES = 186 
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POSTMENOPAUSAL SUBJECTS (weight groups) 
Blacks (B) 
n = 97 
Whites (W) 
n = 66 
Normal to low 
n = 22 
Overweight 
n = 75 
Normal to low 
n = 27 
Overweight 
n = 39 
 
2. METHODS 
An extensive clinical, biochemical, radiological and densitometric evaluation was performed 
on each subject during a single visit to the Department of Endocrinology and Metabolism, at 
Tygerberg Hospital. This evaluation included the following: 
 Standardized interviewer administered questionnaires were used to assess 
conventional osteoporosis risk factors (Addendum II) 
 A detailed dietary history (Addendum III) 
 Anthropometric evaluation 
 Full physical evaluation 
 Assessment of fall risk  
 Evaluation of Bone mineral density (BMD) employing Dual energy X-ray 
absorptiometry (DEXA)  
 Qualitative Bone Ultrasonography employing a Sahara clinical bone sonometer 
 Assessment of Vertebral structure via Conventional Radiology  
 Venesection and urine collection for biochemical evaluation 
2.1.  Clinical assessment 
2.1.1. Risk factor analysis 
A standardized interviewer administered questionnaire (Addendum II) was used to assess 
the following parameters with a potential impact on BMD: age (years), ethnic group (Xhosa 
or White), history of previous fragility fractures, family history of osteoporosis, other 
medication, physical activity, alcohol intake, cigarette smoking, calcium intake (see dietary 
analysis- section 2.1.2), known ailments, gynecological history and a history of recent falls 
(see propensity to falls – section 2.7).   
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PREVIOUS FRACTURES were defined by position, number, date of occurrence and associated 
trauma. 
PHYSICAL ACTIVITY was scored by the following criteria and expressed numerically as 
follows: 
0:   nil physical activity 
1:   light office work 
2:   active in-house (own housework) 
3:   active in-house and outdoors (regular walking, gardening) 
4:   partaking in competitive sporting activities, walking daily for 1/2hour or more 
5:   extreme sporting activities i.e. marathons… 
ALCOHOL INTAKE was expressed in units per week, a unit being equivalent to 28g alcohol 
i.e. one bottle of beer, one glass of wine or one drink of spirits.     
CIGARETTE SMOKING STATUS was expressed as ever, current, never and number of pack-
years. 
The GYNAECOLOGICAL HISTORY included the following: 
 Age at menarche 
 Menstrual cycle i.e. regularity and cycle length 
 Use of hormonal contraceptives (Yes/No) 
o Type 
o Current or past use 
o Duration of usage 
 Menopause 
o Age at onset 
o Spontaneous or surgical  
o Years since the start of menopause (YSM) 
o Hormone therapy (Yes/ No) 
 Date commenced 
 Menopausal years without hormone therapy 
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 Duration and type of hormone therapy 
 Number of pregnancies 
 Breastfeeding (Yes/No) 
o Duration of lactation 
2.1.1.1. Standardization of risk categories 
The average of the lowest quartile of weight, height and BMI for each of the two ethnic 
groups was calculated within the pre- and postmenopausal cohorts and rounded up to low 
cut-off values for the pre-and postmenopausal cohorts as follows: weight: 55kg and 60kg; 
height: 155cm and 156cm; and BMI: 21kg/m2 and 23kg/m2 respectively.  Mean calcium 
intake for black and white women in this study cohort was 613.2 and 864.8 mg respectively. 
A low dietary intake threshold of 500mg/day was used in the present study. Current 
cigarette smoking was categorized as either “yes” or “no” and low physical activity was 
classified as no outdoor activity, i.e. a score of 2 or less (see section 2.1.1). Alcohol intake 
was regarded as excessive if intake exceeded 1U/day, every day or 10U/week. Due to a very 
small percentage of both black and white females who met the criteria for excess alcohol, 
alcohol intake was in fact categorized as “yes” or “no” and compared. A maternal history of 
osteoporosis, prior or current use of contraception (either depo provera or oral preparations) 
and breastfeeding were categorized as either “yes” or “no”. High parity was classified as 3 or 
more prior pregnancies. Past or current use of hormone therapy was noted for the two 
postmenopausal cohorts. 
2.1.1.2. Individual Risk Factors 
One way analysis of variance was used to determine differences between the various ethnic 
subgroups in terms of anthropometric, menstrual and lifestyle risk factors. The prevalence of 
clinical risk factors were also reported on in premenopausal and postmenopausal cohorts and 
compared between the two ethnic groups. 
The frequency for each risk factor, as outlined in section 2.1.1.1, in patients with normal 
bone mass (BMD T-score >-1) and in those with osteopenia (BMD T-score ≤-1SD) was 
determined for spinal and femoral sites. Cross tabulation and the Chi-square test was used 
to determine univariate relationships between risk factors and low bone mass.   
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2.1.1.3. General discriminant analysis 
General discriminant analysis was used to identify variables able to predict osteopenia in 
post-menopausal black and white females. Associations were determined between clinical 
risk factors, as outlined in section 2.1.1.1, and low BMD (T-score ≤-1SD as assessed against 
a uniform white reference population) at the lumbar spine and at the proximal femur (total 
BMD and femoral neck BMD). Linear discriminant analysis was used to pick out the best 
combinations of predictor variables.   
2.1.1.4. Risk Assessment Tools 
Numerous simple risk assessment instruments have also been constructed to identify 
patients who are most likely to have a low BMD warranting a bone density test120-125. These 
risk instruments have been developed based on data obtained via epidemiological risk factor 
identification in Asian countries, the US and Europe. The purpose of these risk assessment 
tools is not to diagnose osteoporosis or low BMD, but to identify women who are more likely 
to have low BMD and who can then be selectively referred for BMD measurements. The 
performance of these risk assessment tools in multi-ethnic populations has never been 
published. 
We calculated risk assessment scores based on the OST, OSIRIS and ORAI tools, and 
evaluated the performance of these tools in identifying non-hormone treated 
postmenopausal black and white women at risk of osteopenia i.e. a  T-score ≤-1 at various 
BMD measurement sites (table 1).  We also determined the sensitivity, specificity, positive 
predictive value and negative predictive value for each of the risk assessment instruments in 
black and white postmenopausal females respectively. 
The Osteoporosis Self-assessment Tool (OST) is based simply on age and weight123,124 . The 
score is calculated by subtracting age from weight and then multiplying by 0.2123. Other risk 
tools are also based on age and weight, in combination with up to four additional risk 
factors. These include, amongst others, the Osteoporosis Risk Assessment Instrument 
(ORAI) and the Osteoporosis Index of Risk (OSIRIS). ORAI differentially score weight and 
age within certain cut-off ranges and include hormone therapy as a risk index to identify 
women likely to have either femoral neck or lumbar spine T-scores ≤-2.0121. The 
Osteoporosis Index of Risk (OSIRIS) is based on four variables: age, body weight, current 
hormone therapy and a history of previous low impact fractures224. Any patient with a OST 
score of less than 2, an ORAI score of 9 or more and a OSIRIS score of 1 or less would be 
advised to have BMD testing.  
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Table 1: Clinical Risk Assessment Instruments – Calculation of the evaluated indices  
Factor Score 
ORAI  
Age > 75 years + 15 
Age 65–74 years + 9 
Age 55–64 years + 5 
Body weight < 60 kg + 9 
Body weight 60–70 kg + 3 
Oestrogen therapy + 2 if not currently using oestrogen 
OSIRIS  
Body weight (kg) + 0.2 x body weight 
Age (years) - 0.2 x age 
History of low impact fracture(s) - 2 
Oestrogen therapy + 2 
OST  
Body weight (kg) 
Age (years) 
 
0.2 x (body weight-age) 
2.1.2. Diet history 
The diet history of all study subjects was obtained by a single qualified dietician (Madele du 
Plessis). The method used was dietary recall (usual intake during two normal week days and 
one weekend day at time of evaluation) obtained during a personal interview (Addendum 
III). The Foodfinder program (Dietary Analysis Software – Medical Technology, South African 
Medical Research Council) was used to analyze the dietary histories. This enabled us to 
obtain estimates of intake for individual nutrients, including calcium, protein, phosphate, 
sodium and Vitamin D. 
2.1.3. Physical evaluation 
A thorough physical examination was performed by a single physician (Magda Conradie) on 
every study subject to ascertain the presence of unsuspected systemic disease (Addendum 
II). 
2.1.4. Anthropometric assessment 
Anthropometric data were obtained from every subject and included weight, height, skin-fold 
measurements, waist and hip circumferences and elbow breadth determination.  
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The following methods were employed: 
 subjects were weighed on a balanced beam scale wearing the minimum of clothes to 
the nearest kilogram 
 height was measured with a sliding headpiece to increase the accuracy of the 
reading, which was taken to the nearest centimeter (cm); the lower segment was 
determined as the distance from the pubic symphysis to the floor and the upper 
segment calculated as total height minus lower segment 
 skinfolds were measured using a Harpenden caliper; all measurements were taken on 
the right side of the body to the nearest millimeter (mm), as follows:  
o biceps – at the midpoint of the biceps muscle 
o triceps – over the triceps muscle,  
o subscapular – just below the tip of the scapula, at 45˚ to the vertical 
o  supra-iliac – just above the iliac crest in the mid-axillary line 
 waist circumference was determined in the erect position through a point one third of 
the distance between the xiphoid process and the umbilicus 
 hip circumference was assessed in the erect position, through a point 4 cm below the 
superior anterior iliac spine 
 elbow breath was measured with a sliding caliper to the nearest 0.1cm, at the point 
of greatest breadth across the joint. 
All the measurements were done by the same researcher (Madele du Plessis) in triplicate, 
and the results averaged. Weight and height measurements were used to calculate body 
mass index (BMI)* and the patients were classified, based on BMI values, as follows: 
*BMI (kg/m2) = Weight (kg) / Height (m2) 
     Normal reference values for all adult ages225 
     Normal to low body weight    < 25 
     Overweight to obese             ≥ 25  
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2.2. Bone Mineral Density determinations 
2.2.1. Dual Energy X-ray Absorptiometry (DEXA) 
Bone mineral content and bone mineral density of the lumbar spine and proximal femur were 
quantitated employing dual-energy X-ray absorptiometry (DEXA) by using a Hologic QDR 
1000 according to standard procedures in a study cohort who included 187 black women and 
186 white women. The BMD of L1-4 was measured in the anterio-posterior position and the 
mean BMD of these four vertebrae was calculated and used. BMD of various proximal femur 
sites were measured (femoral neck, trochanter, intertrochanteric, total hip and Ward’s 
triangle).  A spine phantom was scanned weekly to determine the intrinsic coefficient of 
variation of the machine. During the course of the study, coefficients of variation for BMD 
were < 1.5%.  A single trained DEXA technician (Riana Eager) performed scans on all study 
subjects and the intra-operative variation was found to be below 1% for all skeletal sites. 
Bone mineral content (BMC) and bone mineral density (BMD) are common expressions of 
bone mineral status. BMC (g) represents the amount of mineral in a section of bone 1 cm in 
length. BMD (g/cm2) is derived, at the radius and hip, from BMC divided by bone width (BW) 
and at the lumbar spine by scan area. It represents a partial correction of bone mineral 
status for bone and body size, but is not a true measurement of density, since no 
information is available about bone volume from a two-dimensional scan. Areal BMD is, 
however, strongly correlated with bone strength in vitro and a good predictor of future 
fracture risk25-30.   
Bone mineral density is conventionally expressed as either an absolute value (g/cm2) or a 
deviation from the norm defined as a T-score or Z-score. A T-score refers to the BMD of a 
subject compared to the mean BMD of the young adult reference mean. The Z-score 
compares the BMD of the individual with that of age and gender matched controls within a 
specific ethnic group. As alluded to before, the WHO’s classification12,13 of 
osteopenia/osteoporosis was designed to provide a practical basis for the identification of 
specifically postmenopausal Caucasian women at risk to sustain fragility fractures (please 
refer to chapter 2, pages 3-4). 
No normative data for black South African women exist. In this study we therefore used a 
white female reference population to calculate T- and Z-scores for both ethnic groups. The 
use of white women as a reference for all persons in a multi-ethnic study may well not be 
appropriate, but until these ethnic specific reference ranges become available, it is currently 
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recommended to diagnose osteoporosis among non-Caucasians by using the uniform 
normative database for Whites, as alluded to before183.  
In premenopausal subjects Z-scores were used to define BMD status. A Z-score ≤-1 
indicated osteopenia, whereas a Z-score ≤-2 was regarded as diagnostic for osteoporosis. In 
postmenopausal subjects, osteopenia and osteoporosis were defined based on WHO criteria 
and as measured against a uniform white reference population. In 1994, the World Health 
Organization (WHO) selected a BMD value of 2.5 standard deviations (SD) or more below the 
mean for normal young white women, or a T-score of ≤-2.512, to define osteoporosis in the 
white postmenopausal female population. This cut-off value was based on epidemiologic 
fracture threshold data which captures most women at risk of osteoporotic fracture (hip, 
vertebrae, forearm, humerus and pelvis). The relationship between low BMD and fracture 
risk is, however, a gradient and not a threshold. Therefore this classification was extended to 
include a subset of patients with osteopenia (BMD more than 1 SD, but less than 2.5 SD 
below young normal mean) in whom the presence of additional risk factors other than BMD 
may lead to increased fracture risk13. 
Ethnic differences in bone mineral data were analyzed and reported on in the following 
patient subgroups: 
● Premenopausal black and white subgroups 
● Early and late postmenopausal black and white groups as outlined in section 1.3. 
● Pre-and postmenopausal black and white weight subgroups as outlined in section 1.3 
in order to control for adiposity.  
For all skeletal sites, BMD’s were first compared between the ethnic subgroups by ANOVA 
before adjustment for covariates. To determine whether observed ethnic differences in bone 
mineral status were due to ethnic factors that affect these measurements, the differences 
were then recompared after adjustment for certain covariates. Analysis of co-variance was 
performed to identify covariates with significant univariate association with lumbar and 
femoral BMD. For the premenopausal subjects, covariates included ethnicity, age, weight, 
height, daily calcium intake, pack years of smoking, alcohol intake, physical activity, age at 
menarche, hormonal contraception and number of prior pregnancies. For the 
postmenopausal subjects, covariates included years since menopause in addition to the 
abovementioned. For post hoc testing, the Bonferonni test was used. 
The correlation between BMD at all skeletal sites and anthropometric variables as well as 
between BMD’s and age and years since menopause (where applicable) were determined in 
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blacks and whites in the different patient subgroups as noted above. The distribution of 
BMD’s at all skeletal sites, expressed as either T-or Z-scores, were also compared between 
the two ethnic groups within the menopausal subgroups as described in section 1.3  
2.2.2. Computation of bone mineral apparent density (BMAD)  
Conventional BMD measurements by DEXA are expressed in g/cm2 and are more properly 
referred to as areal BMD than true volumetric BMD expressed in g/cm3. Areal BMD, as 
alluded to before, introduces a scale artifact that causes small bones to have lower areal 
BMD than larger bones. When comparing people from different ethnic groups with potential 
differences in bone size, BMD differences may thus be more apparent than real. This scale 
artifact is reduced by expressing BMD as BMAD, a calculated three-dimensional variable that 
helps account for differences in bone size. For the lumbar spine, BMAD was computed as the 
BMC/(area)3/2 using the method of Carter et al200 . For the femoral neck, BMAD was 
computed as the BMC/(area)2 using the method of Katzman et al201.     
The calculated volumetric BMAD of the lumbar spine and femoral neck, similar to BMD, were 
first compared between the ethnic groups by ANOVA before adjustment for covariates. 
BMAD data were then compared after adjustment for covariates with significant univariate 
association with BMAD as determined by analysis of co-variance (see section 2.2.1, 
covariates as for BMD). 
2.3. Ultrasonography 
Quantitative ultrasound may be a useful measure of both the quality and quantity of bone. 
The technology has evolved from the observation that sound waves through porous 
materials like bone are absorbed, scattered and travel in a manner that reflects the elasticity, 
stiffness and to a lesser degree the density of the material226,227. Indirect and in-vitro 
experience has suggested that ultrasonography may give information not only about the 
bone density, but also about the bone structure, trabecular orientation and micro-
architecture228-231. The speed with which sound travels through bone (SOS) has been shown 
to be a function of both the elasticity of the bone as well as its density229. Broadband 
ultrasound attenuation (BUA) has been found to be related, not only to BMD, but also to 
architectural characteristics such as trabecular density, spacing and orientation228-231.  
We measured calcaneal ultrasonography by using the Sahara Clinical Bone Sonometer 
(Hologic).  
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The non-dominant heel was scanned using the scanning protocol provided by the 
manufacturer. A single trained technician (Riana Eagar) performed the calcaneal 
ultrasonography on all study subjects. A quality control phantom (QC) was scanned weekly 
over the time period of the study to monitor system performance prior to using the system 
to measure patients. The QC was passed prior to using the system to measure patients. A 
passed QC result indicated that the system was functioning properly and that QC results 
were within the acceptable range. Calcaneal QUS was performed on 230 pre-and 
postmenopausal black and white subjects, 97 blacks and 133 whites. This sub-cohort was 
randomly selected based on test availability.  
QUS calcaneal broadband ultrasound attenuation (BUA) and speed of sound (SOS) were 
measured and the quantitative ultrasound index calculated (QUI = 0.41 x SOS + 0.41 x BUA 
-571). A ‘predicted’ calcaneal ultrasound BMD value was obtained by a simple re-scaling of 
the QUI value and is reported as the ‘estimated’ heel BMD in g/cm2. No sonographic 
normative BMD ranges are available in South Africa. Using the manufacturer’s (Sahara) 
normative range for Caucasian females, a BMD T-score was also calculated in the black and 
white postmenopausal subjects.  
Ethnic differences in QUS measurements were analyzed and are reported on in the following 
patient subgroups: 
● Premenopausal black and white subgroups 
● Early and late postmenopausal black and white groups as outlined in section 1.3. 
Parameters directly measured by the Sahara Clinical Bone Sonometer i.e. BUA and SOS were 
first compared between the two ethnic groups by ANOVA before adjustment for covariates in 
the different patient subgroups. To determine whether observed ethnic differences in bone 
mineral status were due to ethnic factors that affect these measurements, the differences 
were then recompared after adjustment for certain covariates. Analysis of co-variance was 
performed to identify covariates with significant univariate association with BUA and SOS. 
For the pre- and postmenopausal subjects, covariates evaluated, included ethnicity, age, 
weight, height, daily calcium intake, physical activity, pack years of smoking, alcohol usage, 
age at menarche, hormonal contraceptive use and number of prior pregnancies. In the 
postmenopausal cohorts years after menopause was also included as covariate. BUA and 
SOS were also compared between blacks and whites after adjustment for differences in 
DEXA measured BMD of the spine and proximal femur in both pre-and postmenopausal 
cohorts. 
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2.4. Femoral Geometry 
DEXA scan printouts were used to measure hip axis length (HAL) and femur neck width as 
described by Faulkner et al (figure 1)166.  The femoral DEXA measurements were all 
performed using a Hologic QDR-1000 scan and all geometric measurements were conducted 
by one investigator. Employing standard DEXA software, HAL was defined as the length 
along the femoral neck axis, from below the lateral aspect of the greater trochanter, through 
the femoral neck, to the inner pelvic brim. Femoral neck width was defined as the shortest 
distance within the femoral neck region of interest (as defined by the DEXA analysis 
software) perpendicular to the femoral neck axis.  
Vertebral size was also determined directly from the DEXA-scan printouts and expressed as 
the total vertebral cross-sectional area and the mean area of vertebrae L1-L4.  
Geometric assessments were performed on the total study cohort and ethnic differences 
were determined and are reported on in the following patient subgroups: 
● Premenopausal black and white subgroups 
● Early and late postmenopausal black and white groups as outlined in section 1.3. 
ANOVA was used to determine significant ethnic differences in geometry between the 
various patient subgroups. Spearman correlations were used to determine relationships 
between geometric measurements and anthropometry (i.e. weight and height) as well as 
between certain femoral geometric measurements (HAL and femoral neck width) and 
between certain anthropometric measurements (weight and height).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Definition of geometric measurements from femoral DEXA scan 
printout. 
AĂ: hip axis length, defined as the length along the femoral neck axis as 
determined by the DEXA analysis software, from below the lateral aspect 
of the greater trochanter, through the femoral neck, to the inner pelvic 
brim 
Dd: neck width, defined as the shortest distance within the femoral neck 
region of interest, as defined by the DEXA analysis software, 
perpendicular to the femoral neck axis  
Adapted from Faulkner et al. 1993, J Bone Miner Res; 8(10): 1211-1217166 
 66 
2.5.  Conventional Radiology 
Conventional radiology of the thoraco-lumbar vertebrae was obtained randomly in as many 
of the study subjects as possible. Patients were referred for radiological evaluation whenever 
possible, but due to financial constraints and logistical difficulties the total cohort was not 
examined. Two hundred and eighty nine of the subjects underwent conventional radiology 
and included 116 blacks (55 premenopausal and 61 postmenopausal subjects) and  
173 whites (69 premenopausal and 104 postmenopausal subjects of whom 42 were on 
hormone therapy). The evaluation was thus performed in 77% of the total study cohort. We 
used a fixed percentage reduction in vertebral height to define incident vertebral deformities. 
A prevalent morphometric vertebral fracture was defined as vertebral height loss of 20% or 
more158,232 when compared with the vertebrae directly above or below the specific vertebra 
in question or a difference in height of 20% or more amongst anterior, middle and posterior 
vertebral diameters. Vertebrae T4 – L5 were assessed and all radiographs were evaluated 
and interpreted by a single specialist radiologist (Professor Alan Sher).  
Females with prevalent vertebral fractures, i.e. vertebral height loss of 20% or more, and 
those with normal vertebral morphometry were compared with regard to clinical 
characteristics, densitometry, ultrasonography, geometry and biochemically determined bone 
turnover and fall tendency within their specific ethnic group. 
2.6. Biochemical assessment  
A fasting overnight blood sample was drawn between 09h00 – 11h00 in all subjects. Fifty 
milliliters were used for immediate analysis.  A second-voided, spot morning urine sample 
was obtained in all study subjects. A 5ml aliquot of urine was immediately protected from 
light (by wrapping the collection tube in foil) for measurement of urinary free 
deoxypyrodinoline and creatinine. Subjects then drank 200ml distilled water, following which 
a 2 hour timed urine specimen was collected. The urine was collected in containers specially 
prepared for analysis of a 2 hour hydrated urine specimen for measurement of renal calcium, 
phosphate and sodium handling. 
ANOVA was used to determine significant ethnic differences in biochemical measurements 
between the various patient subgroups. Spearman correlations were used to determine 
relationships between certain biochemical measurements (serum osteocalcin, urinary free 
DPD, serum PTH and serum 25-OH-Vitamin D), as well as between these biochemical 
measurements and DEXA determined BMD at the spine and proximal femoral sites. 
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2.6.1. Serum minerals, creatinine and alkaline phosphatase levels and urine 
minerals 
The following serum mineral and biochemical parameters were analysed using a multi-
channel analyzer (Technicon DAX 48): serum total calcium, magnesium, phosphate, 
creatinine and total alkaline phosphatase (ALP). Enzymatic, timed end-point calorimetric 
methods were used for quantitation of calcium (reaction with o-cresolphtalein), magnesium 
(xilidyl blue methods) and phosphate (reduction with ammonium molybdate). The serum 
calcium was corrected for albumin employing the following formula: corrected calcium = 
serum calcium + [(40-albumin) x 0.025].   
The two hour hydrated urine specimen was analysed spectophotometrically by the ADVAI® 
1650 system and the following parameters measured: calcium, sodium and creatinine. 
Urinary calcium (Ca) and sodium (Na) were expressed as a function of creatinine and 
documented as U-Ca/U-Creat, U-Ca/100ml GFR and U-Na/U-Creat.   
U- Ca/100ml GFR was calculated using the formula:  
urine calcium (mmol/l)  
urine creatinine (mmol/l)  
The fractional tubular reabsorption of phosphate (TRP) was calculated using the formula: 
                          serum creatinine (mmol/l) x urine phosphate (mmol/l) 
                             serum phosphate (mmol/l) x urine creatinine (mmol/l) 
The ratio of the renal tubular maximum rebsorption rate of phosphate to the glomerular 
filtration rate (TmP/GFR) was calculated using the nomograms of Walton and Bijvoet based 
on the TRP and the serum phosphate concentration. 
Normal reference values for our laboratory: 
S-Calcium (albumin corrected) 2.10 – 2.60  mmol/l 
S-Magnesium      0.75 – 1.00  mmol/l 
S-Phosphate 0.8 – 1.40   mmol/l 
S-Creatinine 80 – 120      µmol/l 
S-Alkaline Phosphatase (ALP) 30 – 85       IU/l 
  
x serum creatinine (mmol/l) 
1 - 
 68 
  
Urine  
TRP % 85 – 95% 
TmP/GFR 1.00 – 1.68 
2.6.2. Bone Turnover 
Bone turnover was assessed by measuring osteocalcin in serum and deoxypyrodinoline in 
urine. Serum osteocalcin was measured using an immunoradiometric assay (RIA kits, CIS Bio 
International, France manufactured by Nicholls). Urinary deoxypyridinoline was measured 
using a chemiluminescence system (Bayer Automated Chemiluminescence System; 
ACS:180).  Results obtained using the Bayer ACS:180 system are expressed as a ratio of 
deoxypyridinoline to creatinine (nanomoles of bone collagen equivalents per liter per 
millimole creatinine per liter, Nm DPD/mM Creatinine). The minimum detectable 
concentration for this system is 5.0nM. Typical recoveries are in the region of 90-95% with 
CV’s for running controls of approximately 8%.  
We attempted to minimize pre-analytical variability of these biochemical bone turnover 
markers by limiting the factors known to contribute233. Serum osteocalcin and urinary free 
DPD was collected in the fasting state and at a specific time of day i.e. in the morning 
between 09h00 and 11h00 to avoid diurnal variability.  We used a second voided spot urine 
sample for collection of urinary DPD as it is the most practical urine type and protected urine 
specimens from UV-light immediately after collection. As serum osteocalcin is rapidly 
degraded in serum in vitro, we collected these specimens on ice and the serum was 
promptly separated and frozen.  
We furthermore analyzed serum osteocalcin and U-DPD in the postmenopausal cohorts 
separately for the early and late postmenopausal groups as age is an important variable to 
control for. All subjects in our study resided in the Western Cape thus eliminating the 
potential impact of geographical differences.  
Normal reference values for our laboratory: 
Osteocalcin 2.4 – 10.0   ng/ml 
Urinary free DPD/Cr ratio 3.0 – 7.4     nM DPD/mM Creatinine 
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2.6.3. Vitamin D-PTH Endocrine system 
Serum albumin was measured with a multi-channel analyser (Technicon DAX 48). 25-OH-
Vitamin D determination, described by Shephard et al234, involves a competitive protein-
binding technique, utilizing titrated 25-OH-cholecalciferol as radio-labelled ligand, unlabelled 
25-OH cholecalciferol as standard, Vitamin D deficient rat serum as binding protein and 
dextran-coated charcoal for phase separation. Typical recoveries are in the region of 90% 
(CV<5%) with CV’s for running controls of approximately 6%.  Serum intact PTH was 
measured using a chemiluminometric system (ADVIA Centaur® system). The ADVIA Centaur 
intact PTH assay measures intact PTH concentrations up to 201pmol/L with a minimum 
detectable concentration (analytical sensitivity) of 0.265pmol/L. 
Normal reference values for our laboratory: 
S-Albumin 35 – 50 g/L 
25 (OH) Vitamin D > 18 ng/L 
PTH 1.3 – 7.6 pmol/L 
2.6.4. Hormonal studies 
Luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin were quantified 
by a manual method using the IRMA (immunoradiometric assay) principle with magnetic 
separation (Sereno diagnostics, Switzerland). Biochemical evaluation of estradiol was 
quantitated by RIA kits (in house) and sex hormone binding globulin (SHBG) by an in-house 
radiometric method. The quantitation of serum total cortisol was performed using a coated 
tube RIA method (Incstar Corporation, Stillwater, USA). Thyroid stimulating hormone (TSH) 
was quantitated by manual methods using the IRMA principle with magnetic separation 
(Sereno Diagnostics, Switzerland). The determination of serum free thyroxin (T4) was 
carried out using the Amerelex-MAB kit (Kodak Clinical Diagnostics).   
2.7. Assessment of propensity to falls 
This assessment was carried out by a single observer (Magda Conradie) throughout the 
study period and included the following: 
QUESTIONNAIRE 
Questions regarding fall tendency were included in the standardized interviewer administered 
questionnaire (Addendum II) and addressed the following: 
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 Recent fall(s) – within the last 12 months (yes/no) 
o Number of falls 
o Where the fall(s) occurred 
o Direction of fall(s) i.e. forward, backwards or sideways 
o Known injuries sustained  
STANDARDIZED TESTS TO ASSESS SENSORY AND NEUROMUSCULAR FUNCTION 
Permission was obtained from Eli-Lilly Pharmaceuticals U.S.A. (Drs Mike Draper, Olaf Johnell) 
to utilize a battery of validated tests235, well established in our Department, as part of a 
previously conducted Raloxifene study (Protocol H3S-MC-GGHV(b) to assess these functions 
(Addendum IV). These tests included: 
 Body sway:   Body sway was measured using a sway meter - a specialized rod is 
attached to the individual’s waist, and anterior-posterior and lateral sway is recorded on 
graph paper (positioned behind the subject) while she stands on a firm surface and on a 
15cm thick piece of foam rubber (reduces proprioceptive inputs so that the individual is 
dependent on visual and vestibular cues to maintain a steady stance)235. 
 Reaction time:  Reaction time, recorded in milliseconds, is measured using a simple 
reaction time task which employs a light as the stimulus and depression of a switch by 
the hand as the response235. 
 Visual contrast sensitivity: Contrast sensitivity was assessed by the Melbourne Edge 
Test235  
 Muscle strength: Quadriceps strength was assessed using a strain gauge system 
attached to a specially constructed chair on which the patients were seated with their 
hips and knees flexed to approximately 90˚. In this position, the presence and degree of 
quadriceps activation was measured. Three maximal voluntary contractions were 
recorded and analyzed offline. The strongest maximal voluntary contraction of the 
dominant leg was noted in data analysis235.  
One way analysis of variance was used to determine ethnic differences in the various patient 
subgroups for fall data and sensory and neuromuscular function tests. Analysis of covariance 
was performed to assess the association between serum 25-OH Vitamin D status and fall risk 
in postmenopausal females.  
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3. Statistical analysis 
All analyses were conducted using Statistica 7.1 software. Cross tabulation and the Chi-
square test was used to compare categorical variables. Spearman correlation was used for 
comparing continuous variables. One way analysis of variance and analysis of co-variance 
was used for comparing measurements between groups. A p-value <0.05 was used as 
guideline for determining statistical significance. 
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CHAPTER 4 
ASSESSMENT OF CLINICAL RISK FACTORS FOR OSTEOPOROSIS IN BLACK 
AND WHITE SOUTH AFRICAN FEMALES 
1. INTRODUCTION 
Age, a positive family history, low weight and BMI, inadequate dietary calcium intake, 
current cigarette smoking, physical inactivity and a history of previous fragility fractures have 
all been shown to be independent risk factors for osteoporosis in population based studies of 
postmenopausal white women115,116,126,236. Age and weight have been shown to be the most 
informative predictors for low bone mineral density126. Studies evaluating clinical risk factors 
for osteoporosis in multi-ethnic groups are limited118,202, but do suggest that risk factors 
similar to those identified in white populations also impact on bone health in other ethnic 
groups. A single study by Blaauw et al in 1993119 identified a positive family history of 
osteoporosis, a fair complexion, lower body mass and height, no breastfeeding of babies, a 
history of smoking, alcohol consumption and fat distribution around the waist to be 
significant risk factors for osteoporosis in white South African females residing in the 
Western Cape. To our knowledge no studies evaluating clinical risk factors for osteoporosis 
have been done in other ethnic groups in South Africa. 
This chapter is a brief overview of the clinical and lifestyle characteristics of our study 
population and an assessment of clinical risk factors regarded to predispose to the 
development of osteoporosis.  
2. PATIENTS AND METHODS 
Our study population consisted of community-dwelling healthy White and Xhosa women 
residing in the Western Cape, South Africa and included 187 blacks and 186 whites. Due to 
known socio-economic and anthropometric differences between the two ethnic groups, 
recruitment aimed to include a representative sample of white and black females and did not 
specifically stratify patients based on socio-economic status or phenotype.  
We analyzed and report results of these 373 subjects in the following patient subgroups: 
• Premenopausal black and white groups 
• Early and late postmenopausal black and white groups:  
As alluded to in chapter 3, postmenopausal subjects were classified based on age and 
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subdivided into early and late postmenopausal groups, i.e. postmenopausal females less 
than 60 yrs of age were included in the early postmenopausal groups whereas 
postmenopausal women 60 yrs and older represented the late postmenopausal groups. 
The clinical characteristics of black and white patient subgroups were compared. One way 
analysis of variance was used to determine differences between the various ethnic 
subgroups in terms of anthropometric, menstrual and lifestyle risk factors. The prevalence of 
clinical risk factors were also reported on in premenopausal and postmenopausal cohorts and 
compared between the two ethnic groups. The standardization of risk categories are 
described in detail in chapter 3 (refer to section 2.1.1.1). 
3. RESULTS 
3.1. Clinical characteristics of the study population 
3.1.1. Anthropometric and menstrual data 
The anthropometric and menstrual data are summarized in table 1. Blacks and whites had 
similar mean ages in all the comparable groups studied.  In the total study population, blacks 
were on average 4 cm shorter and 11 kg heavier than whites. Blacks were significantly 
shorter in the premenopausal (± 7cm) and early postmenopausal groups (± 5cm). Of 
interest was the finding of similar heights in the late postmenopausal black and white 
females. The mean height measured in these subjects was near identical to that of the 
younger black females. Premenopausal and postmenopausal blacks were significantly heavier 
with greater BMI’s than whites, but elbow width, an index of skeletal frame size, was similar 
in all studied groups.  The waist-hip ratio was also higher in black subjects.  Age at 
menarche was statistically significantly older in blacks. In the postmenopausal women 
younger than 60 years of age, white females were older at menopause and the number of 
years since menopause was less compared with the black females. These parameters were 
similar in the older black and white postmenopausal females.  
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Table 1: Summary of Anthropometric and Menstrual data 
Anthropometric and Menstrual data Premenopausal Postmenopausal 
<60 years ≥ 60 years 
Blacks 
n=87 
Whites 
n=76 
p-value Blacks 
n=52 
Whites  
n=63 
p-value Blacks 
n=48 
Whites  
n=47 
p-value 
 
Age (yr) 37 ± 8 39 ± .7 0.1 52 ± 6 52 ± 5 0.43 68  ± 6 68 ± 6 0.49 
Height (cm) 160 ± 6 167 ± 6 <0.01 160  ± 7 165 ± 6 <0.01 159 ± 6 160 ± 7 0.16 
Weight (kg) 79 ± 21 69 ± 15 <0.01 80  ± 19 71 ± 15 <0.01 86  ± 19 71 ± 14 <0.01 
BMI (kg/cm2) 31  ± 8 25 ± 5 <0.01 32 ± 8 26 ± 5 <0.01 34 ± 8 28 ± 5 <0.01 
W/H ratio 0.85 ± 0.1 0.78 ± 0.8  <0.01 0.87 ± 0.1 0.8 ± 0.1 <0.01 0.9 ± 0.1 0.85 ± 0.1 0.03 
Elbow width (mm) 65 ± 5 66 ± 3 0.78 67 ± 4 66 ± 4 0.15 68 ± 6 67 ± 4 0.23 
Age menarche(yrs) 15 ± 3 13 ± 2 <0.01 14 ± 2 13 ±  2 <0.01 14 ± 2 13 ± 2 <0.01 
Age menopause (yrs)    46 ± 5 48 ± 5 0.02 49 ± 5 48 ± 5 0.20 
YSM (yrs)    7  ± 5 5 ± 5 0.04 19 ± 8 19 ± 7 0.37 
Values reported are the mean ±SD.  Abbreviations: W/H: waist-hip; YSM: years since menopause 
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3.1.2. Weight distribution amongst study subjects 
The weight distribution between the black and white female cohorts differed greatly (Table 
2). In the premenopausal cohort, a weight above 90 kg was noted in 27% of blacks, 
whereas only 8% of premenopausal whites weighed more than 90 kg. In the 
postmenopausal subjects a similar trend was noted i.e. 41% of blacks and 12% of whites 
had a weight above 90 kg respectively. It was especially in the older postmenopausal 
females where blacks predominated in the upper portion of the weight range (48% blacks 
vs. 11% whites).  
Table 2: Distribution of study subjects by ethnicity and weight 
Weight (kg) Premenopausal Postmenopausal 
  <60 years ≥ 60 years 
 Blacks 
n=87 
Whites 
n=76 
Blacks 
n=52 
Whites 
n=63 
Blacks 
n=48 
Whites  
n=47 
<50 5 (6)            1 (1) 0 1 (2) 1 (2) 2 (4) 
50 – 59 13 (15) 18 (24) 4 (8) 13 (21) 5 (10) 6 (13) 
60 – 69 13 (15) 30 (40) 16 (31)        21 (34) 3 (6) 15 (32) 
70 – 79 11 (13) 11 (14) 11 (21) 14 (23) 8 (17) 16 (34) 
80 – 89 21 (24) 10 (13) 3 (6) 5 (8) 8 (17) 3 (6) 
90 – 100 9 (10) 3 (4) 8 (15) 5 (8) 13 (27) 4 (9) 
> 100 15 (17) 3 (4) 9 (17) 3 (5) 10 (21) 1 (2) 
Distribution expressed as total number of subjects within the different ethnic cohorts (percentage in brackets) 
3.1.3. Lifestyle  
Table 3 shows the lifestyle characteristics of black and white subjects. Mean calcium intake 
was lower in the black patients compared with white patients in the total study population 
and in all comparable groups studied. Postmenopausal black subjects smoked significantly 
less compared with whites. Mean alcohol intake was well within accepted limits in all the 
black and white studied groups. Intake was comparable amongst the postmenopausal 
subgroups, but premenopausal blacks consumed significantly less alcohol than whites. This 
statistical difference is, however, unlikely to be of any clinical relevance. Postmenopausal 
white females maintained a higher level of physical activity compared with their black 
counterparts especially into old age.   
A positive family history of osteoporosis was present in 49 patients of whom 96% were white 
(47/49 subjects).   
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Table 3: Summary of lifestyle characteristics of the study subjects 
Lifestyle factor                                                                       Premenopausal Postmenopausal 
<60 years ≥ 60 years 
Blacks 
n=87 
Whites 
n=76 
p-value 
 
Blacks 
n=52 
Whites 
n=63 
p-value Blacks 
n=48 
Whites  
n=47 
p-value 
Ca-intake mg/d) 594 ± 298  876 ± 270  <0.01 597 ± 237 891 ± 231 <0.01 667 ± 304 821 ± 272 <0.01 
Smoking (pack yrs) 0.6 ± 1.8 3.8 ± 18 0.24 1.6 ± 4.7 7.2 ± 14 <0.01 0.17 ± 1 8.9 ± 4.1 <0.01 
Alcohol (U/week) 3.8 ± 8.8 4.2 ± 5.3 0.04 3.7 ± 11 2.3 ± 3.7 0.17 1.4 ± 4.2 1.8 ± 3.8 0.3 
PA score (0-4) 2.7 ± 0.9 2.8 ± 1 0.73 2.4 ± 1 2.8 ± 0.9 0.04 1.9 ± 0.9 2.7 ± 0.8 <0.01 
Positive FH (%) 1 28  2 31  0 13  
OC usage (%) 17 72  16 57  29 30  
DP usage (%) 45 3  33 3  6 2  
Pregnancies (n) 3 ± 2 2 ± 1 0.03 3 ± 2 2 ± 1 <0.01 6 ± 3 3 ± 2 <0.01 
B-feeding+ (%) 70 58  78 62  88 68  
HT–current n(%)    3 (6) 30 (46)  0 (0) 18 (38)  
Values reported are the mean ± SD.  Abbreviations: Ca-intake: calcium intake; PA: physical activity; FH: family history; OC: oral contraceptive; 
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Black females had more pregnancies than whites in all the studied groups. The oldest cohort 
had the highest pregnancy rate for both ethnic groups.  A high percentage of both black and 
white females breastfed their babies, with consistently higher percentages documented in 
blacks.   
Pharmacological contraception was used by a significant percentage of the study cohort at 
some time in their lifespan. It appears as if the use of contraception has gained popularity 
with time since the percentage users amongst both black and white females were highest in 
the younger age groups (62 & 75% respectively). An important observation is the increase in 
popularity of depot-medroxyprogesterone acetate (DP) vs. oral estrogen containing 
contraception amongst the younger black females. Only 6% of the black subjects over the 
age of 59 years made prior use of DP compared to 45% of young premenopausal blacks. 
Amongst the premenopausal ever-users of contraception 4 blacks were currently on oral 
contraceptives and 14 (16%) on DP. As only premenopausal subjects with a regular 
menstrual cycle were eligible for study entry, we excluded 17 black current users of DP at 
the start of the study due to DP induced amenorrhea. The percentage current users of DP 
are thus most likely significantly higher in young South African blacks than that noted in our 
study group. In whites, 12 (16%) were currently on oral contraception and 1 patient used 
depot-medroxyprogesterone acetate at the time of the study. Only premenopausal women 
with a regular menstrual cycle were eligible for inclusion into this study, and thus 19 patients 
with oligo-amenorrhea on depo provera (2 white, 17 black) were excluded from study entry 
(chapter 3, section 1.2).  
Past and current use of hormone therapy amongst postmenopausal females was, with the 
exception of 3 blacks, confined to the white cohort.  
3.2. Prevalence of clinical risk factors  
3.2.1. Literature-based risk factors for white women 
In addition to the most significant clinical risk factors for osteoporosis in population based 
studies of white postmenopausal women115,116,126,236 (age, a positive family history, low BMI, 
inadequate dietary calcium intake, current cigarette smoking and physical inactivity), we 
included weight and height (additional anthropometric variables), alcohol intake, the use of  
contraceptives (oral estrogen containing tablets and depo provera), hormone therapy, parity 
(number of prior pregnancies) and absence of breastfeeding in our analysis as there were 
significant differences in these parameters between the two ethnic groups and because they 
have been found to be significant risk factors for osteoporosis in white females, both 
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locally119 and abroad115,116,236. As mentioned earlier, the standardization of risk categories are 
described in detail in chapter 3 (please refer to section 2.1.1.1). 
3.2.2. Prevalence of clinical risk factors by ethnicity and menopausal status 
PREMENOPAUSAL COHORT 
The frequency of each risk factor in premenopausal blacks and whites is presented in  
figure 1A. Marked differences in the frequency of many clinical risk factors for osteoporosis 
were observed between these two racial groups. Blacks were more likely to be short, have a 
low calcium-intake, be an ever-user of DP and be of high parity. A positive family history of 
OP and ever-use of oral contraceptives dominated in whites. Although mean body weight 
was significantly higher in premenopausal blacks (see table 2), the subset of premenopausal 
females presenting with a low body weight was similar in the two ethnic groups (10% 
blacks, 12% whites). The lower percentage of premenopausal blacks with a low BMI is due 
to their significantly lower heights. 
POSTMENOPAUSAL COHORT  
The frequency of each risk factor in postmenopausal blacks and whites is presented in  
figure 1B. Inter-ethnic comparison of risk factors differed between pre- and postmenopausal 
women. A higher percentage of postmenopausal blacks had low height, low calcium intake, 
physical inactivity and high parity. Whites were more likely to be of low body weight and BMI 
and a positive family history and hormone use were almost confined to this ethnic group. 
Black females appear to increase their body weight with ageing (table 1), and it is therefore 
not surprising to find a more pronounced ethnic difference in the percentage of females with 
low body weight and BMI in the postmenopausal cohorts (blacks vs. whites; 10 vs. 20% for 
low weight; 6 vs. 27% for low BMI).  A low BMI was only present in a small minority of black 
females (6%).  
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Figure 1 A & B: Frequency of low weight, height, BMI, low calcium intake, current smoking, physical inactivity, 
high alcohol intake, positive maternal history of OP, prior or current use of depo provera, no prior or current 
use of oral contraceptives, parity and no breastfeeding in premenopausal (fig. 1A) and postmenopausal (fig. 1B) 
black and white females. Current use of hormone therapy was evaluated in the postmenopausal cohorts only 
Low weight    Low BMI     Smoking       Alcohol         Depo+           Parity >2    
         Low height     Low Ca          Physical         FH+               OC              No BF 
                                                        Inactivity 
Low weight  Low BMI      Smoking      Alcohol          Depo+       Parity>2       HT+ 
            Low height   Low Ca       Physical         FH+            OC              No BF 
                                                     Inactivity 
      :  BLACKS 
      :  WHITES 
A 
      :  BLACKS 
      :  WHITES 
B 
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4. DISCUSSION 
We studied black and white females aged 20-82 years with regard to clinical characteristics 
and lifestyle factors known to affect bone health. Significant ethnic differences were noted in 
the presence and frequency of historical clinical and lifestyle risk factors for osteoporosis, 
especially pertaining to body size, mode of contraception, calcium-intake and physical 
activity.  
ANTHROPOMETRY 
Weight 
Blacks were heavier than whites in all the subgroups studied. The percentage of 
premenopausal blacks and whites with low body weight were, however similar, whereas 
more older whites were noted to have a low body weight. The higher mean body weight in 
the black females was accentuated with ageing due to an apparent increase in mean body 
weight in the black females only.  Previous research consistently documented higher body 
weight in the black populations of America144,184,186,193,199 and South Africa1 compared with 
whites. Mean total body weight in our study population was markedly higher in blacks 
compared with whites, especially in the postmenopausal subjects. 
Body weight has been identified as one of the most important determinants of BMD at most 
skeletal sites in postmenopausal black and white women126,184,193,195,199,238,239. Obesity is 
associated with increased peak bone mineral density193,199 , with higher bone mineral density 
in postmenopausal women195,238,239 and with slower rates of vertebral and femoral bone 
loss239,240.  A low body weight, on the other hand, has been identified in numerous studies, 
some performed in multi-ethnic populations, as an important risk factor for low bone density 
and fracture118,136,202,241-245.    
Different mechanisms whereby obesity exerts its skeletal protection have been proposed and 
include both mechanical and hormonal effects239. The mechanical loading of body weight per 
se results in stress on the skeleton and preferentially enhances the bone mass of weight-
bearing sites193,239 . Skeletal loading has the greatest impact on bone mass at those sites that 
directly bear the greatest gravitational force such as the proximal femur239. Excess adipose 
tissue is also positively associated with circulating levels of leptin81,83,85, insulin72, 
adiponectin246, androgens and oestrogens247,248, hormones known to either enhance bone 
formation and/or reduce bone resorption. After menopause, body fat becomes the main 
determinant of endogenous estrogen activity. The production of androgens is higher in 
obese than in normal weight women, and the excess body fat will increase adipocyte 
conversion of androgens to estrogens.  
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These metabolic effects may be more important than the direct mechanical impact of obesity 
at the non-weight-bearing sites of the skeleton, especially in postmenopausal females. The 
relationship between body mass and bone loss is thus influenced by the different 
mechanisms whereby obesity exerts its skeletal protection, as mentioned earlier. One can 
therefore hypothesize that obesity, due to its oestrogenic effects, will preferentially protect 
against rapid trabecular bone loss from the spine in the early postmenopausal period. The 
mechanical loading of obesity, on the other hand, will be expected to exert its dominant 
protective effect on the femoral region and this may be more important in the later 
postmenopausal period when hip fracture risk is highest.   
The effects of weight on BMD are also known to be mediated via both fat and lean body 
mass239. Total body fat mass is a major determinant of BMD in Caucasians and African-
Americans250, but there is also evidence that fat-free (lean) body mass plays an important 
role in determining BMD in both ethnic groups242. The relative contribution of lean versus fat 
mass remains controversial and depends in part on the age of the population studied. Reid 
et al250 have documented that total body fat is the most significant predictor of BMD 
throughout the skeleton in normal postmenopausal females. Zhao et al251  studied Caucasian 
females aged 62 ± 11 yrs and reported that fat mass is inversely correlated with bone mass 
when the mechanical loading effects of body weight on bone mass are controlled for, and a 
recent study by Gilsanz and co-workers documented no beneficial effect of fat mass to bone 
mass in white adolescents and young adults252.  
Although it appeared as if body weight was maintained with ageing in both our ethnic 
groups, a low body weight was present in a higher percentage of older white females, which 
may potentially contribute to femoral bone loss. In elderly women, a low body mass or 
weight loss irrespective of current weight, have been identified as risk factors for increased 
femoral bone loss244,253. A low body weight and weight loss are also risk factors for hip 
fracture in older women, partially because of its association with a lower BMD, but also 
increases hip fracture risk independently of BMD due to an increased propensity to fall or the 
absence of a cushioning effect upon falling253,254.  
Height 
In our study, premenopausal and younger postmenopausal blacks were shorter than whites. 
Heights in the late postmenopausal blacks and whites were similar and similar to heights 
recorded in younger blacks, thus suggestive of an apparent height loss with ageing in whites 
only. Height may impact on bone strength via its influence on BMD and skeletal macro-
geometry. Tallness, in youth, has been associated with higher spinal and femoral BMD115,119 
and as such would protect against fragility fractures. Despite this association, tallness has 
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been implicated as a risk factor for hip fracture. Taller women have a longer hip-axis length 
which has been associated with a greater risk for hip fracture160-166, and they fall from a 
greater height.  
A lower vertebral bone size has been found in women predisposed to spinal fractures167. The 
shorter height in blacks may imply a shorter trunk length and smaller vertebral height and 
bone size203 and may as such potentially compromise vertebral strength and enhance 
vertebral fracture risk in blacks.  
Height may thus have differing effects on fracture risk at different skeletal sites via its effects 
on bone mineral density and on skeletal geometry. Shortness in our black population may be 
associated with a lower BMD and thus increase fragility fracture risk. The expected shorter 
hip-axis lengths in blacks may, however, protect against hip fracture, whereas smaller 
vertebral size may potentially increase vertebral fracture risk. 
REPRODUCTIVE SYSTEM 
In our study, the mode of contraception and the frequency of hormonal therapy differed 
markedly between blacks and whites.  
Mode of contraception 
Oral contraceptives (OCP) were the preferred mode of contraception in white females, 
whereas, depot-medroxyprogesterone acetate (DP) was used most often, and almost 
exclusively, by the younger black females. Use of pharmacological contraception was notably 
low in the older postmenopausal cohorts, and the highest percentage ever users were 
amongst the premenopausal subjects. The impact of hormonal contraceptives on bone 
mineral density has produced conflicting results. OCP are mostly regarded as bone-sparing or 
without BMD effects255,256, whereas DP unequivocally decrease bone mass255,257-262.   
Oral contraceptive use 
Conceptually, the oestrogen content of the oral contraceptive pills should have a beneficial 
effect on the skeleton irrespective of age, but the evidence for this is by no means 
unequivocal. Although it is still generally believed that OCP has no untoward or even a 
beneficial effect255,256 on bone mass in premenopausal women, there has been accumulating 
evidence of late raising the concern that OCP use may interfere with normal acquisition of 
peak bone mass in young women, especially if started at a very young age. Prospective 
studies in young 19 – 22 year old Italian263 and Swedish women264 reported negative 
influences of OCP use on the normal age-related increase in bone mass. In addition, a cross-
sectional study in 524 Canadian women265 documented that OCP use was associated with 
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lower spinal and femoral BMD relative to control subjects. Detrimental effects on peak spinal 
and femoral bone mass have also been documented in a group of healthy 18-24 year old 
German women266; the age of initiating OCP was a major determinant of bone loss.  A 10% 
lowering of femoral neck BMD was observed in girls with OCP use of more than 2 years and 
initiation of therapy within 3 years of menarche in the study by Hartard et al266. Last 
mentioned author hypothesized that potential suppression of periosteal bone apposition by 
estrogen267-269 and profound lowering of androgen levels due to feedback inhibition of the 
hypothalamus-pituitary axis270 may be responsible for the detrimental effects of OCP use in 
young women. It is unclear at present whether the observed negative effect of OCP use on 
bone mass in young women is reversible after discontinuation of OCP’s or whether it poses a 
significant long-term risk for osteoporosis later in life. Most studies suggest a limited impact 
of past use of OCP on BMD in older peri- and postmenopausal women271-274 and no protective 
effect of past OCP use on fracture risk could be demonstrated in two large epidemiological 
studies in Great Britian275,276.  
The influence of OCP use on BMD has mostly been studied in Caucasian populations and 
little is known regarding the impact of OCP on BMD in blacks. OCP use was unrelated to BMD 
in African-American women in a study by Cobb et al277.  It has been hypothesized that 
oestrogen protects against PTH-mediated bone loss. Most previous studies have noted lower 
bone turnover rates in black compared with white women138,140-142,146,196 despite higher 
endogenous PTH-levels. This is ascribed to a relative skeletal resistance to the action of 
PTH138,144,146,196 in blacks, which may explain their relative insensitivity to the oestrogenic 
actions of OCP’s. Due to their higher body weight, black women may also have a higher 
steady state oestrogen production and this might also explain the lack of association 
between OCP’s and BMD in black women.   
Depot-medroxyprogesterone acetate 
In our study depot-medroxyprogesterone acetate (DP) was the preferred hormonal method 
of contraception amongst blacks with the highest percentage ever-users amongst our 
younger black females (40%). In South Africa, hormonal injectable contraceptive use is high, 
with about 60% of black African women practicing contraception either using DP or 
norethisterone enanthate278.  
The main contraceptive action of DP is the suppression of ovulation. Hypo-oestrogenemia, as 
is the case in DP users, may adversely affect bone mass and increase the likelihood of 
osteoporosis.  Most255,257-262  studies show that depot-medroxyprogesterone acetate has a 
negative effect on bone mass. These detrimental effects are particularly apparent when DP is 
used in adolescents who have not yet achieved peak bone mass. In cross-sectional 
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studies258,260,261, the mean BMD of Depo Provera users were below that of non-users, with 
some of the studies suggestive of a preferential impact on lumbar spine BMD261. In 
longitudinal studies, BMD generally decreased more over time in users of DP than among 
nonusers259,262. It has also been noted that associated low BMI enhanced the negative 
impact of DP at the spinal and femoral sites261. The negative effect of DP on BMD was, 
however, noted to be reversible upon discontinuation in longitudinal studies259,262 and the 
impact of past use of Depo Provera on BMD small in postmenopausal women271,279. 
Hormonal contraception, whether in the form of OCP or injectable depot-
medroxyprogesterone acetate, may thus be deleterious to bone health, especially if 
commenced at an early age, used for a prolonged period of time and currently in use. 
Negative effects on bone mass, as a result of hormonal contraception, appears to be 
temporary with significant bone gain observed upon discontinuation of especially DP259,262. 
Whether either mode of contraception has any significant impact on bone mineral density in 
later life, when fracture risk is highest, remains uncertain.  
Menarche, parity and hormone therapy 
Menarche was reached at a statistically significantly later age in blacks (p<0.01) compared 
with whites. The clinical significance of a one year difference in menarchial onset is, 
however, uncertain.  
High parity i.e. 3 pregnancies or more was noted in the majority of postmenopausal black 
females (78%) with the highest pregnancy rate noted amongst the older subjects. In whites 
the number of pregnancies was lower in all the subgroups evaluated. Over a lifetime, 
increasing parity might be expected to protect against bone loss because of pregnancy 
related increases in body weight, intestinal calcium absorption, cumulative estrogen 
exposure and a later age at menopause. Several reports have confirmed this positive 
correlation between parity and BMD280,281, although other studies have reported no 
correlation between parity and BMD282-284 or a negative correlation285. Many of these studies 
have been performed in premenopausal women or in women younger than the age typically 
seen for osteoporotic fracture. In addition, many studies have been conducted in women 
with low (e.g. 1-3) parity280,282. The few studies281,284,285 conducted in very high parity (more 
than or equal to five live births) postmenopausal women have provided conflicting results 
and data suggests that the skeletal benefit of high parity is modest and are overshadowed 
by the BMD changes that occur during the menopausal transition. To what extent differences 
in parity affects bone mineral density in later life remains uncertain.  
 86 
Hormone therapy was used almost exclusively by whites in this study. The mean duration of 
therapy in current hormone users in our white postmenopausal women was 8 years (range 
1–18 years). Current hormone therapy (estrogen ± progestin) protects against 
postmenopausal bone loss, results in significant “bone gain” over time and reduces 
subsequent fractures as shown by numerous previous epidemiological studies285-287, and 
meta-analyses288-290 in healthy postmenopausal subjects and also recently confirmed in the 
Women’s Health Initiative randomized trial291-293.  
LIFESTYLE FACTORS 
In our study, the mean calcium-intake of pre- and postmenopausal blacks was significantly 
lower than whites and a low calcium intake (defined as a daily intake of less than 500mg 
daily) was present in a high percentage of pre- and postmenopausal blacks (48% and 32% 
respectively).  
Calcium-intake 
Calcium nutrition is commonly considered to be important for the attainment of peak bone 
mass and for optimal maintenance of skeletal mass34-37. However, calcium is also recognized 
as a threshold nutrient, i.e., the effect of variations in intake are evident only up to some 
threshold intake level, above which further increases in intake produce no further change in 
skeletal mass.  
Precisely what those threshold values may be at various life-stages remain uncertain. A 
recent meta-analysis of randomized controlled trials by Winzenberg et al294 concluded that 
calcium supplementation in healthy, mostly white children, had no effect on bone mineral 
density at the hip and spine and only a small effect on the upper limb. These changes were 
regarded as insufficient to reduce the risk of fracture, either in childhood or later life. The 
meta-analysis only included a few studies in children with low baseline calcium intakes and 
more such studies are needed to assess potential benefit of calcium supplementation under 
such circumstances.   
In postmenopausal women, there is now clinical trial evidence295-300 that calcium has a 
positive effect on bone mineral density at the hip and spine. Some studies have shown that 
the skeletal benefit of calcium is most evident in the first year of treatment299,300. A sustained 
reduction in bone loss and turnover with long-term calcium supplementation was, however, 
confirmed in a recent large randomized controlled study in healthy older women295. These 
beneficial effects were present throughout the skeleton (lumbar spine, total hip and total 
body), were independent of age and were present in individuals with both high and low 
dietary calcium intakes. Recently published large studies on calcium supplementation295,301,302 
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were, however, unable to confirm the anti-fracture efficacy of calcium supplementation. A 
Cochrane review303 in postmenopausal women concluded that calcium supplementation alone 
has a small positive effect on bone density. A trend toward reduction in vertebral fractures 
was shown, but it remained unclear if calcium reduces the risk of non-vertebral fractures.  
Most studies assessing the skeletal effects of calcium, both in childhood and in later life, 
were conducted in white populations and less is known about the impact of calcium nutrition 
on skeletal health in black populations. Inadequate intake of calcium leads to reduced 
calcium absorption, increased serum parathyroid hormone concentrations, and bone loss54. 
Skeletal resistance to the actions of PTH in blacks may potentially protect them against the 
effects of a low calcium intake. The resistance is, however, relative and secondary 
hyperparathyroidism is known to exert deleterious skeletal effects in all ethnic groups145.  
Smoking and alcohol-intake 
White postmenopausal women smoked more (expressed as total pack years) and were more 
likely to be current smokers than blacks in this study. Alcohol intake was low and comparable 
between blacks and whites. Smoking115,118,119,241,247,304 and excessive alcohol-intake115,119,244,305 
are known risk factors for bone loss, osteopenia and subsequent increased fracture risk. 
Women who smoke have lower serum estrogen levels, a lower body mass and undergo 
menopause at an earlier age.  
Physical activity 
In our study, physical activity levels were similar in the younger blacks and whites, but 
significantly less well maintained amongst blacks, with an impressive 69% of 
postmenopausal blacks not partaking in any form of out-door activity. Exercise has its 
greatest effect on the skeleton during growth and development1,39,40,306-308, and in the 
weight-bearing regions of the skeleton, with the hip region being most receptive to differing 
levels of physical activity309. It is unclear at present whether the effect of exercise is 
maintained once it is stopped and whether prepubertal exercise has any impact on bone 
mass in later life. Life-long exercise may reduce fracture risk by limiting age related bone 
loss310 and by improving muscle strength311 (thereby reducing the frequency and severity of 
falls). In a study on the association between physical activity and bone mass in black and 
white South African schoolchildren, physical activity levels were noted to be lower in 
blacks215. A significant association between hip and spine BMC and BMD and increased levels 
of physical activity was found in white children whereas a significant positive correlation 
were found only between physical activity and whole body BMD in black children. This may 
imply that these black children just did not reach the “threshold” physical activity necessary 
to induce an osteogenic effect, but it remains unclear whether higher activity levels will 
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induce the same benefits in black children as seen in whites. Studies conducted in developed 
countries have shown that inactivity and activity patterns differ by ethnicity208, with black 
groups engaged in less physical activity as seen in our study subjects. Inactivity in our older 
blacks may potentially compromise bone strength and increase fall and fracture risk. 
Family history of OP 
A maternal family history of OP was almost exclusively reported by the white females. A 
maternal history of osteoporosis is associated with lower lumbar and femoral BMD among 
daughters115,116,133,134,312.  
To conclude, in our study population significant ethnic differences were noted in the 
presence and frequency of historical clinical and lifestyle risk factors for osteoporosis. These 
risk factors exert unique effects on skeletal health, varying in terms of magnitude of impact 
on bone mineral density, skeletal site affected, and influence on peak bone mineral density 
and/or on rate of bone loss. Blacks were heavier and shorter; they consumed less calcium, 
were more inactive, preferred depot-medroxyprogesterone acetate as contraceptive agent 
and were of higher parity. Whites smoked more, preferred oral contraceptive tablets and 
were more likely to have a positive family history of osteoporosis. Hormone therapy was 
used almost exclusively by postmenopausal whites. Inter-ethnic differences in weight, 
physical activity and high parity was most marked in the older subjects. The impact of these 
clinical risk profiles on bone strength parameters in blacks and whites may differ significantly 
and must be considered when these parameters are compared. 
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CHAPTER 5 
BONE MINERAL DENSITY IN BLACK AND WHITE SOUTH AFRICAN FEMALES 
1.  INTRODUCTION 
Bone mineral density (BMD) is an excellent predictor of bone strength and fracture risk at all 
skeletal sites25-30. BMD and fracture rates vary among women of differing ethnicities. African-
Americans have higher bone mineral density in the axial and appendicular skeleton 
compared with their white counterparts135,138,143-145,184-199, and these differences may account 
for their lower incidence of osteoporotic fractures135,136,237,243. On the African continent, 
including South Africa, studies are limited but not nearly as unanimous on greater bone 
density in blacks, yet they do have markedly lower fracture rates compared with 
whites20,211,212. Limited studies have reported that South African blacks have similar 
appendicular and lumbar spine bone mineral density (BMD), but higher femoral BMD 
compared with whites1,213. In the 70’s, Solomon reported a ten-fold lower hip fracture rate in 
urbanized SA blacks compared with whites despite very similar bone mass values20. 
This chapter reports on bone mineral density results obtained via dual energy X-ray 
absorptiometry in blacks and whites.  
2. PATIENTS AND METHODS 
We assessed bone mineral density of the lumbar spine and the proximal femur employing 
dual energy X-ray absorptiometry in a study cohort which included 187 black women and 
186 white women. Bone mineral density data pertaining to the group of postmenopausal 
subjects currently on hormone therapy, 44 white females and 3 black females, are not 
reported in this chapter. Due to the well documented skeletal protection offered by hormone 
therapy, data on these subjects were analyzed separately and reported on in Chapter 12.   
We analyzed and report areal bone mineral density (BMD) and ‘volumetric’ bone mineral 
apparent density (BMAD) results in the following subgroups: 
● Premenopausal black and white groups 
● Early and late postmenopausal black and white groups i.e. as outlined in chapter 3 
(section 1.4) postmenopausal females less than 60 yrs of age were included in the 
early postmenopausal groups whereas postmenopausal women 60 yrs and older 
represented the late postmenopausal groups. 
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● To control for adiposity, data were also analyzed by dividing pre- and postmenopausal 
subjects into weight subgroups i.e. a subgroup with normal to low body mass index 
(BMI <25kg/m2) and a subgroup defined as overweight (BMI ≥ 25 kg/m2)223. To 
ensure sufficient numbers within the different weight subgroups to allow analysis of 
BMD data, the total postmenopausal group were not subdivided based on age, but 
assessed in total. 
The baseline clinical characteristics (table 1) of this DEXA cohort (n=326) were identical to 
the total study cohort (refer to chapter 4, tables 1 & 3). Blacks and whites had similar mean 
ages in all the comparable groups studied. In general, blacks were shorter and heavier than 
whites, reached menarche at a later age, preferred injectable hormone contraception, had a 
larger number of pregnancies and consumed less calcium daily. The white women smoked 
more, but maintained a higher level of physical activity post menopause. Mean alcohol 
consumption was low and comparable between the two groups. 
The baseline clinical characteristics of the premenopausal weight groups are shown in table 
2. The black females in the normal to low BMI subgroup were significantly smaller with lower 
mean weight and height compared with the white females. The mean BMI was, however, 
identical in the two ethnic groups. In the overweight subgroup, blacks were significantly 
heavier with greater BMI’s than whites. The number of blacks classified as normal to low BMI 
was about half that of whites and the converse was true for the overweight subgroup i.e. the 
number of overweight blacks was about twice that of the whites. The waist-hip ratio was 
similar in the two ethnic groups in both the normal to low BMI and overweight subgroups. 
Elbow width was lower in the black females compared with whites in the normal to low BMI 
group, but similar in the overweight groups. 
The baseline clinical characteristics of the postmenopausal weight groups are shown in  
table 3. The majority of postmenopausal blacks (77%) and whites (59%) were categorized 
as overweight based on BMI values. In the normal to low BMI group, only BMI and waist-hip 
ratio were noted to be higher in blacks, whereas all the anthropometric variables were 
significantly higher in the overweight blacks compared with whites. Elbow width as an index 
of skeletal frame size was similar between blacks and whites in both weight subgroups. 
Methodological principles with regard to DEXA BMD and BMAD measurements are detailed in 
Chapter 3 (please refer to section 2.2).  For all skeletal sites, BMD’s were first compared, 
using ANOVA, between ethnic subgroups before adjustment for covariates. Thereafter, 
BMD’s were also expressed as adjusted values based on findings of analysis of covariance. 
For the premenopausal subjects, covariates included ethnicity, age, weight, height, daily 
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calcium intake, pack years of smoking, alcohol intake, physical activity, age at menarche, 
hormonal contraception and number of prior pregnancies. For the postmenopausal subjects, 
covariates included years since menopause in addition to the abovementioned. Bonferonni 
testing were used for post hoc comparison. 
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Table 1: Summary of anthropometric, lifestyle and menstrual data of the DEXA cohort 
Clinical characteristics                Premenopausal Postmenopausal 
 < 60 years ≥ 60 years 
Blacks 
n=87 
Whites 
n=76 
p-value Blacks 
n=49 
Whites  
n=35 
p-value Blacks 
n=48 
Whites         
n=31 
p-value 
 
Age (yr) 37 ± 8 39 ± .7 0.1 52 ± 6 52 ± 5 0.43 68  ± 6 70 ± 5 0.49 
Height (cm)                             160 ± 6 167 ± 6 <0.01 160  ± 7 166 ± 7 <0.01 159 ± 6 160 ± 7 0.16 
Weight (kg) 79 ± 21 69 ± 15 <0.01 80  ± 19 71 ± 17 <0.01 86  ± 19 72 ± 15 <0.01 
BMI (kg/cm2) 31  ± 8 25 ± 5 <0.01 32 ± 8 26 ± 6 <0.01 34 ± 8 28 ± 5 <0.01 
Waist/Hip ratio (cm) 0.84 ± 0.1 0.78 ± 0.1 <0.01 0.87  ± 0.1 0.79 ± 0.1 <0.01 0.90 ± 0.1 0.88 ± 0.1 0.03 
Elbow width (mm) 65 ± 5 66 ± 3 0.78 67 ± 4 66 ± 4 0.15 68 ± 6 68 ± 5 0.23 
Age at menarche(yrs) 15 ± 3 13 ± 2 <0.01 14 ± 2 13 ±  2 <0.01 14 ± 2 13 ± 1 <0.01 
Menopause age (yrs)    46 ± 5 49 ± 4 0.02 49 ± 5 49 ± 5 0.20 
YSM (yrs)    7  ± 5 4 ± 4 0.04 19 ± 8 21 ± 7 0.37 
Calcium intake (mg/d) 594 ± 298 876 ± 270 <0.01 597 ± 237 879 ± 230 <0.01 667 ± 304 821 ± 272 <0.01 
Smoking (pack yrs) 0.6 ± 1.8 3.8 ± 18 0.24 1.6 ± 4.7 5 ± 11 <0.01 0.17 ± 1 8.9 ± 14.1 <0.01 
Alcohol (U/week 3.8 ± 8.8 4.2 ± 5.3 0.04 3.7 ± 11 2.9 ± 5.1 0.17 1.4 ± 4.2 1.8 ± 3.8 0.3 
PA score (0-4) 2.7 ± 0.9 2.8 ± 1  2.4 ± 1 3.1 ± 0.9 0.04 1.9 ± 0.9 2.7 ± 0.8 <0.01 
Family history (%) 1 28  2 29  0 13  
OCP use (%) 17 72  16 54  29 30  
DP use (%) 45 3  33 6  6 2  
Nr of pregnancies (n) 3 ± 2 2 ± 1 0.03 3 ± 2 2 ± 1 <0.01 6 ± 3 4 ± 2 <0.01 
Breastfeeding+ (%) 70 58  78 62  88 68  
Values expressed as mean ± SD except where otherwise stated 
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Table 2: Comparison of anthropometric data in premenopausal blacks and white in normal to low BMI and overweight subgroups. 
Clinical characteristics                                                                Premenopausal groups 
Normal to low BMI subgroup (BMI < 25kg/m2)              Overweight subgroup(BMI ≥ 25kg/m2)    
Blacks (n=23) Whites (n = 47) Blacks (n= 64) Whites (n= 29) 
Age (yr) 35*  ±  9 39  ±  6 37  ±  8  37  ±  7 
Height (cm) 157* ±  5 167 ±  6 161* ±  6 167 ±  7 
Weight (kg) 55*±  7 61 ±  6 87* ±  7 83 ±  14 
BMI (kg/cm2) 22 ± 2 22 ±  2 34* ±  6 30 ±  4 
Waist/Hip ratio (cm) 0.78  ±  0.06 0.77 ±  0.05 0.85 ±  0.09 0.81 ±  0.08 
Elbow width (mm) 61* ±  3 64  ± 3 67 ±  5 68 ±  3 
Values reported are the mean±SD; *p < 0.01 premenopausal blacks vs. premenopausal whites within specific subgroup 
Table 3: Comparison of anthropometric data in postmenopausal blacks and whites in normal to low BMI and overweight subgroups. 
Clinical characteristics                                                                                                     Postmenopausal groups 
Normal to low BMI subgroup (BMI < 25kg/m2)       Overweight subgroup(BMI ≥ 25kg/m2)    
Blacks (n=22) Whites (n = 27) Blacks (n= 75) Whites (n=39 ) 
Age (yr) 60 ± 10 58 ± 11 60 ± 9                61 ± 10 
Height (cm) 162 ± 6 164 ± 8 159* ± 7 162 ± 7 
Weight (kg) 61 ± 6 59 ± 8 90* ± 17 80 ± 15 
BMI (kg/cm2) 23* ± 2 22 ± 2 36* ± 7 31 ± 4 
Waist/Hip ratio (cm) 0.83* ± 0.1 0.77 ± 0.1 0.90* ± 0.1 0.86 ± 0.1 
Elbow width (mm) 65 ± 4 65 ± 3 69 ± 5 68 ± 4 
Values reported are the mean ±  SD; *p < 0.01 postmenopausal blacks vs. postmenopausal whites within specific weight subgroup 
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3. RESULTS 
3.1. LUMBAR SPINE BONE MINERAL DENSITY  
3.1.1. Premenopausal subjects 
The premenopausal cohort consisted of 87 black females and 76 white females.  
3.1.1.1. Spinal bone mineral density 
Mean lumbar spine bone mineral content (SBMC), bone area and unadjusted spinal bone 
mineral density (SBMD) were significantly lower in the black premenopausal females 
compared with the white subjects. Univariate tests of significance identified ethnicity, body 
weight (p<0.01) and height (p<0.01) to be significantly associated with SBMD (figure 1 and 
table 4). After adjustment for weight as a covariate, mean SBMD remained significantly 
lower in the black cohort, whereas the difference in SBMD between the two cohorts was 
non-significant after adjustment for height. 
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Figure 1: Mean lumbar spine bone mineral content (SBMC), mean lumbar bone area and unadjusted and adjusted mean SBMD. 
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Table 4: Comparison of mean SBMC, lumbar bone area and SBMD in premenopausal black and white females 
Bone mineral data Premenopausal subjects 
 Blacks (n=87) Whites  (n=76) p-value 
SBMC (grams) 59.57 ± 10.7 66.57 ± 11.2 <0.01       
S-Bone area (cm2) 56.23 ± 5.55     60.38 ± 5.23 <0.01 
SBMD (g/cm2) 
   Unadjusted 
   Adjusted for weight 
   Adjusted for height 
 
1.047 ± 0.12 
1.036 ± 0.12 
1.064 ± 0.13  
 
1.099 ± 0.13 
1.110 ± 0.12 
1.081 ± 0.13 
 
0.01 
<0.01 
0.45 
Values reported are the mean ±  SD 
3.1.1.1.1. Correlation of SBMD with Anthropometric variables 
Except for BMI in the white females, weight, height and BMI correlated significantly with 
SBMD. The association between weight and BMI, and SBMD, is markedly stronger in the 
black cohort (figure 2). This may be partially explained by the much wider weight and BMI 
distribution in the blacks. Elbow width as an index of skeletal frame size, was similar in the 
two premenopausal cohorts and correlated significantly with SBMD in the black group only. 
3.1.1.1.2. SBMD in normal to low weight and overweight subgroups 
As alluded to before, in view of differences in body size between the premenopausal black 
and white females that may partially explain observed ethnic differences in SBMD, BMD was 
reanalyzed in subsets of normal to low BMI and overweight premenopausal women (table 5).  
SBMD was statistically significantly lower in the black females compared with the white 
females in the normal to low BMI group (p<0.01), but similar between the black and the 
white subjects in the overweight group. The mean SBMD of normal to low BMI black patients 
was significantly lower compared with their overweight counterparts, but the mean SBMD of 
white subjects in the two subgroups was similar.  Due to the fact that there was a slight, but 
statistically significant difference in age between the black (35 ± 9yrs) and white (39 ± 6yrs) 
females in the normal to low weight subgroup, BMD was also compared as Z-scores. Results 
were similar to that documented for the absolute BMD values i.e. these blacks had 
significantly lower Z-scores compared with their white counterparts and also significantly 
lower Z-scores compared to their overweight counterparts. The difference in SBMD between 
the total black and white premenopausal cohorts can thus be mainly attributed to the 
difference in SBMD in the subjects with a BMI < 25kg/m2.  
Body size in this subgroup of normal to low BMI premenopausal females was, however, 
significantly smaller in blacks than whites when based on weight and height per se and 
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might, in part, explain why there was a more marked negative impact on BMD in the black 
females compared with whites in this subgroup. 
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Figure 2: Correlation of SBMD with weight, BMI, height and elbow-width in premenopausal black (panels B1-B4) and white (panels W1–W4) groups. 
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Table 5: Spinal bone mineral density data in premenopausal subgroups based on BMI 
BMD (g/cm2)                                                            Premenopausal females 
Normal to low BMI subgroup (BMI<25kg/m2)   Overweight subgroup (BMI ≥ 25kg/m2)   
Blacks  
(n = 23) 
Whites  
(n = 47) 
p-value Blacks  
(n = 64) 
Whites 
(n = 29) 
p-value 
SBMD 0.977 ± 0.09* 1.095 ± 0.13 <0.01 1.074 ± 0.13 1.106 ± 0.13 0.11 
SBMD (Z-score) -0.385 ± 0.86* 0.714 ± 1.17 <0.01 0.535 ± 1.18 0.719 ± 1.22 0.19 
Values reported are the mean ± SD; p-values tabulated refers to comparison between blacks and whites within specific weight 
group * p-value < 0.01 compared to overweight subjects within the same ethnic group 
3.1.1.1.3. Distribution of SBMD in premenopausal cohort 
As previously outlined in chapter 3 (please refer to section 2.2.1) no normative data for black 
South African women exist. In this study we therefore used a white female reference 
population to calculate T- and Z-scores for both ethnic groups and also used the DEXA 
manufacturer’s reference value for North-American blacks to calculate additional T- and Z-
scores in blacks.  A  Z-score less than -1 indicated osteopenia, whereas a Z-score less than -
2 met the diagnostic criterion for osteoporosis in these premenopausal subjects. 
SBMD Z-scores were normal in the majority of premenopausal females in this study. 
Measured against a white reference population, 91% of black females had a normal SBMD, 
9% were osteopenic and 2% (2 subjects) met the diagnostic criteria used to define 
osteoporosis in premenopausal subjects in this study cohort. Measured against the DEXA 
manufacturer’s reference value for North-American blacks, 62% of black females had a 
normal SBMD, 38% were osteopenic and 6% (5 subjects) met the diagnostic criteria for 
osteoporosis. In the white cohort, 93% had a normal SBMD, 7% had osteopenia and 2% (3 
subjects) met the diagnostic criteria for osteoporosis.  A spinal bone mineral density of two 
standard deviations above an age matched white reference population was present in 7% 
and 13% of the black and white groups respectively (figure 3).   
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Distribution of SBMD in premenopausal cohorts 
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Figure 3: Distribution of absolute SBMD within the total black and white premenopausal 
3.1.1.1.4. Correlation of SBMD with age 
SBMD did not correlate with age in either of the two premenopausal ethnic groups (blacks: 
r=0.13, p=0.23; whites: r=-0.04, p=0.74). 
3.1.1.2. Spinal bone mineral apparent density (SBMAD) 
Unadjusted SBMAD was similar in the premenopausal black and white subjects (p=0.50). 
Only weight was positively associated with SBMAD (p<0.01). After adjustment for weight as 
a covariate, SBMAD remained similar in the two ethnic cohorts.  
3.1.1.2.1. SBMAD in normal to low weight and overweight premenopausal 
subgroups   
Comparison of SBMAD values in the premenopausal normal weight and overweight 
subgroups revealed results identical to that of the SBMD data (section 3.1.1.1.2). Significant 
differences were noted between the premenopausal black and white females of normal to 
low weight, as well as between normal to low weight and overweight black females (table 6).  
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Table 6: SBMAD in premenopausal subgroups based on BMI 
BMAD (g/cm3)                                                            Premenopausal females 
Normal to low BMI subgroup (BMI<25kg/m2)   Overweight subgroup (BMI ≥ 25kg/m2)   
Blacks  
(n = 23) 
Whites  
(n = 47) 
p-value Blacks 
(n = 64) 
Whites 
(n = 29) 
p-value 
SBMAD 0.133 ± 0.01 0.141 ± 0.02 0.02 0.142 ± 0.02 0.142 ± 0.02       0.43 
p-values tabulated refers to comparison between blacks and whites within specific weight group.  
† Significantly lower compared with overweight black subjects (p = 0.02) 
3.1.2. Postmenopausal subjects  
The postmenopausal black and white females were divided into early (<60yrs) and late        
(≥60 yrs) postmenopausal groups based on age, and included 97 black subjects and 66 
white females.  
3.1.2.1. Spinal bone mineral density 
Mean SBMC was similar in the blacks and whites, whereas mean spinal bone area was 
significantly lower in the black females. Unadjusted mean SBMD was similar amongst black 
and white females in both the early and late postmenopausal groups (table 7). 
In the early postmenopausal group, in addition to ethnicity, body weight (p<0.01) was 
positively associated and alcohol intake showed a tendency towards a negative association 
(p=0.09) with SBMD.  In the late postmenopausal group, body weight (p<0.01) was 
positively associated with SBMD, whereas a tendency towards an association was also noted 
for the number of pregnancies (p=0.07). After adjustment for weight as a covariate, SBMD 
was significantly lower in the black females compared with whites in the early 
postmenopausal group (p=0.01), whereas SBMD remained similar in the late 
postmenopausal cohorts (p=0.18). Mean SBMD in the early and late postmenopausal black 
groups were near identical, but tended to be lower in the late postmenopausal white female 
group compared with the early postmenopausal white group (p=0.07). This suggests that, 
compared with blacks, more pronounced postmenopausal spinal bone loss occurs in white 
females with ageing (table 7).  
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Table 7: Comparison of SBMC, lumbar bone area and SBMD in postmenopausal black and white females 
 Postmenopausal females 
< 60 years  (Early) ≥ 60 years (Late) 
  Blacks 
(n= 49) 
Whites  
(n=35) 
p-value Blacks 
 (n=48) 
Whites   
(n=31) 
p-value 
SBMC (grams) 52.79 ± 13.6 58.5 ± 13.6 0.22 53.39 ± 13.4 57.06 ± 14.8 0.81 
S -Bone area (cm2) 55.72 ± 5.18   59.34 ± 5.18 0.01 56.70 ± 5.16 60.73 ± 7.20 <0.01 
SBMD (g/cm2) 
Unadjusted 
Adjusted for weight 
   
0.940 ± 0.18 
0.921 ± 0.16 
 
0.988 ± 0.17 
1.015 ±  0.16 
 
0.61 
0.01 
 
0.939 ± 0.21 
0.911 ± 0.18 
 
0.925 ± 0.16 
0.968 ± 0.18 
 
1.00 
0.18 
Values reported are the mean ±  SD; p-values tabulated refers to the comparison between blacks and whites within each age-
group. *p =0.07 compared with late postmenopausal white cohort 
3.1.2.1.1. Correlation of SBMD with Anthropometric variables 
Except for BMI in the late postmenopausal white group, weight and BMI correlated 
significantly with SBMD (figure 4). Height only correlated with SBMD in the late 
postmenopausal white group (r=0.46, p=0.01) and elbow width correlated with SBMD in the 
late postmenopausal blacks and whites.  
3.1.2.1.2. SBMD in normal to low weight and overweight subgroups  
SBMD was lower in the black females compared with the white females in the normal to low 
BMI group and neared statistical significance (p=0.05), but similar between the black and 
the white subjects in the overweight group. The mean SBMD of normal to low BMI black 
patients was significantly lower compared with their overweight counterparts (p=0.01). The 
mean SBMD of white subjects was lower in the normal to low weight group, but the 
difference did not reach statistical significance (p=0.1). The difference in SBMD between the 
total black and white postmenopausal cohorts can thus be mainly attributed to the difference 
in SBMD in the subjects with a BMI < 25kg/m2, a finding similar to that observed in the 
premenopausal cohort (table 8). 
Table 8: Spinal bone mineral density data in postmenopausal subgroups based on BMI 
BMD (g/cm2)                                                            Postmenopausal females 
Normal to low BMI subgroup (BMI<25kg/m2)    Overweight subgroup (BMI ≥ 25kg/m2)    
Blacks (n = 23) Whites (n = 47) p-value Blacks (n = 64) Whites(n = 29) p-value 
SBMD 0.854* ± 0.12 0.926 ± 0.15 0.05 0.963 ± 0.21 0.981 ± 0.18 0.32 
Values reported are the mean ± SD; p-values tabulated refers to comparison between blacks and whites within specific weight 
group. * Significantly lower compared with overweight black subjects (p= 0.01) 
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Figure 4: Correlation of SBMD with weight and BMI in postmenopausal black (panel B1-B4) and white (panel W1-W4) females. Significant 
correlations noted except for SBMD and BMI in the late postmenopausal white group (panel B4) 
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3.1.2.1.3. Distribution of SBMD in postmenopausal cohorts 
Measured against a white reference population, 53% of the postmenopausal black subjects 
had spinal osteopenia (51 subjects) and 14% (14 subjects) met the diagnostic criteria of the 
WHO for spinal osteoporosis. Measured against the DEXA manufacturer’s reference value for 
North American blacks 70% (68 subjects) had BMD measurements consistent with spinal 
osteopenia and 37% (36 subjects) had spinal osteoporosis.  In the white postmenopausal 
cohort, 44% of females were osteopenic (29 subjects) and 14% (9 subjects) had spinal 
osteoporosis. A bone mineral density of 2SD above the normal reference population was 
present in less than 1% (6 black patients and 3 white patients) of both postmenopausal 
cohorts (table 9). 
Table 9: Distribution of SBMD in the total postmenopausal black and white cohorts 
SBMD status * Blacks (n=97) Whites (n=66) 
Osteopenia n(%) 
    White reference population 
    Black** reference population  
 
51 (53%) 
68 (70%)              
 
29 (44%)                     
Osteoporosis n(%) 
    White reference population 
    Black** reference population 
 
14 (14%) 
36 (37%) 
 
9 (14%) 
SBMD 2SD above normal n(%) 6 (<1%) 3 (<1%) 
* Classification based on WHO criteria1,2; ** DEXA manufacturer’s reference for North-American blacks 
3.1.2.1.4. Correlation of SBMD with age and years since menopause (YSM) 
SBMD did not correlate significantly with age or the years since menopause in the black or 
the white postmenopausal cohorts [early and late postmenopausal groups combined] (table 
10).   
Table 10: Correlation of SBMD with age and years since menopause  
 Blacks Whites 
 r-value p-value r-value p-value 
SBMD and age -0.04 0.74 -0.23 0.06 
SBMD and YSM -0.14 0.38 0.163 0.39 
3.1.2.2. Spinal bone mineral apparent density (SBMAD) 
SBMAD was similar in the black and white subjects in both the early and the late 
postmenopausal groups before and after adjustment for covariates, although there was a 
tendency towards higher SBMAD values in the late postmenopausal black cohort after 
adjustment for the number of pregnancies (p=0.07). Weight was positively associated with 
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SBMAD in the early and late postmenopausal cohort (p<0.01), whereas the number of 
pregnancies (p<0.01) had a negative impact on SBMAD in the late postmenopausal groups 
only. 
The black subjects in the early and late postmenopausal groups had similar mean SBMAD 
values (p=0.41), whereas near statistically significantly lower SBMAD was noted in the older 
white postmenopausal females compared to their younger counterparts (p=0.06).  The 
SBMAD data in the postmenopausal cohort is thus similar to that of the areal SBMD data 
(section 3.1.2.1). 
3.1.2.2.1. SBMAD in normal to low weight and overweight subgroups 
Comparison of SBMAD values in the postmenopausal normal weight and overweight 
subgroups revealed results identical to that of the SBMD data (section 3.1.2.1.2). Results are 
shown in table 11. 
Table 11: Spinal bone mineral apparent density data in postmenopausal subgroups based on BMI 
BMAD (g/cm3)                                                            Postmenopausal females 
Normal to low BMI subgroup (BMI<25kg/m2)   Overweight subgroup (BMI ≥ 25kg/m2)   
Blacks  
(n = 23) 
Whites  
(n = 47) 
p-value Blacks  
(n = 64) 
Whites 
(n = 29) 
p-value 
SBMAD 0.112* ± 0.01 0.121 ± 0.02 0.05 0.128 ± 0.03 0.126 ± 0.02 0.30 
Values reported are the mean ± SD; p-values tabulated refers to comparison between blacks and whites within specific weight 
group * Significantly lower compared with overweight black (p<0.01) 
3.2. FEMORAL BONE MINERAL DENSITY 
Bone mineral density was measured at various proximal femur sites (femoral neck, 
trochanter, intertrochanteric, total hip and ward’s triangle). This section will primarily report 
on the analyses of the femoral neck and total hip BMD measurements. 
3.2.1. Premenopausal subjects 
3.2.1.1.  Proximal femoral bone mineral status 
The BMC of the femoral neck was similar in the premenopausal black and white subjects.  
The mean area of the femoral neck was significantly smaller in the black cohort, which 
resulted in blacks having higher mean unadjusted femoral neck bone mineral density 
(FNBMD) than whites. Weight and height (p<0.01) were found to be significantly associated 
with FNBMD. After adjustment for height as a covariate, mean FNBMD remained significantly 
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higher in the premenopausal black cohort whereas the difference in mean FNBMD between 
the two cohorts was non-significant after adjustment for weight.  
The BMC of the total femoral area tended to be lower in blacks. Mean total femoral area was 
significantly smaller in blacks, which resulted in a similar mean unadjusted total femoral 
bone mineral density (FTBMD) in the two cohorts. Weight (p<0.01) and height (p=0.04) was 
significantly associated with FTBMD. After adjustment for weight mean FTBMD remained 
similar in the two cohorts, whereas mean FTBMD was significantly higher in the black 
compared with the white cohort after adjustment for height.  
Unadjusted BMD of the trochanteric and intertrochanteric areas and Ward’s triangle were 
similar in the two ethnic groups (table 12). 
Table 12: Comparison of femoral neck BMC, bone area and femoral BMD in the premenopausal black and white females 
 Premenopausal subjects 
Femoral bone mineral data Blacks  (n=87) Whites  (n=76) p-value 
Femoral neck 
   BMC (g) 
    Bone-area (cm2) 
    BMD (g/cm2) 
     Unadjusted 
     Adjusted for weight 
     Adjusted for height 
 
4.73 ± 0.78 
5.27 ± 0.50 
 
0.896 ± 0.12 
0.885 ± 0.11 
0.894 ± 0.13 
 
4.60 ± 0.74 
5.47 ± 0.42 
 
0.842 ± 0.13 
0.855 ± 0.11 
0.845 ± 0.13 
 
0.5 
<0.01 
 
<0.01        
0.1 
<0.01 
Femur Total 
    BMC (g) 
     Bone-area (cm2) 
    BMD (g/cm2) 
      Unadjusted 
      Adjusted for weight 
      Adjusted for height 
 
32.85 ± 5.72 
33.05 ± 3.35 
 
0.993 ± 0.27 
0.979 ± 0.12 
1.005 ± 0.14 
 
34.55 ± 7.35 
35.75 ± 4.78 
 
0.964 ± 0.12 
0.979 ± 0.12 
0.952 ± 0.14 
 
0.06 
<0.01 
 
0.16 
0.98 
0.03 
Trochanteric BMD (g/cm2) 0.734 ± 0.02 0.738 ± 0.02 0.84 
Intertrochanteric BMD (g/cm2) 1.173 ± 0.03 1.125 ± 0.04 0.07 
Ward’s triangle (g/cm2) 0.751 ± 0.03 0.748 ± 0.04 0.90 
Values reported are the mean ±  SD 
3.2.1.1.1. Correlation of femoral BMD with anthropometric variables 
Anthropometric variables i.e. weight, height, BMI and elbow-width correlated significantly 
with FNBMD in black and white premenopausal subjects.  Similarly, all these variables also 
correlated significantly with FTBMD. 
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3.2.1.1.2. Femoral bone density in normal to low weight and overweight 
subgroups. 
FNBMD and FTBMD in normal to low weight and overweight subgroups are shown in table 13. 
FNBMD was significantly lower in the premenopausal whites compared to blacks in the 
normal to low weight group (p=0.05), whereas the FTBMD was similar. There was a 
significant difference in age between the black (35 ± 9 years) and white (39 ± 6 years) 
females in the normal to low weight subgroup; hence BMD was also expressed as Z-scores. 
The normal to low weight black females had similar Z-scores for the FNBMD and the FTBMD 
compared to the normal to low weight white females, with a non-significant tendency 
towards lower FNBMD Z-scores. FNBMD and FTBMD were similar between overweight white 
and black subjects. The difference in FNBMD between the black and white premenopausal 
cohorts can thus be mainly attributed to the lower FNBMD in white subjects with a BMI < 
25kg/m2.  
FNBMD and FTBMD values tended to be lower in the normal to low weight compared with 
overweight blacks, but the difference did not reach statistical significance. Both femoral 
measurements were significantly lower in the normal to low weight whites compared to their 
overweight counterparts (p<0.01). The Z-scores differed significantly between the normal to 
low weight and overweight white females similar to that observed for the absolute femoral 
BMD values, but differed from the absolute femoral data in that Z-scores were also 
significantly different between the normal to low weight and overweight black females for 
both femur neck (p=0.04) as well as the total femoral measurements (p<0.01).  
Table 13: Femoral bone mineral density data in premenopausal subgroups based on BMI 
BMD (g/cm2)                                                                Premenopausal groups 
 Normal to low BMI subgroup (BMI < 25kg/m
2) Overweight subgroup (BMI ≥ 25kg/m2) 
 Blacks (n=23) Whites (n =47) p-value Blacks (n= 64) Whites (n= 29) p-value 
FNBMD 
  Absolute value 
  Z-score 
 
0.863    ± 0.14 
0.41* ± 1.12 
 
0.814*    ± 0.12 
0.03*  ± 1.08 
 
0.05 
0.09 
 
0.909 ± 0.11 
0.89 ± 1.08 
 
0.888 ± 0.11 
0.58 ± 1.05 
 
0.20 
0.10 
FTBMD 
   Absolute value  
  Z-score 
 
0.926  ± 0.13 
0.04* ± 0.96 
 
0.934*   ± 0.12 
0.15*  ± 0.94 
 
0.46 
0.32 
 
0.984 ± 0.30 
0.87 ± 1.19   
 
1.012 ± 0.12 
0.70 ± 0.97 
 
0.50 
0.26 
Values reported are the means ± SD; p-values in table refer to comparison between blacks and whites within specific BMI 
groups. *Significantly lower compared with overweight subjects within the same ethnic group (p<0.05) 
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3.2.1.1.3. Distribution of femoral BMD in premenopausal cohort. 
FNBMD and FTBMD Z-scores were normal in the majority of premenopausal females in this 
study. Measured against a white reference population, 98% of black females had a normal 
FNBMD and 92% had a normal FTBMD. Only 2% (2 females) had osteopenia based on 
FNBMD, whereas 8% (7 patients) had a FTBMD value compatible with osteopenia. None of 
the black subjects had osteoporosis. A Z-score of 2SD above the reference norm was present 
in 15% and 11% of blacks based on FNBMD and FTBMD measurements respectively.  
Measured against the DEXA manufacturer’s reference values for North-American blacks, 15% 
(13 females) had osteopenia based on FNBMD, whereas 18% (16 patients) had a FTBMD 
value compatible with osteopenia. None of the subjects had osteoporosis. A Z-score of 2SD 
above the reference norm was only present in 1% of blacks based on both FNBMD and 
FTBMD measurements.   
In the white cohort 12% (9 subjects) had femoral neck osteopenia and 8% had osteopenia 
based on FTBMD measurements. None of the white premenopausal subjects had 
osteoporosis.  A Z-score of 2SD above the reference norm was present in 7% and 5% of 
whites based on FNBMD and FTBMD measurements respectively (figure 8 & table 14). 
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       Figure 8: Distribution of FNBMD and FTBMD data in premenopausal blacks and whites. 
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Table 14: Femoral BMD distribution in the premenopausal black and white cohorts based on Z-scores 
Z-scores*                                                     Premenopausal subjects 
FNBMD FTBMD 
Blacks (n=87) 
n (%) 
Whites (n=76) 
 n (%) 
Blacks (n=87)       
n (%) 
Whites (n=76)       
n (%) 
Osteopenia 
   White reference 
   Black reference 
 
2 (2%) 
13 (15%) 
 
9 (12%) 
 
 
7 (8%) 
16 (18%) 
 
6 (8%) 
Osteoporosis 
   White reference 
   Black reference 
 
0 (0%) 
0 (0%) 
 
0 0%) 
0 (0%) 
 
0 (0%) 
0 (0%) 
 
0 (0%) 
0 (0%) 
BMD > 2 SD  
   White reference 
   Black reference 
 
13 (15%) 
1 (1%) 
 
5 (7%) 
 
10 (11%) 
1 (1%) 
 
4 (5%) 
* Classification based on Z-scores 
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3.2.1.1.4. Correlation of femoral BMD with age 
FNBMD and FTBMD did not show a statistically significant correlation with age in either of the 
two ethnic groups (table 15).  
Table 15: Correlation of femoral BMD with age in premenopausal females  
 Premenopausal groups 
Blacks Whites 
r-value p-value r-value p-value 
FNBMD and age -0.10 0.38 -0.18 0.12 
FTBMD and age 0.07 0.54 -0.1 0.40 
3.2.1.2. Femoral neck bone mineral apparent density (FNBMAD) 
Unadjusted FNBMAD was significantly higher in the black subjects. In addition to ethnicity, 
age (p=0.06) tended to be negatively associated with FNBMAD in both the black and white 
cohorts. After adjustment for age as a covariate, FNBMAD was still higher in the blacks (table 
16).  
Table 16: FNBMAD in the premenopausal cohort 
 
 
  
Premenopausal cohort 
Blacks (n=87) Whites (n=76) p-value 
FNBMAD  (g/cm3) 
     Unadjusted   
     Adjusted (for age)     
 
0.170 ± 0.03 
0.170 ± 0.03  
 
0.155 ± 0.03 
0.156 ± 0.03 
 
<0.01 
<0.01 
Values reported are the mean ± SD 
3.2.1.2.1. FNBMAD in normal weight and overweight premenopausal subgroups   
FNBMAD was higher in premenopausal blacks compared with whites in both weight 
subgroups. The ethnic difference was, however, more pronounced in the group with a 
normal to low BMI (table 17). FNBMAD was significantly lower in the normal to low weight 
black (p=0.02) and white (p<0.01) subgroups compared to their overweight counterparts 
respectively and the difference appeared to be more pronounced in whites.  
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Table 17: Femoral neck bone mineral apparent density in premenopausal subgroups based on BMI 
 
 
 
 
Premenopausal females 
 
Normal to low BMI subgroup (BMI<25kg/m2)    
 
Overweight subgroup (BMI ≥ 25kg/m2)    
    
FNBMAD (g/cm3) 
Blacks   
(n = 23) 
Whites  
(n = 47) 
p-value Blacks  
(n = 64) 
Whites  
(n = 29) 
p-value 
0.177* ± 0.03  0.153* ± 0.03  <0.01 0.168 ± 0.03  0.158 ± 0.03 0.05 
Values reported are the means ± SD; p-values in table refer to comparison between blacks and whites within specific weight 
groups *Significantly lower compared with overweight subjects wi        thin the same ethnic group (p<0.05)  
3.2.2. Postmenopausal females 
3.2.2.1. Proximal femoral bone mineral status 
Femoral neck and total femoral measurements are depicted in table 18 and illustrated by 
figure 16. The FNBMC was similar in all the comparable study groups. FN-bone area was 
significantly smaller in the black subjects in both the early and late postmenopausal groups 
compared with whites. Blacks therefore had higher mean unadjusted FNBMD than whites in 
the early and late postmenopausal groups. Likewise, FTBMC was similar, FT-bone area was 
smaller and mean unadjusted FTBMD thus statistically significantly higher in blacks compared 
with whites in the early and late postmenopausal groups. 
Only weight (p<0.01) was significantly associated with mean FNBMD and FTBMD in the early 
postmenopausal subjects. Adjustment for weight diminished the difference in mean FNBMD 
and FTBMD between the blacks and whites. Mean FNBMD, however, remained significantly 
higher in the black cohort after adjustment, whereas adjustment for weight resulted in 
similar mean FTBMD between the two ethnic groups.  
In the late postmenopausal cohorts, age, weight, number of pregnancies and number of 
pack years smoked were all significantly associated with both FNBMD and FTBMD. After 
adjustment for age, number of pregnancies and pack years smoked, mean FNBMD and 
FTBMD remained significantly higher in blacks. Adjustment for weight, however, resulted in 
similar mean FNBMD and FTBMD in the late postmenopausal black and white groups.  
FNBMD and FTBMD were lower in the late postmenopausal subjects compared with the early 
postmenopausal subjects of both ethnic groups, but these differences did not reach 
statistical significance.  
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Bone density measured in the trochanteric and intertrochanteric areas and Ward’s triangle 
was similar in black and white groups with the exception of a higher intertrochanteric BMD in 
the older postmenopausal black subjects compared with whites.  
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Femoral BMD measurements 
 
 
Postmenopausal cohorts 
< 60 years ≥ 60 years 
Blacks                    
(n= 49)                 
Whites 
 (n=35) p-value 
Blacks     
(n=48)                           
Whites 
(n=31) p-value 
Femoral neck 
 FNBMC (grams) 
 
4.41 ± 0.80 
 
4.02 ± 0.78 
 
0.07 
 
4.23 ± 0.84 
 
3.95 ± 0.99 
 
0.47 
 
FN-bone area (cm
2) 
 
5.255 ± 0.37 
 
5.477 ± 0.35 
 
<0.01 
 
5.326 ± 0.37 
 
5.55 ± 0.496 
 
<0.05 
  
FNBMD(g/cm
2) 
     Unadjusted 
     Adjusted for weight 
     Adjusted for age 
     Adjusted for nr of pregnancies             
     Adjusted for smoking  
 
 
0.834 ± 0.13 
0.818 ± 0.11 
       - 
       - 
       -  
 
 
0.736 ± 0.13 
0.762 ± 0.11 
       - 
       - 
       -  
<0.01 
0.03 
 
 
 
0.794 ± 0.14 
0.770 ± 0.12 
0.788 ± 0.13 
0.802 ± 0.13 
0.807 ± 0.13 
 
 
0.698 ± 0.12 
0.728 ± 0.12 
0.707 ± 0.13 
0.681 ± 0.14 
0.677 ± 0.13 
 
 
<0.01 
0.11 
<0.01 
<0.01 
<0.01 
Total femur 
  FTBMC (grams) 
 
34.20 ± 8.08  
 
32.50 ± 6.83 
 
0.16 
 
32.52 ± 7.02 
 
31.25 ± 7.09 
 
0.23 
  
 FT-bone area (cm
2) 
 
35.03 ± 4.19 
 
36.53 ± 3.46 
 
0.05 
 
34.74 ± 3.36 
 
36.56 ± 3.63 
 
0.02 
  
 FTBMD (g/cm
2) 
     Unadjusted 
     Adjusted for weight 
     Adjusted for age 
     Adjusted for no of pregnancies 
     Adjusted for smoking  
 
 
0.973 ± 0.16 
0.946 ± 0.11 
       - 
       - 
       -  
 
 
0.890 ± 0.15 
0.925 ± 0.11 
      - 
      - 
      - 
 
 
<0.01 
0.42 
 
 
0.931 ± 0.15 
0.907 ± 0.13 
0.926 ± 0.15 
0.943 ± 0.15 
0.944 ± 0.15 
 
 
0.840 ± 0.14 
0.877 ± 0.13 
0.848 ± 0.15 
0.816 ± 0.15 
0.812 ± 0.15 
 
 
<0.01 
0.35 
0.03 
<0.01 
<0.01 
 
F-trochanter BMD (g/cm2) 
 
0.706 ± 0.113 
 
0.675 ± 0.109 
 
0.69 
 
0.676 ± 0.12 
 
0.643 ± 0.11 
 
0.15 
 
F-intertroch BMD (g/cm2) 
 
1.138 ± 0.186 
 
1.058 ± 0.189 
 
0.13 
 
1.113 ± 0.19 
 
1.000 ± 0.19 
 
<0.01 
 
F-Ward’s BMD (g/cm2) 
 
 
0.642 ± 0.153 
 
0.597 ± 0.141 
 
0.57 
 
0.552 ± 0.14 
 
0.502 ± 0.14 
 
0.07 
 
Table 18: Proximal femoral bone mineral status in postmenopausal cohorts 
Values reported are the mean ±SD; p-values refers to the comparison between blacks and whites within menopausal age-groups 
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  Figure 16b. FNBMD and FTBMD before and after adjustment for weight as a covariate in the late postmenopausal cohorts 
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Early postmenopausal cohorts 
p<0.01 p =0.42 
p =0.03 p <0.01 
    Figure 16a. FNBMD and FTBMD before and after adjustment for weight as a covariate in the early    
    postmenopausal cohorts 
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3.2.2.1.1. Correlation of femoral BMD with anthropometric variables 
Weight, BMI and elbow width correlated significantly with FNBMD and FTBMD in black and 
white females in both postmenopausal groups. Weight had the strongest association with 
FNBMD and FTBMD.  Height only correlated significantly with FNBMD and FTBMD in the older 
white postmenopausal females.  
3.2.2.1.2. Femoral bone density in normal to low weight and overweight 
subgroups. 
Femoral neck and total femoral BMD was higher in blacks compared with whites in the 
normal to low and overweight subgroups, although significance was not reached for FTBMD 
in the normal to low weight subgroup between blacks and whites. This may be partially due 
to small numbers of both black and white women in this weight subgroup. Both femoral BMD 
measurements were significantly lower in normal to low weight blacks and whites compared 
to their respective overweight counterparts (table 19).  We did not compare Z-scores as age 
was comparable in all weight groups studied. 
Table 19: Femoral bone mineral density data in postmenopausal subgroups based on BMI 
BMD (g/cm2) Postmenopausal groups 
 Normal to low BMI subgroup (BMI < 25kg/m
2) Overweight subgroup (BMI ≥ 25kg/m2) 
 Blacks (n=22) Whites (n =27) p-value Blacks (n= 75) Whites (n= 39) p-value 
FNBMD 
  Absolute value   
 
0.766* ± 0.11 
 
0.684* ± 0.11 
 
<0.01 
 
0.829 ± 0.14 
 
0.749 ± 0.13 
 
<0.01 
FTBMD 
  Absolute value 
 
0.851* ± 0.13 
 
0.816* ± 0.12 
 
0.17 
 
0.979 ± 0.15 
 
0.910 ± 0.15 
 
0.01 
Values reported are the means ± SD; p-values in table refer to comparison between blacks and whites within specific BMI 
groups. *Significantly lower compared with overweight subjects within the same ethnic group (p<0.05) 
3.2.2.1.3. Distribution of femoral bone density in postmenopausal cohorts. 
The classification of femoral bone mineral status was based on WHO criteria and results 
shown in table 20. Measured against a white reference population, 35% of the 
postmenopausal black subjects had a FNBMD value in the osteopenic range (34 patients), 
and 28% had FTBMD values in keeping with osteopenia (27 patients). None of the 
postmenopausal blacks met the diagnostic criteria of femoral neck osteoporosis, whereas 3 
patients were osteoporotic based on total femoral measurements. Measured against the 
DEXA manufacturer’s reference values for North-American blacks,  51% of the 
postmenopausal black subjects had a FNBMD value in the osteopenic range (49 patients) and 
35% had FTBMD values in keeping with osteopenia (34 patients). Three of the black subjects 
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met the diagnostic criteria for femoral neck osteoporosis (OP) and 5 had a FTBMD value in 
keeping with OP. 
In the white cohort 61% of females had femoral neck osteopenia (40 patients) and 48% of 
whites had total femoral values in keeping with osteopenia (32 patients). Seven (11%) of 
the white subjects met the diagnostic criteria for femoral neck osteoporosis and 2 had a 
FTBMD value in keeping with OP.  
FNBMD 2SD above the white reference population was present in only 2 of the black females 
and 3 of the white subjects.  FTBMD 2SD or more above the normal reference population 
was present in only 4 of the black patients and 2 of the white subjects.  None of the black 
subjects had a FNBMD or FTBMD ≥ 2SD above the DEXA manufacturer’s black reference 
range.  
Measured against a uniform white reference population, a higher percentage of white 
postmenopausal females have FNBMD and FTBMD compatible with osteopenia. A significant 
percentage of postmenopausal black females in this study do, however, also have femoral 
measurements below normal.  
Table 20: Distribution of femoral BMD in the total postmenopausal black and white cohorts 
Femoral BMD status *  
FNBMD 
 
 
FTBMD 
 
Blacks       
(n=97) 
Whites 
(n=66) 
Blacks 
(n=97) 
Whites 
(n=66) 
Osteopenia n(%) 
    White reference population 
    Black reference population  
 
34 (35%) 
49 (51%) 
 
40 (61%) 
    - 
 
27 (28%) 
34 (35%) 
 
32 (48%) 
    - 
Osteoporosis n(%) 
    White reference population 
    Black reference population 
 
0 (0%) 
3 (3%) 
 
7 (11%) 
    - 
 
3 (3%) 
5 (5%) 
 
2 (3%) 
    - 
SBMD 2SD above normal n(%) 
    White reference population 
    Black reference population 
 
2 (2%) 
0 (0%) 
 
3 (5%) 
    - 
 
4 (4%) 
0 (0%) 
 
2 (3%) 
    - 
Classification based on WHO criteria1,2 
3.2.2.1.4. Correlation of femoral BMD with age and years since menopause  
A significant negative correlation was noted between FNBMD and FTBMD, and age in the total 
postmenopausal black group, whereas there was also a tendency towards a negative 
association between FNBMD and FTBMD, and age in the postmenopausal whites. FNBMD and 
FTBMD correlated with years since menopause in postmenopausal blacks only (table 21). 
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Table 21. Correlation of femoral BMD with age and years post menopause 
 Total postmenopausal cohort 
Blacks Whites 
r-value p-value r-value p-value 
FNBMD and age 
FNBMD and yrs since menopause 
-0.29 
-0.29 
0.01            
0.01 
-0.22 
-0.05 
0.08           
0.68 
FTBMD and age 
FTBMD and yrs since menopause 
-0.21 
-0.25 
0.05 
0.02 
-0.23 
-0.05 
0.07 
0.69 
3.2.2.2. Femoral neck bone mineral apparent density (FNBMAD) 
Unadjusted FNBMAD was significantly higher (p<0.01) in the black subjects compared to 
whites in both the early and late postmenopausal cohorts. Weight was the only covariant 
significantly associated with FNBMAD in the early postmenopausal subjects and both weight 
and number of pregnancies were identified as significantly associated with FNBMAD in the 
late postmenopausal cohorts. After adjustment for these covariates, FNBMAD remained 
significantly higher (p<0.01) in blacks in both early and late postmenopausal groups 
compared with whites (table 22).  
In both black (p=0.06) and white (p=0.09) postmenopausal subjects, a trend towards a 
lower FNBMAD was noted in the older (≥60 yrs) compared to the younger (<60 yrs) 
subgroups (figure 16).  
Table 22: FNBMAD in postmenopausal blacks and whites  
FNBMAD  (g/cm3) Postmenopausal groups 
Blacks Whites p-value 
  Early postmenopausal group 
     Unadjusted 
     Adjusted for weight 
 
0.158 ± 0.02 
0.155 ± 0.02  
 
0.134 ± 0.02 
0.138 ± 0.02 
 
<0.01 
<0.01 
  Late postmenopausal group 
     Unadjusted 
     Adjusted for weight 
     Adjusted for no of pregnancies 
 
0.150 ± 0.03     
0.148 ± 0.01  
0.151 ± 0.02      
 
0.127 ± 0.02 
0.130 ± 0.01 
0.124 ± 0.02 
 
<0.01 
<0.01 
<0.01 
Values reported are the mean ± SD 
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Figure 16: Unadjusted FNBMAD in the postmenopausal cohort. Higher values noted in the black compared with white females in 
the early and late postmenopausal groups (p<0.01). FNBMAD lower in the older blacks and whites compared to their respective 
younger counterparts (p=0.06 for blacks and p=0.09 for whites). 
3.2.2.2.1. FNBMAD in normal weight and overweight subgroups   
FNBMAD was significantly higher in postmenopausal blacks compared with whites in both 
weight subgroups (table 23). FNBMAD tended to be lower in the normal to low weight black 
(p=0.06) and white (p=0.08) subgroups, but the difference was not statistically significant.  
Table 23: Femoral neck bone mineral apparent density in postmenopausal subgroups based on BMI 
 
 
Postmenopausal females 
Normal to low BMI subgroup (BMI<25kg/m2)   Overweight subgroup (BMI ≥ 25kg/m2)   
    
FNBMAD (g/cm3) 
Blacks   
(n = 22) 
Whites 
(n = 27) 
p-value Blacks  
(n = 75) 
Whites  
(n = 39) 
p-value 
0.146 ± 0.02  0.127 ± 0.02  <0.01 0.156 ± 0.03  0.135 ± 0.02 <0.01 
Values reported are the means ± SD; p-values in table refer to comparison between blacks and whites within specific weight 
groups 
3.3. CORRELATION OF AREAL BMD WITH AGE AND PATTERNS OF BONE 
LOSS IN THE TOTAL STUDY COHORT 
Areal spinal and femoral BMD did not correlate significantly with age when assessed within 
the different menopausal subgroups, with the exception of a negative correlation noted 
between age and proximal femoral BMD in the total postmenopausal black group (table 21).  
A significant negative correlation between age and BMD measurements at all skeletal sites 
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was however present when evaluated in the larger total black and white cohorts (figure 17). 
The correlations between age and BMD measurements were lower in blacks compared with 
whites, the difference reaching statistical significance for spinal (p=0.02) and total femoral 
(p=0.02) measurements. 
The pattern of bone loss with ageing appeared to differ between the two racial groups, 
although longitudinal data must be interpreted with caution in this cross-sectional study. The 
percentage decline in lumbar spine BMD between the premenopausal and early 
postmenopausal black and white cohorts appeared to be near identical (9% and 10% 
respectively). Our data, however suggests that postmenopausal black females maintained 
their lumbar BMD better into old age compared with whites (Table 24), implying a slower 
rate of postmenopausal decline in spinal bone mineral density. This resulted in improvement 
of lumbar BMD in blacks compared with whites with ageing with resultant similar spinal BMD 
values in the late postmenopausal black and white females despite lower peak lumbar spine 
BMD.  The percentage bone loss at the femoral neck and total femoral regions across the 
menopausal transition i.e. between the premenopausal and early postmenopausal black and 
white cohorts appeared to be higher in white females (femoral neck region: 13% versus 7%; 
total femoral region: 8% versus 2%), resulting in higher femoral neck and total femoral BMD 
measurements in the younger postmenopausal black females compared with whites. 
Thereafter an apparent similar rate of postmenopausal decline in BMD measurements at the 
proximal femoral sites was noted in blacks and whites with black females thus maintaining 
significantly higher mean femoral neck and total femoral BMD values into old age.  
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Figure 17. Correlation between age and spinal and proximal femoral BMD in the TOTAL black and white study 
cohorts. Correlation between age and BMD lower in blacks reaching significance only for spinal (p=0.02) and total 
femoral BMD (p=0.02). 
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Table 24:  Bone loss with ageing in black and white cohorts 
Ethnicity Premenopausal  % decline Early Postmenopausal % decline Late postmenopausal 
S-BMD 
Blacks                  1.047 ± 0.12 9 0.940 ± 0.18                   0 0.939 ± 0.21 
Whites 1.099 ± 0.13 10 0.988 ± 0.17 6 0.925 ± 0.16 
Femoral neck BMD 
Blacks 0.896 ± 0.12 7 0.834 ± 0.13 5 0.794 ± 0.14 
Whites 0.842 ± 0.13 13 0.736 ± 0.13  5 0.698 ± 0.12 
Femoral total BMD 
Blacks 0.993 ± 0.27 2 0.973 ± 0.16 4 0.931 ± 0.15 
Whites 0.964 ± 0.12 8 0.890 ± 0.15 6 0.840 ± 0.14 
Values reported are the mean ± SD. Percentage decline noted in red. 
4. DISCUSSION  
In our study, spinal bone mineral density (SBMD) was lower in premenopausal blacks 
compared with whites and similar in postmenopausal black and white women. Spinal bone 
density, expressed as a volumetric calculation, namely spinal bone mineral apparent density 
(SBMAD), was similar in all menopausal subgroups studied. Correction of both SBMD and 
SBMAD for marked ethnic differences in anthropometry, i.e. weight and height, did not alter 
these findings. It is thus not surprising that a similar percentage of black and white pre- and 
postmenopausal women had spinal osteopenia as measured against a uniform white 
reference population (53% of postmenopausal blacks and 44% of postmenopausal whites). 
In the postmenopausal cohort, 14% of both blacks and whites met the diagnostic criteria for 
osteoporosis. 
Significant ethnic differences in bone density of the proximal femur were, however, evident 
in our study subjects. Femoral neck BMD and total femoral BMD were significantly higher in 
both younger and older postmenopausal blacks, whereas femoral neck BMD was also 
significantly higher in premenopausal blacks. The higher femoral BMD values in blacks were, 
however, mostly accounted for by the marked difference in weight between blacks and 
whites. Adjustment for weight thus eliminated most of the observed ethnic difference in 
these measurements. After adjustment of femoral neck and total femoral BMD for weight, a 
significant ethnic difference was confined to higher femoral neck BMD values in the early 
black postmenopausal subgroup.   
Femoral neck bone mineral apparent density (FN-BMAD), a volumetric calculation of femoral 
neck bone mineral content, was higher in blacks in all the subgroups studied. FN-BMAD 
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remained significantly higher in blacks after correction for clinical covariates with significant 
univariate association.  
Although a higher percentage of postmenopausal whites were osteopenic at the proximal 
femoral sites, a significant percentage of postmenopausal blacks also presented with femoral 
neck (35%) and total femoral (28%) osteopenia. The greatest difference in percentage 
subjects with proximal femoral osteopenia in postmenopausal blacks and whites was noted 
for the femoral neck region where osteopenia was present in 35% of blacks and 61% of 
whites. Osteoporosis as defined by WHO criteria, and measured against a uniform white 
reference population, was confined to the white group affecting 11% of the postmenopausal 
population. 
The findings of lower or similar spinal BMD and higher femoral neck BMD in blacks versus 
whites are consistent with the limited data previously reported in other female populations 
on the African continent. Studies conducted in The Gambia consistently documented lower or 
similar spinal BMC and spinal BMD in Gambian women compared with British subjects6,212.  
Other studies in West-African populations also found lower lumbar spine BMD in Africans 
compared to European females218,219. In the only other previous study employing DEXA in 
BMD measurement of adult South African black and white females, spinal BMD was similar 
and femoral BMD significantly higher1, findings very similar to ours. Our BMD findings differ 
from the American data, where BMD at all skeletal sites has invariable been found to be 
higher in blacks than in whites135,138,143-145,184-199.  
PEAK BONE MINERAL DENSITY 
In our study, ethnic differences in attainment of peak BMD were noted in premenopausal 
blacks and whites. In blacks significantly lower peak SBMD was observed and this finding 
was mostly due to significantly lower peak SBMD observed in the premenopausal blacks with 
normal to low BMI. The black females in the normal to low BMI subgroup were significantly 
smaller with lower mean weight (p<0.01) and height (p<0.01) compared with the white 
females. In whites, the observed lower peak femoral neck BMD was mostly due to lower 
values in the smaller sized whites (normal to low BMI group). Peak spinal and proximal 
femoral BMD values were similar in the overweight premenopausal subgroups, blacks in this 
subgroup was significantly heavier with greater BMI’s than whites. 
The majority of studies indicate that the higher bone mass in adult African-American women 
is due to the attainment of a greater peak bone mass by early adulthood185,186,190-193.196-199. 
Recent studies consistently demonstrated greater bone mineral density at the proximal 
femur in black versus white SA schoolchildren, whereas spinal BMD was either higher or 
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similar215,216. It is thus plausible that South African blacks, similar to their American 
counterparts, may have a genetic tendency to greater BMD than whites. This hypothesis is 
supported by studies that suggest that the South African black population and the African-
American population share a common genetic pool as both originated and migrated from 
West-Africa217. The finding of lower peak spinal bone mineral density in our premenopausal 
blacks compared with whites contrasts that of American data and suggests that SA blacks do 
not realize their genetic potential at the spine. Although peak bone mass is largely (± 70%) 
genetically determined, it can be substantially affected by environmental factors34-42,257,258.  
In our study, significant differences in historical clinical risk profiles between premenopausal 
blacks and whites were noted especially with regard to phenotype, use of hormonal 
contraception and calcium-intake. 
Weight 
Body weight was significantly associated with peak BMD measurements at all skeletal sites in 
both our blacks and whites. Obesity is associated with increased peak bone mineral 
density193,195,199,238,239 and it is therefore surprising that the heavier young black females in 
our study had lower peak spinal BMD compared with whites. Analysis of bone mineral 
densities in premenopausal females in weight subgroups, however, revealed that the lower 
peak spinal BMD in the black females compared with whites was mainly attributable to lower 
measurements in the subset of black females with a normal to low weight. Body weight was 
significantly lower in blacks than whites in the normal to low weight subgroup. This may 
explain the more marked impact on spinal BMD measurements in blacks in the normal to low 
BMI subgroup, given the significant association between weight and spinal BMD documented 
in our study and the fact that low body weight is a well-known risk factor for low bone 
density244,253.  It appears as if a low body weight had a more marked deleterious effect on 
spinal versus femoral BMD in blacks. Contrary to the lower spinal BMD findings in the normal 
to low weight subgroup, blacks maintained higher peak proximal femoral BMD values 
compared with whites in this weight subgroup and similar peak proximal femoral BMD values 
compared with their overweight white counterparts.  
Excess weight exerts its positive skeletal effects mainly via direct mechanical loading, but 
also has an impact on bone mass via the metabolic effects of adipocyte derived adipokines 
and androgen aromatization to estrogen in fat cells. The mechanical impact of obesity is 
most prominent in the weight-bearing sites of the skeleton193,239,313 and this may be the main 
mechanism whereby the heavier premenopausal blacks in our study cohort obtained higher 
unadjusted proximal femoral BMD measurements than whites. The metabolic/hormonal 
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impact of obesity in premenopausal females may be less important given the background of 
normal estrogen status and based on recent work by Gilsanz and colleagues252. In our study, 
adjustment for weight, resulted in similar femoral measurements between blacks and whites, 
and the higher peak proximal femoral BMD values in blacks can thus be mainly attributed to 
the difference in body weight between the two racial groups and not to ethnicity per se.  
Height   
Greater height is associated with higher spinal and femoral BMD115,119. Blacks in this study 
were significantly shorter than whites. Height was positively associated with peak spinal and 
proximal femoral BMD obtained in premenopausal blacks and whites. Adjustment for height 
as a covariate improved BMD measurements in blacks versus whites as expected. The impact 
of height on BMD was, however, modest. Adjustment for height did alter observed spinal 
BMD differences between these two ethnic cohorts i.e. peak spinal BMD was similar in blacks 
and whites after correction for height, whereas both peak femoral neck and total femoral 
BMD were higher in blacks compared with whites after correction for height.   
Calcium-intake 
Calcium-intake in premenopausal black females was substantially lower than that of whites. 
Calcium nutrition is commonly considered to be important for the attainment of peak bone 
mass and for optimal maintenance of skeletal mass34-37. Most studies assessing the skeletal 
effects of calcium, both in childhood and in later life, were, however, conducted in white 
populations and less is known about the impact of calcium nutrition on skeletal health in 
black population groups. In our study, a significant association between calcium-intake and 
peak spinal and femoral BMD was not demonstrated in either of the two racial groups. 
Hormonal contraception 
Oral contraceptives (OCP) were the preferred mode of contraception in white females, 
whereas depot-medroxyprogesterone acetate (DP) was used most often, and almost 
exclusively, by the younger black females as discussed in Chapter 4. OCP are mostly 
regarded as bone-sparing or without BMD effects255,256, although recent studies raised 
concern that  OCP use  may have a negative impact on normal physiological bone accretion 
in adolescents and young females263,264,266. Hypo-oestrogenemia, as a result of DP use, may 
adversely affect optimal attainment of peak bone mass255,257,258-262 These detrimental effects 
are particularly apparent in adolescents who have not yet achieved peak bone mass, in 
current users and it has also been noted that associated low body weight enhances the 
negative impact of DP261. In our study, univariate tests of significance did not identify the 
different modes of contraception as significantly associated with peak BMD in either of the 
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two ethnic groups. The majority of our study subjects were, however, past-users of 
contraception and we furthermore only included premenopausal patients with a regular 
menstrual cycle, thereby excluding all current DP users with amenorrhea. The presence of a 
regular cycle in someone on DP may be indicative of ineffective suppression of ovulation and 
a lesser degree of hypo-oestrogenemia and these patients may thus be expected to have 
less detrimental effects on the skeleton. Our study, therefore, do not exclude potential 
adverse skeletal effects of current DP use in premenopausal black females who are 
amenorrhoeac.  
Premenopausal blacks had lower spinal bone mineral density compared with whites and this 
finding was mostly accounted for by lower SBMD values in blacks with lower body weight. 
Although poor calcium nutrition and frequent ever use of depot-medroxyprogesterone 
acetate (DP) were not individually associated with peak BMD in our black premenopausal 
cohort, a combination of these factors along with a lower body weight may be deleterious to 
bone health in blacks. Blacks were significantly and markedly heavier than whites and it is 
possible that the positive impact of higher body weight193,195,199,238,239 overshadowed the 
effects of other clinical and environmental factors in our premenopausal cohort. The modern 
tendency towards a lower ideal body weight in black urbanized societies may thus increase 
the likelihood of suboptimal attainment of peak BMD in blacks, especially at the spine, and 
the presence of other historical clinical risk factors for osteoporosis may potentially enhance 
the deleterious skeletal effects of a low body weight. 
BONE LOSS 
In our study, as alluded to before, spinal BMD was similar in postmenopausal blacks and 
whites, whereas proximal femoral BMD values were consistently higher in blacks. A 
significant negative correlation between age and both spinal and femoral BMD in the total 
black and white cohorts was documented. An apparent decrease in BMD at all skeletal sites 
was observed between the premenopausal and postmenopausal blacks and whites. Although 
cautious with regard to interpretation of longitudinal changes in this cross-sectional study, 
our BMD data in blacks and whites do, however, suggest ethnic differences in the pattern of 
observed bone loss with ageing at both the hip and spine. There appears to be a slower 
decline in especially femoral BMD during the menopausal transition period in blacks, whereas 
spinal BMD appears to be better maintained in postmenopausal blacks with ageing (table 
24). The slower decline in BMD in blacks compared with whites with ageing at both the 
spinal and femoral sites favor the aforementioned ethnic group at a time when fracture risk 
is highest. 
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The different patterns of bone loss in our black and white female cohorts have also been 
observed in previous multi-ethnic studies1,213. Our observation of a slower rate of decline in 
spinal and femoral bone density in black females compared with whites in the peri- or 
postmenopausal period is consistent with the findings in the nurses’ study by Daniels et al1. 
The pattern of femoral bone loss in our study was also remarkably similar to that observed 
by Solomon213 more than 30 years earlier. He noted that black females appeared to reach 
peak bone mass at a later stage and showed very limited loss in the late premenopausal and 
perimenopausal periods. A slower rate of cortical and trabecular bone loss, especially in the 
early postmenopausal period, has also been noted in American blacks compared with whites 
in some139,184,197, but not all144,194,196  studies.  
A lower bone turnover in blacks, as shown in most previous studies138,142,146,196, may in part 
be responsible for the slower postmenopausal decline in trabecular and cortical bone 
observed in this ethnic group. Previous studies reported that black women have lower bone 
turnover rates than white women despite higher endogenous PTH-levels and this is ascribed 
to a relative skeletal resistance to the action of PTH138,142,146,196  in blacks.  
Significant differences in historical clinical risk profiles between postmenopausal blacks and 
whites in our study were also noted especially with regard to phenotype, calcium-intake, 
smoking, physical activity and parity. These clinical risk factors may also influence and 
impact on BMD and patterns of loss. In the early postmenopausal group, weight was the 
only clinical covariate with significant BMD associations, whereas, apart from weight; age, 
parity and the number of pack years smoked significantly correlated with femoral BMD 
measurements in the older postmenopausal females.  
Weight 
In our study, the postmenopausal blacks were heavier than whites and they also appeared 
to maintain their body weight better into old age compared with whites. Weight was 
positively associated with spinal and femoral BMD in our postmenopausal black and white 
women; in fact, the observed significant difference in femoral BMD between postmenopausal 
blacks and whites was fully accounted for by ethnic differences in body weight. Univariate 
tests of significance identified weight to be significantly correlated with every single areal 
and volumetric BMD parameter measured in our postmenopausal cohort. The positive impact 
of increased body weight on BMD is also demonstrated in the postmenopausal weight 
subgroups where spinal, femoral neck and total femoral BMD are all consistently lower in the 
low to normal weight blacks and whites compared to the overweight subjects. 
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Adjusted BMD data (for body size) in this study were different from the data obtained in the 
SA nurses’ study1. In the nurses’ study, femoral neck and total femoral BMD remained 
significantly higher in blacks even after correction for weight. Our findings also differ from 
the American data, where BMD before and after adjustment for covariates (including body 
weight) at all skeletal sites has invariably been found to be higher in blacks than in 
whites135,138,143-145,184-199. Differences in anthropometric variables, particularly body weight or 
body mass index, do account for a significant part of the difference in BMD between African-
American and Caucasian women186,199.  Ettinger et al186 found that adjustment for a series of 
anthropometric, lifestyle, and biochemical variables reduced the difference in BMD between 
black and white premenopausal women by 34%. Finkelstein et al199 found that adjustment 
for anthropometric and lifestyle factors, particularly body weight, reduced the magnitude of 
the difference in lumbar and femoral neck BMD between late premenopausal and early 
perimenopausal African-Americans and Caucasians, Chinese and Japanese (unadjusted 
difference lumbar spine BMD 7-12%, adjusted difference 3-6%; unadjusted difference 
femoral neck BMD 14-24%, adjusted difference 6-9%). 
Adiposity may have a role in maintaining BMD in postmenopausal females as reported by 
other researchers239,240,242,247,250,314-316. After menopause, body mass becomes the main 
determinant of endogenous estrogen activity, as mentioned before, and excess body mass 
may be a protective factor for osteoporosis due to increased conversion of androgens to 
estrogens by fat tissue317. This may be particularly relevant in the early postmenopausal 
period characterized by estrogen withdrawal and increased bone loss. The progressive 
increase in adiposity with age noted in the black subjects in our study, may thus potentially 
contribute to the apparent lower rates of postmenopausal decline in spinal BMD and femoral 
BMD observed in our black cohort.  
Calcium-intake 
The mean calcium-intake of postmenopausal blacks was significantly lower compare with 
whites (p<0.01). No significant correlation could be demonstrated between daily calcium-
intake and bone mineral density at any of the skeletal sites evaluated.  
Physical activity 
Physical activity was significantly less well maintained amongst blacks in our study with an 
impressive 69% of postmenopausal blacks not partaking in any form of out-door activity. 
Life-long exercise may reduce fracture risk by limiting age related bone loss310 and by 
improving muscle strength (thereby reducing the frequency and severity of falls)311. A 
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significant association between physical inactivity and BMD could not be demonstrated in our 
postmenopausal cohort. 
Parity  
In our study, older postmenopausal black females had significantly higher parity compared 
with whites and this clinical variant was significantly and positively associated with femoral 
BMD measurements in this menopausal subgroup. As mentioned in chapter 4, several 
previous reports have also confirmed a positive correlation between parity and BMD280,281, 
although other studies have reported no correlation between parity and BMD282-284 or a 
negative correlation285. The few studies conducted in very high parity (more or equal to five 
births) postmenopausal women have not been unanimous regarding beneficial skeletal 
effects281,284,285.  
Smoking 
Smoking, especially current smoking, is a known risk factor for osteopenia and subsequent 
fracture, especially hip fracture115,118,119,318. Our postmenopausal white women smoked more 
than blacks when expressed as total pack years (p<0.01) and a higher percentage of current 
smokers was also noted amongst the white postmenopausal cohort. The number of pack 
years smoked was negatively associated with both femoral neck and total femoral BMD in 
the late postmenopausal subjects. Correction for this clinical variant, however, did not 
significantly alter ethnic differences in femoral BMD i.e. after correction for number of pack 
years smoked femoral BMD values remained higher in blacks. 
IMPACT OF BONE SIZE ON BMD MEASUREMENTS 
Conventional areal BMD measurements by DEXA introduce a scale artifact that causes small 
bones to have lower areal BMD than larger bones. When comparing people from different 
ethnic groups with potential differences in bone size, BMD differences may thus be more 
apparent than real. Although black women in this study are heavier than white women, their 
lumbar spine and femoral neck bone areas, as measured by DEXA, are significantly smaller, 
a finding also observed in African-American women compared with Caucasian women199. 
Areal measurements may thus be inappropriately low in the black cohorts due to smaller 
bone size i.e. may be an underestimate of true volumetric bone density.    
This scale artifact is reduced by expressing BMD as BMAD, a calculated three-dimensional 
variable that helps account for the size of the bones (methodology as described in chapter 3, 
section 2.2.2). Spinal BMAD was similar in blacks and whites in all the age and menopausal 
subgroups studied. When analysis was restricted to females of normal to low weight, spinal 
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BMAD was lower in blacks than whites, similar to that observed for spinal BMD. Spinal BMAD 
after adjustment for weight as a covariate remained similar in the pre- and postmenopausal 
blacks and whites. Femoral neck BMAD, before and after adjustment for covariates, was 
consistently higher in black females in all the comparable groups studied.  Partial correction 
of bone size, via this volumetric calculation, thus increased bone mineral measurements of 
the black females relative to whites and resulted in similar mean volumetric spinal bone 
mineral density and significantly higher mean volumetric femoral bone mineral density in 
pre- and postmenopausal black women.   
Numerous previous studies have reported that BMD is a major predictor of fracture risk in 
postmenopausal women12,13,30,106,109,130,135,136,156,180,319-321. In general, for every SD that BMD is 
reduced, the risk of fragility fractures doubles166. Most of these studies have been conducted 
in white female populations and less is known about the association of BMD with fracture 
risk in other ethnic populations. In a recent multi-ethnic study by Barrett-Conner et al136, 
women with osteopenia or osteoporosis had an increased risk of fracture in every ethnic 
group, but the absolute risk of fracture at any given BMD differed among ethnic groups. 
These findings were confirmed in a prospective study by Cauley et al135 who showed that 
reduced BMD of the total hip and femoral neck is associated with an increased risk of all 
non-spinal fractures in older black women, but that the absolute fracture incidence was 30 – 
40% lower among black women compared with whites - the lower fracture rate in blacks 
was independent of BMD and other historical clinical risk factors and implied that non-BMD 
determinants of fracture risk may be responsible for the difference observed. The estimated 
volumetric apparent bone density of the femoral neck is not regarded as superior to femoral 
BMD in the prediction of hip fracture in elderly postmenopausal white women321.  As women 
of different racial and ethnic groups have substantially different sizes of femoral neck, BMAD 
might be a better predictor than BMD of hip fracture in a more diverse population.  
BMD DISTRIBUTION AND FRACTURE RISK IN POSTMENOPAUSAL BLACK AND WHITE 
FEMALES 
A significant percentage of postmenopausal black and white females in this study cohort had 
spinal and/or femoral osteopenia based on WHO criteria and as measured against a uniform 
white reference population. Spinal osteopenia was noted in a similar percentage of black and 
white females affecting ~50% of both postmenopausal groups. Spinal osteoporosis was 
present in 14% of black and white females. Although a higher percentage of white 
postmenopausal females had femoral osteopenia, a significant percentage of 
postmenopausal blacks also had femoral BMD measurements compatible with osteopenia 
(~30%). These data imply that, based on individual BMD measurements, a significant 
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percentage of postmenopausal black females in this study were also at increased risk of 
fracture.   
The differences in mean BMD at most measured sites, along with the finding of spinal and 
femoral osteopenia in a significant percentage of both black and white postmenopausal 
female cohorts cannot explain the apparent marked difference in fracture risk observed in 
previous studies between black and white SA female populations. The higher mean areal and 
volumetric BMD at the femoral neck and total femoral sites in blacks may partially explain 
the finding of lower hip fracture risk in this ethnic group. It is doubtful whether the 
differences in mean areal and volumetric BMD at the femoral neck and total femoral sites 
between blacks and whites alone can explain a ten-fold difference in hip fracture risk and 
other non-BMD determinants of hip fracture risk must be considered as potential contributors 
such as differences in body size, bone geometry and bone quality.   
Lumbar spine BMD was not higher in postmenopausal black women compared with white 
women and can thus not explain the lower vertebral fracture prevalence previously 
documented in SA blacks compared with whites211. Data pertaining to vertebral fracture 
prevalence in SA black females are, however, limited and old. The abovementioned disparity 
may thus be explained in more than one way. It may be that the assumed lower vertebral 
fracture prevalence previously reported in SA black women is not relevant at present and 
emphasize the need for further studies to clarify this issue. It has, on the other hand, been 
noted in other African populations that the prevalence of minimal trauma fractures is 
extremely low despite documented low spinal BMC and spinal BMD compared with British 
subjects212. These fractures do, however, refer mostly to non-spinal fractures and do not 
include the presence of asymptomatic vertebral deformities. If vertebral fracture prevalence 
in African blacks is indeed very low, it challenges the concept of bone mineral status as a 
primary determinant of vertebral fracture risk.  
To conclude, we found that peak spinal BMD was lower, but peak femoral BMD similar or 
higher (depending on the specific proximal femoral site measured) in black South-African 
females compared with whites. The lower peak spinal BMD was mainly attributed to lower 
BMD’s in the subgroup of black females with normal to low body weight indicating that 
obesity either protected black females against a low spinal BMD or enhanced optimal 
attainment of bone mineral. An apparent slower rate of decline in both spinal- and femoral 
BMD with ageing was noted in the black females compared with whites. This resulted in 
similar spinal BMD values in postmenopausal blacks and whites, and significantly higher 
femoral BMD measurements in blacks. The volumetric calculation of bone mineral apparent 
density at the lumbar spine and femoral neck yielded similar results to that of BMD. Spinal 
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BMAD was similar in blacks and whites and femoral neck BMAD was consistently higher in all 
the menopausal subgroups studied.  
Weight significantly correlated with peak- and postmenopausal BMD at all sites in the black 
and white female cohorts. Greater and better maintained body weight may be partially 
responsible for slower rates of bone loss observed in black postmenopausal females. Most of 
the observed ethnic difference in BMD was explained by differences in body weight between 
the two cohorts and not by ethnicity per se. The modern tendency towards a lower ideal 
body weight in black urbanized societies may increase the likelihood of suboptimal 
attainment of peak BMD and may impact on bone loss rates with potentially lower BMD in 
later life in black populations of SA.  
The differences in mean BMD at most measured sites, along with the finding of spinal and 
femoral osteopenia in a significant percentage of both black and white postmenopausal 
females, cannot explain the marked difference in fracture risk observed in previous studies 
between black and white SA female populations. The higher proximal femoral BMD results in 
postmenopausal blacks may increase bone strength in the hip region and protect against 
fragility fracture, but unlikely to fully account for a ten-fold difference in hip fracture risk. If 
the present prevalence of vertebral fractures is indeed lower in SA blacks, the lower or 
similar spinal bone density values in blacks compared with whites suggest that factors other 
than BMD are important determinants of vertebral bone strength in black South African 
females. BMD independent determinants of bone strength and fracture risk such as bone 
quality, bone geometry and fall risk must be considered in an attempt to explain ethnic 
differences in fracture risk in our study population.  
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CHAPTER 6 
WHICH CLINICAL RISK FACTORS ARE ABLE TO PREDICT LOW BONE MASS 
IN POSTMENOPAUSAL BLACK AND WHITE SOUTH AFRICAN FEMALES? 
1. INTRODUCTION 
In recent years, BMD testing has become more widely available. Measuring BMD in all 
postmenopausal women is, however, logistically impossible, prohibitively expensive and 
probably unnecessary, since most postmenopausal women will have a normal bone mass 
and are at low risk of fracture. Targeted testing, i.e. testing persons identified as high risk of 
having osteoporosis (based on the presence of known clinical risk factors for low bone loss) 
is an appealing alternative. Assessment of clinical risk factors to identify women likely to 
benefit from BMD testing has great appeal especially in the primary care setting since it is 
inexpensive and readily obtainable.  
Numerous studies on the ability of clinical risk factors to predict the presence of osteopenia 
have been reported101,115-119,126,128,236. Large epidemiological and population based studies 
have noted that current anthropometric and lifestyle factors only explain 20 - 35% of the 
variance in bone density at different skeletal sites115,117. Most of these studies have been 
performed in postmenopausal Caucasian females and there are only limited data available 
regarding risk factor assessment in other population groups118,119. 
Numerous simple risk assessment instruments have also been constructed to identify 
patients who are most likely to have a low BMD warranting a bone density test120-125. These 
risk instruments have been developed based on data obtained via epidemiological risk factor 
identification in Asian countries, the US and Europe. The purpose of these risk assessment 
tools is not to diagnose osteoporosis or low BMD, but to identify women who are more likely 
to have low BMD and who can then be selectively referred for BMD measurements. It is thus 
not necessary that a risk assessment tool has both a high sensitivity and specificity.  
The Osteoporosis Self-assessment Tool (OST) is based simply on age and weight123,124  
(table 1). The score is calculated by subtracting age from weight and then multiplying  
by 0.2123.  Lower OST scores are associated with greater likelihood of low BMD, and a score 
of <2 suggests that BMD be tested. It was developed and tested in women from eight Asian 
countries and yielded a sensitivity of 91% and a specificity of 45% to identify women with 
femoral neck osteoporosis (T-score ≤-2.5). It has been validated in several individual Asian 
countries and has also been validated in five large samples of primarily Caucasian 
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women122,124. Other risk tools are also based on age and weight, in combination with up to 
four additional risk factors. These include, amongst others, the Osteoporosis Risk 
Assessment Instrument (ORAI) and the Osteoporosis Index of Risk (OSIRIS) [table 1].  ORAI 
differentially score weight and age within certain cut-off ranges and include hormone 
therapy as a risk index to identify women likely to have either femoral neck or lumbar spine 
T-scores ≤-2.0121. Any patient with a score of 9 or higher would be advised to have BMD 
testing. The development cohort comprised women from the Ontario participants in the 
Canadian Multicenter Osteoporosis Study (CaMOS) and in this population the sensitivity was 
90% and the specificity was 45%. The Osteoporosis Index of Risk (OSIRIS) is based on four 
variables: age, body weight, current hormone therapy and a history of previous low impact 
fractures224. The sensitivity and specificity for the OSIRIS value of +1 were respectively 
78.5% and 51.4%. The cohort studied was 1303 postmenopausal Canadian women from an 
out-patient osteoporosis clinic. The performance of these risk assessment tools in multi-
ethnic populations has never been published. 
Table 1: Clinical Risk Assessment Instruments – Calculation of the evaluated indices  
Factor Score 
 
ORAI  
Age > 75 years + 15 
Age 65–74 years + 9 
Age 55–64 years + 5 
Body weight < 60 kg + 9 
Body weight 60–70 kg + 3 
Oestrogen therapy 
 
+ 2 if not currently using oestrogen 
OSIRIS  
Body weight (kg) + 0.2 x body weight 
Age (years) - 0.2 x age 
History of low impact fracture(s) - 2 
Oestrogen therapy 
 
+ 2 
OST  
Body weight (kg) 
Age (years) 
 
0.2 x (body weight-age) 
This chapter reports on the ability of historical risk factors to predict low bone mass and on 
the performance of risk assessment instruments in our population of black and white South 
African females. 
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2. PATIENTS AND METHODS 
BMD was normal in the majority of premenopausal subjects thus making it near impossible 
to determine the impact of clinical risk factors in them. The analysis of risk based on the 
presence of historical risk factor(s) or via the use of risk assessment tools was thus restricted 
to postmenopausal blacks and whites.   
Hormone treated white postmenopausal females were included in the analysis of frequency 
of individual clinical risk factors by BMD status. Individual risk factors were thus assessed in 
100 blacks and 110 whites (clinical characteristics of postmenopausal study cohort as 
outlined in chapter 4, table 1 & 3). 
Risk assessment tools and general discriminant analysis models were evaluated in the non-
hormone treated cohorts only, since hormone therapy was used almost exclusively by 
whites. This cohort thus included 97 blacks and 66 whites, (clinical characteristics of 
postmenopausal non-hormone treated cohort as outlined in chapter 5, table 1). 
The standardization of risk categories are described in detail in chapter 3 (please refer to 
section 2.1.1.1). Age was also included in this analysis of risk as the postmenopausal group 
was evaluated in total, and age was regarded as a clinical risk factor if ≥65 years.  
The frequency for each risk factor (refer to chapter 3, section 2.1.1.1) in patients with 
normal bone mass (BMD T-score>-1) and in those with osteopenia (BMD T-score ≤-1SD) 
was determined for spinal and femoral sites (tables 2 & 3). The BMD of all patients were 
measured against a uniform white reference population (in this study we used a white 
female reference population to calculate T- and Z-scores for both ethnic groups as no 
normative data for black South African women exist, previously outlined in chapter 3, section 
2.2.1.).  
General discriminant analysis was used to identify variables able to predict osteopenia in 
postmenopausal black and white females (table 4). Associations were determined between 
clinical risk factors and low BMD (T-score ≤-1SD as assessed against a uniform white 
reference population) at the lumbar spine and at the proximal femur (total BMD and femoral 
neck BMD). 
We calculated risk assessment scores based on the OST, OSIRIS and ORAI tools, and 
evaluated the performance of these tools in identifying non-hormone treated 
postmenopausal black and white women at risk of osteopenia i.e. a T-score ≤-1 at various 
BMD measurement sites (table 5). These risk tools were originally evaluated in terms of their 
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ability to predict the presence of osteoporosis (T-score ≤-2.5) or moderate osteopenia  
(T-score of ≤-2). Due to very limited numbers of black and white patients with a proximal 
femoral T-score ≤-2, we used ≤-1 as our cut-off at all skeletal sites, but also evaluated the 
performance of these risk tools in individuals with a lumbar spine T-score ≤-2.   
The sensitivity, specificity, positive predictive value and negative predictive value for each of 
the risk assessment tools within the specific ethnic groups were also calculated.  
Cross tabulation and the Chi-square test was used to determine univariate relationships 
between risk factors and low bone mass.  For multivariate prediction of low bone mass in all 
subsets, linear discriminant analysis was used to pick out the best combinations of predictor 
variables.   
3. RESULTS 
3.1. CLINICAL RISK FACTORS AND LOW BONE MINERAL DENSITY  
3.1.1. Frequency of clinical risk factors by BMD status in the postmenopausal  
cohorts 
Amongst the black females, the only clinical risk factor that was associated with osteopenia 
at all skeletal sites was a low weight and BMI. The association between body size, expressed 
as body weight (p=0.02) or BMI (p<0.01) was strongest for spinal osteopenia.  Only one 
black female with low body weight and none of the black females with a low BMI had normal 
spinal BMD. The presence of these anthropometric findings thus indicated a high risk for 
spinal osteopenia in black females (high specificity 98-100%, positive predictive value 91-
100%). The majority of black females with spinal osteopenia were, however, of normal 
weight (80%) and BMI (88%) and although a significant association was observed between 
these risk factors and spinal osteopenia, the sensitivity (<20%) and negative predictive value 
(~50%) were very poor, implying that many normal to overweight black females also have 
osteopenia. Older age and a low physical activity score were present in a significantly higher 
percentage of black females with femoral neck osteopenia compared to those with normal 
femoral neck BMD. The past use of oral contraceptives or Depo Provera did not impact on 
the presence of osteopenia in the black cohort. 
The frequency distribution of clinical risk factors within the white female cohort, based on 
the presence or absence of osteopenia, is remarkably similar irrespective of the skeletal site 
affected (tables 2,3). Older age, low body weight and the non-use of hormone therapy was 
consistently associated with osteopenia at all skeletal sites. The frequency of hormone 
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therapy use was significantly higher in the normal BMD subgroups for all skeletal sites 
compared with the osteopenic groups (p<0.01). A normal BMD at the spine and femoral 
sites was documented in 83% (spinal), 90% (total femoral) and 71% (femoral neck) of white 
postmenopausal females on hormone therapy. A significant percentage of postmenopausal 
white females not on hormone therapy, however, also had normal BMD measurements thus 
limiting the specificity of this factor to predict protection against osteopenia (sensitivity:78%; 
specificity:53%). Previous oral contraceptive users were evenly distributed in the normal 
BMD and osteopenic subgroups. 
Table 2: Clinical factors that affect risk for spinal bone loss in white and black postmenopausal females 
 BLACK COHORT WHITE COHORT 
Clinical Risk Factor Normal 
(n=43) 
Osteopenia  
(n=51) 
p-value 
 
Normal  
(n=74) 
Osteopenia 
 (n=36) 
p-value 
Age (>65yrs) 12 (28) 17 (33) 0.41 13 (18) 13 (36) 0.04 
Weight (≤60 kg) 1 (2) 10 (20) 0.02 14 (19) 13 (36) 0.07 
Height (≤156 cm) 13 (30) 13 (25) 0.49 12(16) 9 (25) 0.31 
BMI (<23 kg/m2) 0 (0) 6 (12) <0.01 17 (23) 13 (35) 0.18 
Daily  Ca-intake (<500mg/d) 17 (40) 13 (25)  0.15 5 (7) 2 (6) 0.84 
Current smoking (Y) 8(19) 7 (14) 0.49 30(41) 8 (22) 0.02 
Low PA (score ≤2) 25 (58) 38 (75) 0.09 28 (38) 16 (43) 0.51 
Alcohol usage (Y)  11 (26) 11 (22) 0.65 27 (36) 17 (46) 0.25 
Maternal history of OP (Y) 0 (0) 1 (2) - 16 (22) 10 (28) 0.51 
Oral contraceptive use (Y) 12 (28) 9 (18) 0.23 32 (43) 18 (50)  0.55 
Depo Provera use (Y) 10 23) 7 (14) 0.23 2 (3) 1 (3)  - 
Hormone therapy (Y) 2 (5) 0 (0)  - 40 (54) 8 (22)  <0.01 
Breastfeeding (Y) 35 (81) 40 (78) 0.72 47 (64) 24 (67) 0.82 
High parity (≥3) 33 (78) 40 (78) 0.84 43 (58) 20 (56) 0.79 
(Y): yes, indicating presence of specific risk factor. Expressed as number of patients, percentage of patients in brackets, p-value 
refers to comparison of specific ethnic cohort and skeletal site measured 
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           Table 3: Clinical factors that affect risk for hip bone loss in white and black postmenopausal females 
 Femur total Femur neck 
BLACK  COHORT WHITE COHORT BLACK  COHORT WHITE COHORT 
Clinical Risk Factor Normal  
n=69 
Osteopenia 
n=27 
p-value Normal  
n=74 
Osteopenia 
n=36 
p-value Normal  
n=62 
Osteopenia 
n=33 
p-value Normal  
n=57 
Osteopenia 
n=53 
p-value 
Age (>65 yrs) 20 (30) 8 (30) 0.57 11 (15) 15 (42) 0.02 13 (22) 14 (42) 0.03 7 (12) 19 (36) 0.03 
Weight (≤60 kg) 6 (9) 6 (22) 0.73 12 (16) 15 (42) <0.01 5 (8) 7 (21) 0.73 8 (14) 19 (36) 0.05 
Height (≤ 156 cm) 18 (26) 9 (33) 0.44 6 (8) 12 (33) 0.01 14 (23) 12 (36) 0.16 7 (12 14 (26) 0.06 
BMI (<23kg/m2) 2(3) 4(15) 0.04 17(23) 113(36) 0.14 2(3) 4(12) 0.09 12(21) 18(34) 0.14 
Calcium (<500mg/d) 23(33) 7(26) 0.55 6(8) 1(1) 0.26 20(32) 9(27 0.61 4(7) 3(6) 0.82 
Current smoking 12 (14) 4 (15) 0.79 30 (41) 11 (31) 0.42 12 (19) 4 (12) 0.39 20 (35) 19 (36) 0.96 
Low PA (score ≤ 2) 46(67) 18(67) 0.81 31(42) 14(39) 0.39 37(60) 27(82) 0.02 25(44) 18(34) 0.26 
Alcohol usage (Y) 14(20) 9(33) 0.16 27(36) 16(44) 0.41 13(21) 9(27) 0.49 20(35) 23(43) 0.21 
F/H of OP (Y) 0(0) 1(4) 0.11 16(22) 10(28) 0.44 0(0) 1(3)  - 11(19) 15(28) 0.27 
Depo Provera use (Y) 13 (19) 4 (15) 0.69 1 (1) 2 (6) 0.21 14 (23) 4 (12) 0.20 0 (0) 3 (6)  -  
OC use (Y) 17(25) 5(19) 0.57 35(47) 15(42) 0.66 17(27) 5(15) 0.17 28(49) 22(42) 0.42 
Hormone therapy (Y) 2 (3) 0 (0) - 43 (58) 5 (14) <0.01 2 (3) 0 (0) - 34 (60) 14 (26) <0.01 
Breastfeeding (Y) 56 (81) 20 (74)  0.65 48 (65) 23 (64) 0.94 49 (79) 27 (82) 0.75 36 (63) 35 (66) 0.76 
High parity (≥3) 53 (77) 20 (74) 0.79 40 (54) 23 (64) 0.29 47 (76) 25 (76) 0.55 33 (59) 30 (57) 0.98 
           (Y): yes, indicating presence of specific risk factor.  Values expressed as absolute number with percentage in brackets p-value refers to comparison of specific ethnic cohort and skeletal site measured 
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3.1.2. Association between individual risk factors and osteopenia 
General discriminant analysis identified clinical risk factor subsets best able to identify 
osteopenia in postmenopausal blacks and whites (table 4). 
3.1.2.1. Lumbar spine osteopenia 
Discriminant analysis identified 3 variables used for combined prediction of spinal osteopenia 
in blacks namely low body weight, low physical activity score and a low calcium intake. The 
model was able to correctly identify 74% of blacks with spinal osteopenia. The absence of 
these risk factors correctly predicted normal bone mass in 71% of black subjects. In the 
postmenopausal white cohort, 4 variables were identified by discriminant analysis to be 
associated with osteopenia, namely low body weight, high parity, breastfeeding and alcohol 
usage.  This model was able to correctly identify 75% of whites with spinal osteopenia. The 
absence of these risk factors correctly predicted normal bone mass in 54% of white females. 
3.1.2.2. Total hip osteopenia 
Variables identified by discriminant analysis for prediction of total femoral osteopenia in 
blacks included a low body weight, breastfeeding and smoking whereas only a low body 
weight was identified in whites. This model was able to correctly identify the presence of a 
low BMD in 78% of black females and in only 56% of white postmenopausal women. The 
absence of a low body weight correctly predicted normal total femoral BMD in 69% and 83% 
of the postmenopausal blacks and whites respectively.     
3.1.2.3. Femoral neck osteopenia 
Discriminant analysis identified 5 variables used for combined prediction of femoral neck 
osteopenia in blacks namely low body weight, low BMI , low physical activity score, high 
parity and prior use of oral contraception.  The model was able to correctly identify 67% of 
blacks with femoral neck osteopenia. The absence of these risk factors correctly predicted 
normal femoral neck BMD in 63% of black subjects. In the postmenopausal white cohort, 2 
variables were identified by discriminant analysis, namely a low body weight and prior use of 
oral contraceptives. This model was able to correctly identify only 58% of whites with 
femoral neck osteopenia. The absence of these risk factors correctly predicted normal 
femoral neck BMD in 100% of white females. 
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Table 4: Risk factors identified by general discriminant analysis to predict osteopenia in black and white females 
 Risk factor subset PPV NPV 
LUMBAR SPINE BMD 
Blacks 
Whites 
 
Low body weight, low PA, low calcium-intake 
Low body weight, high parity, breastfeeding, alcohol usage  
 
74% 
75% 
 
71% 
54% 
TOTAL FEMORAL BMD 
Blacks 
Whites 
 
Low body weight, breastfeeding, smoking 
Low body weight 
 
78% 
56% 
 
69% 
83% 
FEMORAL NECK BMD 
Blacks    
Whites 
 
Low body weight, low BMI, low PA, high parity, prior use OC 
Low body weight, prior use of OC 
 
67% 
58% 
 
63% 
100% 
PPV: positive predictive value, NPV: negative predictive value Risk factor subset: risk factors as listed in tables 17 and 18 
3.1.3. Use of Risk Assessment Tools  
The majority of postmenopausal black and white females included in this study cohort fell 
into the low risk category for all three risk tools (table 5).  Increasing prevalence of 
osteopenia (T-score ≤-1 at all sites, T-score ≤-2 at lumbar spine) with ascending risk 
category low to moderate was apparent for all three risk tools in both black and white post-
menopausal females. Due to the very small percentage of the total patient population in the 
high risk category, this trend was not universally apparent with ascending risk category from 
moderate to high risk. An increased prevalence of osteopenia of the lumbar spine in the 
black cohort and of the femur neck region in whites was, however noted with ascending risk 
category moderate to high for all three risk tools. The ORAI risk assessment instrument was 
most sensitive in both ethnic groups and thus identified most women to be at risk (moderate 
to high risk categories). The prevalence of lumbar spine osteopenia in the black cohort was 
44%, 60% and 100% at the low (58% of black women), moderate (37% of black women) 
and high (5% of black women) ORAI risk levels respectively. In the white cohort, the 
prevalence of femoral neck osteoporosis was 39%, 72% and 78% at the low (36% of white 
women), moderate (50% of white women) and high (14% of white women) ORAI risk levels 
respectively. 
The sensitivity, specificity, positive predictive value and negative predictive value for each of 
the risk assessment tools are tabulated in table 6 (black cohort), table 7 (white cohort) and 
table 8 (black and white cohort, lumbar spine T-score ≤-2). 
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Table 5: Prevalence of low BMD by BMD measurement site and risk category 
Risk category Total 
 
n=97 
(100%) 
                Postmenopausal black females 
         Osteopenia: T-score ≤ -1                        T-score ≤ -2  
     Hip                 FN               L1-L4                  L1-L4 
    (28%)           (35%)            (53%)                 (30%) 
Total 
 
n=66 
(100%)           
Postmenopausal white females 
    Osteopenia: T-score ≤ -1                             T-score ≤ -2  
   Hip              FN                 L1-L4                        L1-L4 
  (48%)        (61%)              (44%)                       (23%) 
OST            
>1 (low risk) 83% 24% 27% 45% 25% 59% 34% 37% 34% 16% 
-3 to 1 (moderate risk) 14% 38% 78% 83% 50% 35% 64% 77% 64% 38% 
<-3 (high risk) 3% 33% 33% 100% 67% 6% 75% 100% 50% 40% 
<2* 26% 32% 64% 78% 42% 55% 64% 83% 61% 37% 
OSIRIS           
>1(low risk) 77% 19% 23% 44% 25% 55% 29% 40% 29% 11% 
-3 to 1 (moderate risk) 20% 53% 79% 79% 47% 38% 71% 88% 67% 42% 
<-3 (high risk) 3% 33% 33% 100% 67% 8% 80% 100% 60% 40% 
≤ 1* 23% 50% 73% 82% 50% 45% 72% 90% 66% 41% 
ORAI           
<9 (low risk) 58% 22% 18% 44% 23% 36% 26% 39% 30% 13% 
9-17 (moderate risk) 37% 40% 60% 60% 37% 50% 56% 72% 56% 31% 
>17 (high risk) 5% 20% 40% 100% 60% 14% 67% 78% 44% 33% 
≥ 9* 41% 38% 59% 67% 40% 64% 58% 73% 54% 32% 
Hip: Total hip; FN: Femoral neck; L1-L4: Lumbar spine L1 to L4.   
*Scores for each Instrument used to recommend BMD testing70,72-73.  
Table depicts percentage of patients with osteopenia (defined by a T-score of ≤ -1 or ≤ -2) within different risk categories for the different risk assessment instruments i.e. low risk, moderate risk 
and high risk at the different skeletal sites i.e. total hip, femoral neck and lumbar spine 
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Table 6: Performance of the risk indices by BMD measurement site and T-score cut-off (%) in blacks 
 Total hip 
(T-score < -1) 
Femoral neck 
(T-score < -1) 
Lumbar spine 
(T-score < -1) 
Any site 
(T-score < -1) 
 Sens Spec PPV NPV Sens Spec PPV NPV Sens Spec PPV NPV Sens Spec PPV NPV 
OST (<2 vs. ≥ 2) 27 80 33 74 42 89 67 74 33 91 81 53 37 100 100 51 
OSIRIS (≤ 1 vs.  >1) 40 84 50 81 48 88 73 77 36 91 82 56 38 95 91 55 
ORAI (< 9 vs. ≥ 9) 52 69 40 78 65 79 63 80 52 80 74 60 53 89 86 53 
 
 
Table 7: Performance of the risk indices by BMD measurement site and T-score cut-off (%) in whites 
 Total hip 
(T-score < -1) 
Femoral neck 
(T-score < -1) 
Lumbar spine 
(T-score < -1) 
Any site 
(T-score < -1) 
 Sens Spec PPV NPV Sens Spec PPV NPV Sens Spec PPV NPV Sens Spec PPV NPV 
OST (<2 vs. ≥ 2) 66 64 64 66 63 71 79 53 72 67 64 75 62 75 85 47 
OSIRIS (≤ 1 v.s  >1) 68 76 72 71 65 88 90 60 66 71 66 71 63 90 93 54 
ORAI (< 9 vs. ≥ 9) 81 55 63 75 78 63 78 63 79 50 56 75 76 65 83 54 
 
Table 8: Performance of the risk indices by BMD measurement site and T-score cut-off of < -2 (%) in blacks and whites 
 Lumbar spine -Blacks 
(T-score < -2) 
Lumbar spine- Whites 
(T-score < -2) 
 Sens Spec PPV NPV Sens Spec PPV NPV 
OST (<2 vs. ≥ 2) 33 79 42 72 45 69 37 75 
OSIRIS (≤ 1 v.s  >1) 38 83 50 75 75 65 34 89 
ORAI (< 9 vs. ≥ 9) 55 64 40 77 81 42 32 87 
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3.1.3.1. Black cohort 
All three risk assessment tools had very low sensitivity to identify black individuals with 
osteopenia at the different skeletal sites. Sensitivities of these risk tools were unacceptably 
low as screening instruments in blacks with the best performer, the ORAI risk tool, only 
reaching sensitivities of 50-65% at the different skeletal sites. The specificity of these risk 
assessment tools in the black cohort was substantially better i.e. these instruments were 
able to correctly identify 80-100% of the black female cohort with normal BMD at most of 
the skeletal sites (see table 5). The OSIRIS and OST tools had better specificity at all skeletal 
sites compared with the ORAI tool. 
3.1.3.2. White cohort 
The ORAI tool had the highest sensitivity for low BMD at all skeletal sites, similar to that 
observed in blacks. Risk tools were universally more sensitive to predict osteopenia in whites, 
with sensitivities of the ORAI risk tool >75% for all skeletal sites in whites. The OSIRIS tool 
was most specific re low BMD at all skeletal sites with values ranging between 71-90% (most 
specific for femoral neck osteopenia).  
4. DISCUSSION 
A low body weight and advanced age was identified as by far the most informative individual 
risk factors for osteopenia in our black and white females, whereas physical inactivity was 
also identified as an important individual risk factor in blacks only. A low body weight was 
noted more frequently amongst blacks and whites with osteopenia at all skeletal sites 
measured. Low body weight was, however, only present in a minority of both black and 
white females (10% of blacks, 20% of whites). The majority of blacks and whites with 
osteopenia were of normal weight thus resulting in poor sensitivity of low body weight to 
predict the presence of osteopenia. An older age was noted more frequently amongst whites 
with osteopenia at all skeletal sites and in blacks with femoral neck osteopenia. Physical 
inactivity was significantly associated with femoral neck osteopenia in blacks, whereas the 
frequency of physical inactivity amongst normal BMD and osteopenic whites was similar for 
all sites measured. In whites, hormone therapy use was significantly higher in the normal 
BMD group at all skeletal sites compared with the osteopenic groups (p<0.01). The majority 
of whites on hormone therapy had normal BMD measurements (sensitivity 78%), but many 
females not on hormone therapy also had normal BMD measurements thus limiting the 
specificity of this factor to predict protection against osteopenia (58%). The frequency of 
other risk factors i.e. daily dietary calcium-intake, current smoking, alcohol intake, 
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breastfeeding, high parity and use of hormonal contraception did not differ significantly 
between the black and white normal BMD and osteopenic subgroups. 
Combinations of clinical risk factors are also useful to identify patients at highest risk of 
osteopenia. In our study, specific risk factor subsets identified by general discriminant 
analysis as best able to identify the osteopenic individual, differed between the two ethnic 
groups and for different skeletal sites. The positive predictive value of these risk factor 
subsets were similar for the lumbar spine in backs and whites (~75%), but higher in blacks 
(67-78%) compared with whites (56-58%) for the proximal femoral sites. The absence of 
the specific risk factor subsets for the proximal femoral sites in whites (low body weight ± 
use of oral contraceptives), however, excluded osteopenia in 83-100% of cases. 
Risk assessment tools 
In our study, the risk assessment tools evaluated i.e. OST, OSIRIS an ORAI, were found to 
be of  limited value to differentiate women with normal BMD from those with osteopenia i.e. 
T-scores of ≤-1 at all sites and T-scores of ≤-2 at the lumbar spine. As alluded to before, 
these risk tools were originally evaluated in terms of their ability to predict the presence of 
osteoporosis (T-score ≤-2.5) or moderate osteopenia (T-score of ≤-2) in Asian and 
Caucasian populations121-124,224. Due to very limited numbers of black and white patients with 
a proximal femoral T-score ≤-2, we used ≤-1 as our cut-off at all skeletal sites, but also 
evaluated the performance of these risk tools in individuals with a lumbar spine T-score ≤-2.   
Although increased risk of osteopenia was noted with ascending risk categories for all risk 
assessment tools evaluated, they were not sensitive enough to effectively identify women 
with osteopenia who should undergo BMD testing in our study cohort. All these tests depend 
heavily on body weight i.e. a low body weight determines, to a great extent, categorization 
into low and high risk groups. Calculations developed for the OST and OSIRIS are identical 
for incorporation of weight and age into the final score, therefore, in any individual where 
weight exceeds age, a positive score will be obtained and the patient will thus be categorized 
as low risk in the absence of fragility fractures. The ORAI tool more specifically scores 
individuals based on the presence of specific weight ranges and was documented to be the 
most sensitive tool to depict osteopenia in both our black and white female groups. In the 
blacks’ sensitivities for the ORAI were still unacceptable low (52-65%) at all sites, whereas 
sensitivities approached 80% in whites. These tools were mainly developed in Asia, Europe 
and Canada where average body size are significantly smaller than in our study cohort and 
calculations of these risk tools thus appear to be inappropriate for our heavier study group. 
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To conclude, 
● Low body weight and advanced age were significantly associated with osteopenia at 
most skeletal sites in our blacks and whites. Low weight (<60 kg) only affected a small 
subset of our study population with low BMD and therefore, although highly specific, 
low body weight had poor sensitivity to identify individuals with osteopenia.  
● Risk assessment tools, developed and validated in Asian and European populations, 
demonstrated poor sensitivity for identification of SA women at increased risk of 
osteopenia. The ORAI showed the best results, with sensitivities to identify osteopenic 
whites’ at most skeletal sites approaching 80% (78% - 81%). A higher percentage of 
our study population categorized as low risk by the risk assessment instruments had 
osteopenia compared to the study populations in which these tools were validated. The 
risk assessment tool scores appear to be inappropriate for our larger sized study 
cohort, especially our black subjects, thus resulting in incorrect risk stratification and 
poor test sensitivity.  
● Risk factor subsets identified for combined prediction of osteopenia were most 
sensitive in blacks at all skeletal sites, whereas the ORAI risk tool was more sensitive 
than discriminant analysis risk models for combined prediction of osteopenia in whites. 
Local risk factor questionnaires should, among others, include all the risk factors 
identified by our general discriminant analyses i.e. low body weight and BMI, physical 
inactivity, low calcium intake, current smoking and alcohol intake, high parity and past 
use of oral contraceptives. 
● Larger population based studies are needed in South Africa to better define the role of 
clinical risk factors and usefulness of risk assessment instruments. Risk assessment 
instruments and scores more relevant to our population should be developed to ensure 
improved sensitivity.  
● In a developing country with limited resources, where BMD measurement is not 
feasible in all postmenopausal females, identification of optimal risk factor subsets and 
development of easy to use risk assessment instruments may help to ensure that BMD 
resources are allocated to those who are most likely to benefit. 
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CHAPTER 7 
CALCANEAL ULTRASONOGRAPHY IN BLACK AND WHITE SOUTH AFRICAN 
FEMALES 
1. INTRODUCTION 
The most commonly used tool for assessing bone mineral density (BMD) is dual-energy X-ray 
absorptiometry (DEXA). Although precise, this method provides almost no information about 
the bone microarchitecture and elasticity. Since microfractures and bone architectural 
changes may contribute to weakening, a combination of information about bone elasticity, 
structure and density might be a more sensitive predictor of fracture risk than DEXA, which 
measures only density. Quantitative ultrasound may be a useful measure of both the quality 
and quantity of bone. The technology has evolved from the observation that sound waves 
through porous materials like bone are absorbed, scattered and travel in a manner that 
reflects the elasticity, stiffness and to a lesser degree the density of the material229,323. 
Indirect and in-vitro experience has suggested that ultrasonography may give information 
not only about the bone density, but also about the bone structure, trabecular orientation 
and micro-architecture228-230. The speed with which sound travels through bone (SOS) has 
been shown to be a function of both the elasticity of the bone as well as its density229. 
Broadband ultrasound attenuation (BUA) has been found to be related, not only to BMD, but 
also to architectural characteristics such as trabecular density, spacing and orientation228-230.  
In the past ~ 20 years quantitative ultrasound (QUS) methods have been introduced for the 
assessment of skeletal status in osteoporosis. QUS is particularly attractive as a 
measurement tool because it is simple, inexpensive, portable, non-invasive and free of 
ionizing radiation. As such, QUS has much greater potential for widespread application than 
traditional X-ray bone densitometry approaches and would thus be a good candidate for 
screening purposes. The association between QUS and osteoporotic fractures (both non-
spinal and vertebral fractures), especially in elderly Caucasian women, has shown promising 
results in many studies226,324-331. Fracture risk discrimination by means of QUS was about as 
strong as for absorptiometric techniques such as DEXA. Four independent prospective 
studies with sample sizes of 400 – 10 000 women showed that QUS results (as measured at 
the calcaneus) can be used to predict fracture risk in early postmenopausal227,321 and 
older226,325 Caucasian women. Two QUS parameters were shown to perform equally well: 
BUA226.227,321 and SOS227,325. Results from two of these studies (EPIDOS325 and SOF226 studies) 
are shown in Figures 1 & 2, demonstrating the increase in non-spine fracture risk. The 
gradients of risk reported for QUS were similar to those for DEXA.   
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All the aforementioned studies also reported that QUS parameters predicted fractures 
independently of BMD226,227,321,325, hence the assumption that QUS also measures bone 
properties other than BMD. Correlations between QUS measurements and DEXA measured 
BMD of the spine and the proximal femur have been found to be modest (r < 0.5) and QUS 
results can therefore not be used to predict BMD of the main fracture sites332,333. Whether a 
combined assessment of QUS and DEXA measured bone density improve fracture risk 
prediction remains controversial334 and requires further studies.  
Although calcaneal QUS is an independent predictor of OP fractures, the widespread clinical 
use of QUS has been hampered by the absence of a generally accepted fracture threshold335, 
limited normative data, uncertainty regarding its reproducibility (precision) and sensitivity to 
monitor skeletal changes. 
 
                  
 
 
Older African-American blacks have greater ultrasonographic BUA and SOS values compared 
with whites in most336,337 but not all studies189.  Most of the ethnic difference in these QUS 
parameters is, however, eliminated when corrected for weight and DEXA measured BMD. No 
data are available on racial differences in calcaneal ultrasonography in South African 
females. 
Figure 1: Relative risk of hip fractures as predicted 
prospectively from QUS (BUA,SOS) of the calcaneus, and 
BMD calcaneus (BMDcal) and the femoral neck BMD 
(BMDfn) measured with DEXA. Expressed as relative risk 
ratios per standard deviation change with 95% confidence 
intervals. Adapted from the EPIDOS study325 [A] and the 
SOF study226[B]. 
Figure 2: Relative risk of fractures of any type except 
spine fractures as predicted prospectively from QUS 
(BUA) of the calcaneus, and BMD calcaneus (BMDcal) and 
the femoral neck BMD (BMDfn) measured with DEXA. 
Expressed as relative risk ratios per standard deviation 
change with 95% confidence intervals. Adapted from the 
SOF study226.  
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2. PATIENTS AND METHODS 
Calcaneal QUS, employing the SAHARA Clinical Bone Sonometer, was performed on 230 pre-
and postmenopausal black and white subjects, 97 blacks and 133 whites. This sub-cohort 
was randomly selected based on test availability. 
QUS calcaneal broadband ultrasound attenuation (BUA) and speed of sound (SOS) were 
measured and the quantitative ultrasound index calculated (QUI = 0.41 x SOS + 0.41 x BUA 
-571). A ‘predicted’ calcaneal ultrasound BMD value was obtained by a simple re-scaling of 
the QUI value and is reported as the ‘estimated’ heel BMD in g/cm2. Using the 
manufacturer’s (Sahara) normative range for Caucasian females, a BMD T-score was also 
calculated in both black and white postmenopausal subjects.  
Ethnic differences in QUS measurements were analyzed and are reported on in the following 
patient subgroups: 
● Premenopausal black and white subgroups 
● Early and late postmenopausal black and white groups as outlined in Chapter 3, section 
1.3. 
Parameters directly measured by the Sahara Clinical Bone Sonometer i.e. BUA and SOS were 
compared between the two ethnic groups before and after adjustment for covariates. For the 
pre- and postmenopausal subjects, covariates included ethnicity, age, weight, height, daily 
calcium intake, physical activity, pack years of smoking, alcohol usage, age at menarche, 
hormonal contraceptive use and number of prior pregnancies. In the postmenopausal 
cohorts years after menopause was also included as covariate. BUA and SOS were also 
compared between blacks and whites after adjustment for differences in DEXA measured 
BMD of the spine and proximal femur in both pre- and postmenopausal cohorts in order to 
demonstrate ethnic differences in QUS parameters independent of DEXA measured BMD.   
Correlations between QUS parameters and DEXA measured BMD at the lumbar spine and 
proximal femur, as well as correlations between QUS parameters and age in the total patient 
population and the postmenopausal cohort respectively, were determined and are reported 
on in this chapter. 
The baseline clinical characteristics (table 1) of black and white females studied were 
identical to the total study cohort (refer to chapter 4, tables 1 & 5). Blacks and whites had 
similar mean ages in all the comparable groups studied. In general, blacks were shorter and 
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heavier than whites, reached menarche at a later age, preferred injectable hormone 
contraception, had a larger number of pregnancies and consumed less calcium daily. The 
white women smoked more, but maintained a higher level of physical activity post 
menopause. Mean alcohol consumption was low and comparable between the two groups.
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Table 1: Baseline characteristics of the ultrasound study cohort 
Characteristic Premenopausal Postmenopausal 
               <60 years                                               ≥ 60 years                        
 Blacks 
n=39 
Whites 
n=73 
p-value Blacks 
n=27 
Whites  
n=32 
p-value Blacks 
n=31 
Whites  
n=28 
p-value 
Age (yr) 38 ± 7.9 39 ± 6.4 0.41 52 ± 7 52 ± 4.6 0.47 68   ±  6.0 70 ± 5.6 0.09 
Height (cm) 161   ± 6 167 ± 6 <0.01 160  ± 7 166 ± 6 <0.01 158 ± 6 160 ± 7 0.16 
Weight (kg) 78  ± 19 70 ± 15 <0.01 76   ±  16 71 ± 17 0.11 84 ± 18 71 ± 16 <0.01 
BMI (kg/cm2) 30 ± 7 25 ± 5 <0.01 30 ± 8 26 ± 6 <0.01 34 ± 8 28 ± 5 <0.01 
Elbow width (mm) 65.6 ± 5.3 65.5 ± 3.4 0.47 67 ± 3.3 66 ±4.2 0.28 68 ± 6.1 68.8 ± 4.0 0.43 
Age at menarche (yrs) 14.8 ± 2.1 13.2 ± 1.6 <0.01 14   ±  1.8 13 ± 2.0 0.03 15   ± 2.1 13 ± 1.4 <0.01 
Age menopause (yrs)    47  ±  5.0 49 ± 3.8 0.02 50 ± 4.9 49 ± 4.7 0.20 
YSM (yrs)    6.1  ±  4.1 3.7 ± 3.9 0.02 18.5 ± 8.3 20 ± 6.8 0.19 
Ca intake (mg/d) 644 ± 307 882 ± 272 <0.01 572 ± 222 879 ± 237 <0.01 668 ± 338 820 ± 266 0.05 
Smoking (pack yrs) 0.6 ± 2.1 1.8 ± 4.7 0.06 1.5  ± 2.7 5.2 ± 11.6 0.05 0.3  ± 1.4 6.8 ± 13.7 <0.01 
Alcohol (U/week) 5.7 ± 10.3 4.0 ± 4.8 0.13 5.9 ± 14.0 3.2 ± 5.2 0.1 2.0 ± 5.1  2.0 ± 3.8 0.5 
PA score ( 0-4) 2.7 ± 0.9 2.8 ± 1.0 0.28 2.4 ± 1.1 3.1 ± 0.8 <0.01 1.9  ± 0.8 2.4 ± 0.8 0.01 
OCP use (%) 31 71  19 56  26 25  
DP use   (%) 38 3  26 3  3 0  
Nr of pregnancies (n)  2.3  ± 1.5 1.8 ± 1.2 0.02 3.6 ± 2.6 1.9 ± 1.5 <0.01 5.0 ± 2.4 3.8 ± 1.6 0.01 
Breastfeeding +(%) 70 58  78 62  88 68  
Values reported are the mean ± SD  
YSM: years since menopause; PA: physical activity;  DP: depo provera; OCP: oral contraceptive 
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3.  RESULTS 
3.1. Quantitative Ultrasound parameters 
3.1.1.  Premenopausal cohort 
All QUS parameters were higher in the premenopausal blacks compared to whites, but the 
ethnic difference only reached significance for SOS and QUI (table 2). In the premenopausal 
cohort ethnicity was the only clinical covariant significantly associated with BUA and SOS. 
Ultrasound data thus remained unchanged after adjustment for clinical covariates between 
the two ethnic groups. Body size, based on weight and height, was significantly associated 
with densitometric evaluations of the lumbar spine and femoral region in the premenopausal 
cohorts (chapter 5), but did not have a significant impact on ultrasound parameters.  
Table 2: Unadjusted ultrasound findings in the black and white premenopausal cohorts 
Ultrasonographic parameters Premenopausal subjects 
 Blacks 
n=39 
Whites 
n=73 
p-value 
Calcaneal BMD (g/cm2) 0.617 ± 0.15 0.565 ± 0.13 0.06 
BUA (dB/MHz) 83.5 ± 22.0 75.2 ± 18.4 0.08 
SOS (m/s) 1577 ± 36 1563 ± 33 0.04 
QUI (0-150) 109.7 ± 23.1 100.9 ± 20.3 0.04 
Values expressed as mean ± SD 
Adjustment of BUA and SOS for DEXA measured BMD at the lumbar spine and proximal 
femoral sites resulted in significantly higher values in blacks compared with whites (table 3).  
Table 3: Adjusted ultrasound findings in the black and white premenopausal cohorts 
*Adjusted ultrasonographic parameters  Premenopausal subjects 
 Blacks 
n=39 
Whites 
n=73 
p-value 
BUA (dB/MHz) 82.5 ± 21 75.2 ± 18 0.02 
SOS (m/s) 1576 ± 36 1564 ± 33 0.04 
*Ultrasonographic parameters adjusted for DEXA measured BMD at the lumbar spine and proximal femoral sites. Values 
expressed as mean ± SD 
3.1.2. Postmenopausal cohorts 
Ultrasound parameters in the postmenopausal cohorts are depicted in table 4 and illustrated 
in figure 3. Mean calcaneal BMD, BMD T-score, unadjusted SOS and BUA and the calculated 
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quantitative ultrasound index (QUI) were similar in the early postmenopausal black and 
white female cohort. Amongst the clinical covariates weight was significantly associated with 
BUA (p=0.02) and height with SOS (p<0.01). After appropriate adjustment for clinical 
variables and DEXA measured BMD, BUA and SOS remained similar in the early 
postmenopausal blacks and whites. However, all ultrasound parameters were significantly 
higher in the older postmenopausal black subjects compared with the white subjects with the 
exception of weight adjusted BUA. In the late postmenopausal cohorts calcium intake was 
significantly associated with SOS (p<0.01), whereas age (p=0.02) and weight (p<0.01) were 
both associated with BUA. BUA was still higher in the older blacks after correction for body 
weight, the difference nearing statistical significance (p=0.06). After adjustment for DEXA 
measured BMD at the lumbar spine and at the proximal femoral sites, BUA and SOS 
remained higher in the older postmenopausal blacks and whites, reaching statistical 
significance for BUA only (table 4) 
QUS parameters were identical in the younger and older black postmenopausal females. This 
finding is suggestive of limited decline in QUS measurements with ageing in blacks. In 
contrast to this observation in blacks, significantly lower values for all QUS parameters was 
noted in the older versus the younger postmenopausal white females (even after correction 
of BUA and SOS for DEXA measured BMD) and implies a significant decline in QUS 
parameters in whites with ageing. This pattern of change in QUS parameters is similar to 
DEXA measured BMD changes at the spine and proximal femur in ageing blacks and whites 
(refer to chapter 5, sections 2.2.1 and 3.2.1).  
 
. 
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Table 4: Ultrasound findings in postmenopausal black and white females 
 Postmenopausal females 
                          < 60 years                                                                                    ≥ 60 years 
  Blacks 
  (n=27) 
Whites 
(n=32) 
p-value Blacks 
(n=31) 
Whites  
(n=28) 
p-value 
Calcaneal BMD (g/cm2) 
 
BMD T-score 
 
BUA (dB/MHz) 
Unadjusted 
Adjusted for age 
Adjusted for weight 
Adjusted for DEXA measured BMD** 
 
SOS (m/s) 
Unadjusted 
Adjusted for height 
Adjusted for calcium-intake 
Adjusted for DEXA measured BMD**                   
 
QUI (0-150) 
0.510 ± 0.16 
 
-0.62 ± 1.4 
 
 
69.3 ± 21 
       - 
68.0 ± 25 
67.8 ± 22 
 
 
1551 ± 39 
1545 ± 35 
      - 
1549 ± 39 
 
93.1 ± 24.0 
0.516* ± 0.12 
 
-0.58* ± 1.0 
 
 
71.0* ± 17 
       - 
72.0* ± 25.1 
71.0* ± 17 
 
 
1551* ± 30 
1557 ± 35 
      - 
1551 ± 30 
 
92.9* ± 19.0 
0.47 
 
0.44 
 
 
0.63 
  - 
0.41 
0.16 
 
 
0.73 
0.23 
  - 
0.55 
 
0.49 
0.512 ± 0.18 
      
-0.61 ± 1.6 
 
 
69.3 ± 27 
68.1 ± 21 
66.7 ± 21 
69.3 ± 26 
 
 
1551 ± 46 
      - 
1554 ± 36 
1550 ± 46 
 
93.3 ± 29.1 
0.413 ± 0.11 
 
-1.51 ± 0.9 
 
 
53.1 ± 15 
54.4 ± 21 
55.8 ± 21 
53.8 ± 15  
 
 
1528 ± 28 
       - 
1520 ± 38 
1529 ± 28 
 
77.4 ± 16.7 
0.03 
   
0.02 
 
 
0.01 
0.01 
0.06 
0.02 
 
 
0.03 
  - 
<0.01 
0.11 
 
0.02 
Values expressed as mean ±  SD, p-values shown in table refer to inter-ethnic differences within younger and older cohort  
Unadjusted BUA and SOS values shown in green  
* QUS parameter significantly higher in early postmenopausal white cohort compared with late postmenopausal white cohort (p<0.05)  
** Adjusted for DEXA measured BMD of the lumbar spine and proximal femoral sites 
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Figure 3. Ultrasound findings in postmenopausal black and white females. Measurements significantly different from others indicated by * (p-value <0.05) . 
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Figure 3: Ultrasound findings in postmenopausal black and white females. Measurements significantly different from others indicated by  (p-value <0.05) . 
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3.2. Correlations of QUS parameters  
3.2.1. QUS parameters and DEXA measured lumbar spine and femoral BMD 
3.2.1.1. Premenopausal cohorts 
Calcaneal BMD 
Calcaneal BMD did not correlate with DEXA measured BMD at the lumbar spine or proximal 
femur in blacks, whereas significant, albeit weak, correlations were noted between calcaneal 
BMD and DEXA measured BMD at both the lumbar and proximal femoral sites in whites 
(table 5).  
BUA, SOS and the QUI 
A correlation between QUS parameters and DEXA measured BMD in premenopausal blacks 
was limited to a significant correlation between QUS BUA and total femoral BMD (r=0.40; 
p=0.02). In the white cohort significant correlations between DEXA findings at the spine and 
proximal femur and all these QUS variables was evident with the best correlation noted 
between QUS BUA and DEXA measured BMD at all sites (table 5). These correlations were, 
however modest with r-values <0.5. 
Table 5: Correlation between DEXA measured BMD at different skeletal sites and QUS variables in premenopausal black and 
white females 
DEXA measurements QUS variables 
 BMD (g/cm2) SOS (m/sec) BUA (dB/MHz) QUI /Stiffness 
 r-value p-value r-value p-value r-value p-value r-value p-value 
Lumbar spine BMD         
Black 0.22 0.20 0.19 0.26 0.26 0.13 0.22 0.20 
White 0.32 <0.01 0.29 0.01 0.40 <0.001 0.34 <0.01 
Femoral neck BMD         
Black 0.22 0.21 0.16 0.36 0.30 0.08 0.21 0.22 
White 0.31 <0.01 0.28 0.02 0.37 <0.01 0.32 0.01 
Total femoral BMD         
Black  0.31 0.07 0.24 0.16 0.40 0.02 0.31 0.07 
White 0.29 0.01 0.23 0.05 0.33 <0.01 0.28 0.02 
Significant correlations noted in italic red 
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3.2.1.2. Postmenopausal cohorts 
Calcaneal BMD 
Calcaneal BMD did not correlate significantly with DEXA measured lumbar spine BMD in the 
early and late postmenopausal blacks, whereas a significant correlation was demonstrated 
between calcaneal BMD and most of the DEXA measured proximal femoral BMD 
measurements. In whites significant correlations between calcaneal BMD and DEXA 
measured BMD at both the lumbar spine and proximal femoral sites were noted in the early 
postmenopausal cohort, whereas no correlation was noted in the older whites. Significant 
correlations were, similar to the premenopausal group, modest with r-values of 0.48-0.52.   
BUA, SOS and the QUI 
Amongst these QUS parameters, BUA correlated best with DEXA measured BMD in both the 
black and white cohorts. BUA correlated significantly with BMD at most proximal femoral 
sites in both the early and late black and white cohorts. BUA also correlated significantly with 
spinal BMD in the late postmenopausal black cohort and in both the early and late 
postmenopausal white cohorts. QUS SOS correlated significantly only with DEXA measured 
BMD of the total proximal femur in early and late postmenopausal black cohorts. In whites, 
significant correlation between QUS SOS and DEXA measured BMD at all sites could be 
demonstrated in the early postmenopausal cohort only (table 6). 
3.2.2. QUS parameters and age 
Age was negatively related to all ultrasound parameters in the total black and the white 
study population (figure 4). In the postmenopausal cohorts, a significant negative correlation 
between age and QUS parameters was present in whites (figure 5).  Due to the apparent 
minimal decline in all QUS parameters in ageing postmenopausal blacks, the regression lines 
for all these measurements had an insignificant slope with advancing age. 
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Table 6: Correlation between DEXA measured BMD at different skeletal sites and QUS variables in postmenopausal black and white females 
DEXA measurements QUS variables 
 BMD (g/cm2) SOS (m/sec) BUA (dB/MHz) QUI /Stiffness 
 r-value p-value r-value p-value r-value p-value r-value p-value 
Lumbar spine BMD         
EARLY postmenopausal         
   Black 0.24 0.23 0.21 0.29 0.24 0.22 0.23 0.25 
   White 0.50 <0.01 0.44 0.01 0.56 <0.01 0.52 0.01 
LATE postmenopausal         
   Black 0.33 0.07 0.27 0.14 0.45 0.01 0.34 0.06 
   White 0.29 0.12 0.20 0.29 0.42 0.02 0.29 0.12 
Femoral neck BMD         
EARLY postmenopausal         
   Black 0.39 0.04 0.32 0.10 0.45 0.02 0.38 0.05 
   White 0.48 <0.01 0.41 0.02 0.52 0.03 0.48 0.01 
LATE postmenopausal         
   Black 0.31 0.09 0.29 0.11 0.32 0.08 0.31 0.09 
   White 0.24 0.20 0.17 0.37 0.34 0.07 0.24 0.20 
Total femoral BMD         
EARLY postmenopausal         
   Black  0.57 <0.01 0.50 <0.01 0.52 <0.01 0.52 <0.01 
   White 0.52 <0.01 0.44 0.01 0.56 <0.01 0.52 0.01 
LATE postmenopausal         
   Blacks 0.40 0.02 0.37 0.04 0.43 0.02 0.40 0.03 
   Whites 0.27 0.16 0.19 0.32 0.37 0.04 0.27 0.16 
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Figure 4: Correlation of age with calcaneal BMD, BUA and SOS in the total black and white study population 
 
r = -0.32 
p < 0.001 
r = -0.37 
p < 0.001 
r = -0.32 
p < 0.001 
r = -0.37 
p < 0.001 
r = -0.31 
p < 0.001 
r = -0.32 
p < 0.001 
 162 
 
              Age: QUS BMD (postmenopausal blacks)
35 40 45 50 55 60 65 70 75 80 85
Age
0.2
0.4
0.6
0.8
1.0
1.2
US
 
BM
D
 
           Age: QUS BMD (postmenopausal whites) 
35 40 45 50 55 60 65 70 75 80 85
Age
0.2
0.4
0.6
0.8
1.0
1.2
US
 
BM
D
 
 
 
               AGE: QUS SOS (postmenopausal blacks)
35 40 45 50 55 60 65 70 75 80 85
Age
1440
1480
1520
1560
1600
1640
1680
1720
US
 
SO
S
 
               AGE: QUS SOS (postmenopausal whites)
35 40 45 50 55 60 65 70 75 80 85
Age
1440
1480
1520
1560
1600
1640
1680
1720
US
 
SO
S
 
 
 
              Age: QUS BUA (postmenopausal blacks)
35 40 45 50 55 60 65 70 75 80 85
Age
0
40
80
120
160
US
 
BU
A
 
            Age: QUS BUA (postmenopausal whites)
35 40 45 50 55 60 65 70 75 80 85
Age
0
40
80
120
160
US
 
BU
A
 
Figure 5: Correlation of age with calcaneal BMD, BUA and SOS in the postmenopausal black and white female cohorts 
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4. DISCUSSION 
As alluded to previously (chapter 5), the lower fracture rates among SA black women relative 
to Caucasian women could not be readily explained on the basis of a significantly higher 
DEXA measured bone mineral density at all skeletal sites. Ethnic comparison of calcaneal 
QUS was thus performed in an attempt to determine why fracture rates vary so much 
between ethnic groups. 
QUS measurements were mostly similar in premenopausal and younger postmenopausal 
blacks and whites in this study population, but statistically significantly higher in older blacks 
compared with whites. Taking due cognizance of the limitations inherent to a cross-sectional 
study, this data do, however, suggest a faster rate of decline in QUS parameters with ageing 
in whites compared with blacks. Older blacks had similar QUS values compared with younger 
blacks suggesting an insignificant deterioration with ageing, whereas most QUS 
measurements were significantly lower in older whites compared with their younger 
counterparts. 
Calcaneal QUS BMD was similar in the premenopausal and early postmenopausal black and 
white females, but significantly higher in the late postmenopausal black females. Our data, 
although cross-sectional in nature, thus suggests a slower rate of decline with ageing in 
blacks. The higher calcaneal BMD in the older black females in our study is consistent with 
previous reports in American elderly black populations189 and similar to our DEXA BMD 
findings. Differing patterns of DEXA measured bone loss were also observed between these 
two ethnic groups with a slower rate of decline at the spine and proximal femur in 
postmenopausal blacks compared with whites (refer to chapter 5, sections 2.2.1 and 3.2.1) 
and are in agreement with data from previous studies regarding bone loss in multi-ethnic 
populations both locally1,213 and abroad139,184,197. Black females in our study thus appear to 
preserve BMD (as measured by DEXA and QUS) better into old age. 
Inter-ethnic differences in unadjusted calcaneal BUA, SOS and calculated QUI were similar to 
that observed for calcaneal and DEXA measured BMD i.e. these variables were mostly similar 
in the younger black and white subgroups (premenopausal and early postmenopausal 
groups), but consistently and significantly higher in older blacks compared with whites. 
Weight adjustment attenuated the observed ethnic difference in BUA and although BUA was 
still higher in older blacks, the difference only neared significance (p=0.06). 
Correction of BUA and SOS for other clinical covariates (weight excluded) with significant 
univariate association resulted in modest changes. Adjusted SOS and BUA thus remained 
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significantly higher in older black females compared with whites. After adjustment of BUA 
and SOS for DEXA measured spinal and femoral BMD, both QUS parameters remained higher 
in the older blacks compared with whites, but only the BUA difference reached statistical 
significance. Greater ultrasonographic BUA and SOS values have been noted in older African-
American women compared with whites in most336,337 but not all studies189. Correction for 
weight and DEXA measured BMD attenuated, but did not eliminate, the ethnic differences in 
QUS parameters in these studies336,337, findings in accordance with that observed in our 
study. 
BMD-adjusted BUA and SOS values appeared to decline significantly with ageing in 
postmenopausal whites with lower values recorded in the older versus the younger white 
postmenopausal women (p<0.05). In contrast to our findings in whites, QUS values were 
similar in younger and older postmenopausal blacks, thus suggestive of minimal loss in the 
postmenopausal period. No longitudinal prospective studies comparing changes in BUA and 
SOS with ageing in postmenopausal women of different ethnicities have been published to 
date. It is thus not known whether other black populations preserve QUS parameters 
differently into old age compared with whites.  
Prospective studies in postmenopausal Caucasian women have shown that QUS parameters 
can be used to predict fracture risk independently of BMD226,227,321,325, hence the assumption 
that QUS measures bone qualitative parameters independently of BMD. Histomorphometric 
analyses previously carried out on iliac crest bone from 171 South African black and 175 
white men and women revealed significant racial differences in trabecular bone architecture 
with ageing131. Black females showed no decline in trabecular number and no increase in 
trabecular separation, whereas whites suffered deterioration of trabecular architecture with 
regard to trabecular thickness, number and connectivity. The trabecular bone of South 
African blacks therefore appeared to have a sturdier microstructure, and underwent a less 
destructive ageing process than that of South African whites. If QUS parameters indeed 
measure bone qualitative properties independent of BMD, our QUS data support these 
histomorphometric findings of better bone quality preservation in elderly SA blacks. BUA, 
specifically, has been proposed to measure, not only BMD, but also architectural 
characteristics such as trabecular density, spacing and orientation228-230. In our study, BUA 
was found to be statistically significantly higher in older blacks compared with whites, even 
after correction for differences in DEXA measured BMD, and thus supports previously 
reported histomorphometric findings131 of better trabecular preservation with ageing in 
blacks. A reduced absolute fracture risk at any given BMD value, has been documented in 
blacks135,136 compared with whites. This implies that ethnic differences may exist in factors, 
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other than BMD, which affect bone fragility. Improved bone quality (as determined by QUS) 
in our elderly blacks may thus help to explain the lower fracture prevalence previously 
documented in SA blacks compared with whites. 
In our study, the correlation between calcaneal BMD and DEXA measured BMD differed in 
blacks and whites by age and site, and was noticably poorer in blacks compared with whites 
(see tabulated summary below). Amongst the QUS measurements, BUA correlated best with 
DEXA measured spinal and femoral BMD in both blacks and whites. The majority of previous 
studies assessing correlations between QUS measurements and DEXA determined BMD are 
limited to evaluation of the association between femoral BMD and QUS variables189,325,329 and 
furthermore often only look at a single QUS parameter such as BUA189. Correlations between 
QUS parameters and DEXA measured BMD of the spine and the proximal femur have been 
found to be modest (range of r-values 0.4 – 0.7), in previous studies332,333 and are in 
accordance with our findings. Most of these studies have, however, been performed in 
Caucasian populations and very little is known regarding the association between QUS 
measurements and DEXA measured BMD in other ethnic groups. 
SUMMARY: Correlation between DEXA measured BMD and different QUS parameters 
DEXA measured BMD Female subgroups studied 
 Premenopausal  Early postmenopausal  Late postmenopausal 
WHITES    
  Lumbar  +++ +++ BUA+ 
  Total femoral +++ +++ BUA+ 
  Femoral neck +++ +++ NIL 
BLACKS    
  Lumbar NIL NIL BUA+ 
  Total femoral BUA+ +++ +++ 
  Femoral neck NIL BMD+ // BUA+ NIL 
+++: correlation significant for all QUS parameters, +: as specified, NIL: no correlation with any QUS parameters 
The reason(s) for the poorer correlation between BUA and SOS, and DEXA measured BMD at 
all sites in blacks compared with whites are not known. Previous studies have suggested an 
increased likelihood of unreliable QUS findings in African Americans compared with whites228. 
This may in part be due to larger body size reported to add to technical difficulties with 
ultrasonography in previous studies228. Preservation of bone quality, independently of BMD, 
may also potentially contribute to the limited association between QUS and DEXA measured 
BMD noted in blacks. 
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In summary: 
● Elderly black SA women have higher calcaneal BMD than white women.  
● Significant ethnic differences in absolute values and apparent patterns of decline in 
BUA and SOS were noted. Higher QUS measurements were documented in our elderly 
blacks compared with whites, even after correction for differences in DEXA determined 
BMD at the spine and proximal femoral sites.  
● BUA and SOS showed no decline with ageing in blacks, in contrast to a significant 
deterioration in both parameters in ageing whites. 
● If these QUS parameters do measure qualitative properties of bone in our black 
population, independent of BMD, as has been suggested in previous work in Caucasian 
populations, the higher values documented in elderly blacks imply better preservation 
of bone quality and may indeed help to explain the lower fracture prevalence in SA 
black women previously documented.    
● the correlation between calcaneal BMD and DEXA measured BMD at the hip and spine 
was best in the premenopausal and younger postmenopausal white groups and 
generally poorer in blacks. At best, these correlations were modest and QUS calcaneal 
BMD thus unable to predict DEXA measured BMD at clinically important fracture sites.  
● BUA was the QUS parameter that correlated best with DEXA measured BMD. A poorer 
correlation between BUA and SOS and DEXA measured BMD at all sites was, however, 
noted in blacks compared with whites. This may indicate preservation of QUS 
measured bone quality in blacks that are not associated and thus independent of DEXA 
determined BMD.  
To conclude, elderly SA black women have significantly higher BUA and SOS measurements 
(even after correction for differences in DEXA measured spine and hip BMD) compared with 
whites due to an apparent slower rate of decline with ageing. These results suggest that 
racial differences in bone quality, as measured by ultrasound attenuation and speed of 
sound, may contribute to the lower fracture prevalence previously documented in SA blacks. 
Prospective longitudinal studies are needed to confirm our findings obtained in this cross-
sectional work. 
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CHAPTER 8 
BONE TURNOVER, MINERAL HOMEOSTASIS AND CALCIOTROPIC 
HORMONES IN BLACK AND WHITE SOUTH AFRICAN FEMALES. 
1. INTRODUCTION  
Bone strength is a function of both BMD and bone quality. Bone quality describes the set of 
characteristics that influence bone strength independently of BMD and include structural and 
material properties. Bone turnover is a function of the bone renewal process in which old or 
damaged bone is resorbed (bone resorption) and new bone is created (bone formation) to 
replace it. Under normal circumstances the temporal sequence is always that of resorption 
followed by formation, with these processes tightly coupled and balanced, to ensure that the 
amount of bone resorbed and formed within individual bone remodeling units are 
quantitatively similar.  An imbalance of bone turnover may significantly impact on BMD and 
bone quality with high turnover states generally regarded as deleterious to bone (please 
refer to chapter 2, section 3.1.2.1). 
Ethnic variation in bone formation and/ or bone resorption rates during skeletal development 
and adult remodeling may help to explain observed ethnic differences in BMD as well as 
bone strength independent of BMD.   
Serum osteocalcin is a marker of bone formation and normal to high levels may indicate 
adequate bone formation and as such be positively associated with bone strength. Given the 
normal temporal sequence of events, high osteocalcin levels may also be an indirect marker 
of increased bone resorption and may as such be negatively associated with BMD and bone 
strength. Urinary free deoxypyrodinoline is a degradation product of the bone resorption 
process. Elevated levels imply increased bone resorption with expected negative effects on 
BMD and bone quality. 
Histomorphometric studies on racial differences in bone turnover in blacks and whites have 
yielded conflicting results. Schnitzler et al131 have reported histomorphometric evidence 
suggesting that black South Africans have higher rates of bone turnover than whites. The 
authors, contrary to current belief, hypothesized that the more frequent cycles of renewal 
would ensure better bone quality and hence, favorably influence fracture rates in blacks. In 
contrast to this study, Weinstein and Bell140 reported lower bone turnover in blacks. On the 
assumption that coupling between resorption and formation is maintained, the authors 
suggested that a lower rate of bone resorption would help maintain a higher peak bone mass 
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in blacks. However, the number of subjects in each group was small, and data from men and 
women were combined in this study. Parisien et al204 found no difference in 
histomorphometric turnover parameters between black and white premenopausal women, 
whereas Han and co-workers141 noted a 25% lower mean bone formation rate in both 
premenopausal and postmenopausal blacks compared with whites.  
Most previous studies biochemically assessing bone turnover rates in blacks and whites by 
looking at serum osteocalcin and urinary pyridinium cross-link excretion have documented 
either a similar turnover144,145, or lower turnover138,142,146,186,196 in blacks.  Most studies have 
reported similar urinary pyridinium cross-link excretion in pre- and postmenopausal 
Caucasians and African-Americans142,144,185,186.  In the only study to date in which bone 
turnover was assessed biochemically in South African blacks and whites, turnover was similar 
in blacks and whites5.  No data is available regarding ethnic differences in biochemical bone 
turnover markers with ageing.   
Lower serum 25-hydroxy-vitamin D, lower urinary calcium excretion rates and higher serum 
PTH have been documented in African-Americans138,145-147,196 and in South African blacks5 
compared with whites. These biochemical findings, in the presence of similar or lower bone 
turnover rates and generally higher femoral BMD documented in blacks compared to whites, 
have prompted the theory of a relative skeletal resistance to the action of PTH in blacks. 
2. PATIENTS AND METHODS 
We evaluated biochemical bone turnover rates, mineral status and calciotropic hormones in a 
group of black and white premenopausal and postmenopausal South African females. Please 
refer to Chapter 3, section 2.6 for details regarding laboratory methodology. 
The clinical characteristics of the study cohort are shown in table 1. The premenopausal 
cohort consisted of 70 black females and 63 white females. The early and late 
postmenopausal cohorts  were identical to those evaluated for BMD (chapter 5, table 1) and 
included a total of 97 black subjects and 66 white females. Premenopausal women taking 
oral estrogens or depo provera within the month before blood and urine collections were 
excluded from this analysis. All premenopausal subjects reported a regular menstrual cycle 
and the postmenopausal state was confirmed biochemically in all the females classified as 
postmenopausal (FSH>40mIU/l). None of the subjects sustained a fracture within 12 months 
before blood or urine collections.  
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Clinical characteristics                                    Premenopausal Postmenopausal 
 < 60 years ≥ 60 years 
Blacks 
n=70 
Whites 
n=63 
p-value Blacks 
n=49 
Whites  
n=35 
p-value Blacks 
n=48 
Whites         
n=31 
p-value 
 
Age (yr) 38 ± 8 39 ± 6 0.14 52 ± 6 52 ± 5 0.43 68  ± 6 70 ± 5 0.49 
Height (cm)                             159 ± 6 167 ± 6 <0.01 160  ± 7 166 ± 7 <0.01 159 ± 6 160 ± 7 0.16 
Weight (kg) 80 ± 21 69 ± 14 <0.01 80  ± 19 71 ± 17 <0.01 86  ± 19 72 ± 15 <0.01 
BMI (kg/cm2) 32 ± 8 25 ± 5 <0.01 32 ± 8 26 ± 6 <0.01 34 ± 8 28 ± 5 <0.01 
Waist/Hip ratio (cm) 0.84 ± 0.1 0.78 ± 0.1 <0.01 0.87  ± 0.1 0.79 ± 0.1 <0.01 0.90 ± 0.1 0.88 ± 0.1 0.03 
Elbow width (mm) 65 ± 5 66 ± 3 0.78 67 ± 4 66 ± 4 0.15 68 ± 6 68 ± 5 0.23 
Age at menarche(yrs) 15 ± 3 13 ± 2 <0.01 14 ± 2 13 ±  2 <0.01 14 ± 2 13 ± 1 <0.01 
Menopause age (yrs)    46 ± 5 49 ± 4 0.02 49 ± 5 49 ± 5 0.20 
YSM (yrs)    7  ± 5 4 ± 4 0.04 19 ± 8 21 ± 7 0.37 
Calcium intake (mg/d) 591 ± 308 901 ± 268 <0.01 597 ± 237 879 ± 230 <0.01 667 ± 304 821 ± 272 <0.01 
Smoking (pack yrs) 0.7 ± 2.0 4.1 ± 19.3 0.08 1.6 ± 4.7 5 ± 11 <0.01 0.17 ± 1 8.9 ± 14.1 <0.01 
Alcohol (U/week 4.5 ± 9.6 3.7 ± 4.5 0.28 3.7 ± 11 2.9 ± 5.1 0.17 1.4 ± 4.2 1.8 ± 3.8 0.3 
PA score (0-4) 2.8 ± 0.9 2.8 ± 0.9  0.35 2.4 ± 1 3.1 ± 0.9 0.04 1.9 ± 0.9 2.7 ± 0.8 <0.01 
Family history (%) 1 25  2 29  0 13  
OCP use (%) 16 68  16 54  29 30  
DP use (%) 39 2  33 6  6 2  
Nr of pregnancies (n) 3 ± 2 2 ± 1 0.03 3 ± 2 2 ± 1 <0.01 6 ± 3 4 ± 2 <0.01 
Breastfeeding+ (%) 70 58  78 62  88 68  
Values expressed as mean ±SD except where otherwise stated, p-values tabulated refer to comparison between ethnic groups within specific menopausal sunbgroup 
Table 1: Summary of anthropometric, lifestyle and menstrual data of the study cohort 
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Clinical characteristics of the black and white pre-and postmenopausal cohorts were similar 
to that of the densitometric study population, with the exception that alcohol intake did not 
differ significantly between this cohort of premenopausal black and white females (p=0.28). 
ANOVA was used to determine significant ethnic differences in biochemical measurements 
between the various patient subgroups. Spearman correlations were used to determine 
relationships between certain biochemical measurements (serum osteocalcin, urinary free 
DPD, serum PTH and serum 25-OH-Vitamin D) as well as between these biochemical 
measurements and DEXA determined BMD at the spine and proximal femoral sites. 
Densitometric findings were furthermore compared within the two ethnic groups based on 
PTH tertiles.  
3. RESULTS 
3.1. BIOCHEMISTRY 
3.1.1. Biochemical assessment of bone turnover 
3.1.1.1. Premenopausal subjects 
SERUM OSTEOCALCIN  
Serum osteocalcin levels were similar in premenopausal black and white females (table 2, 
figure 1). 
URINARY FREE DEOXYPYRIDINOLINE (DPD) 
A tendency towards lower urinary DPD was noted in blacks compared with whites, but 
statistical significance was not reached (table 2, figure 2).   
Table 2: Biochemical parameters of bone turnover in premenopausal subjects 
Biochemical Parameter   Premenopausal females Normal  values 
Blacks 
(n=70) 
Whites  
(n=63) 
p-value  
Serum 
Osteocalcin (ng/ml)   
  
7.8 ± 7.8 
 
7.2 ± 6.8 
 
0.33 
 
2.4 - 10.0 
Urine 
Free DPD/creatinine (nmol/mmol)   
 
5.45 ± 4.13 
 
6.80 ± 2.73 
 
0.07 
 
3.0 - 7.4 
Values are the mean ± SD, p-values in the table refer to comparison between premenopausal blacks and whites 
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3.1.1.2. Postmenopausal subjects 
SERUM OSTEOCALCIN  
Changes in osteocalcin levels with ageing are demonstrated in figure 1 and shown in table 3. 
An increase in OC levels occurred with ageing in both blacks and whites. This resulted in a 
significant difference in mean OC levels between pre- and postmenopausal women (p<0.01) 
of both ethnic groups. The pattern of increase in OC, however, appeared to differ between 
blacks and whites. In whites most of the increase occurred during menopausal transition 
resulting in higher levels in the early postmenopausal women compared with the 
premenopausal women (p<0.01). In blacks this increase occurred later, with highest OC 
levels documented in the late postmenopausal subgroup. Mean OC levels were thus highest 
and near identical in the early postmenopausal whites and in the late postmenopausal 
blacks. Due to these different patterns of change a tendency towards lower OC levels in the 
younger postmenopausal blacks compared with whites (p=0.08) and higher OC levels in the 
older blacks compared with whites (p=0.06) were noted. In the total postmenopausal 
cohorts unadjusted OC-levels were similar between blacks and whites (p=0.48).  
URINARY FREE DEOXYPYRIDINOLINE 
Changes in urinary DPD levels with ageing are shown in table 3 and demonstrated in figure 
2. Urinary DPD remained unchanged in blacks with ageing. There was not the expected 
increase from the pre- to the postmenopausal state and no change with further ageing in 
blacks. In whites a slight increase in mean urinary DPD was noted between pre- and early 
postmenopausal women. With further ageing a near significant decrease in DPD levels was 
observed in whites (p=0.08). The pattern of change in DPD in whites is thus very similar to 
that noted for OC except that the changes are less marked. In the total postmenopausal 
black and white cohorts, urinary DPD was similar.  
Table 3: Biochemical parameters of bone turnover in early and late postmenopausal cohorts 
Biochemical 
Parameter 
 
 
Postmenopausal subjects Normal 
values 
< 60 years ≥ 60 years 
Blacks 
(n= 48) 
Whites 
(n=35) 
p-value Blacks 
(n= 49) 
Whites  
(n= 31) 
p-value 
Serum 
Osteocalcin (ng/ml) 
 
10.2 ± 8.8 
 
14.3 ± 13 
 
0.08 
 
14.04 ± 11 
 
9.2 ± 5.8 
 
0.06 
 
2.4 - 10.0 
Urine 
DPD/creatinine 
(nMl/mMl)    
 
5.37 ± 4.4 
 
7.16 ± 6.2 
 
0.08 
 
5.42 ± 4.2 
 
4.89 ±2.8 
 
0.30 
 
3.0 - 7.4 
Values expressed as mean ± SD, p-values in the table refer to comparison between blacks and whites within specific subgroups 
 173 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Mean (± SD) unadjusted serum OC levels of A: premenopausal blacks and whites; B1: early postmenopausal blacks and whites; B2: late postmenopausal blacks and whites; B:: 
total postmenopausal black and white cohort. OC levels increased significantly from the premenopausal state to the early postmenopausal period in whites only. OC shows tendency 
towards lower values in the early postmenopausal blacks compared with whites, whereas mean OC value tends to be higher in the older postmenopausal blacks vs. whites. No significant 
difference between early and late postmenopausal black and white groups respectively, p-values as indicated above arrows 
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Figure 2: Mean (± SD) unadjusted urine DPD levels of A: premenopausal blacks and whites; B1 early postmenopausal blacks and whites; B2: late postmenopausal blacks and whites; B: 
total postmenopausal black and white cohort. DPD levels did not increase significantly from the premenopausal state to the early postmenopausal period in blacks and whites. U-DPD levels 
shows tendency towards higher values in the early postmenopausal whites compared with older whites and with blacks, p-values as indicated 
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3.1.2. Mineral status and calciotropic hormones 
3.1.2.1. Premenopausal subjects 
Blacks had similar albumin corrected serum calcium than whites.  Serum total alkaline 
phosphatase (ALP) levels were significantly higher in the black females. We did not obtain 
iso-enzymes of ALP and are thus unable to comment on the relative contribution of bone and 
liver to the total ALP value obtained (table 4). 
25-OH-Vitamin D levels were low in blacks and whites, but tended to be lower in blacks. A 
tendency towards higher PTH-levels was noted in blacks, although statistical significance was 
not reached. Significantly higher serum phosphate levels and better renal phosphate re-
absorption, when expressed as a function of creatinine clearance (TmP/GF), were present in 
blacks. The higher renal phosphate re-absorption, in the presence of near significantly higher 
serum PTH levels in blacks, suggests a relative renal resistance to the action of PTH. Blacks 
conserved calcium better compared with whites despite a significantly higher urinary sodium 
loss (table 4).  
The higher serum phosphate levels in premenopausal blacks was not explained by higher 
dietary intake of either protein or phosphate as determined by dietary recall and analyzed by 
the Foodfinder program (see chapter 3, section 2.1.2). Sodium-intake was comparable 
between blacks and whites (p=0.31) and not the reason for the higher sodium excretion in 
blacks.  
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Table 4: Biochemical data for premenopausal subjects 
Biochemical Parameter Premenopausal females 
Blacks (n=70) Whites (n=63) p-value Normal  reference values 
Serum     
Total albumin corrected calcium (mmol/l) 2.21 ± 0.13 2.17 ± 0.12 0.05 2.10 - 2.60 
Phosphate (mmol/l) 1.13 ± 0.16 1.05 ± 0.16 <0.01 0.80 - 1.40 
Magnesium (mmol/l) 0.86 ± 0.13 0.90 ± 0.10 <0.05 0.75 - 1.00 
Creatinine (umol/l) 78 ± 13 81 ± 13 0.12 80 - 120 
Alkaline phosphatase (IU/l) 64 ± 19 49 ± 12 <0.01 30 - 85 
25-(OH)D (ng/ml) 16.5 ± 5.8 17.9 ± 4.6  0.07 >18 
PTH (pmol/l) 6.1 ± 4.5 5.1 ±  3.5 0.09 1.3 – 7.6 
Urine     
Calcium/creatinine (mmol/mmol) 0.19 ± 0.17 0.25 ± 0.17 <0.05  
Ca/100ml GF 0.01 ± 0.01 0.02 ± 0.01 <0.01  
TRP (%) 90 ± 15 89 ± 7 0.27 85 - 95 
TmP/GF 1.15 ± 0.27 1.07 ± 0.26 0.04 1.00 – 1.68 
Sodium/creatinine (mmol/mmol) 21.6 ± 11.3 15.6 ± 8.6 <0.001  
Values are the mean ± SD, p-values in the table refer to comparison between premenopausal blacks and whites 
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3.1.2.2. Postmenopausal subjects 
Blacks and whites in the early and late postmenopausal group had similar mean albumin 
corrected serum calcium values (table 5), whereas serum phosphate levels was higher in the 
early postmenopausal black cohort. Total alkaline phosphatase levels were significantly 
higher in blacks compared with whites in both postmenopausal cohorts and was also noted 
to be significantly higher in older compared with younger postmenopausal blacks (p=0.04).  
Significantly lower 25-OH-Vitamin D levels were noted in blacks compared with whites in 
both postmenopausal cohorts (table 5). Vitamin D levels appeared to decline significantly 
with ageing in the black females only (p<0.01). PTH-levels were similar in the younger 
postmenopausal black and white subjects, but a tendency towards higher PTH was noted in 
the older blacks compared with whites. Tubular phosphate handling was similar in the early 
postmenopausal blacks and whites as expected given similar PTH values. In the older blacks, 
with higher PTH levels, no PTH-induced renal phophaturic effect was noted, suggesting 
resistance to the biological actions of this hormone. In fact, late postmenopausal black 
females had higher mean phosphate re-absorption despite higher PTH values.  Urinary 
calcium excretion was significantly lower in the younger postmenopausal black females, but 
similar in the older black and white subjects. Higher mean urinary sodium loss was noted in 
both black postmenopausal groups, similar to that observed in the premenopausal subjects.  
Dietary intake of protein was similar in postmenopausal blacks and whites in both the early 
(p=0.46) and the late (p=0.30) group. Phosphate intake tended to be lower in younger 
postmenopausal blacks (p=0.06), whereas phosphate intake was similar in the older blacks 
and whites. Sodium intake varied between the two ethnic groups with a tendency towards 
higher intake in the younger postmenopausal blacks (p=0.05) and lower intake in the older 
blacks compared with whites (p=0.02). Dietary intake of phosphate and sodium were thus 
unable to explain neither the observed renal conservation of phosphate nor the higher 
sodium loss in blacks.  
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Table 5: Biochemical data for early and late postmenopausal cohorts 
Biochemical Parameter  
 
 
Postmenopausal subjects Normal reference  
values 
< 60 years ≥ 60 years 
Blacks 
(n= 48) 
Whites 
(n=35) 
p-value 
 
Blacks 
(n= 49) 
Whites  
(n= 31) 
p-value 
 
Serum        
Alb corrected calcium (mmol/l) 2.25 ± 0.12      2.24 ± 0.10     0.24 2.31 ± 0.16 2.26 ± 0.09 0.06         2.10-2.60 
Phosphate (mmol/l) 1.15 ± 0.19 1.07 ± 0.16 0.02 1.06 ± 0.15 1.02 ± 0.16 0.1 0.80-1.40 
Magnesium (mmol/l) 0.87 ± 0.09 0.89 ± 0.11 0.12 0.87 ± 0.11 0.92 ± 0.1 0.02 0.75-1.00 
Creatinine (umol/l) 87 ± 16 87 ± 30 0.48 92 ±  16 94 ± 29 0.40 80-120 
Alkaline phosphatase (IU/l) 79 ± 23* 71 ± 18 0.03 90 ± 36 71 ± 31 <0.01 30-85 
25-(OH)D (ng/ml) 15 ±  6.5* 18 ± 5.4 0.02 11 ± 4.9 18 ± 6.4 <0.01 >18 
PTH (pmol/l) 7.5 ± 5.1 6 ± 6.2 0.12 7.8 ± 4.2 6.4 ± 2.5 0.05 1.3 – 7.6 
Urine        
Calcium/creatinine (mM/mM) 0.21 ± 0.15 0.43 ± 0.30 <0.01 0.27 ± 0.29 0.30 ± 0.21 0.29  
Ca/100ml GF 0.018 ± 0.01 0.03 ± 0.02 <0.01 0.024 ± 0.02 0.025 ± 0.02 0.29  
TRP (%) 87 ± 7 87 ± 7 0.41 88 ± 7 84 ± 8 0.01 85-95 
TmP/GF 1.14 ± 0.27 1.1 ± 0.23 0.07  1.06 ± 0.21 0.93 ± 0.21 <0.01 1.00–1.68 
Sodium/creatinine (mM/mM) 25.4 ± 18.3 17.3 ± 10.9 0.01  24.0 ± 16 18 ± 12 0.05  
Values expressed as mean ± SD, p-values in the table refer to comparison between blacks and whites within specific subgroups 
*p-value <0.05 younger postmenopausal blacks versus older postmenopausal blacks   
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3.1.3. Correlation between biochemical parameters  
3.1.3.1. Premenopausal subjects 
Correlations between OC, DPD, PTH and 25-OH-Vitamin D were determined in the 
premenopausal cohort. The only near significant correlation was noted between serum 
osteocalcin and urinary DPD in blacks (r=0.37, p=0.06).  
3.1.3.2. Postmenopausal subjects 
Significant correlation between the different biochemical parameters were confined to the 
late postmenopausal groups.  In blacks, a significant positive correlation was noted between 
U-DPD and serum PTH (r=0.30, p=0.02), and in whites a significant negative correlation was 
documented between serum PTH and serum 25-OH-Vitamin D (r=-0.47, p=0.01). 
3.1.4. Correlation between biochemistry and BMD of the spine and hip 
3.1.4.1. Premenopausal subjects 
S-Osteocalcin (OC) correlated significantly with spinal measurements in blacks (r=-0.41; 
p<0.01 for BMD; r=-0.35, p=0.01 for BMAD) and whites (r=0.35; p<0.01 for BMD; r=0.29, 
p=0.03 for BMAD). PTH correlated significantly with femoral neck BMAD in blacks only     
(r=-0.24, p=0.04). The correlation between OC and spinal BMD in blacks was negative and 
in contrast with the positive correlations noted in whites. No correlation was noted between 
U-DPD or 25-OH- Vitamin D, and any of the densitometric data in premenopausal women.  
3.1.4.2. Postmenopausal subjects 
Correlations between biochemistry and BMD of the spine and hip are shown in table 6 and 7. 
In the early postmenopausal females, significant correlations between biochemical 
parameters and BMD were confined to blacks, with a negative correlation noted between OC 
and all femoral measurements (table 6). In the older women, significant correlations 
between PTH and 25-OH-Vitamin D and BMD/BMAD at all the proximal femoral sites were 
noted in blacks and whites (correlation negative for PTH, positive for 25-OH-Vitamin D). In 
addition, in whites, OC showed a positive correlation with spinal BMD and spinal BMAD  
(table 7). 
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3.1.5. Densitometry in postmenopausal black and white subgroups based on 
PTH-tertiles 
Densitometric findings in postmenopausal blacks and whites based on PTH tertiles are 
demonstrated in tables 8 and 9. Ages were comparable in the low, middle and high PTH 
tertile subgroups in blacks, whereas whites in the high PTH tertile were significantly older 
than those in the low PTH tertile. The mean serum PTH value was significantly higher in the 
high PTH tertile in blacks compared with whites. A significant negative impact of high PTH on 
proximal femoral BMD was demonstrated in postmenopausal blacks, especially at the femoral 
neck region. BMD was comparable in all the PTH tertile subgroups in whites.   
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Table 6: Correlation between DEXA measured BMD/BMAD at different skeletal sites and biochemical variables in early postmenopausal black and white females. 
DEXA measurements Biochemical parameters 
 OC DPD PTH 25-OH-Vitamin D 
 r-value p-value r-value p-value r-value p-value r-value p-value 
Lumbar spine BMD         
Black -0.22 0.26 -0.2 0.25 0.08 0.63 0.03 0.82 
White -0.17 0.37 -0.19 0.28 -0.14 0.42 0.09 0.62 
Lumbar spine BMAD         
Black -0.32 0.14 -0.18 0.35 0.08 0.63 0.08 0.66 
White -0.24 0.24 -0.15 0.42 -0.15 0.41 0.09 0.64 
Femoral neck BMD         
Black -0.38 0.05 -0.10 0.58 0.18 0.25 0.10 0.51 
White -0.15 0.43 -0.26 0.14 -0.11 0.54 0.09 0.96 
Femoral neck BMAD         
Black -0.35 0.07 -0.15 0.40 0.02 0.89 0.08 0.62 
White -0.26 0.19 -0.27 0.13 -0.09 0.62 -0.09 0.58 
Total femoral BMD         
Black -0.43 0.02 -0.2 0.23 0.07 0.64 -0.01 0.97 
White -0.17 0.39 -0.29 0.09 -0.03 0.88 -0.38 0.83 
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Table 7: Correlation between DEXA measured BMD/BMAD at different skeletal sites and biochemical variables in late postmenopausal black and white females. 
DEXA measurements Biochemical parameters 
 OC DPD PTH 25-OH-Vitamin D 
 r-value p-value r-value p-value r-value p-value r-value p-value 
Lumbar spine BMD         
Black 0.09 0.60 0.02 0.90 -0.16 0.31 -0.04 0.77 
White 0.55 0.05 0.07 0.76 -0.10 0.61 0.15 0.47 
Lumbar spine BMAD         
Black 0.04 0.82 -0.10 0.59 0.23 0.16 0.01 0.99 
White 0.52 0.09 -0.01 0.96 -0.26 0.24 0.17 0.42 
Femoral neck BMD         
Black 0.13 0.43 -0.01 0.99 -0.38 0.01 0.19 0.20 
White 0.14 0.62 0.22 0.33 -0.39 0.04 0.43 0.02 
Femoral neck BMAD         
Black 0.20 0.23 -0.01 0.94 -0.35 0.02 0.24 0.12 
White 0.33 0.29 0.02 0.95 -0.53 0.01 0.58 <0.01 
Total femoral BMD         
Black 0.20 0.22 0.16 0.35 -0.20 0.04 0.35 0.02 
White 0.09 0.76 0.24 0.29 -0.35 0.07 0.47 0.01 
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Table 8: Densitometric findings in postmenopausal black subgroups based on PTH tertiles 
 Postmenopausal black subgroups based on PTH tertiles 
 Low PTH tertile 
            1 
Middle PTH tertile 
                2 
High PTH tertile 
              3 
p-value( 1 vs 3)   p-value (2 vs 3) 
Age 60.3 ± 9.6 59.6 ± 10.1 59.9 ± 9.4 0.42 0.47 
S-PTH 4.1 ± 0.68 6.8 ± 0.96 12.5 ± 5.2 <0.01 <0.01 
SBMD 
   Absolute 
   T-score 
   Z-score 
 
0.903 ± 0.18 
-1.19 ± 1.7 
0.13 ± 1.63 
 
0.983 ± 0.21 
-0.61 ± 1.96 
0.88 ± 1.99 
 
0.914 ± 0.17 
-1.16 ± 1.48 
0.18 ± 1.78 
 
0.47 
0.47 
0.48 
 
0.07 
0.09 
0.06 
F-neck BMD 
   Absolute 
   T-score 
   Z-score 
 
0.831 ± 0.13 
-0.19 ± 1.15 
1.09 ± 1.29 
 
0.832 ± 0.12 
-0.15 ± 1.08 
1.17  ± 0.90 
 
0.766 ± 0.13 
-0.77 ± 1.21 
0.53 ± 1.05 
 
0.02 
0.02 
0.02 
 
0.02 
0.01 
<0.01 
F-total BMD    
   Absolute 
   T-score 
   Z-score 
 
0.938 ± 0.13 
-0.06 ± 1.06 
0.41 ± 1.11 
 
0.991 ± 0.16 
0.40 ± 1.31 
0.18 ± 1.20 
 
0.914 ± 0.16 
-0.24 ± 1.34 
0.26 ± 1.20 
 
0.20 
0.22 
0.19 
 
0.02 
0.02 
0.01 
Values expressed as mean ± SD. 
 p-value (1 vs 3): refers to comparison between low and high PTH tertile; p-value (2 vs 3): refers to comparison between middle and high PTH tertile;  
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Table 9: Densitometric findings in postmenopausal white subgroups based on PTH tertiles 
 Postmenopausal white subgroups based on PTH tertiles 
 Low PTH tertile 
              1 
Middle PTH tertile 
               2 
High PTH tertile 
             3 
p-value( 1 vs 3)   
 
p-value (2 vs 3) 
  
Age 55 ± 9.4 61 ± 9.8 63.6 ± 11.7 0.07 0.20 
S-PTH 3.5 ± 0.74 5.3 ± 0.49 8.2 ± 1.81 <0.01 <0.01 
SBMD 
   Absolute 
   T-score 
   Z-score 
 
0.989 ± 0.16 
-0.44 ± 1.56 
0.52 ± 1.46 
 
0.966 ± 0.17 
-0.71 ± 1.53 
0.71 ± 1.52 
 
0.914 ± 0.19 
-1.21 ± 1.69 
0.46 ± 1.69 
 
0.09 
0.07 
0.45 
 
0.18 
0.17 
0.32 
F-neck BMD 
   Absolute 
   T-score 
   Z-score 
 
0.726 ± 0.12 
-1.10 ± 1.045 
-0.04 ± 1.1 
 
0.728 ± 0.12 
-1.08 ± 1.09 
0.27 ± 1.1 
 
0.678 ± 0.14 
--1.58 ± 1.25 
-0.05 ± 1.26 
 
0.12 
0.09 
0.49 
 
0.12 
0.09 
0.20 
F-total BMD    
   Absolute 
   T-score 
   Z-score 
 
0.867 ± 0.13 
-0.61 ± 1.06 
0.17 ± 1.1 
 
0.876 ± 0.16 
-0.54 ± 1.31 
0.501 ± 1.2 
 
0.826 ± 0.16 
-0.95 ± 1.34 
0.25 ± 1.2 
 
0.19 
0.19 
0.41 
 
0.15 
0.15 
0.26 
Values expressed as mean ± SD. 
 p-value (1 vs 3): refers to comparison between low and high PTH tertile; p-value (2 vs 3): refers to comparison between middle and high PTH tertile;  
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4. DISCUSSION 
Our data demonstrated that bone turnover, as assessed biochemically, were similar in the 
pre-and postmenopausal black and white cohorts. Although longitudinal changes must be 
interpreted with caution given the cross-sectional nature of our study, our data do, however, 
suggest differing patterns of bone turnover with ageing between the two racial groups.  
A marked increase in serum osteocalcin levels was noted in whites at the time of the 
menopausal transition, whereas the difference in serum OC levels between premenopausal 
and early postmenopausal blacks were non-significant. The percentage increase in OC levels 
was 50% in whites compared with a 14% increase in blacks. Serum osteocalcin is a marker 
of bone formation, but as the processes of bone formation and bone resorption is normally 
tightly coupled, serum osteocalcin levels also reflect bone turnover. The relative contribution 
of bone formation and bone resorption to the ultimate bone turnover rate cannot be 
determined. This may result in varying associations between serum osteocalcin levels and 
BMD status, albeit positive or negative.  The association between OC levels and BMD data in 
the early postmenopausal blacks and whites were consistently negative, with significant 
associations confined to that between serum OC and femoral measurements in blacks. This 
may imply that, in our study, the raised serum OC levels in early menopause reflect a 
general increase in bone turnover and not only an increase in bone formation, with resultant 
detrimental effects on BMD status. Bone formation is so highly correlated with bone 
resorption that a value for either process usually correlates very well with bone loss338. OC 
has been suggested to be the best single biochemical marker for estimating the rate of bone 
loss in untreated postmenopausal women339,340. 
Neither of the two racial groups demonstrated a significant increase in urinary DPD from the 
premenopausal to the early postmenopausal state. The reason why the increased bone 
turnover is not reflected by an associated significant increase in urinary DPD levels is 
uncertain, but may be partially explained by the limitations of a single evaluation of a 
biochemical parameter known to have a significant day-to-day variation233. Vesper et al233 
reviewed the literature and noted the reported day-to day variation in U-DPD averaged 
17.4% (range, 5-24%). We did try to minimize the pre-analytical variability of urine DPD as 
outlined in chapter 3 section 2.6.2. 
Due to these apparent differing patterns of change in biochemical parameters of bone 
turnover, a tendency towards lower serum OC and urinary DPD was noted in our early 
postmenopausal blacks compared with whites (p=0.08).   
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There was no difference in biochemical markers of bone turnover including osteocalcin and 
urinary DPD in a relatively young postmenopausal South African black and white female 
group (mean age 45-64 yrs) studied by Daniels et al5 . Our findings are, however, consistent 
with data obtained by Finkelstein et al142 who noted significantly lower serum OC levels in 
early perimenopausal African-Americans compared with Caucasians, but failed to show 
significantly different urinary NTX levels between these two ethnic groups. Our findings are 
further supported by other previous studies showing lower OC levels in African 
Americans138,146,196 and studies reporting similar urinary pyridinium cross-link excretion in 
postmenopausal Caucasians and African-Americans142,144,185,186.   
In our study, the percentage bone loss at the proximal femoral regions at the time of the 
menopausal transition appeared to be lower in blacks compared with whites (chapter 5, table 
20) and this may be partially explained by the observed lower bone turnover at this time in 
our blacks. Our observation of an apparent slower rate of decline in femoral bone density in 
black females compared with whites in the peri- and early postmenopausal period is 
consistent with the findings in the nurses’ study by Daniels et al1. This pattern of femoral 
bone loss was also remarkably similar to that observed by Solomon213 more than 30 years 
earlier. He noted that South African black females appeared to reach peak bone mass at a 
later stage than whites and showed that black females had very limited bone loss in the late 
premenopausal and perimenopausal periods. A slower rate of cortical and trabecular bone 
loss, especially in the early postmenopausal period, has also been noted in American blacks 
compared with whites in some139,184,197, but not all144,194,196 studies.  
During the latter part of menopause (early to late menopause) apparent differences in bone 
turnover rates were again observed between blacks and whites. An increase in bone 
formation/turnover as assessed by serum OC levels was noted in ageing blacks, whereas a 
tendency towards lower bone formation/turnover was observed in ageing whites (percentage 
change OC: blacks – 28% increase; whites – 36% decrease). Urinary DPD levels remained 
unchanged in blacks from the early to the late postmenopause, whereas a decrease of 32% 
was shown in whites.  
Daily dietary calcium-intake was statistically significantly lower in postmenopausal blacks 
compared with whites in the early and late postmenopausal cohorts (p<0.01, table 1). The 
25-OH-Vitamin D levels were also consistently lower in postmenopausal blacks compared 
with whites and decreased with ageing. Lower urinary calcium excretion in blacks, especially 
in the younger postmenopausal subjects was also noted, and this would support the concept 
of a more negative calcium balance in blacks compared with whites. Since metabolic 
balancing studies were, however, not performed, the ability of black subjects to conserve 
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calcium more stringently regardless of PTH status cannot be ruled out. The lower calcium 
excretion in blacks was noted despite significantly higher urinary sodium loss. Although renal 
sodium loss is directly proportional to dietary sodium intake, higher dietary intake of sodium 
were not consistently noted in our blacks and were thus unable to explain the observed 
higher renal sodium loss in blacks.  
This negative calcium balance in blacks compared with whites evoked a more marked 
increase in PTH-levels in blacks with ageing, with resultant near significantly higher PTH 
levels in older postmenopausal blacks (p=0.05). The observed increased bone turnover in 
ageing postmenopausal blacks may thus be explained, at least in part, by the associated 
increase in PTH-levels in blacks and this would argue against the belief that black skeletons 
are markedly PTH resistant138,144,146,196. Similar and significant associations were also noted 
between 25-OH-Vit D (positive) and PTH (negative) and all proximal femoral BMD 
measurements in both blacks and whites, once again contesting the idea that blacks do not 
suffer the detrimental bony effects due to secondary hyperparathyroidism. The PTH 
sensitivity of the black skeleton is furthermore demonstrated by the finding of lower femoral 
neck densitometric measurements in the tertile of postmenopausal blacks with the highest 
PTH levels compared to the tertile with lowest PTH levels (table 10 & table 11). The absence 
of any association between BMD and ascending PTH-tertiles in whites may be due to a more 
modest increase in PTH-levels from the low to the high tertile, with values in the highest 
tertile varying from high normal to only slightly elevated. 
Some degree of resistance to the biological action of PTH was, however, noted at a renal 
level in postmenopausal blacks (higher renal phosphate re-absorption despite higher PTH-
levels). Our study data do not exclude some degree of skeletal resistance to PTH in blacks, 
but cautions against the belief that PTH will have no adverse skeletal effects in blacks.  
A study by Harris et al in low income, elderly black and white individuals with secondary 
hyperparathyroidism (HPT) also contested the belief that this is a benign condition with no 
deleterious skeletal effects in blacks145. Although bone turnover has repeatedly been shown 
to be lower or similar in black versus white groups, bone turnover was noted to be higher 
and BMD lower in the subgroups of patients with secondary HPT in both black and white 
ethnic groups145 (see chapter 2, figure 12). 
The tendency towards higher PTH-levels in older blacks, and the observed significant 
negative associations between PTH and proximal femoral BMD measurements, did not result 
in a higher percentage decline in femoral BMD in older blacks (transition from the early to 
the late postmenopausal phase) compared with whites. The percentage decline in BMD at 
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proximal femoral sites in our older study population appeared to be similar in blacks and 
whites. Better preservation of femoral BMD was, however, observed at the time of the 
menopausal transition in blacks compared with whites (chapter 5, table 20), implying that 
femoral BMD loss increased in blacks relative to whites in later years. This may be ascribed, 
at least in part, to the presence of secondary hyperparathyroidism in older blacks. Protective 
mechanisms independent of bone turnover and the presence of secondary 
hyperparathyroidism appear to protect the black skeleton, especially at the femoral sites, 
into old age.  
 To conclude,  
● Bone turnover, as assessed biochemically, was similar in the total pre- and 
postmenopausal black and white cohorts. 
● Bone turnover rates appeared to differ with ageing between the two racial groups.   
● A lower bone turnover rate was noted in blacks at the time of the menopausal 
transition and is consistent with the finding of a lower percentage bone loss at the 
femoral sites at this time in blacks compared with whites. 
● Bone turnover increased in ageing postmenopausal blacks only. This could be ascribed, 
at least in part, to the more pronounced secondary hyperparathyroidism noted in 
blacks. 
● Deleterious effects of secondary hyperparathyroidism on bone mineral density at the 
proximal femoral sites were demonstrated in our postmenopausal blacks and contest 
the idea of an absolute skeletal resistance to the action of PTH in blacks. 
● The increase in bone turnover and the presence of secondary hyperparathyroidism 
may thus potentially aggravate bone loss in ageing blacks, especially at the proximal 
femoral sites. 
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CHAPTER 9 
BONE GEOMETRY IN BLACK AND WHITE SOUTH AFRICAN FEMALES 
1.  INTRODUCTION 
The role of BMD and micro-architectural (bone quality) properties in the pathophysiology of 
skeletal fracture has previously been alluded to. Bone mineral density (BMD) is an excellent 
predictor of bone strength and fracture risk at all skeletal sites26-30. The relationship between 
low BMD and the risk of subsequent hip fracture is strongest for measurements of femoral 
bone density341, but many women who present with hip fracture have BMD higher than that 
usually associated with osteoporosis342. Bone mineral density is thus not the sole factor 
influencing whether a fracture occurs. Based on engineering principles, geometric 
measurements of femoral size should be related to femoral strength and the risk for hip 
fracture. Differences in the length, width and angle of the femoral neck may affect hip 
fracture risk160-166, whereas differences in vertebral body size may influence vertebral fracture 
risk167,343.  
Numerous studies have confirmed the relationship between hip axis length (HAL) and risk of 
hip fracture, independent of bone mineral density status160-166,344,345. Analyses of results 
obtained in the study by Faulkner et al166 showed a near doubling of the risk of hip fracture 
with every SD increase in hip axis length.   
The femoral neck-shaft angle was also shown in some161 but not all studies166 to affect hip 
fracture, whereas most studies161,166 failed to show a significant association between the 
neck width and risk of hip fracture. Identifying women at high risk of hip fracture is likely to 
be substantially enhanced by combining bone density with data on the structural geometry 
of the hip, especially HAL.  
Vertebral strength is also influenced by the geometry of the vertebrae. Vertebral size has 
been documented to be reduced in women predisposed to vertebral fractures167,343. 
Most studies of hip geometry have documented a shorter HAL in African-Americans 
compared with Caucasians3,4. A shorter HAL was also documented in SA black female nurses 
compared with whites5 and Gambians had shorter mean HAL compared with British 
subjects6. Although American blacks are heavier than whites, their lumbar spine and femoral 
neck areas are actually smaller167. Neck width has been reported to be smaller in blacks3,4,346 
along with documentation of thicker cortices4,346. Blacks also have shorter trunk lengths 
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compared with whites which imply reduced vertebral height203. Vertebral size in adult South 
African blacks and whites has not been studied previously. 
2. PATIENTS AND METHODS 
To assess previous observations of racial differences in skeletal geometry, the hip axis length 
(HAL) and the femoral neck width was determined directly from the DEXA-scan printouts as 
defined in figure 1166. The femoral DEXA measurements were all performed using a Hologic 
QDR-1000 scan and all geometric measurements were conducted by one investigator. 
Employing standard DEXA software, HAL was defined as the length along the femoral neck 
axis, from below the lateral aspect of the greater trochanter, through the femoral neck, to 
the inner pelvic brim. Femoral neck width was defined as the shortest distance within the 
femoral neck region of interest (as defined by the DEXA analysis software) perpendicular to 
the femoral neck axis. Vertebral size was also determined directly from the DEXA-scan 
printouts and expressed as the total vertebral cross-sectional area and the calculated mean 
area of individual vertebrae L1-L4. (please refer to chapter 3, section 2.4 for a more detailed 
outline of methodology).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  Definition of geometric measurements 
from femoral DEXA scan printout. 
AĂ: hip axis length, defined as the length along the femoral 
neck axis as defined by the DEXA analysis software, from below 
the lateral aspect of the greater trochanter, through the femoral 
neck, to the inner pelvic brim  
Dd: neck width, defined as the shortest distance within the 
femoral neck region of interest, as defined by the DEXA analysis 
software, perpendicular to the femoral neck axis  Adapted from 
Faulkner et al. 1993, J Bone Miner Res; 8(10): 1211-1217166 
Geometric assessments were performed on the total study cohort who included 187 blacks 
and 186 whites (see Chapter 4, section 3.1.1 & 3.1.3 for detail regarding clinical 
characteristics).  
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Ethnic differences were determined and are reported on in the following patient subgroups: 
● Premenopausal black and white subgroups 
● Early and late postmenopausal black and white groups as outlined in section 1.3. 
ANOVA was used to determine significant ethnic differences in geometry between the 
various patient subgroups. Spearman correlations were used to determine relationships 
between geometric measurements and anthropometry (i.e. weight and height) as well as 
between certain femoral geometric measurements (HAL and femoral neck width) and 
between certain anthropometric measurements (weight and height).  
3. RESULTS 
3.1. Geometric measurements 
Mean hip axis length (HAL) and mean femoral neck width was significantly shorter in 
premenopausal and postmenopausal black females compared with whites. A marked 
difference of ±1SD in hip axis length between blacks and whites in all the different 
subgroups studied was noted. The mean cross-sectional area of the lumbar vertebral bodies 
and the mean of the average of the cross-sectional areas of individual lumbar vertebrae L1-
L4 of the black females in this study were significantly smaller than whites in all the 
subgroups studied (table 1). 
3.2. Correlations of Geometric measurements 
Correlations between anthropometry and geometry are shown in table 2 and correlations 
between weight and height and between the different femoral geometric measurements are 
depicted in table 3.   
Height was strongly and positively associated with all geometric measurements i.e. HAL, 
femoral neck width and vertebral bone area in blacks and whites. Weight correlated with 
femoral neck width in both blacks and whites, but correlated with vertebral bone area and 
HAL in whites only (table 2). 
Weight and height correlated significantly in whites in all the subgroups and only in 
premenopausal blacks. The absent correlation between weight and height in the 
postmenopausal blacks is consistent with the finding of increasing weight and unchanged 
height with ageing in blacks only. A correlation between weight and geometric 
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measurements was absent in the postmenopausal black subgroups where height and weight 
did not correlate (table 3).  
A significant association between hip axis length and femoral neck width was noted in both 
blacks and whites. The association tended to be stronger in whites.  
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Table 1: Femoral and vertebral geometry in the premenopausal and postmenopausal blacks and whites 
Geometric measurements Premenopausal Postmenopausal 
 <60 years ≥ 60 years 
Blacks 
n=87 
Whites 
n=76 
p-value 
 
Blacks 
n=52 
Whites  
n=63 
p-value 
 
Blacks 
n=48 
Whites  
n=47 
p-value 
 
HAL (mm) 62.5 ± 4.1 66.8 ± 4.3 <0.01 61.9 ± 3.8 66.8 ± 4.2 <0.01 62.5 ± 4.2 66.1 ± 4.0 <0.01 
F- neck width (mm) 19.2 ± 1.8 19.7 ± 2.1 0.07 19.1 ± 1.6 20.1 ± 1.4 <0.01 19.0 ± 2.0 19.7 ± 1.3 0.04 
Vertebral BA  (cm2) 
  Total 
  Mean of L1-L4  
 
56.6 ±  5.6  
14.1 ± 1.4 
 
60.4 ± 5.2 
15.1 ± 1.3 
 
<0.01 
<0.01 
 
56.1 ± 6.1 
14.0 ± 1.5 
 
60.2 ± 5.6 
15.1 ± 1.4 
 
0.01 
<0.01 
 
57.0 ± 5.2 
14.2 ± 1.3 
 
59.8 ± 6.7 
15.0 ± 1.7 
 
0.02 
0.02 
Values reported are the mean ±SD. HAL: hip axis length; F-neck: femoral neck; BA: bone area 
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Table 2: Correlation between Anthropometry and Geometric measurements in black and white females 
Anthropometry and racial group Geometric measurements 
HAL (mm) FEMORAL NECK WIDTH (mm) VERTEBRAL BONE AREA (cm2) 
r-value p-value r-value p-value r-value p-value 
WEIGHT (kg)       
Premenopausal       
   Black 0.11 0.34 0.36 <0.01 0.22 0.06 
  White 0.28 0.02 0.46 <0.01 0.30 0.11 
EARLY postmenopausal       
   Black 0.09 0.58 0.30 0.05 0.17 0.31 
   White 0.32 0.01 0.42 <0.01 0.55 <0.01 
LATE postmenopausal       
   Black 0.27 0.06 0.29 0.05 0.09 0.56 
   White 0.30 0.05 0.34 0.02 0.39 0.01 
HEIGHT (cm)       
Premenopausal       
   Black 0.44 <0.01 0.32  <0.01 0.65 <0.01 
  White 0.57 <0.01 0.25 0.03 0.63 <0.01 
EARLY postmenopausal       
   Black 0.60 <0.01 0.34 0.03 0.47 <0.01 
   White 0.62 <0.01 0.52 <0.01 0.71 <0.01 
LATE postmenopausal       
   Black 0.66 <0.01 0.15 0.29 0.61 <0.01 
   White 0.56 <0.01 0.58 <0.01 0.48 <0.01 
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Table 3: Additional correlation between weight and height and between HAL and femoral neck width in black and white females 
Anthropometry and racial group Geometric measurements 
 HEIGHT (cm) FEMORAL NECK WIDTH (mm) 
 r-value p-value r-value p-value 
WEIGHT (kg)     
Premenopausal     
   Black 0.32 <0.01   
  White 0.36 <0.01   
EARLY postmenopausal     
   Black 0.03 0.83   
   White 0.34 <0.01   
LATE postmenopausal     
   Black 0.06 0.71   
   White 0.39 <0.01   
HAL (mm)     
Premenopausal     
   Black   0.39 <0.01 
  White   0.45 <0.01 
EARLY postmenopausal     
   Black   0.34 0.03 
   White   0.60 <0.01 
LATE postmenopausal     
   Black   0.35 0.02 
   White   0.55 0.02 
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4. DISCUSSION 
In our study population significant differences in skeletal morphology were noted between 
blacks and whites and these differences were consistent throughout all the subgroups 
evaluated. Hip axis length and femoral neck width was significantly shorter in the black 
females compared with whites. Vertebral size based on assessment of lumbar vertebral bone 
area was significantly smaller in blacks. Height was strongly and positively associated with 
geometric measurements in both blacks and whites. 
A markedly lower hip fracture rate has been documented in South African and African black 
populations compared with whites20,212. The HAL findings in our black study group will be 
expected to enhance femoral strength independent of femoral BMD160-166. An approximate 1 
SD difference in hip axis length between blacks and whites in all the different subgroups 
studied was noted.  In the study by Faulkner et al166 a hip axis length of 1 standard deviation 
longer than average was associated with an almost twofold increase in the risk of 
subsequent hip fracture, after age adjustment. Although increased height is associated with 
increased BMD115,119, probable mostly due to associated increased body weight, tallness had 
been previously identified as a risk factor for hip fracture109. Given the very strong 
association between height and HAL it is plausible that the increased hip fracture risk in tall 
individuals are due, at least in part, to an increased HAL. 
The precise mechanism by which the hip axis length is associated with fracture risk is not 
known. A longer hip axis might cause the greater trochanter to extend beyond the pelvis to a 
larger degree, thus creating a more vulnerable target for impact.   
We demonstrated a significant positive association between hip axis length and femoral neck 
width in both blacks and whites in our study population, as has been previously documented 
in African-Americans and Caucasians elsewhere. Most studies161,166 failed to show a 
significant association between the neck width and risk of hip fracture or ability of neck 
width to predict the risk of fracture in the hip region independent of BMD and HAL. The 
association between hip fracture risk and femoral neck width is thus most likely 
circumstantial due to the association of femoral neck width with HAL. 
Vertebral size was noted to be smaller in our black females. A study in SA schoolchildren 
found that the black children had shorter lumbar vertebral heights for the same bone area, 
before and after correction for differences in height, suggesting that the vertebrae in the 
black children are wider191,216. We documented significantly smaller vertebral bone area in 
our adult black females compared with whites. This may be accounted for primarily by 
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differences in vertebral height and do not necessarily imply differences in vertebral 
transverse diameter. We did not specifically calculate vertebral heights in our black cohort 
and can therefore not comment on the height or width of individual vertebrae. 
A vertebral body’s strength, similar to femoral bone strength, is determined predominantly 
by the BMD of the area, but is also influenced by geometrical properties. The major 
mechanical role of the vertebral body is to withstand compressive loads. The surface area of 
the vertebral endplates determines the compressive stress concentration imparted to the 
cancellous bone and explains why smaller vertebral cross-sectional dimensions may enhance 
the risk of vertebral compression fractures. Smaller vertebral size has been documented in 
women predisposed to vertebral fractures167,343.  
To conclude, shorter, adult black women have a significantly shorter hip axis length than 
whites. This geometric feature has been documented to protect against hip  
fracture160-166,344,345. The approximately one standard deviation difference in HAL between our 
blacks and whites may definitely contribute to the significantly lower hip fracture rate 
previously reported in South African black females compared with whites20. Average 
vertebral size was, however, smaller in black females and fail to explain the apparent lower 
vertebral fracture risk previously reported in this population. Racial differences in vertebral 
dimensions (height, width) and/or other qualitative bone properties as has been suggested 
by our QUS data may, however, account for different vertebral fracture rates in white and 
black women – that is, if such a difference in fact exists.  
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CHAPTER 10 
FALL RISK IN BLACK AND WHITE SOUTH AFRICAN FEMALES 
1. INTRODUCTION 
Fall risk contributes significantly to fracture risk, especially in the elderly. Bone density at the 
age of 75 yrs is only about 4% lower than at the age of 65 yrs109. The incidence of hip 
fracture, however, is about four times as great at 75 years as at 65 years, and 12 times as 
great at 85 years. This increase is not primarily due to further loss of bone, but rather to a 
large increase in the risk of falling at more advanced ages. 
Hip fractures occur almost exclusively after a fall, spontaneous hip fractures without prior 
falling is extremely rare168. A history of recent falls is a major contributing factor to the 
occurrence of symptomatic fractures in postmenopausal women, independent of and additive 
to the risk attributable to age and osteoporosis169,170,347. 
Some206,207, but not all studies208,209, suggest that Caucasians may fall as much as 50-60% 
more often than African-Americans or other ethnic groups. However, in a study by Faulkner 
and co-workers209 the frequencies of falling between older Caucasian and African-Americans 
were similar, but the circumstances during which a fall occurred differed which might 
partially explain ethnic differences in fracture risk. No data regarding possible differences in 
the propensity to fall between black and white South Africans exist. 
Epidemiological data have revealed that some 50% of mostly white osteoporotic patients 
have muscle loss/weakness (“sarcopenia”), 30% have postural hypotension and many have 
poor visual acuity or problems with depth perception, cognitive dysfunction or use drugs that 
may predispose to falls173-176. Low 25-OH Vitamin D levels are associated with sarcopenia and 
neuromuscular dysfunction especially in the elderly176,348,349, and poor vitamin D status has 
been shown to be independently associated with an increased risk of falling in the elderly350. 
2. PATIENTS AND METHODS 
A history of falls and an assessment of sensory and neuromuscular function were obtained in 
all study subjects. Detailed methodologies are discussed in Chapter 3 (refer to section 2.1.3).  
We analyzed and report on fall data and sensory and neuromuscular function tests results in 
different patient subgroups as follows: 
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● A total study population comprised of pre- and postmenopausal black and white 
females and included women who were currently using hormone therapy (blacks: n=3; 
whites: n=43). The baseline clinical characteristics of the total postmenopausal study 
population are outlined in Chapter 4 (section 2.2 & 2.4) and were noted to be near 
identical to the baseline clinical characteristics of the postmenopausal black and white 
women not using hormone therapy (chapter 5, table 1). The baseline clinical 
characteristics of the white postmenopausal hormone never-users and current 
hormone users are summarized in table 1. Anthropometric variables, reproductive 
factors and lifestyle risk factors, with the exception of age at menarche and smoking, 
were comparable between the two cohorts. The women currently on hormone therapy 
(HT+) reached menarche at an earlier mean age (p=0.03) and they smoked more 
(p=0.04) compared with the never-users. A positive family history of osteoporosis was 
present in 21% and 26% of the users and the never-users respectively. 
● A postmenopausal cohort only including postmenopausal black and white females not 
using hormone therapy. 
● An additional subgroup of elderly blacks and whites (age ≥ 65yrs), included due to the 
known significant contribution of falling to fracture risk especially in the elderly109. The 
baseline clinical characteristics of this subgroup are shown in table 2. 
● We also analyzed data separately in postmenopausal white females currently on 
hormone therapy and compared data between hormone never-users and current 
hormone users. 
● Results of sensory and neuromuscular function tests are also compared between 
postmenopausal fallers and non-fallers. 
One way analysis of variance was used to determine differences between the various ethnic 
subgroups with regard to falls and sensory and neuromuscular function tests. Cross 
tabulation was used to summarize categorical variables. Analysis of covariance was 
performed to assess the association between serum 25-OH Vitamin D status and fall risk in 
postmenopausal females. Partial correlations between Vitamin D status and physical 
performance tests i.e. quadriceps strength, AP-sway and lateral sway were drawn after 
correction for co-factors namely age, weight, BMI, exercise, smoking, alcohol intake and 
serum creatinine levels in postmenopausal females.  
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Table 1.  Baseline characteristics of the white postmenopausal hormone never-users (HT-) and hormone users (HT+) 
 White postmenopausal women 
Characteristic Hormone never-users (n=60) Current hormone users (n=43) p-value 
Age (yr) 59 ± 9 56 ± 7 0.06 
Height (cm) 163 ± 17 160 ± 26 0.18 
Weight (kg) 71.6 ± 15 69 ± 11 0.20 
BMI (kg/cm2) 27 ± 5 26 ± 4 0.14 
Elbow width (mm) 67 ± 4 67 ± 4 0.34 
Age (yrs) at menarche 13.2 ± 1.8 12.6 ± 1.7 0.03 
Years since menopause  10.9 ± 8.7 10.5 ± 7.0 0.39 
Calcium intake (mg/d) 855 ± 250 855 ± 255 0.28 
Smoking (pack yrs) 5.9 ± 14.4 11.0 ± 16.1 0.04 
Alcohol (U/week) 2.4 ± 4.0 1.7 ± 3.2 0.20 
Physical activity score ( 0-4) 2.8 ± 0.9 2.7 ± 0.8 0.24 
Number of pregnancies  2.7 ± 1.6 2.6 ± 1.4 0.38 
Past OC use  n (%) 25 (38) 24 (52)  
Past Depo Provera use  n(%) 2 (3) 0 (0)  
Positive family history n (%) 14 (21) 12 (26)  
Values are reported as average ± SD except where otherwise stated 
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Table 2: Baseline clinical characteristics of the elderly black and white postmenopausal females 
Postmenopausal females  ≥ 65 years 
Characteristic Blacks  (n= 28) Whites (n= 28) p-value 
Age (yr) 72 ± 4 72 ± 4 0.26              
Height (cm) 158 ± 7 158 ± 7 0.43 
Weight (kg) 83 ± 17 70 ± 15 <0.01 
BMI (kg/cm2) 33.5 ± 8 27.4 ± 5 <0.01 
Waist/Hip ratio (cm) 0.87 ± 0.1 0.87 ± 0.1 0.45 
Elbow width (mm) 67 ± 5 68 ± 5 0.24 
Age at menarche(yrs) 14 ± 2 13 ±  2 0.01 
Menopause age (yrs) 49 ± 5 48 ± 4 0.02 
YSM (yrs) 23  ± 6 23 ± 5 0.45 
Calcium intake (mg/d) 616 ± 168 745 ± 207 0.01 
Smoking (pack yrs) 0 6 ± 11 <0.01 
Alcohol (U/week) 0.83 ± 3.9 1.96 ± 4.0 0.15 
PA score (0-4) 1.7 ± 1 2.6 ± 0.9 <0.01 
Family history (%) 0% 7%  
OCP use (%) 21% 18%  
DP use (%) 7% 4%  
Nr of pregnancies (n) 5 ± 3 4 ± 2 <0.01 
Breastfeeding+ (%) 86% 79%  
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3. RESULTS 
3.1. Fall results in the total study population 
A recent fall (within 12 months) occurred in 73 of the study subjects, 29 blacks and 44 
whites.  
Fall subjects thus represented 16% and 24% of the two ethnic groups respectively. The 
majority of these falls occurred in postmenopausal females and affected 22% of blacks and 
29% of whites. A similar percentage of white postmenopausal hormone users (28%) and 
non-users sustained a recent fall (30%).  
A recent fall resulted in non-spine fractures in two postmenopausal white females (one 
Colle’s fracture, one rib fracture). In patients with recent falls, non-spine fractures occurred 
following prior fall(s) in a further 6 patients.  
Reliable information regarding the direction of the fall was only available in 42 subjects. 
Twenty-three subjects reported a forward fall, 10 fell sideways and 9 backwards. The only 2 
documented fractures at the time of a recent fall were sustained following a lateral fall (table 
3).  Although numbers are very limited, 90% of lateral falls occurred in the postmenopausal 
females.  
3.2. Falling and bone mineral density in the postmenopausal cohort 
Bone mineral density data pertaining to the postmenopausal fallers and non-fallers amongst 
blacks and whites is depicted in table 4 (please refer to chapter 3, section 2.2.1 for 
definitions of osteopenia and osteoporosis used in this study).  
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Table 3. Falls in the total study population 
 Black cohort White cohort 
 Premenopausal 
(n=87) 
Postmenopausal 
(n=100) 
Premenopausal 
(n=76) 
Postmenopausal 
(n=110) 
    Total  
(n=110) 
Non-hormone users(n=64) Hormone users(n=46) 
 
FALLS:       
  Total 7 22 12 32 19 13 
  Multiple 1 4 0 4 2 2 
DIRECTION:       
  Uncertain 6 11 3 11 7 4 
  Forwards 1 7 6 9 5 4 
  Backwards 0 1 2 6 3 3 
  Lateral  0 3 1 6 4 2 
FRACTURES*       
  Recent fall 0 0 0 2 1   1   
  Past fall(s) 1  3  0 4 3  0 
* Historical fractures as reported by subjects 
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3.2.1. Blacks 
A higher percentage of black females with a recent fall had documented proximal femoral 
osteopenia compared to those without falls. Lumbar osteopenia was present in a similar 
percentage of blacks with and without a history of a recent fall.  Osteoporosis at any skeletal 
site was noted in 23% (5/22) of fallers and in 12% (9/78) of non-fallers. 
3.2.2. Whites 
In whites a somewhat higher percentage of lumbar osteopenia was noted in fallers 
compared to non- fallers, whereas femoral osteopenia occurred in a similar percentage of 
whites with and without recent falls. Documented osteoporosis at any skeletal site was 
present in 16% (5/32) and 9% (7/78) of fallers and non-fallers respectively. 
Table 4  Bone mineral density at different skeletal sites in postmenopausal females with and without recent falls 
Postmenopausal 
Population 
Regional bone mineral density 
Lumbar spine BMD Femoral neck BMD Total femoral BMD 
 
 
Normal 
BMD n(%) 
Osteopenic 
n(%) 
Normal 
BMD n(%) 
Osteopenic 
n(%) 
Normal 
BMD n(%) 
Osteopenic 
n(%) 
Black cohort       
    Falls (n=22) 12 (55) 10 (45) 10 (45) 12 (55) 13 (59) 9 (41) 
    No falls (n=78) 39 (50) 39 (50) 58 (74) 20 (26) 62 (79) 16 (21) 
White cohort       
     Falls (n=32) 19 (59) 13 (41) 18 (56) 14 (44) 22 (69) 10 (31) 
     No falls (n=78) 54 (69) 24 (31) 38 (49) 40 (51) 52 (67) 26 (33) 
Values expressed as total number with percentage in brackets  
3.3. Elderly study population (age ≥65yrs) 
Twenty-nine black females and twenty-eight white postmenopausal females were 65 years 
and older. Twenty-one of the 80 recent falls occurred in these elderly women. About one 
third of females older than 65 years reported a recent fall - 10 falls occurred in blacks (34%) 
and 11 falls in whites (39%). None of these falls occurred in the five elderly white women on 
hormone therapy. In blacks 8 of the 10 falls (80%) occurred in patients with osteopenia at 
one or more skeletal site, whereas 10 of the 11 white females (91%) who reported a recent 
fall had osteopenia. A significant percentage of elderly females without a recent fall was also 
osteopenic at one or more skeletal sites in blacks and whites representing 68% and 71% of 
the two ethnic groups respectively. Osteoporosis at any skeletal site was present in 36% of 
white fallers and in 40% of black fallers. In the non-fallers, 18% (3/17) of whites and 21% 
(4/19) of blacks had osteoporosis at one or more skeletal sites (table 5). 
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Table 5 Bone mineral density at different skeletal sites in elderly postmenopausal females (≥ 65 years) with and without recent 
falls 
Values expressed as total number with percentage in brackets  
3.4. Hormone therapy and falls 
As mentioned before, a similar percentage of white postmenopausal hormone users (28%) 
and non-users sustained a recent fall (30%). None of the five elderly white women on 
hormone therapy reported a recent fall. 
4. SENSORY AND NEUROMUSCULAR FUNCTION 
4.1. Body Sway 
4.1.1. Total study cohort 
Body sway was objectively assessed in all study subjects. A significantly greater mean 
anterior-posterior sway, but similar mean lateral sway was documented in white 
premenopausal females compared with blacks. Early and late postmenopausal blacks and 
whites had similar mean anterior-posterior sway, but a greater mean lateral sway was noted 
in blacks compared with whites. No increase in AP sway was noted with ageing in either 
racial group, whereas increased lateral sway was present in the late postmenopausal women 
compared to the younger subgroups (table 6). 
4.1.2. Postmenopausal females  
Body sway data in the early and late postmenopausal groups not using hormone therapy 
was near identical to that of the total cohorts (table 7). Black and white women had similar 
mean anterior-posterior sway, whereas lateral sway was greater in blacks compared with 
whites. Hormone therapy in whites had very little impact on body sway in the younger 
Elderly postmenopausal  
population (≥ 65 years) 
Regional bone mineral density 
Lumbar spine  
BMD 
Femoral neck 
BMD 
Total femoral 
BMD 
Any site 
 
 
Osteopenic 
n(%) 
Osteopenic 
n(%) 
Osteopenic 
n(%) 
Osteopenic 
n(%) 
Osteoporotic 
n(%) 
Black cohort      
    Falls (n=10) 6  (60) 8 (80) 5 (50) 8  (80) 4 (40) 
    No falls (n=19) 11 (58) 7 (37) 3 (16) 13 (68) 4 (21) 
White cohort      
    Falls (n=11) 7 (64) 9  (82) 7 (64) 10 (91) 4 (36) 
    No falls (n=17) 6 (35) 11 (65) 8 (59) 12 (71) 3 (18) 
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postmenopausal group. Near-significant reduction in lateral sway was however noted in the 
older white hormone users compared with the non-users (p=0.05) [table 8]. 
4.1.3. Fallers versus non-fallers 
Black females had similar mean body sway in the group of fallers and non-fallers, whereas 
the white fallers had a significantly greater anterior-posterior body sway compared to non-
fallers (table 9). 
4.2. Reaction Time 
4.2.1. Total study cohort 
Mean reaction time was significantly longer in premenopausal and postmenopausal blacks 
compared with whites. Reaction time increased with ageing in both blacks and whites  
(table 6). 
4.2.2. Postmenopausal females  
Mean reaction time in the early and late postmenopausal blacks and whites not on hormone 
therapy was near identical to that of the total cohorts (table 7). Mean reaction time in the 
white females with and without hormone therapy was similar in the early and late 
postmenopausal groups (table 8). 
4.2.3. Fallers versus non-fallers 
In the postmenopausal blacks, the reaction time in females who reported a recent fall was 
near identical to non-fallers. In whites there was a tendency towards a longer mean reaction 
time in the postmenopausal white female fallers compared with the non-fallers, but this did 
not reach statistical significance (table 9).   
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Values reported are the mean ± SD 
Table 6. Sensory and neuromuscular function tests in premenopausal and the total postmenopausal black and white cohorts 
Function  Premenopausal  females Postmenopausal females 
 <60 years ≥ 60 years 
Blacks 
(n=87) 
Whites 
(n=76) 
p-value Blacks 
(n=52) 
Whites 
(n=63) 
p-value Blacks 
(n=48) 
Whites  
(n=47) 
p-value 
Body sway (mm) 
 Anterio-posterior 
 Lateral 
Reaction time (ms) 
Visual contrast  
Quadriceps  strength (kg) 
 
17.6 ± 6.3 
13.9 ± 8.2 
391 ± 171  
18.0 ± 3.2* 
26.6 ± 9.3 
 
20.4 ± 7.2 
13.6 ± 9.4* 
262 ± 39* 
19.4 ± 2.8* 
32.6 ± 6.2 
 
<0.01 
0.39 
<0.01 
<0.01 
<0.01 
 
19.4 ± 7.0 
14.8 ± 9.1 
428 ± 152 
15.4 ± 4.4 
24.5 ± 9.0 
 
19.0 ± 5.9 
10.7 ± 5.9 
275 ± 42** 
18.1 ± 2.2** 
32.5 ± 8.1** 
 
0.35 
<0.01 
<0.01 
<0.01 
<0.01 
 
20.9 ± 7.6 
20.1 ± 8.6** 
529 ± 189** 
14.7 ± 2.4 
21.3 ± 7.7** 
 
20.0 ± 8.3 
12.8 ± 9.6 
320 ± 78 
15.8 ± 2.5 
26.1 ± 6.9 
 
0.29 
<0.01 
<0.01 
0.01 
<0.01 
Values reported are the mean ± SD.  p-values tabulated refers to the comparison between blacks and whites within each age-group  
* p-value <0.05 compared with early postmenopausal cohort of same racial group  
** p-value <0.05 compared with late postmenopausal cohort of same racial group 
Table 7. Sensory and neuromuscular function tests in postmenopausal blacks and whites not using hormone therapy 
Function Postmenopausal females 
<60 years ≥ 60 years 
Blacks 
(n=49) 
Whites 
(n=35) 
p-value Blacks 
(n=48) 
Whites  
(n=31) 
p-value 
Body sway (mm) 
 Anterio-posterior 
 Lateral 
Reaction time (ms)               
Visual contrast  
Quadriceps strength (kg) 
 
18.9 ± 7.2    
15.2 ± 9.3 
433 ± 153 
15.3 ± 4.5 
24.1 ± 9.2 
 
19.2 ± 5.9 
10.9 ± 6.1 
274 ± 48 
18.5 ± 1.9 
34.2 ± 7.9 
 
0.42           
0.01 
<0.01 
<0.01 
<0.01 
 
21.6 ± 8.0 
20.1 ± 8.6 
529 ± 189 
14.7 ± 2.6 
21.3 ± 7.7 
 
22.2 ± 7.0 
15.3 ± 11.2 
325 ± 86 
16.0 ± 2.4 
25 ± 7.0 
 
0.37            
<0.01 
<0.01 
0.01 
0.02 
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Values expressed as mean ± SD 
Values expressed as mean ± SD 
Table 8. Sensory and neuromuscular function tests in white postmenopausal hormone non-users (HT-) and users (HT+) 
Function Postmenopausal females 
<60 years ≥ 60 years 
Whites ( HT-) 
(n=35) 
Whites (HT+) 
(n=28) 
p-value Whites (HT-)  
(n=31) 
Whites (HT+) 
(n=18) 
p-value 
Body sway (mm) 
 Anterio-posterior 
 Lateral 
Reaction time (ms) 
Visual contrast  
Quadriceps strength (kg) 
 
19.2 ± 5.9 
10.9 ± 6.1 
274 ± 48 
18.5 ± 1.9 
34.2 ± 7.9 
 
19.4 ± 5.1 
10.7 ± 5.7 
276 ± 33 
17.7 ± 2.3 
30.6 ± 8.1 
 
0.46 
0.45 
0.42 
0.09 
0.04 
 
22.2 ± 7.0 
15.3 ± 11.2 
325 ± 86 
16.0 ± 2.4 
25 ± 7.0 
 
23.6 ± 8.3 
10.5 ± 5.7 
307 ± 57 
15.9 ± 2.4 
28.5 ± 6.3 
 
0.10 
0.05 
0.22 
0.46 
0.05 
 
 
Table 9. Sensory and neuromuscular function tests in postmenopausal black and white female fallers and non-fallers 
Function Postmenopausal females 
Black fallers 
(n= 22) 
Black non-fallers 
(n=78) 
p-value White fallers 
(n=32) 
White non-fallers  
(n=78) 
p-value 
Body sway (mm) 
 Anterio-posterior 
 Lateral 
Reaction time (ms) 
Visual contrast  
Quadriceps strength (kg) 
 
22.0 ± 9.0 
17.3 ± 7.7 
475 ± 184 
14.4 ± 3.0 
22.9 ± 8.6 
 
19.6 ± 9.9 
17.4 ± 6.1 
480 ± 177 
15.2 ± 3.7 
23.1 ± 8.6 
 
0.12 
0.42 
0.48 
0.19 
0.35 
 
22.4 ± 7.5 
11.9 ± 9.3 
306 ± 81 
17.3 ± 2.6 
27.3 ± 8.1 
 
19.3 ± 5.2 
12.0 ± 6.9 
288 ± 53 
17.2 ± 2.5 
31.0 ± 8.0 
 
0.01 
0.49 
0.09 
0.38 
0.02 
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4.3. Visual Contrast Sensitivity (Melbourne Edge Test) 
4.3.1. Total study cohort 
Visual acuity was assessed by the Melbourne Edge test. Whites scored significantly better 
than blacks in all the different subgroups of the total cohort. Visual contrast sensitivity 
decreased with ageing in both blacks and whites (table 6).  
4.3.2. Postmenopausal females  
Visual acuity results remained better in whites compared with blacks when hormone users 
were excluded and as expected no significant impact of hormone therapy on visual contrast 
sensitivity could be demonstrated in whites (table 8).  
4.3.3. Fallers versus non-fallers 
Visual contrast studies yielded similar results in black and white fallers and non-fallers 
respectively (table 9).   
4.4. Quadriceps Strength 
4.4.1. Total study cohort 
Significantly higher mean quadriceps muscle strength was documented in the whites 
compared with blacks in all the subgroups of the total study cohort. Reduced quadriceps 
strength was noted with ageing in postmenopausal blacks and whites (table 6). 
4.4.2. Postmenopausal females  
Mean quadriceps strength remained significantly higher in the postmenopausal whites 
compared with blacks when only hormone non-users were analyzed (table 7). In whites, 
greater quadriceps strength was documented in the older postmenopausal women on 
hormone therapy compared with non hormone users, but statistical significance was not 
reached (table 8).  
4.4.3. Fallers versus non-fallers 
Mean quadriceps strength was similar in postmenopausal black fallers and non-fallers, but 
significantly weaker in the white fallers compared with non-fallers (table 9). 
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5. 25-OH VITAMIN D STATUS, FALLS AND NEUROMUSCULAR TESTING  
5.1. Vitamin D status and recent falls in postmenopausal blacks and 
whites 
Analysis of covariance was performed to assess the association between serum 25-OH 
Vitamin D status and fall risk in postmenopausal females. Two main factors i.e. race and 
Vitamin D, were included to assess the combined effect on fall risk as signified by recent falls 
within the last twelve months. The influence of co-factors namely age, weight, BMI, exercise, 
smoking, alcohol intake and serum creatinine levels were corrected for. A non-significant 
interaction between race and fall risk was demonstrated thus implying that a difference 
between fallers and non-fallers regarding Vitamin D status was the same irrespective of race. 
This allowed pooling of data obtained in the two race groups in order to determine possible 
differences in serum 25-OH Vitamin D status between fallers and non-fallers. Our results 
indicated no significant difference in this parameter between fallers and non-fallers. As 
reported in Chapter 8, serum 25-OH Vitamin D levels were significantly lower in blacks 
compared with whites in this study (p<0.01). 
5.2. Vitamin D status and physical performance tests in 
postmenopausal blacks and whites 
Partial correlations between Vitamin D status and physical performance tests i.e. quadriceps 
strength, AP-sway and lateral sway were drawn after correction for co-factors namely age, 
weight, BMI, exercise, smoking, alcohol intake and serum creatinine levels in 
postmenopausal females.  A significant association between quadriceps strength and Vitamin 
D status was noted in blacks whereas a weaker, non-significant tendency to correlate was 
also noted in whites. No correlation was noted between serum 25-OH Vitamin D status and 
AP-sway or between serum 25-OH Vitamin D status and lateral sway in neither blacks nor 
whites (table 10).  
Table 10. Partial correlations between 25-OH-Vitamin D status and physical performance in postmenopausal blacks and whites 
Parameters correlated Postmenopausal blacks Postmenopausal  whites 
 r-value p-value r-value p-value 
25-OH-Vit D and quadriceps strength 0.3 0.01 0.23 0.12 
25-OH-Vit D and AP-sway -0.09 0.41 -0.16 0.28 
25-OH-Vit D and lateral sway -0.03 0.78 -0.05 0.75 
Parameters correlated after correction for age, weight, BMI, exercise, smoking, alcohol intake and serum creatinine levels. 
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6. DISCUSSION 
FALLS 
In our study population of ambulatory community dwelling females, a similar percentage of 
black and white females sustained a recent fall (16% black; 24% white). The majority of 
falls occurred in older postmenopausal females. Thirty-nine percent of blacks and 36% of 
whites over the age of 65 years sustained a recent fall, values similar to those reported in 
the literature351. Although numbers are limited, the fall direction appeared to be different in 
blacks and whites, with whites documented to more often fall laterally and backwards than 
blacks.  It has been suggested in some studies206,207 that African Americans fall less than 
whites. In other studies208,209 the frequency of falling was similar, but the fall circumstances 
differed i.e. whites were significantly more likely to fall outdoors versus indoors and laterally 
versus forward209. It has been documented that the nature of the fall determines the type of 
fracture i.e. that women with wrist fractures were more likely to have fallen backward than 
those who fell without a fracture, whereas women who suffered hip fractures were more 
likely to have fallen sideways or straight down174.  Falls per se, especially in the elderly, 
contribute significantly to the occurrence of symptomatic fractures169,170,319.  Fall frequency 
was similar in our blacks and whites, but whether fall circumstances differ significantly 
between these two ethnic groups will have to be confirmed in a larger population sample.  
No significant correlation between 25-OH Vitamin D status and fall risk could be 
demonstrated in our postmenopausal blacks and whites. Patient numbers were, however, 
small and may account for the lack of such a correlation. No studies assessing the impact of 
low 25-OH Vitamin D status on fall risk in blacks have been published, whereas the positive 
association between low 25-OH Vitamin D status and fall risk in Caucasian populations have 
been documented previously176,350. Given the absence of any significant association, it will, 
therefore, be interesting to assess 25-OH-Vitamin D status in a larger black and white South 
African population to verify whether any association does exist with fall risk. 
Femoral osteopenia was present in a higher percentage of black fallers compared to those 
who did not fall, whereas white fallers and non-fallers were similarly affected. Osteoporosis 
at any skeletal site was noted in a higher percentage of black and white fallers compared 
with non-fallers in the total postmenopausal groups (black: 23% vs. 13%; whites: 16% and 
9%) and in the older subgroup (black: 40% vs. 22%; whites: 36% and 18%).  A higher fall 
risk has been noted in older women with osteoporosis compared with their age-matched 
counterparts without osteoporosis352 and is ascribed in part to associated sarcopenia in up to 
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50% of osteoporotic patients173-176. This highlights the importance of fall risk screening and 
fall risk reduction to prevent fractures in women with osteoporosis.  
NEUROMUSCULAR AND VISUAL ASSESSMENT  
Neuromuscular and visual assessment based on postural sway, reaction time, visual contrast 
sensitivity studies and quadriceps strength yielded consistently better results in whites than 
blacks. We conducted a cross-sectional study with a single patient contact visit. As test 
outcomes were heavily dependent on patient understanding, results might have been 
suboptimal in our black cohort due to the language barrier in some of the subjects. 
Premenopausal, as well as postmenopausal black females, had significantly weaker 
quadriceps strength with greater lateral sway, along with poorer vision and slower reaction 
time. Our black females were also less active than whites especially into old age (see 
Chapter 4, section 3.1.3) which may partially explain their poorer performance with regard to 
neuromuscular testing. Poor 25-OH Vitamin D status has been associated with poor physical 
performance and sarcopenia in older white populations176,348,349. 25-OH Vitamin D levels were 
significantly lower in blacks in our study (p<0.01). A modest association between 25-OH 
Vitamin D status and quadriceps strength in blacks and whites was documented in this 
study, reaching significance only in the black population. Low 25-OH Vitamin D status may 
thus contribute to the finding of weaker quadriceps strength in blacks. Based on 
neuromuscular and visual studies, and a more inactive cohort with ageing, one might have 
expected more falls in our blacks, but this was not the case. Similar fall histories were 
documented in blacks and whites in this study, but numbers are limited and may as such 
mask significant differences. Previous studies have documented poorer muscle strength and 
less physical activity, but similar fall histories, in African American females compared with 
whites208, findings similar to ours.  
Neuromuscular impairment and poor vision have been shown to be independent predictors 
of hip fracture risk in numerous studies178,319,342,351. Neuromuscular impairment may have two 
distinct roles in the occurrence of hip fractures: it may not only increase the risk of falling, 
but also influence an individuals speed, coordination and protective responses during a fall 
and as such may increase the risk of fracture independently of fall frequency. No difference 
in neuromuscular parameters and visual test results between black fallers and non-fallers 
was documented in this study, whereas a larger AP-sway and weaker quadriceps strength 
were noted in the white fallers compared with the white subjects who did not fall. These 
tests of neuromuscular function and visual contrast sensitivity have been shown to be able to 
identify individuals in the community at risk of falls and fall related fractures178,319,342,351. Most 
of these studies were conducted in postmenopausal white females and little is known 
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regarding the ability of these functional and visual tests to predict fall and fracture risk in 
blacks. In our white cohort, quadriceps weakness and a slower reaction time was noted in 
the group of fallers and may in part explain why these individuals did sustain a recent fall. 
The finding of similar neuromuscular function and visual contrast sensitivity in black fallers 
and non-fallers may be explained in more than one way. These tests may be a true reflection 
of function and may indicate that these modalities do not significantly contribute to falls in 
our black female population. As alluded to before, we conducted a cross-sectional study with 
a single patient contact visit. Outcome of these tests are heavily dependent on patient 
understanding and co-operation and might have been compromised in our black cohort due 
to a suboptimal grasp of the English language in some of the subjects. These differences in 
neuromuscular function tests between blacks and whites should therefore be interpreted 
with caution. 
HORMONE THERAPY 
The use of hormone therapy in whites had an impact on falls in the elderly. A significantly 
lower percentage of falls occurred amongst the older postmenopausal white females using 
hormone therapy compared with non-users (11% versus 45%) and none of the white female 
hormone users over the age of 65 years sustained a recent fall. Current hormone therapy 
reduced lateral sway and improved quadriceps strength in older white females in this study 
which may partially explain why older white female hormone users fell less than those 
without hormone therapy.  
To conclude, the percentage fallers in our black and white cohorts was similar and in both 
ethnic groups the risk of falling increased with age. There is a suggestion that the nature of 
falls in our black and white postmenopausal females may differ, but numbers are limited. 
Fallers in our postmenopausal study population were more likely than non-fallers to have 
osteoporosis. Postmenopausal blacks in our study demonstrated poorer outcomes regarding 
neuromuscular function, Vitamin D status and visual contrast testing and were shown to be 
more inactive with ageing compared with whites. This, however, did not result in an 
increased fall tendency amongst the black females. Quadriceps weakness and slower 
reaction time indicated an increased fall risk amongst whites, but were unable to distinguish 
black female fallers from non-fallers. Hormone therapy improved quadriceps strength and 
reduced lateral sway and significantly reduced fall risk in older white females. Data regarding 
fall tendencies, risk factors for falling and the association with reduced BMD amongst South 
African black and white females are limited at present and further studies are clearly needed 
to better define these important issues.  
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CHAPTER 11 
VERTEBRAL FRACTURE PREVALENCE IN BLACK AND WHITE SOUTH 
AFRICAN FEMALES 
1. INTRODUCTION 
In South Africa, osteoporosis related fractures occur more frequently in whites. The only 
documented fracture data in South Africa, however, date back to the 1970’s when Solomon 
et al noted that the urban Black population of the Johannesburg Metropolitan Area had a 
more than ten fold lower hip fracture rate compared to that seen in Western European 
populations, and that black males and females were affected equally20.  In 1968 Dent and 
co-workers published their data on spinal osteoporosis in rural and urban black females, and 
white females residing in the Durban area. They noted severe osteoporosis of the spine (as 
defined by structural abnormalities of the vertebrae on conventional X-rays of the lumbar 
spine) in 14% of Whites compared to a 3% and 2% prevalence in the rural and urban blacks 
respectively211.   
In West Africa, a very low incidence of minimal trauma fractures of the hip and wrist has 
also been observed212. This clinical impression is supported by the experience of the UK 
Medical Research Council (MRC) field station in Keneba, The Gambia, where there have been 
no reported cases of osteoporosis-related fractures during the past 40 years.  
Most studies evaluating risk factors for vertebral fracture in women have been conducted in 
Caucasian populations. The Study of Osteoporotic Fractures (SOF) identified a low BMD at 
peripheral or central sites353, prevalent vertebral fractures354, low estradiol levels355,356 and 
depression357 as risk factors for incident vertebral fracture in a prospective cohort of women 
≥ 65 years of age, followed for an average of 3.8 years. In this same cohort, Nevitt et al305  
recently reported that low BMD at all sites measured, previous non-spine fracture, falls in the 
last year, increased age, smoking, and low body mass index increased risk for a first 
vertebral fracture, whereas physical activity and estrogen use were associated with 
decreased risk. In contrast, The European Osteoporosis study (EPOS)358 found that smoking 
and physical inactivity did not increase risk of incident vertebral fracture in women or men, 
50-79 years of age, after 4 years of follow-up. The Rotterdam study359, with a slighter longer 
duration of follow-up (6.3 years), found that prevalent vertebral fracture and low BMD were 
associated with an increased incidence of vertebral fracture in women and men, whereas 
increased age and smoking increased risk in women only. Long-term risk of incident 
vertebral fractures was assessed in middle-aged persons as part of the Framingham Study158. 
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Prevalent vertebral fracture was identified as the only factor able to predict long-term 
incidence of fractures in these women. Age, height, weight, grip strength, physical activity 
and estrogen use had little or no influence on cumulative incidence of vertebral fractures. In 
the Chingford study360 spinal bone density was similar for fracture and non-fracture cases.   
In a single study by Vokes et al361, risk factors for prevalent vertebral fractures in black and 
white females were assessed and included age, height loss, history of non-vertebral 
fractures, BMD and corticosteroid use. Among whites all risk factors evaluated were 
significantly associated with vertebral fractures, whereas only age and corticosteroid use 
were found to be significant predictors of vertebral fracture presence in blacks.   
The purpose of this chapter is to describe the prevalence of vertebral fractures in this group 
of community-dwelling and otherwise healthy black and white South African women and to 
examine the  relationship between parameters of bone strength (clinical and lifestyle factors, 
BMD, geometry, ultrasonography, biochemistry and falls and fall tendency) and vertebral 
fracture in blacks and whites. 
2. PATIENTS AND METHODS 
Conventional radiology of the thoraco-lumbar vertebrae was obtained randomly in as many 
of the study subjects as possible. Patients were referred for radiological evaluation whenever 
possible, but due to financial constraints and logistical difficulties the total cohort was not 
examined. Two hundred and eighty nine of the subjects underwent conventional radiology 
and included 116 blacks (55 premenopausal and 61 postmenopausal subjects) and 173 
whites (69 premenopausal and 104 postmenopausal subjects of whom 42 were on hormone 
therapy). The evaluation was thus performed in 77% of the total study cohort. We used a 
fixed percentage reduction in vertebral height to define incident deformities. A vertebral 
fracture was defined as vertebral height loss of 20% or more232 and all radiographs were 
evaluated and interpreted by a single specialist radiologist (please refer to chapter 3, section 
2.5 for a more detailed outline of methodology).  Analysis of vertebral compression fractures 
reported here was restricted to the premenopausal and non-hormone treated 
postmenopausal cohorts.  
One way analysis of variance (ANOVA) was used to compare black and white fracture cases 
as well as females with and without prevalent vertebral fractures with regard to clinical 
characteristics, densitometry, ultrasonography, geometry and biochemically determined bone 
turnover and fall tendency within the two ethnic groups.  
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Clinical characteristics of the study population evaluated for vertebral fractures are 
summarized in table 1 and was similar to the total study cohort (refer to Chapter 4, section 
3.1.1 and 3.1.2).  Blacks and whites had similar mean ages in the comparable groups studied 
except for older age noted in the older white postmenopausal females. In general, blacks 
were shorter and heavier than whites, reached menarche at a later age, preferred injectable 
hormone contraception, had a larger number of pregnancies and consumed less calcium 
daily. The white women smoked more but maintained a higher level of physical activity post 
menopause. Mean alcohol consumption was low and comparable between the two groups. 
3. RESULTS 
3.1. VERTEBRAL FRACTURE PREVALENCE 
3.1.1. Comparison between black and white fracture subjects 
A total of 13 patients with vertebral compression fractures were identified and included 8 
black patients and 5 white patients. Characteristics of the subjects with vertebral fracture(s) 
are summarized in table 2 and illustrated in figure 1. Blacks with fracture were younger than 
whites and the difference neared statistical significance (p=0.05). Mean weight, height and 
BMI were comparable between the black and white fracture groups. The subjects with 
vertebral factures were all postmenopausal (with the exception of one black female with a 
single vertebral fracture) and represented 11.5% and 8.1% of postmenopausal blacks and 
whites respectively. Vertebral osteopenia was present in 6/7 (86%) black postmenopausal 
females with fracture, vertebral osteoporosis in 2/7 (29%), and femoral osteopenia in 6/7 
(86%). In whites, vertebral osteopenia was present in 3/5 (60%) of fracture cases, vertebral 
osteoporosis in one patient, femoral osteopenia in 5/5 cases (100%) and femoral 
osteoporosis in 2/5 cases (40%). It thus appears as if vertebral and femoral BMD-values are 
of similar value to predict vertebral fractures in blacks, but that femoral BMD is better in the 
white cohort. 
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Table 1: Baseline characteristics of the study cohort in which vertebral fractures were assessed 
 Premenopausal females Postmenopausal females 
<60 years ≥ 60 years 
Blacks 
n=55 
Whites 
n=69 
p-value Blacks 
n=31 
Whites 
n=32 
p-value Blacks 
n=30 
Whites 
n=30 
p-value 
Age (yr) 37 ± 8 39 ± 7 0.05 52 ± 5 51 ± 5.0 0.42 67 ± 5 70 ± 5 0.02 
Height (cm) 160 ± 6 167 ± 6 <0.01 161 ± 6 165 ± 7 <0.01 159 ± 6 160 ± 7 0.36 
Weight (kg) 80 ± 21 69 ± 15 <0.01 81 ± 17 72 ± 17 0.02 89 ± 19 72 ± 15 <0.01 
BMI (kg/cm2) 31 ± 7.6 25 ± 5.0 <0.01 31 ± 7.1  26 ± 5.6 <0.01 35 ± 8.1 28 ± 5.3 <0.01 
Elbow width (mm) 64.6 ± 5.6 65.3 ± 3.4 0.22 67.1 ± 3.8 66.0 ± 4.1 0.19 69.6 ± 6.4 67.8 ± 4.9 0.22 
Age at menarche (yrs) 15 ± 2.2 13 ± 1.6 <0.01 14 ± 1.8  13 ± 2.0 0.09 15 ± 2.0 13 ± 1.4 <0.01 
Age at menopause (yrs)    46 ± 4.4 49 ± 3.9 <0.01 49 ± 5.0 49 ± 4.4 0.47 
YSM (yrs)     6.3 ± 4.4  4.0 ± 4.1 0.03 18 ± 7.4 21 ± 7.1 0.09 
Nr of pregnancies (n)  2.2 ± 1.6 1.8± 1.3 0.03 3.7 ± 2.6 1.9 ± 1.4 <0.01 5.8 ± 2.3 3.7 ± 1.6 <0.01 
Calcium intake (mg/d) 592 ± 312 882 ± 278 <0.01 556 ± 217 865 ± 230 <0.01 665 ± 272 802 ± 264 0.04 
Smoking (pack yrs) 0.6 ± 1.9 4.1 ± 18.6 0.08 1.1 ± 2.4 4.4 ± 11.1 0.06 0.28 ± 1.3 6.5 ± 13.1 <0.01 
Alcohol (U/week) 4.8 ± 10.3 4.1 ± 5.5 0.34 3.8 ± 10 3.0 ± 5.2 0.34 0.8 ± 2.8 2.0 ± 3.9 0.1 
PA score ( 0-4) 2.8 ± 1.0 2.8 ± 1.0  0.44 2.5 ± 1.1 3.1 ± 0.9 <0.01 1.7 ± 1.0 2.4 ± 0.8 <0.01 
OCP use (%) 18% 75%   - 13% 52% - 33% 24% - 
DP use (%) 45% 1%   - 33% 6% - 7% 0% - 
Breastfeeding + (%) 64% 54%   - 80% 61% - 90% 79% - 
Values expressed as mean ± SD,  YSM: years since menopause; PA: physical activity; DP: Depo Provera; OCP: oral contraceptive 
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Table 2: Characteristics of the study subjects with vertebral fractures 
Characteristics                                              Patients 
 Black  
n=8 
White  
n=5 
p-value 
Age (yrs) 57  ±  8 67 ± 14 0.05 
Weight (kg) 75 ± 14 70 ± 18 0.40 
Height (cm) 160 ± 4 161 ± 12 0.43 
BMI (kg/cm2) 30 ± 6 27 ± 6 0.33 
Fractures: 
      Site 
          Thoracic 
          Lumbar  
          Both  
      Single 
      Multiple 
      % of 
postmenopausal 
cohort 
 
 
6 
1 
1 
5 
3 
11.5% 
 
 
5 
0 
0 
2 
3 
8.1% 
 
Spinal bone mineral 
status: 
        Osteopenia   n (% 
of fracture group) 
       Osteoporosis n (% 
of fracture group) 
 
6 (86%) 
2 (29%) 
 
3 (60%) 
1 (20%) 
 
Femoral bone 
mineral status: 
        Osteopenia   n (% 
of fracture group) 
       Osteoporosis n (% 
of fracture group) 
 
6 (86%) 
0 
 
5 (100%) 
2 (40%) 
 
Values expressed as mean ± SD unless otherwise specified 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Number of ffracture cases in black and white postmenopausal females  within specified age groups 
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3.1.2. Comparison between subjects with and without vertebral fracture 
Postmenopausal females with prevalent vertebral fractures and those with normal vertebral 
morphometry were compared with regard to clinical characteristics, densitometry, 
ultrasonography, geometry and biochemically determined bone turnover and fall tendency 
(table 3 and 4). We limited our comparison to postmenopausal females as, with the 
exception of one black female with vertebral fracture, all other vertebral fractures occurred 
in postmenopausal women. 
3.1.2.1. Postmenopausal blacks 
Proximal femoral BMD, as determined by DEXA, was consistently lower in blacks who 
fractured compared with the non-fracture group. This included the areal and ‘volumetric’ 
measurement of femoral neck bone mineral status and the total areal femoral BMD 
expressed as both absolute and T-score values. The densitometric evaluations of the spine 
(BMD: p=0.05 and BMAD: p=0.06) also appeared to be lower in the black fracture group. 
Clinical characteristics were similar in the black fracture and non-fracture cases, although a 
tendency towards lower weight and BMI was noted in the fracture group. The average BMI, 
however, was still in the overweight range. Macro-geometry, ultrasonography, biochemical 
bone turnover parameters, 25-OH-Vit D status, falls and neuromuscular assessment were 
similar in blacks with and without fractures.  
3.1.2.2. Postmenopausal whites 
Proximal femoral BMD, as determined by DEXA, was similar to the findings in blacks and 
consistently lower in whites who fractured compared with the non-fracture group. 
Densitometric evaluations of the spine were similar between the white fracture and non-
fracture groups. A higher percentage of whites who fractured were physically inactive, and a 
significantly higher alcohol intake was noted in these subjects. Weight and BMI in whites 
were similar in the absence or presence of fractures. HAL, a known independent predictor of 
hip fracture risk, was significantly greater in the fracture group. Vertebral bone area was 
similar in white fracture and non-fracture cases.  
A lower 25-OH-Vit D level, along with significantly weaker quadriceps strength, greater 
lateral sway, and reduced visual contrast sensitivity were present in the fracture group 
compared with those who had not sustained a fracture. 
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Table 3: Comparison between black subjects with and without vertebral  fracture 
 Postmenopausal blacks 
COMPARATORS Fracture cases 
  (n = 7) 
Non-fracture cases  
(n = 53) 
p-value 
CLINICAL CHARACTERISTICS    
Age (yrs) 57 ± 7.5 60.0  ± 8.0 0.19 
Weight (kg) 75 ± 14.1 86 ± 18.7 0.06 
Height (cm) 160 ± 3.9 160 ± 6.4 0.48 
BMI (kg/cm2) 30 ± 6.1 34 ± 7.9 0.07 
Family History + (%) 0% 3%  - 
Age at menarche (yrs) 14.3 ± 2.7 14.2 ± 1.8 0.47 
YSM (yrs) 14 ± 1.8 12 ± 8.3 0.28 
Nr of pregnancies (n) 5 ± 3 4.7 ± 3 0.40 
Calcium intake (mg/d) 692 ± 249 599 ± 252 0.18 
Low  PA (PA score ≤ 2) (%) 55% 70%  - 
Alcohol intake (U/week) 3.8 ± 5.3 2.2 ± 7.5 0.29 
 
DENSITOMETRY 
   
SBMD (g/cm2) 0.852 ± 0.18 0.989 ± 0.21 0.05 
SBMAD(g/cm3) 0.115 ± 0.02 0.131 ± 0.03 0.06 
SBMD T-score  -1.6 ± 1.6 -0.46 ± 1.96 0.06 
FN-BMD (g/cm2)  0.717 ± 0.06 0.848 ±  0.14 <0.01 
FN-BMAD (g/cm3) 0.135 ± 0.01 0.160 ± 0.03 0.01 
FN-BMD T-score -1.22 ± 0.59 -0.04 ±  1.23 <0.01 
FT-BMD (g/cm2)  0.808 ± 0.06 0.985 ±  0.16 <0.01 
FT-BMD T-score -1.13 ± 0.49 +0.33 ±  1.27 <0.01 
  
GEOMETRY 
   
HAL (mm) 62 ± 2.3 62 ± 3.7 0.42 
Femur-width (mm) 19 ± 0.4 19 ± 1.9 0.24 
Vertebral BA (cm2) 55 ± 6.9 57 ± 5.7 0.2 
 
ULTRASONOGRAPHY 
   
Calcaneal BMD (g/cm2) 0.47 ± 0.1 -0.52 ±  0.2 0.19 
Calcaneal BMD-T-score -1.03 ± 0.89 -0.55 ± 1.38 0.18 
Calcaneal  BUA (dB/MHz) 63 ± 16 71 ± 22 0.16 
Calcaneal  SOS (m/s) 1539 ± 23 1552 ± 40 0.20 
BIOCHEMISTRY    
S-ALP (IU/l) 88 ± 45 88 ± 30 0.49 
S-PTH (pg/ml) 5.4 ± 3.2 7.6 ± 5.4 0.14 
S-Osteocalcin (ng/ml) 15.0 ± 8.8 11.9 ± 8.0 0.19 
Free U-DPD/ creatinine (nmol/mmol) 8.2 ± 6.3 5.8 ± 4.2 0.10 
S-25OH Vitamin D (ng/ml) 16 ± 5 13 ± 7 0.10 
FALLS AND FALL TENDENCY    
Recent falls  (%) 43% 23%   - 
Quadriceps strength (kg) 24.3 ± 9.2 23.8 ± 9.9 0.45 
Lateral sway (mm) 12.9 ± 8.0 16.6 ± 8.9 0.14 
AP sway (mm) 16.5 ± 6.2 19.6 ± 8.0 0.17 
Reaction time (ms) 466 ± 160 464 ± 187 0.49 
Visual contrast  sensitivity 14.4 ± 4.3 15.0 ± 4.0 0.35 
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Table 4: Comparison between white subjects with and without vertebral fracture 
 Postmenopausal whites 
COMPARATORS Fracture cases 
  (n = 5) 
Non-fracture cases  
(n = 57) 
p-value 
CLINICAL CHARACTERISTICS    
Age (yrs) 67  ± 14 60 ± 10 0.07 
Weight (k) 70 ± 19 71 ± 19 0.44 
Height (cm) 161 ± 12 163 ± 7 0.30 
BMI (kg/cm2) 27 ± 6 27 ± 6 0.50 
Family History + (%) 20% 23%   - 
Age at menarche (yrs) 13.4 ± 2.3 13.3 ± 1.7 0.43 
YSM (yrs) 17.1 ± 13.6 11.4 ± 9.5 0.11 
Nr of pregnancies (n) 3 ± 3 2.7 ± 1.6 0.37 
Calcium intake (mg/d) 908 ± 470 833 ± 228 0.28 
Low Physical activity (PA score ≤ 2) 80% 33%   - 
Alcohol intake (U/week) 7 ± 10 2 ± 4 0.01 
 
DENSITOMETRY 
   
SBMD (g/cm2) 0.895 ± 10.2 0.960 ± 0.17 0.21 
SBMAD(g/cm3) 0.110 ± 0.01 0.124 ± 0.02 0.07 
SBMD T-score  -1.38 ± 1.32 -0.76 ± 1.59 0.20 
FN-BMD (g/cm2)  0.606 ± 0.05 0.726 ± 0.13 0.02 
FN-BMAD (g/cm3) 0.106 ± 0.01 0.133 ± 0.02 <0.01 
FN-BMD T-score -2.2 ± 0.46 -1.12 ± 1.13 0.02 
FT-BMD (g/cm2)  0.742 ± 0.10 0.876 ± 0.15 0.03 
FT-BMD T-score -1.64 ± 0.78 -0.54 ± 1.20 0.03 
  
GEOMETRY 
   
HAL (mm) 69 ± 6.1 66 ± 3.6 0.04 
Femur-width (mm) 21 ± 2.5 20 ± 1.2 0.02 
Vertebral BA (cm2) 57.69 ± 5.8 59.3 ± 5.4 0.27 
 
ULTRASONOGRAPHY 
   
Calcaneal BMD (g/cm2) 0.417 ± 0.10 0.472 ± 0.12 0.12 
Calcaneal BMD-T-score -1.56 ± 0.93 -0.98 ± 1.08 0.12 
Calcaneal  BUA (dB/MHz) 55 ± 14 63 ± 18 0.17 
Calcaneal  SOS (m/s) 1524 ± 28 1541 ± 31 0.12 
BIOCHEMISTRY    
S-ALP (IU/l) 80 ± 19 70 ± 24 0.19 
S-PTH (pg/ml) 7.6 ± 4.0 6.6 ± 5.1 0.24 
S-Osteocalcin (ng/ml) 24.4 ± 9.4 11.4 ±  11 0.10 
Free U-DPD/ creatinine (nmol/mmol) 8.6 ± 4.7 6.3 ± 5.3 0.21 
S-25OH Vitamin D (ng/ml) 13 ± 7 18 ± 6 0.02 
FALLS AND FALL TENDENCY    
Recent falls  (%) 40% 30%   - 
Quadriceps strength (kg) 20 ± 8.2 30.3 ± 8.4 0.01 
Lateral sway (mm) 24.1 ± 17.7 11.9 ± 7.2 <0.01 
AP sway (mm) 23.4 ± 10.4 20.3 ± 6.2 0.16 
Reaction time (ms) 345 ± 147 294 ± 62.8 0.07 
Visual contrast sensitivity 14.8 ± 3.6  17.5 ± 2.3 0.01 
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4. DISCUSSION 
This cross-sectional study of healthy free-living postmenopausal black and white females 
found that the prevalence of morphometric vertebral fractures was not higher in 
postmenopausal white females compared with blacks. In our study population, vertebral 
fractures occurred in 11.5% of black postmenopausal females compared with 8.1% of 
whites. Taking due cognizance of the small patient numbers employed in the present study, 
our data none the less appears to differ from the only other vertebral fracture study 
performed on a South African multi-ethnic population by Dent and co-workers in 1968211. 
Lateral X-rays of only the lumbar vertebrae were obtained in 100 rural blacks, 100 urbanized 
blacks and 100 women of European origin. Significant vertebral compression was noted in 3 
rural blacks, 2 urbanized black subjects and 14 white subjects.  The urbanized black females 
were all domestic workers, indicating a work entailing significant physical activity, and not 
necessarily representative of present urbanized black individuals’ occupations.     
World-wide very little has been published on vertebral fracture prevalence in black 
populations. Mui et al157 found a 25% prevalence of vertebral fractures in inner-city, multi-
ethnic postmenopausal women that included 40% blacks in the age group 55-89 yrs (mean 
age 65), whereas Vokes et al361 documented a prevalence of 21% in both black and white 
patients aged 64 ± 13 yrs who were referred for densitometry. Based on data obtained from 
hospital records of vertebral fracture discharges, Jacobsen et al380 suggested that the 
vertebral fracture incidence is higher in white women compared with blacks. Vertebral 
fracture prevalence in blacks have not been adequately documented and researched. The 
presumed lower vertebral fracture prevalence in blacks on the African continent compared 
with whites is largely based on old studies and clinical experience. Our study, although 
limited by its cross-sectional nature and small numbers, did not show lower vertebral 
fracture prevalence in blacks. Larger population studies are needed to determine the exact 
prevalence of vertebral fractures in the different ethnic populations of South Africa.  
Weight, height and BMI were comparable between the black and white fracture groups. With 
the exception of one case, all the black females with vertebral fractures had spinal and 
femoral osteopenia (86%). Femoral osteopenia was present in 100% of whites with vertebral 
fractures, whereas vertebral osteopenia was only present in 3/5 cases (60%). White fracture 
cases tended to be older than blacks, a finding similar to that observed by Dent et al211. Age 
may influence the presence of concomitant degenerative/ sclerotic changes that may impact 
on the accuracy of vertebral BMD measurements by DEXA, especially in the older whites, and 
 227 
may thus explain why femoral BMD more accurately predicted vertebral fractures in our 
whites. 
In our study, racial differences could be documented in the occurrence of risk factors known 
to predispose to the development of vertebral fracture. A low femoral BMD was the only 
bone strength parameter that was consistently associated with fracture in both black and 
white cohorts. In blacks, a tendency towards lower body weight in those who fractured was 
also observed. In whites’ alcohol intake, physical activity, quantifiable physical performance 
parameters and 25-OH-Vitamin D levels were also noted to be significantly different between 
fracture and non-fracture cases. A longer HAL was also noted in whites with fractures and 
may indicate, in addition to vertebral fracture risk, also an increase in hip fracture risk in this 
group of patients. Vertebral BA was non-significantly lower in both black and white fracture 
cases. 
As alluded to, low BMD at the proximal femoral sites was identified as the only risk factor for 
fractures in both blacks and whites in this study. A tendency towards lower lumbar spine 
BMD was also noted in black fracture cases, whereas lumbar spinal BMD was similar for 
white fracture and non-fracture groups. In the SOF353 and Rotterdam359 studies, BMD at both 
spinal and proximal femoral sites were associated with an increased risk of vertebral 
fractures, whereas other studies360 have also noted similar spinal BMD in fracture and non-
fracture cases in agreement with our findings. Concomitant degenerative changes may 
explain these apparent discrepancies. 
In our study, several clinical and lifestyle factors, including age, weight, height, BMI, family 
history of OP or fractures, age at menarche, parity, calcium intake, physical inactivity and 
alcohol intake did not differ between fracture and non-fracture cases in blacks. An 
association between clinical and lifestyle factors and fracture risk was similarly absent in 
whites except for physical inactivity and alcohol intake where a higher prevalence was noted 
in our fracture cases. 
The Rotterdam Study359, EPOS358 and Framingham Vertebral fracture Study158 found no 
association between physical activity and incident vertebral fracture in Caucasian women, 
similar to our findings in blacks, whereas physical activity was identified as a protective 
factor against first vertebral fracture in the SOF353 study as noted in our white women. 
Skeletal geometry, ultrasonography, biochemistry, falls and fall tendency assessed in the 
present study were similar in black fracture and non-fracture cases. In whites, significant 
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differences were documented in skeletal geometric measurements, 25-OH-Vit D levels and 
neuromuscular function tests.  
Serum 25-OH-Vitamin D levels were significantly lower in white women with fractures 
compared with non-fracture cases. White fracture cases also showed evidence of poor 
physical performance i.e. weaker quadriceps strength, greater lateral sway and reduced 
visual contrast sensitivity, and in addition a higher percentage of white women with fractures 
were physically inactive (80% versus 33%) and consumed more alcohol. Despite these 
findings, fall risk was not clearly different between the white fracture and non-fracture 
groups (40% versus 30%).  
Low 25-OH-Vitamin D levels have been documented in previous studies to be associated with 
poorer physical performance (tests of muscle strength, reaction time and postural body 
sway)176,348,349 and have been independently associated with an increased risk of falling in the 
elderly, particularly those aged 65-75yrs350. In our study, 25-OH-Vitamin D status was not 
significantly associated with fall risk or postural sway, and only a modest correlation with 
quadriceps strength was observed (see chapter 10, section 5). The number of recent falls in 
our postmenopausal blacks and whites was similar, despite significantly lower 25-OH-Vitamin 
D levels and poorer physical performance in blacks. Previous studies have noticed less 
muscle strength and less activity, but similar fall histories, in African American females 
compared with whites208, findings similar to ours. The association between 25-OH-Vitamin D 
status and physical performance is particularly noted in those above 65yrs of age. The 
average age of our black fracture cases was 57±8yrs, i.e. not a single one above 65yrs of 
age, and may therefore partly explain this lack of association. 
A history of recent falls is a major contributing factor to the occurrence of symptomatic non-
spinal fractures in postmenopausal women, independent of and additive to the risk 
attributable to age and osteoporosis169,170. Hip fractures occur almost exclusively after a fall 
and spontaneous hip fractures without prior falling is extremely rare168. The exact role and 
significance of falls with regard to vertebral fractures is less well defined. Of the 13 subjects 
in our study with radiological evidence of vertebral fracture, five subjects (38%) reported a 
recent fall (3 blacks, 2 whites). None of these subjects were aware that they sustained a 
back injury at the time of the fall.  
To conclude, despite the small patient numbers and other limitations of the present study, it 
does argue against the widely held belief that SA blacks have a lower vertebral fracture 
prevalence compared with whites. Vertebral fractures occurred in a similar percentage of 
postmenopausal blacks and whites in our study (11.5% and 8.1% respectively).  Proximal 
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femoral BMD best identified black and white vertebral fracture cases in this study. Quite a 
number of other risk factors i.e. physical inactivity, alcohol-intake, poorer physical 
performance test results and a longer HAL were more frequent in the white fracture cases 
and could therefore serve as markers of increased fracture risk, although not necessarily 
implicated in the pathophysiology of OP or falls. However, in blacks, only femoral BMD 
served as risk factor. Similar risk factors for blacks and whites cannot therefore be assumed 
and is deserving of further study. White fracture cases did not fall more despite lower 25-
OH-Vitamin D, poorer physical performance and lower activity levels than non-fracture cases. 
Calcaneal ultrasonography and biochemical parameters of bone turnover were similar in 
fracture and non-fracture cases in both ethnic groups.  
Our study data on vertebral fractures in this cohort of urbanized blacks thus cautions against 
the belief that blacks are not at risk to sustain vertebral compression fractures and 
emphasize the need for further studies to better define fracture prevalence in the different 
ethnic populations of SA.    
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CHAPTER 12:  
THE IMPACT OF HORMONE THERAPY ON BONE MINERAL DENSITY, 
CALCANEAL ULTRASONOGRAPHY, BONE TURNOVER AND FALL RISK IN 
WHITE POSTMENOPAUSAL SOUTH AFRICAN FEMALES 
1. INTRODUCTION 
Hormone therapy in white females protects against bone loss during the menopausal 
transition and sustains this protective effect with continuous use. Observational data285,286 
and several recent meta-analyses288-290 have documented the efficacy of hormone therapy in 
the reduction of fractures in postmenopausal women. The anti-fracture efficacy of hormone 
therapy was confirmed by the Women’s Health Initiative (WHI)291,292,293 a large randomized 
double-blinded clinical trial designed to determine the effects of estrogen plus progestin or 
unopposed estrogen compared with placebo on a number of chronic diseases of older 
women. Combination and unopposed estrogen hormone therapy increased BMD at the hip 
and spine and reduced the risk of fractures at the hip, vertebrae and wrists in healthy 
postmenopausal white and black women, the majority of whom had normal BMD at study 
entry (only 4% of women in the estrogen-plus-progestin group and 6% of women in the 
placebo group had osteoporosis at the total hip at baseline). All types of hormone therapy 
appear to confer benefit. In a prospective, cohort study of over a million women362 (the 
Million Women Study), current users of hormone therapy had a significantly lower risk of 
fracture than non-users. The protective effect was seen for all types of hormone therapy 
(unopposed estrogen, combined estrogen-progestin, different estrogen and progestin 
formulations, different routes of administration [oral versus transdermal], and different 
patterns of administration [cyclic versus continuous]). 
One of the major advantages of hormone therapy in the prevention of fractures lies in the 
ability of this treatment modality to reduce fracture risk in non-osteoporotic patients. The 
bisphosphonate trials showed a reduction in risk of hip and spine fractures in women with 
osteoporosis, but not in women without osteoporosis363-365.  
2. PATIENTS AND METHODS 
In our study population, hormone therapy was used almost exclusively by the white females. 
We did not include white females currently using hormone therapy when differences in BMD, 
ultrasonography and bone turnover between blacks and whites were assessed in previous 
chapters and also analyzed fall data separately due to the fact that use was confined to one 
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ethnic group and because of the fact that long-term use of HT is currently not recommended 
primarily for bone protection. 
In this chapter, data regarding BMD, ultrasonography, biochemically determined bone 
turnover, fall risk and the radiological presence of vertebral fractures are compared between 
current users of hormone therapy [duration of at least 12 months] (n=43) and never-users 
(n=60) in the white postmenopausal cohort. The mean duration of hormone therapy in 
current users was 8.3 ± 5.5 years (range 1-18 years).  One way analysis of variance was 
used to determine differences between current hormone users and never-users regarding 
abovementioned variables. Cross tabulation was used to summarize categorical variables. 
Anthropometric variables, reproductive factors and lifestyle risk factors, with the exception of 
age at menarche and smoking, were comparable between the two cohorts (table 1). The 
women on hormone therapy (HT+) reached menarche at an earlier mean age (p=0.03) and 
smoked more (p=0.04) compared with the never-users. 
Table 1: Baseline characteristics of the white postmenopausal hormone never-users (HT-) and hormone users (HT+) 
Characteristic Postmenopausal (HT-) 
(n=60) 
Postmenopausal (HT+) 
(n=43) 
p-value 
Age (yr) 59  ±  9  56  ±  7 0.06 
Height (cm) 163  ±  17 160  ±  26 0.18 
Weight (kg) 71.6  ±  15 69 ± 11 0.20 
BMI (kg/cm2) 27 ± 5 26 ± 4 0.14 
Elbow width (mm) 67 ± 4 67 ± 4 0.34 
Age (yrs) at menarche 13.2 ± 1.8 12.6 ± 1.7 0.03 
Years since menopause  10.9 ± 8.7 10.5 ± 7.0 0.39 
Calcium intake (mg/d) 855 ± 250 855 ± 255 0.28 
Smoking (pack yrs) 5.9 ± 14.4 11.0 ± 16.1 0.04 
Alcohol (U/week) 2.4 ± 4.0 1.7 ± 3.2 0.20 
Physical activity score ( 0-4) 2.8 ± 0.9 2.7 ± 0.8 0.24 
Number of pregnancies  2.7 ± 1.6 2.6 ± 1.4 0.38 
Past OC use  n (%) 25 (38) 24 (52)  
Past Depo Provera use  n(%) 2 (3) 0 (0)  
Positive family history n (%) 14 (21) 12 (26)  
Values are reported as average ± SD except where otherwise stated 
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3. RESULTS 
3.1. BONE MINERAL DENSITY 
3.1.1. Spinal bone mineral status  
The mean S-BMC, SBMD and SBMAD were significantly higher in hormone users (table 2, 
figure 1) compared with never-users. The BMD expressed as a T-score as well as a Z-score 
(to compensate for the tendency towards lower mean age in the hormone users, p=0.06) 
was also statistically significantly different between the groups, with lower deviations from 
the norm noted in the group receiving hormone therapy. 
3.1.2. Femoral bone mineral status  
The mean FNBMC, FNBMD, FNBMAD and FTBMD were all significantly higher in the group of 
hormone users. The femoral BMD expressed as T- and Z-scores were also significantly 
different between the two groups with lower deviations from the norm noted in the hormone 
users (table 3 and figure 2). 
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Table 2: Spinal bone mineral status of white postmenopausal hormone never-users (HT-) and hormone users (HT+) 
Spinal bone mineral  status 
 
Postmenopausal (HT-) 
(n=60) 
Postmenopausal (HT+) 
(n=43) 
p-value 
BMC 57.63 ± 12.6  62.01 ± 9.79 0.02 
BMD 
   Total 
   T-score 
   Z-score 
 
0.948 ± 0.16 
-0.79 ± 1.50 
0.51 ± 1.43 
 
1.060 ± 0.13 
0.11 ± 1.15 
1.31 ± 1.16 
 
<0.01 
<0.01 
<0.01 
BMAD 0.123 ± 0.02 0.136 ± 0.02 <0.01 
Values expressed as average ± SD 
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Figure 1: Spinal bone mineral status in the white postmenopausal hormone therapy never-users (HT-)  
and users (HT+). Bone mineral status significantly better in the cohort on hormone therapy (p-values  
as illustrated). 
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Table 3: Femoral bone mineral status of white postmenopausal hormone never-users (HT-) and users (HT+) 
Bone mineral  status Postmenopausal (HT-) 
(n=60) 
Postmenopausal (HT+) 
(n=43) 
p-value 
Femoral neck    
  BMC 3.99 ± 0.77 4.30 ± 0.50 0.03 
  BMD 
       Total 
       T-score 
       Z-score 
 
0.718 ± 0.12 
-1.18 ± 1.13 
0.109 ± 1.12 
 
0.800 ± 0.12 
-0.470 ± 0.99 
0.641 ± 0.96 
 
<0.01 
<0.01 
<0.01 
  BMAD  0.131 ± 0.02 0.147 ± 0.03 <0.01 
Femur Total    
  BMC 31.88 ± 6.10 33.68 ± 4.50 0.08 
  BMD  
        Total 
        T-score 
        Z-score 
 
0.865 ± 0.143 
-0.60 ± 1.14 
0.38 ± 1.14 
 
0.957 ± 0.12 
0.05 ± 0.89 
0.88 ± 0.96 
 
<0.01 
<0.01 
0.01 
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Figure 2: Femoral bone mineral status in the white postmenopausal hormone therapy never-users (HT-) 
 and users (HT+). Bone mineral status significantly better in the cohort on hormone therapy (p-values as  
illustrated). 
 
3.2. BONE TURNOVER STATUS 
Bone turnover status in these two cohorts was evaluated biochemically via determination of 
serum-osteocalcin (OC) levels and urine-deoxypyrodinoline (DPD). OC was significantly lower 
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in the hormone users compared with never-users. No significant difference was, however, 
noted in DPD between the two groups (table 4). 
Table 4: Biochemical evaluation of bone turnover status in white postmenopausal hormone never-users (HT-) and users (HT+) 
Biochemical parameter Postmenopausal (HT-) 
(n=60 ) 
Postmenopausal (HT+) 
(n=43) 
p-value 
Serum Osteocalcin 12.5 ± 9.9 6.95 ± 5.3 <0.01 
Urinary free DPD/creatinine 6.4 ± 4.6 6.0 ± 3.5 0.37 
Values expressed as mean ± SD 
3.3. ULTRASONOGRAPHIC MEASUREMENTS 
All QUS measured parameters of bone (US BMD, US BMD T-scores, SOS, BUA and QUI) were 
significantly higher in the hormone users compared with those who had never used hormone 
therapy (table 5). QUS SOS and BUA remained higher in the hormone treated group after 
correction for DEXA determined BMD at the spine and proximal femur. The difference in BMD 
adjusted QUS SOS remained significantly higher in the HT group, whereas the difference in 
QUS BUA levels neared statistical significance.   
Table 5: Ultrasound measurements in white postmenopausal hormone never-users (HT-) and users (HT+) 
Ultrasound measurement Postmenopausal (HT-) 
(n=60 ) 
Postmenopausal (HT+) 
(n=43) 
p-value 
Calcaneal BMD (g/cm2) 0.457 ± 0.12 0.573 ± 0.11 <0.01 
Calcaneal  BMD T-score -1.11 ± 1.04 -0.04 ± 0.97 <0.01 
SOS (m/s) 
Unadjusted 
Adjusted (for DEXA BMD) 
 
1537 ± 29 
1538 ± 29 
 
1567 ± 30.1 
1566 ± 31 
 
<0.01 
<0.01 
BUA (dB/MHz) 
Unadjusted 
Adjusted (for DEXA BMD) 
 
61.5 ± 18 
62.5 ± 18 
 
76.1 ± 15.0 
75.4 ± 17  
 
<0.01 
0.05 
QUI (0-150) 83.9 ± 18.4 102.6 ± 17.5 <0.01 
Values expressed as mean ± SD 
3.4. FALL RISK 
3.4.1. History of recent fall(s) 
A history of a recent fall was present in 13 (30%) of the hormone users and in 19 (32%) 
never-users. Hormone therapy had an impact on falls only in the older (≥ 60 years) 
postmenopausal females and especially in those over the age of 65 years. Less falls occurred 
amongst the older postmenopausal females using hormone therapy (11%) compared with 
 237 
non-users (45%) and none of the hormone users over the age of 65 years sustained a 
recent fall. 
3.4.2. Sensory and neuromuscular tests 
Current hormone therapy reduced lateral sway and improved quadriceps strength in older  
females only (table 6). Near significant differences in lateral sway and quadriceps strength 
were thus found between hormone non-users and users in the late postmenopausal group 
(p=0.05).  
Table 6: Sensory and neuromuscular function tests in white postmenopausal hormone never-users (HT-) and 
users (HT+)  
Values expressed as mean ± SD 
3.5. VERTEBRAL FRACTURES 
Only one patient amongst the hormone users (2%) had radiological evidence of vertebral 
fractures compared with four patients (6%) amongst the never-users.  
4. DISCUSSION 
Parameters of bone strength parameters evaluated in the present study were significantly 
greater among current users of hormone therapy compared with never users. Bone mineral 
density at the hip and spine, and all QUS parameters were higher among current hormone 
users. Hormone therapy furthermore resulted in reduced bone turnover based on 
determination of serum osteocalcin levels. Urinary DPD levels were, however, similar 
between current hormone users and never users. Fall risk was significantly lower in older 
postmenopausal hormone users along with a tendency towards reduced lateral sway and 
improved quadriceps strength. Although numbers are very limited, the positive impact of 
hormone therapy in our healthy postmenopausal white cohort appeared to culminate in 
reduced vertebral fracture prevalence amongst the hormone users (2% vs. 6% in never 
users). 
Function Postmenopausal females 
<60 years ≥ 60 years 
Whites ( HT-) 
n=35 
Whites (HT+) 
n=25 
p-
value 
Whites (HT-)  
n=31 
Whites (HT+) 
n=18 
p-
value 
Body sway (mm) 
 Anterio-posterior 
 Lateral 
Reaction time (ms) 
Visual contrast  
Quadriceps strength (kg) 
 
19.2 ± 5.9 
10.9 ± 6.1 
274 ± 48 
18.5 ± 1.9 
34.2 ± 7.9 
 
19.4 ± 5.1 
10.7 ± 5.7 
276 ± 33 
17.7 ± 2.3 
30.6 ± 8.1 
 
0.46 
0.45 
0.42 
0.09 
0.04 
 
22.2 ± 7.0 
15.3 ± 11.2 
325 ± 86 
16.0 ± 2.4 
25 ± 7.0 
 
23.6 ± 8.3 
10.5 ± 5.7 
307 ± 57 
15.9 ± 2.4 
28.5 ± 6.3 
 
0.10 
0.05 
0.22 
0.46 
0.05 
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It has been recognized for more than 50 years that bone loss in women is unequivocally 
accelerated by estrogen deficiency. Estrogen halts or slows bone loss – probably for as long 
as it is continued in the majority of women. The Postmenopausal Estrogen/progestin 
Interventions (PEPI) trial381 showed sustained increases in bone mineral density when 
conjugated equine estrogen (CEE) was used alone or in combination with 
medroxyprogesterone acetate or micronized progesterone. The positive impact of hormone 
therapy was also confirmed in the more recent Women’s Health Initiative (WHI) trial291-293. 
After 3 years of combination hormone treatment, the percentage difference in favor of 
hormone therapy was greater, with mean differences of 4.5% and 3.6% at the lumbar spine 
and total hip respectively. In our study, the difference between hormone users and never-
users was 10.6% for the lumbar spine, 9.7% for the total hip and 10.3% for the femoral 
neck. The mean duration of hormone therapy was 8.3 years ranging from 1-18 years. The 
positive impact of hormone therapy on BMD at the hip and spine observed in our study are 
thus consistent with the findings from the PEPI381 and WHI trial291-293 as well as observational 
data obtained from numerous previous epidemiological studies286,287,344. The increase in BMD 
at the lumbar spine and proximal femur documented in our hormone treated subjects were 
very similar – this differs from the WHI trial which showed a more marked increase at the 
lumbar spine, a site that contains a large proportion of metabolically active trabecular bone, 
which is more likely to reflect acute or short-term permutations. The difference in BMD at 
the hip and spine was also greater in our study, compared with the results of the WHI trial. 
These differences can probably be accounted for by the significantly longer duration of 
hormone therapy used by our study subjects, compared with the 3 year observation period 
of the WHI. 
QUS parameters can be used to predict fracture risk independently of BMD226,227,321,325, hence 
the assumption that QUS BUA and SOS measures bone qualitative parameters independently 
of BMD. All QUS variables, including BUA, SOS and the calculated calcaneal BMD and QUI 
were significantly higher in our hormone users. Correction of BUA and SOS for DEXA BMD at 
the spine and proximal femoral sites attenuated the difference in BUA values only (p=0.05), 
with SOS values remaining statistically significantly higher in the hormone users. In 
agreement with our data, numerous previous studies367-368 have also documented higher QUS 
measurements in hormone users compared with non-users. Hormone therapy thus appears 
to prevent deterioration in BUA and SOS as measured by QUS at the calcaneus in ageing 
postmenopausal women, an effect similar to that observed for DEXA BMD.  If these QUS 
parameters do indeed measure qualitative properties of bone independent of BMD, as has 
been suggested in previous work228-230, the higher values documented in hormone users 
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imply better preservation of bone quality compared with non-users and may indeed 
contribute to a lower fracture prevalence in hormone treated postmenopausal white women.    
Menopause is associated with adverse changes in bone turnover, and bone biochemical 
markers have been suggested to reflect postmenopausal high bone turnover. Both bone 
resorption and bone formation increase. When bone resorption exceeds formation, bone loss 
and osteoporosis will occur. According to the results of previous studies, hormone therapy 
decreases the concentration of serum OC in postmenopausal women369-372. OC has been 
suggested to be the best single biochemical marker for estimating the rate of bone loss in 
untreated postmenopausal women339,340. Its value as a follow-up marker during preventative 
medication i.e. hormone therapy of osteoporosis has also been established. Several studies 
have shown a positive correlation between lowering of biochemical markers and BMD 
changes in women receiving HT368,372-375. Owing to a close coupling between osteoblasts and 
osteoclasts, the lowering of bone formation markers in serum during hormone therapy is 
most likely a consequence of decreased bone resorption. In our study, OC was significantly 
lower in the hormone users compared with never-users. No significant difference was, 
however, noted in urinary DPD between the two groups. This may be partially explained by 
the greater variations/lower sensitivity of urinary as opposed to serum biomarkers as well as 
the limitations of a single measurement of a biochemical parameter known to have a 
significant day-to-day variation233 (see in chapter 8).  
It may be that treatment with estrogen also reduces fractures in women without 
osteoporosis through a reduction in falls and improvement in muscle strength, although the 
evidence for this is sparse and conflicting376-378.  In our study the fall frequency was 
significantly reduced in older postmenopausal hormone users, along with a tendency towards 
reduced lateral sway and improved quadriceps strength. Neuromuscular impairment and 
poor vision have been shown to identify individuals in the community at risk of falls and fall 
related fractures178,319,342,351. Falls per se, especially in the elderly, contribute significantly to 
the occurrence of symptomatic fractures169,170,319.  It has also been documented that the 
nature of the fall determines the type of fracture and that women who suffered hip fractures 
were more likely to have fallen sideways or straight down174. Hormone therapy significantly 
reduced fall frequency in our elderly females, in part due to improved quadriceps strength 
and a tendency towards reduced lateral sway and may thus potentially reduce hip fracture 
risk in these women.  
To conclude, in our study hormone therapy in postmenopausal white women improved bone 
strength parameters and reduced fall risk. In hormone treated whites compared with non-
hormone users: 
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● Higher BMD at the spine and proximal femur as determined by DEXA was documented. 
● All QUS measurements were significantly higher.  
● The bone turnover rate as reflected by lower serum osteocalcin levels was lower. 
● The fall frequency was lower in the older hormone treated women (≥ 60yrs) and 
greater quadriceps strength and reduced lateral sway was noted. 
This may have contributed to the fact that only one patient amongst the hormone users 
(2%) had radiological evidence of vertebral fractures, compared with four patients (6%) 
amongst the never-users. Our subject numbers were, however, limited and this data needs 
to be confirmed in a larger population study. Moreover, the impact of hormone therapy also 
needs to be assessed in black postmenopausal females. 
 
 
 
 241 
CHAPTER 13  
FINAL CONCLUSIONS AND REFLECTIVE SUMMARY 
The major goal of this study was to define bone strength parameters in black (Xhosa) and 
white South African women in an attempt to assess ethnic differences in fracture risk. 
Although limited by its cross-sectional nature and small patient numbers, the study has 
nonetheless provided potentially valuable information. 
A significantly lower hip fracture rate has previously been documented in SA black females 
compared with whites. Evidence obtained in the present study suggests higher bone 
strength in the femoral region in blacks, especially with ageing and at a time when hip 
fracture risk is highest. Older postmenopausal black females was documented to have higher 
densitometric determined bone mineral density of the femoral region, higher 
ultrasonographic measures of qualitative bone properties and significantly shorter hip axis 
length compared with whites.  Ethnic differences in proximal femoral bone mineral density 
could be ascribed to higher peak BMD, but also to an apparent better maintenance of BMD 
with ageing. The higher proximal femoral bone strength in blacks, in the presence of 
documented similar fall frequencies in blacks and whites, is in accordance with previously 
documented lower hip fracture rates in SA black females compared with whites. 
A similar vertebral fracture rate was, however, documented in black and white females in our 
study and is in keeping with the finding of similar spinal BMD measurements in 
postmenopausal blacks and whites. Ethnic differences in vertebral dimensions and qualitative 
bone properties, as has been suggested by our quantitative ultrasound data, may impact on 
vertebral fracture risk, but was found to be similar in our fracture and non-fracture cases.   
Westernization and urbanization may alter risk factor profiles for osteopenia in black females. 
A trend towards a lower ideal body weight may significantly impact on optimal BMD 
attainment and may attenuate, and even eliminate, the apparent better maintenance of BMD 
in blacks with ageing - in fact - most of the observed ethnic difference in BMD in this study 
was explained by differences in body weight between the two cohorts and not by ethnicity 
per se.  
Although cautious with regard to interpretation of longitudinal changes in this cross-sectional 
study, an apparent better preservation of vertebral and femoral bone mineral density as well 
as quantitative ultrasound parameters i.e. BUA and SOS were noted in aging black females 
compared with whites. In fact, most of the observed higher femoral bone mineral density 
and QUS measurements in older blacks compared with whites appeared to be due to an 
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attenuated decline in these parameters rather than higher peak values obtained in 
premenopausal black females. The apparent ethnic differences in bone mineral and bone 
qualitative changes with ageing observed and documented in this study, however, needs to 
be verified in prospective population based studies. Following completion of this dissertation, 
my future research objectives thus include a prospective follow-up evaluation of the majority 
of the black and white study subjects who participated in this cross-sectional evaluation. 
Larger, prospective studies are also clearly needed to identify appropriate risk factor subsets 
for our SA female population to ensure that BMD resources are allocated to those who are 
most likely to benefit, and to better define the current vertebral- and hip fracture prevalence 
in the different ethnic populations of South Africa. 
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ADDENDUM I 
TELEPHONIC  QUESTIONNAIRE 
1.   AGE 
2.   ETHNIC GROUP 
3.    JOB 
 CURRENT 
 PAST 
4.    ANY KNOWN SYSTEMIC AILMENT/ILLNESS? 
OSTEOPOROSIS 
OSTEOMALACIA 
HYPERPARATHYROIDISM 
RENAL BONE DISEASE 
PAGETS 
ENDOCRINE DISEASE:          CUSHINGS 
    PROLACTINOMA 
    THYROID DISEASE 
    ACROMEGALY 
      OVARIAN FAILURE (Not menopause related) 
MALABSORPTION (Gastric disease, chronic diarrhoea) 
MALIGNANCY 
KNOWN RENAL/HEPATIC DISEASE 
ALCOHOL ABUSE ( > 4U/day, impact on daily functioning) 
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5.   HAVE YOU TAKEN ANY THERAPY DURING THE PAST SIX MONTHS? 
PLEASE NAME THEM:   
VITAMIN D,  BISPHOSPHONATES,  ANTIACIDS, CORTICOSTEROIEDS   
SEX HORMONES Estrogen/Testosterone,  ANTICONVULSANTS Epanutin/Tegretol…. 
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ADDENDUM II 
PATIENT QUESTIONNAIRE:  OSTEOPOROSIS STUDY  
PATIENT NUMBER: 
AGE: 
ETHNIC GROUP: 
JOB: 
  CURRENT: 
  PAST:  
HISTORY 
A.  BONE COMPLAINTS 
• PAIN 
• DEFORMITY 
YES NO 
B.  FRACTURES 
       IF YES: 
• POSITION 
• NUMBER 
• DATES 
• ASSOCIATED TRAUMA 
 
YES NO 
C. RISK FACTOR ANALYSIS 
FAMILY HISTORY 
• OSTEOPOROSIS 
• Affected family member 
• RENAL STONES 
• OTHER BONE DISEASES 
RENAL DISEASE 
YES NO 
GYNAECOLOGICAL HISTORY 
AGE AT MENARCHE 
MENSTRUAL CYCLE: 
• REGULAR/ IRREGULAR 
• CYCLE LENGTH (DAYS) 
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• USE OF CONTRACEPTIVE (Y/N) 
• TYPE 
• DURATION OF USAGE 
• CURRENT/PAST 
MENOPAUSE: 
• AGE AT MENOPAUSE 
• SPONTANEOUS/SURGICAL 
• SURGICAL: OOPHERECTOMY- Y/N  
• DURATION OF MENOPAUSE (YRS) 
• HRT, YES OR NO 
• DATE COMMENCED 
• MENOPOUSAL YEARS WITHOUT 
HRT 
• DURATION OF USAGE 
• COMPLIANCE  
• CURRENT/PAST 
PREGNANCIES 
• TOTAL NUMBER  
• WHEN  
• GRAVIDA 
BREASTFEEDING  
• YES / NO 
• DURATION 
MEDICATION (including Ca-supplements) 
     1.  
• TYPE 
• DOSAGE  
• DURATION OF USAGE 
     2. 
• TYPE 
• DOSAGE  
• DURATION OF USAGE 
     3. 
• TYPE 
• DOSAGE  
• DURATION OF USAGE 
 
EXERCISE 
• TYPE 
• INTENSITY 
• DAILY IN-HOUSE (1-2) 
• ADDITIONAL 
• MODERATE (3) 
• STRENUOUS (4) 
• DURATION 
• IMMOBILIZATION 
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DIETARY ANALYSIS 
• CALCIUM 
• PROTEIN 
• PHOSPHATE 
• MAGNESIUM 
• SALT 
• CALORIES 
• EATING DISORDER YES/NO 
 
TOXINS 
 ALCOHOL 
• PREVIOUS/PRESENT 
• AMOUNT 
• TYPE 
• DURATION 
NICOTINE 
• PREVIOUS/PRESENT 
• AMOUNT/DAY 
• DURATION 
 
OTHER KNOWN SYSTEMIC ILLNESSES 
1.  
          3. 
 
D.  FALL-TENDENCY 
• ANY FALLS  Y/N (within last year) 
• WHEN 
• NUMBER 
• WHERE 
• DIRECTION 
• INJURIES 
 
PHYSICAL EXAMINATION 
ANTROPOMETRIC DATA 
• LENGTH (cm) 
• Arm span 
• Leg length 
• Sitting length 
• WEIGHT (KG) 
• BMI 
• WHR 
• SKINFOLDS 
• Triceps 
• Subscapular 
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CARDIOVASCULAR 
• BP 
• Sitting 
• PULSE 
• HEART 
 
LUNGS  
GASTRO-INTESTINAL  
NEUROLOGICAL SYSTEM  
VASCULAR SYSTEM  
GENITO-URINARY SYSTEM  
MUSCULO-SKELETAL SYSTEM 
• DEFORMITIES 
• Type 
• Location 
OTHER 
 
GENERAL  
BIOCHEMISTRY 
INVESTIGATION COMPLETED () 
A. SERUM  
CALCIUM 
   Serum Total (Corrected)       
 
PO4  
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Mg  
ALBUMIN  
CREATININE  
ALP  
PTH  
LH  
INVESTIGATION COMPLETED () 
FSH  
E2  
TESTOSTERONE  
SHBG  
T4  
TSH  
CORTISOL  
25OH VITD  
OSTEOCALCIN  
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DEOXYPIRODINOLINE  
GGT  
GENETIC STUDIES  
INVESTIGATION COMPLETED () 
B. URINE  
2ND VOIDED URINE 
  DEOXIPIRODINOLINE,CREAT 
 
2HR HYDRATED URINE 
  CA,CREATININE,NA 
 
RADIOLOGY 
INVESTIGATION DONE () 
THORACICO-LUMBAR VERTEBRAE  
DEXA  
ULTRASOUND  
FALL TESTS 
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ADDENDUM III 
DIET INFORMATION 
Name:                                                                  Weight: 
Diagnosis:                                                            Length: 
Date of Birth: 
Age: 
TIME FOOD ITEM DESCRIPTION CODE MASS 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
Adapted from: Department of Nutrition, Tygerberg Hospital  
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A SIMPLIFIED FOOD FREQUENCY QUESTIONNAIRE 
FOOD ITEM FREQUENCY AMOUNT 
Sweets   
Chocolate   
Cake/Tarts   
Biscuits   
Fruits   
Fruit Juice   
Dried fruit   
Can fruit   
Chips   
Peanuts   
Pudding   
Ice-cream   
Sugar   
Jam   
Rusks   
Yoghurt   
Popcorn   
Egs   
Milo/ Horlicks / Ovaltine   
Sodas   
Milk   
Cheese   
Alcohol   
   
   
   
Adapted from: Department of Nutrition, Tygerberg Hospital 
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ADDENDUM IV 
 
SENSORY AND NEUROMUSCULAR TESTS 
 
 
MELBOURNE EDGE TEST 
 
DB 
 
 
QUADRICEPS STRENGHT 
 
 
kg 
REACTION TIME - HAND (msec) 
 
 
 
 
 
 
1 
5 
9 
13 
17 
 
 
 
2 
6 
10 
14 
18 
 
 
3 
7 
11 
15 
19 
 
 
4 
8 
12 
16 
20 
 
 
SWAY TEST 
 
Sway on floor- Anterior-Posterior 
   Lateral 
Sway on floor-Anterior-Posterior 
  Lateral 
 
 
 
mm 
mm 
mm 
mm 
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